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Abstract 
Hypoxia, defined as low oxygen tension, is a common characteristic of growing 
tumours. Tumour cells adapt to their hypoxic microenvironment by inducing 
angiogenesis and escaping cell death. In doing so, tumour cells become resistant to 
radiotherapy and many forms of chemotherapy. Hypoxia signalling and angiogenesis is 
mediated by the hypoxia-inducible factor (HIF) transcriptional complex. HIF can cross-
talk to the p53 tumour suppressor protein, a critical regulator of cell cycle and cell death 
responses to stress. 
 
This study aims to understand how cell death responses are regulated in tumour cells 
by HIF and p53, in normoxia and in hypoxia. Recently, activation of p53 by the small 
molecule RITA has been investigated. Flow cytometry, comet assays and western blot 
analysis have been used to reveal a novel p53-dependent DNA damage response that 
activates cell cycle checkpoints, and induces significant cell death of hypoxic tumour 
cells. Activation of p53 also achieves anti-angiogenic effects, both in vitro and in vivo 
by inhibition of HIF-1α protein synthesis and HIF target genes, including VEGF.  
 
The MEK-ERK MAPK pathway has also been investigated as a critical modulator of 
p53-dependent cell death in normoxia and hypoxia. Inhibition of MEK1/2 by the MAPK 
signalling inhibitor PD98059 significantly inhibits p53 induction and cell death 
responses by RITA. The anti-tumour effect of p53 activation in response to RITA is 
therefore dependent on MEK-ERK signalling. By understanding p53 interactions with 
HIF signalling, and the role of p53 in responding to DNA damage and apoptotic signals, 
this study has potential to improve the therapeutic targeting of resistant tumours with 
deregulated angiogenic and cell death pathways. 
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1.1 Overview of cancer 
The earliest records of cancer date back to almost 1600 BC when Egyptians 
documented the first methods of treatment for tumours. Later, the ancient Greek 
physician Hippocrates (ca.460 BC-370 BC) described the appearance of solid tumour 
sections as ‘carcinos’ (meaning crab or crayfish in Greek), from which the name cancer 
was derived. Today, one in three people are likely to develop cancer during their 
lifetime in the UK and in 2008, up to 27% of all deaths in the UK were caused by 
cancer. Globally, cancer accounts for 13% of all deaths, making cancer the leading 
cause of mortality in the developed world (Jemal et al., 2011). With greater 
understanding of the basic principles of tumour development, and significant progress 
in screening programmes, earlier detection, and new cancer treatments, the survival 
rate for patients diagnosed with cancer has doubled over the last forty years. Despite 
this, patients with complex and diverse tumours still have poor survival outcomes and 
there continues to be a clear need for further improving treatment regimes and patient 
care. 
 
There are over 200 types of cancers originating from distinct cells within the body. 
Therefore, understanding cancer as a disease is challenging, as each tumour type will 
have unique characteristics defined by where and when it originated. Clearly, tumour 
evolution is a multistep process, and over time, every tumour will undergo distinct 
changes that contribute towards the formation of a complex tumour microenvironment. 
Such changes have been categorised into defined processes and are commonly 
referred to as the hallmarks of cancer. The interactions that various hallmarks of cancer 
have between each other and the impact this makes on the tumour phenotype will be 
discussed in detail later. To begin studying molecular pathways that are involved in 
cancer, and how these can be targeted for therapy, it is first important to address the 
basic principles of how normal cells become transformed into tumour cells. 
1.1.1 The building blocks of life 
Cells are the basic building blocks of all forms of life and are organised into distinct 
tissues and organs within the human body. Every cell must grow, divide and die 
efficiently, according to the demands and function of the tissues in which it resides. The 
instructions for these processes lie within the genetic material of every cell. Normal 
cells that suffer from genetic defects undergo either repair, or cell death so that they 
can be replaced with healthy cells. However, some cells which have damaged DNA 
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bypass these mechanisms and continue to survive and replicate in an uncontrolled 
way, posing a significant threat to the surrounding tissue.  
1.1.2 Deregulated cell control in cancer 
Cancer is defined as a disease in which normal cells lose control of their cell cycle. 
There are multiple cell types in the body, and tumours can arise from any of these 
cells. Tumours which form as a result of uncontrolled cell division are either benign or 
malignant. Benign tumours are not cancerous, they can be removed from the organ 
with surgery and do not reoccur, whilst malignant tumours are those formed by cancer 
cells. Malignant tumours are the most threatening tumours due to the ability of cells to 
invade surrounding tissues and form tumours at distant organs in the body. This 
process is known as metastasis and is one of the hallmarks of cancer. It is by 
metastasis that tumour cells ensure nutrient and oxygen supplies are not limiting 
factors. 
1.2 The causes of cancer 
Genes are comprised of nucleotide base pair sequences that are inherited by every cell 
to provide the coding instructions for functional proteins. Cancer is a common genetic 
disease, and is formed by changes in the DNA sequence of specific genes. Such 
changes, or mutations, provide significant growth advantages to cells and lead to the 
accumulation of further changes that promote the cancer phenotype. The majority of 
genetic mutations in cancer are somatic mutations, i.e. those that are acquired during 
life (Anand et al., 2008; Futreal et al., 2004). Environmental and lifestyle factors such 
as smoking, alcohol, pollution, and diet play an important role in determining the 
likelihood of acquiring somatic mutations. The remainder are inherited mutations which 
significantly increase the susceptibility of developing cancer. For example, women that 
inherit mutations in the BRCA1/BRCA2 genes have a 75% risk of developing either 
breast cancer, or ovarian cancer during their lifetime (Roukos, 2009).   
 
The first draft of the human genome was published in 2001, describing a vast 
collaborative effort to dissect the human genetic code (Lander et al., 2001; Venter et 
al., 2001). Such information has been invaluable for mapping genetic data to identify 
cellular signatures and understand evolutionary conservation, gene transcription 
programmes, and associations or alterations in genes that underlie numerous disease 
types (Lander, 2011). The information provided by the human genome, along with 
technical advances in DNA sequencing, high throughput mutation detection, and 
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bioinformatics has significantly advanced the identification of several gene variants, or 
cancer genes that are critical for the development of cancer. Before the human 
genome project was published, approximately 80 cancer genes involved in the 
formation of solid tumours had been described. In 2004, the number of cancer genes 
identified had increased to almost 300, providing important clues to the molecular 
mechanisms by which cancers arise, and greatly improving opportunities for treatment 
(Futreal et al., 2004). Various projects are currently underway to catalogue the genes 
that have an increased susceptibility to mutations in various cancer types. These 
include the Cancer Genome Project (being conducted by the Wellcome Trust Sanger 
Institute), the Cancer Genome Atlas (National Institute of Health), and the International 
Cancer Genome Consortium (ICGC). 
 
Gene sequencing has also been instrumental in designing clinical trials for targeted 
agents. Initial sequencing of human cancer genes involved those that were known to 
be deregulated during tumour progression. Somatic point mutations in the BRAF gene, 
for example, were identified in over 50% of melanomas. However targeted inhibitors of 
the BRAF signalling pathway showed poor response rates until patients genes could be 
sequenced and treated according to their particular BRAF mutation status (Davies et 
al., 2002). In other clinical studies, treatment of patients with non small cell lung cancer 
using Gefitinib (Iressa) showed poor efficacy (Giaccone et al., 2004a; Giaccone et al., 
2004b; Herbst et al., 2004). The discovery of EGFR (epidermal growth factor) 
mutations in nearly 10-15% of lung cancers allowed better predictions for sensitivity to 
Gefitinib and significantly improved response rates (Costanzo et al.; Lynch et al., 2004; 
Paez et al., 2004). 
1.2.1 The genetic footprints of cancer 
Cancer associated genes are often referred to as either oncogenes, or tumour 
suppressor genes (Kinzler and Vogelstein, 1997). Oncogenes have a gain of function 
effect and initiate tumour formation by enhancing cell proliferation. Point mutations in 
the RAS oncogene for example are common in lung, colorectal, and pancreatic 
cancers (Downward, 2003b). Another example of a common oncogene is the c-MYC 
oncogene, encoding a nuclear protein that regulates transcription of various genes 
involved in cellular proliferation, differentiation and apoptosis. Amplification or 
overexpression of c-MYC by mutation is found in 15-25% of breast tumours (Nass and 
Dickson, 1997).  
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Unlike oncogenes, tumour suppressor genes inhibit tumour formation by negatively 
regulating cell division. Genetic mutations in tumour suppressor genes that lead to their 
loss of function promote the malignant phenotype. The first tumour suppressor protein 
to be identified was the retinoblastoma protein, encoded by the human retinoblastoma 
gene, Rb. Since then, numerous other tumour suppressors have been discovered, 
including the p53 tumour suppressor protein, now the most studied tumour suppressor 
protein whose deregulation is involved in cancer progression.  Originally studied as a 
tumour suppressor gene involved in the pathogenesis of lung cancer (Takahashi et al., 
1989), mutations in the p53 gene are now shown to occur in up to 50% of all human 
cancers (Hollstein et al., 1991).  
 
Alleles are copies of genes, often found on each chromosome that is inherited through 
the germline. Sequence variations in alleles are either inherited, or arise spontaneously 
by somatic mutation (Futreal et al., 2004). Mutational activation of an oncogene is often 
coupled with loss of several tumour suppressor genes throughout different stages of 
tumour development (Vogelstein et al., 1988). In fact, it is now accepted that multiple 
independent mutational events are required for transition of a benign tumour to 
malignancy (Kinzler and Vogelstein, 1996a). This hypothesis was proposed as early as 
1953 by the simple observation that cancer death rates increase with age, therefore, 
cancer depends on a series of mutational events in genes that accumulate throughout 
life (Nordling, 1953). Later, statistical analysis of the death rate for women with gastric 
cancer suggested that between three to seven mutational events were required for the 
development of cancer (Ashley, 1969). Today the most accepted model for tumour 
formation by genetic mutation is that proposed by Knudson in 1971. Using statistical 
analysis, Knudson hypothesised that retinoblastoma is initiated by as little as two 
independent mutational events in the retinoblastoma gene, Rb (Knudson, 1971). That 
is, individuals who have a greater risk of developing cancer often inherit one mutated 
allele, while the other is mutated somatically later in life. Such individuals are therefore 
heterozygous for cancer causing genes, and although they have a greater risk of 
developing cancer compared to those that are homozygous, it is not until the second 
wildtype allele is mutated that the malignant phenotype of tumours is unmasked.  
 
Knudson’s so called ‘two hit’ hypothesis is proven in the development of colorectal 
cancer, the second leading cause of cancer related deaths in the United States (Parker 
et al., 1996). Colorectal cancers develop over many years. Mutational events in the 
adenomatous polyposis coli (APC) gene significantly increase the risk of developing 
colorectal cancers. Individuals that inherit germline mutations of APC have a greater 
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predisposition to both familial adenomatous polyposis (FAP), and hereditary non-
polyposis colorectal cancer (HNPCC), compared to the general population. However, 
such cancers are only initiated following an additional somatic mutation that inactivates 
the remaining wildtype APC allele inherited from the unaffected parent (Ichii et al., 
1992). The probability by which a second mutational hit is achieved in the APC gene is 
further increased by defects in important DNA repair pathways, thereby increasing 
genomic instability and the number of mutations that accumulate over time (Huang et 
al., 1996a).  
 
Studies suggest that not only the nature, but the order of genetic changes are 
important for determining tumour progression (Jen et al., 1994a). Again, the colorectal 
cancer model illustrates this well. Although p53 is mutated in over 80% of colorectal 
cancers, mutations in p53 are not necessary for the initiation of colorectal cancer 
(Baker et al., 1990; Garber et al., 1991). Mutations in the p53 gene are therefore 
considered to be late events in colorectal tumourigenesis (Baker et al., 1990). Similarly, 
mutations in KRAS are common in colon cancer, but are not necessary for tumour 
initiation (Jen et al., 1994b). Only biallelic inactivation of the APC tumour suppressor 
gene is considered as an important determinant of tumour onset, and it is important 
that mutations in APC alleles precede those in KRAS and p53 alleles during tumour 
development. 
 
Oncogenes and tumour suppressor genes are further categorised as either 
‘gatekeepers’, or ‘caretakers’. Gatekeeper genes function to maintain normal cell 
proliferation. The APC gene is an example of a gatekeeper gene, as inactivation of a 
single APC allele enhances colonic epithelial cell proliferation. Although this change in 
proliferation rate is not sufficient to induce malignancy, it contributes towards tumour 
formation by increasing the likelihood of cells acquiring further genetic changes as they 
divide (Kinzler and Vogelstein, 1996b). Other examples of gatekeeper genes include 
the retinoblastoma gene (Rb) which, when mutated, is involved in initiating 
transformation of retinal epithelial cells, and the VHL gene (von Hippel-Lindau) involved 
in the transformation of kidney cells (Knudson, 1993). Caretaker genes are responsible 
for maintaining genomic integrity and genetic instability following loss of caretaker 
alleles accelerates the mutation frequency in other alleles, including those defined as 
gatekeepers, to promote tumour formation. Common examples of caretaker genes 
include BRCA1 and BRCA2, involved in DNA repair which are often mutated in breast 
cancers, and the MSH2 gene, a mismatch repair gene that is often mutated in 
hereditary nonpolyposis colorectal cancer.  
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Li-Fraumeni syndrome is a rare familial disorder involving increased predisposition to 
leukaemia, breast and brain cancers. Li-Fraumeni syndrome results from a germline 
mutation of p53, and the risk of developing cancer increases with age following somatic 
mutation of the remaining p53 allele (Malkin et al., 1990). Similarly, germline 
inactivation of the VHL tumour suppressor gene gives rise to VHL hereditary cancer 
syndrome, involving increased predisposition to neuronal and retinal 
hemangioblastomas, clear cell renal carcinomas, and pheochromocytomas (Kim and 
Kaelin, 2004). Individuals with VHL disease are therefore VHL heterozygotes, they 
harbour one wildtype VHL allele, and another that is genetically inactivated. Renal cell 
carcinoma and hemangioblastomas are only formed following somatic inactivation of 
the remaining wildtype VHL allele. Like the APC gene in colorectal cancer, p53 and 
VHL also serve as early gatekeeper genes, initiating the process of deregulated cell 
growth and promoting accumulation of further genetic changes that are required for 
cancer initiation and progression.  
 
Clearly, cancer is a complex disease, and the involvement of numerous cancer-
associated genes is critical in determining how efficiently cells progress from a normal 
to a cancerous phenotype. Although the number of cancer causing genes is vast, the 
cell cycle and cell death pathways that they regulate can be arranged into distinct 
categories. These categories have helped researchers to simplify the properties that 
are commonly shared by each cancer, and are often referred to as the hallmarks of 
cancer. Studying the hallmarks of cancer enables an understanding of the cell 
signalling pathways that are deregulated by specific genes and how these pathways 
are shared amongst distinct malignancies.  
1.2.2 The hallmarks of cancer 
All cells regulate proliferation, differentiation and death by complex pathways that 
interact with one another. Many cancers share common traits in their molecular, 
biochemical and cellular characteristics. Hanahan and Weinberg first defined six 
hallmarks that were shared by all cancer cells (Hanahan and Weinberg, 2000). These 
included: 1. Sustained proliferative signalling, often by growth factors, 2. Evasion of 
growth suppressor pathways, those involving tumour suppressor genes, or 
‘gatekeeper’ genes, 3. Resistance to cell death by mechanisms such as apoptosis, 
autophagy and necrosis, 4. Angiogenesis, 5. Invasion and metastasis, and, 6. Genomic 
instability and mutation, by loss of ‘caretaker’ genes that maintain genomic integrity 
(Hanahan and Weinberg, 2000). Since then, two further hallmarks of cancer have 
emerged (Hanahan and Weinberg). These are evasion of the immune system to inhibit 
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targeting of cancer cells by immune cells for destruction, and reprogramming of energy 
metabolism to fuel cell growth and division, an idea that was proposed by Warburg as 
early as 1930 (Warburg et al., 1927).  
 
The hallmarks of cancer that we are interested in exploring are angiogenesis and 
evasion of cell death by apoptosis. Tumour cells which evolve to induce angiogenesis 
in a growing tumour mass while escaping cell death in a stressful microenvironment 
have a significant growth advantage (Graeber et al., 1996). Our laboratory aims to 
understand the relationship between angiogenesis and cell death as a basis for how 
these processes may be deregulated in tumour development. These hallmarks will be 
briefly introduced, and then the key regulators of the pathways involved will be 
discussed in greater detail later. 
1.2.3 Control of cell survival and cell death 
Cell survival is maintained by intracellular sensors that monitor stress signals such as 
hypoxia, DNA damage, loss of survival factors, nutrient deprivation and various 
signalling imbalances (Evan and Littlewood, 1998). Cellular stress can lead to either 
cell cycle arrest, or cell death, often by an organised process referred to as apoptosis. 
The p53 tumour suppressor protein maintains genetic stability by inhibiting cell cycle 
progression in response to stress (Lane, 1992; Tlsty, 1997). In this way, the cell 
controls for further damage and protects surrounding cells and tissues.  
1.2.3.1 Deregulated apoptosis is a hallmark of cancer 
Loss of cell cycle control by p53 is recognised as an important determinant of tumour 
development and deregulated p53 activity is linked to over 50% of human cancers 
(Harris, 1996; Vousden and Lane, 2007). The overall importance of p53 in regulating 
cell fate is shown by its association  with the pathology of various neurodegenerative 
diseases such as Huntington’s disease (Bae et al., 2005), Parkinson’s disease 
(Bretaud et al., 2007), and Alzheimer’s disease (Culmsee and Landshamer, 2006). 
Expression of p53 has also been shown to regulate survival, self renewal and 
differentiation of neural stem cells, as well as those found in the mammary epithelium 
(Cicalese et al., 2009; Meletis et al., 2006). Studies in which p53 has been associated 
with ageing have also been described (Arum and Johnson, 2007; Feng et al., 2007). 
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1.2.4 Regulation of angiogenesis 
Cells need a continuous supply of oxygen and nutrients to survive. When the blood 
supply becomes limited, tumour cells induce the formation of new blood vessels by a 
highly regulated process described as angiogenesis (Carmeliet and Jain, 2000). 
Angiogenesis (also referred to as neoangiogenesis) is the process by which new 
capillaries branch from pre-existing vessels (Carmeliet, 2000; Risau, 1995). During 
embryogenesis, blood vessels may also develop by vasculogenesis, whereby 
endothelial cells are born from progenitor cell types, however angiogenesis only occurs 
in adult tissues at times of wound healing and during tumour growth.  
1.2.4.1 Sustained angiogenesis is a hallmark of cancer 
Angiogenesis is a common hallmark of cancer and contributes significantly to the 
invasive and metastatic potential of tumour cells into surrounding tissues and organs. 
In normal tissues, vessel structure and density are maintained by a dynamic and 
controlled angiogenic process, whereby oxygen supply meets demand. In the tumour 
microenvironment however, cell density and the demand for survival factors and 
oxygen exceeds the rate at which these can be supplied through the vascular network. 
Tumour cells therefore use distinct strategies to induce angiogenesis and receive the 
oxygen and nutrients they require. The resulting vascular networks formed within 
tumours are disorganised with irregular and ineffective blood flow, and the surrounding 
tumour tissues often suffer from acute and chronic regions of low oxygen tension (or 
hypoxia).  
 
Tumours that contain large regions of hypoxia are associated with poor prognosis and 
poor patient survival. Such tumours promote an aggressive phenotype and are often 
associated with resistance to many standard lines of therapy. The transient opening 
and collapse of blood vessels through hypoxic tumours leads to increased genomic 
instability in hypoxic cells that are re-exposed to oxygen. Genomic instability increases 
mutation rates that deregulate key signalling pathways and promote tumourigenesis 
(Yuan and Glazer, 1998). Hypoxic tumours are also more invasive (Pennacchietti et al., 
2003) and metastatic (Rofstad and Halsor, 2000).  
 
The hypoxia inducible factor (HIF) is a transcription factor that maintains oxygen 
homeostasis and regulates angiogenesis (Bardos and Ashcroft, 2005). The HIF 
transcription factor is formed by dimerisation of various subunits that are part of the HIF 
family, and when activated, regulates expression of numerous genes involved in the 
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adaptive response to low oxygen concentration. HIF activation is deregulated across a 
broad range of tumours including colon, gastric, skin, pancreatic and renal carcinomas 
(Zhong et al., 1999) and is also known to play an important role in embryonic 
development (Ryan et al., 1998), stroke, and cardiovascular disease (Semenza and 
Wang, 1992).  
 
As discussed, deregulation of both angiogenic and cell death responses are important 
hallmarks of cancer. The angiogenic response is a complex, controlled process that 
regulates vascular structure in both normal tissues and malignant tumours. Activation 
of HIF in response to hypoxia is central to angiogenesis. The mechanisms by which 
HIF transcription is activated in hypoxia will be discussed in greater detail below. 
1.3 The HIF family 
Hypoxia inducible factors are members of the basic helix-loop-helix Per-ARNT-Sim 
(bHLH-PAS) family of transcription factors that bind specific sequences on DNA called 
hypoxia response elements (HREs). The HIF family is divided into the HIF-α subunits, 
of which there are HIF-1α, HIF-2α, and HIF-3α, and the HIF-β subunits, comprising 
HIF-1β, and HIF-2β. The active HIF transcription factor is a heterodimer consisting of 
an oxygen sensitive HIF-α subunit, complexed with a constitutively expressed HIF-1β 
subunit. 
 
HIF-1 (comprising HIF-1α and HIF-1β) was discovered following identification of a 
nuclear factor binding sequence in the 3’ enhancer region of the hypoxia induced 
erythropoietin gene (EPO, encoding a renal hormone that promotes haemoglobin 
synthesis), (Semenza et al., 1991). Subsequent studies showed that the HIF 
transcriptional complex is necessary for binding to this enhancer region in hypoxia, and 
inducing the transcription of erythropoietin (Wang and Semenza, 1995). Since then, 
both HIF-1α and HIF-2α subunits of the HIF-1 and HIF-2 transcription factors 
respectively, have been well studied. The physiological significance of HIF-1α in 
regulating angiogenesis is shown by in vivo mouse knockout models whereby deletion 
of Hif-1α leads to early embryonic lethality due to abnormal vascular development (Iyer 
et al., 1998; Ryan et al., 1998). 
 
HIF-2α is also known as EPAS1 (endothelial PAS domain protein 1) and shares 48% 
amino acid sequence identity to HIF-1α (Tian et al., 1997). Compared to HIF-1α which 
is expressed at a fairly similar level in many cell types, HIF-2α expression is more 
variable and partially evident in endothelial cells, type II pneumocytes, cardiomyocytes 
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and hepatocytes (Wiesener et al., 2003). Deletion of Hif-2α however has distinct 
phenotypes in vivo depending on the mouse strain used. For this reason, elucidating 
the distinct functions of HIF-2α from HIF-1α has been challenging. In some models, Hif-
2α knockout mice survive until adulthood (Scortegagna et al., 2005). In other studies, 
Hif-2α knockout mice are embryonic lethal, and this is shown to occur by numerous 
phenotypes including heart failure (Tian et al., 1998), respiratory distress syndrome 
(Compernolle et al., 2002), and severe vascular defects (Peng et al., 2000). 
 
Regardless of these discrepancies, adult mice in which Hif-2α is deleted suffer from 
severe anaemia suggesting a critical for role for HIF-2α in regulating erythropoiesis in 
both physiological and stress induced conditions (Gruber et al., 2007). In humans, 
mutations in the HIF-2α gene are associated with erythrocytosis, a condition whereby 
erythropoietin synthesis is deregulated (Percy et al., 2008). Patients that suffer from 
erythrocytosis have increased erythropoietin levels, elevated haemoglobin counts, and 
blood volumes. Genome wide linkage analysis has shown that a single activating 
mutation in the HIF-2α gene is responsible for causing erythrocytosis in certain families 
(Gale et al., 2008). Furthermore, genetic selection of HIF-2α variants in Tibetan 
highlanders has also been shown to alter haemoglobin concentrations and protect 
against high altitude (Beall et al., 2010). Finally, in VHL defective hemangioblastomas, 
pheochromocytomas and renal cell carcinomas, HIF-2α overexpression upregulates 
the expression of genes that are important in promoting tumour progression (Kondo et 
al., 2003; Mandriota et al., 2002).  
 
Although HIF-3α shares structural similarities with HIF-1α and HIF-2α, less is known 
about its regulation. HIF-3α protein is found in the human kidney, thymus, lung, brain, 
heart and liver (Hara et al., 2001; Makino et al., 2001). As with HIF-1α and HIF-2α, HIF-
3α forms a heterodimer with its corresponding HIF-β subunit in response to low oxygen 
conditions (Gu et al., 1998). However, function of the activated HIF-3α transcription 
factor in mediating gene expression in vivo is not well understood (Gu et al., 1998). 
HIF-3α has a number of splice variants. The truncated HIF-3α variant that lacks a 
transactivation domain in its C terminus forms an IPAS protein (inhibitory domain PAS 
protein) that binds to HIF-1β and can inhibit HIF-1α mediated gene expression to 
repress tumour growth in vivo (Hara et al., 2001; Makino et al., 2001). 
 
The HIF-β subunits of the HIF family are also known as aryl receptor nuclear 
transporter (ARNT) proteins, and three isoforms have been described: HIF-1β/ARNT1, 
HIF-2β/ARNT2, and HIF-3β/ARNT3. Like the HIF-α subunits, HIF-β subunits contain 
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bHLH, PAS and transactivation domains, however, they lack an oxygen-dependent 
degradation domain (ODD) allowing constitutive and ubiquitous expression in all 
tissues (Huang et al., 1996b). HIF-1β/ARNT1 was identified due to its requirement for 
dioxin (aryl hydrocarbon) receptor function in hepatocytes (Reyes et al., 1992). Later 
studies showed that disruption of the Hif-1β/Arnt1 gene in mice led to inhibition of 
transcriptional responses by low glucose and oxygen, and early embryonic lethality due 
to severe vascular defects (Maltepe et al., 1997). HIF-2β/ARNT2 has 57% sequence 
similarity to HIF-1β/ARNT1, however it is only expressed in the brain and kidney, and 
has unique functions in embryonic development compared to HIF-1β/ARNT1 (Hirose et 
al., 1996). Less is known about HIF-3β/ARNT3 (also known as Mop3/BMAL1), 
although interactions with HIF-1α, and HIF-2α have been described (Hogenesch et al., 
1998). A role for HIF-3β/ARNT3 in regulating circadian rhythm has been suggested due 
to its dimerisation with CLOCK (circadian locomotor output cycles kaput) (Bunger et al., 
2000).  
1.3.1 Oxygen dependent regulation of HIF-1α 
While HIF-β (defined here as including HIF-1β and HIF-2β) is constitutively expressed, 
the HIF-α subunit (defined here as both HIF-1α and HIF-2α, unless otherwise specified) 
is stabilised transiently in response to low cellular oxygen. The oxygen dependent 
degradation domain (ODD) of HIF-α regulates protein stability by forming a complex 
with the pVHL ligase complex (Maxwell et al., 1999). With similarities to the SCF 
complex in yeast (Stebbins et al., 1999), the VHL protein (pVHL) binds to elongin B, 
elongin C (Kibel et al., 1995), cullin 2 (Cul2), (Pause et al., 1997), and Ring-box 1 
(Rbx1) (Kamura et al., 1999) to form an E3 ubiquitin ligase complex. This complex is 
involved in binding and polyubiquitinating HIF-α for destruction by the 26S proteasome. 
Interactions between HIF-α and the pVHL ligase complex are regulated by prolyl 
hydroxylase enzymes (PHD, prolyl hydroxylase domain-containing proteins), also 
referred to as the egg-laying-defective nine (EGLN) enzymes. Members of the PHD 
hydroxylase family hydroxylate HIF-α at one of two conserved prolyl residues within the 
ODD domain to form a binding site for the pVHL ubiquitin ligase complex (Jaakkola et 
al., 2001). In HIF-1α PHD hydroxylation sites correspond to proline residues 402 and 
564 within the ODD domain, and in HIF-2α, these correspond to proline residues 405 
and 531 (Jaakkola et al., 2001; Masson et al., 2001; Patel and Simon, 2008).  
 
In hypoxia, the Siah E3 ligase targets prolyl hydroxylases for proteasomal degradation, 
consequently inhibiting hydroxylation and degradation of HIF-α (Nakayama et al., 
2004). The nuclear localization sequences (NLS) at the N-terminal and C-terminal 
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regions of HIF-α are important for localising stabilised HIF-α protein to the nucleus. 
Once HIF-α is translocated into the nucleus, the PAS domain of HIF-α interacts with 
HIF-β to form a heterodimer. The transactivation domain (TAD) of HIF-α binds to key 
transcriptional co-activators such as the CAMP-response element binding protein 
(CREB)-binding protein (CBP)/p300 to promote gene expression. HIF-1α transcriptional 
activity is also regulated by the iron dependent hydroxylase, factor inhibiting HIF (FIH), 
which hydroxylates HIF-α at specific asparagine residues. Hydroxylation by FIH inhibits 
recruitment of p300/CBP to the transactivation domain, thereby inhibiting HIF 
transcriptional activity (Mahon et al., 2001).  
 
As well as binding of co-activators, many post-translational modifications also occur at 
the transactivation domain of HIF-α including phosphorylation and acetylation which 
further mediate activation of HIF transcription (Schmid et al., 2004). The HIF 
transcriptional complex binds to a specific consensus sequence in the promoter of key 
target genes known as the hypoxia response element (HRE). Binding of HIF to DNA 
has been shown to occur from cellular oxygen concentrations less than 6%, and is 
maximised at 0.5% (Jiang et al., 1996). When HIF transcription is activated, expression 
of numerous target genes are induced to promote cellular adaptation to low oxygen 
(Semenza, 1999). The structural domains of the HIF-α subunits, HIF-1α and HIF-2α, 
and of HIF-1β/ARNT are summarised in Figure 1.3.1. Regulation of the HIF-α subunits 
is summarised in Figure 1.3.2. 
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Figure 1.3.1: Schematic representation of HIF-1α, HIF-2α and HIF-1β/ARNT proteins  
The HIF transcription factor belongs to the bHLH-PAS family of eukaryotic transcription 
factors. Both HIF-α and HIF-1β/ARNT subunits contain the highly conserved bHLH-PAS 
domains.  While HIF-β is constitutively expressed in the nucleus, HIF-α activity and protein 
abundance is only increased by oxidative stress (hypoxia). The oxygen dependent 
degradation domain (ODD) is important in maintaining HIF-α protein stability. The ODD 
contains two prolyl hydroxylation sites at proline residues 402 and 564 (P402, P564) in HIF-
1α, and at proline residues 405 and 531 (P405, P531) in HIF-2α. In normoxia, these sites are 
hydroxylated by prolyl hydroxylase enzymes that target the protein for proteosomal 
degradation by the pVHL E3 ligase complex. In hypoxia, prolyl hydroxylase enzymes are 
inhibited and HIF-α protein is stabilised. The N-terminus and C-terminus nuclear localisation 
signal (NLS) enable translocation of HIF-α to the nucleus, and binding to HIF-β to form an 
active HIF transcriptional factor complex. The PAS domain present in both HIF-α and HIF-
1β/ARNT is responsible for dimerising the two partners. Transcriptional activity of HIF is 
regulated by the transactivation domains (TAD).  
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Figure 1.3.2: HIF-α interacts with HIF-1β/ARNT in the nucleus 
HIF-α (HIF-1α or HIF-2α) is an important regulatory component of the HIF transcription 
factor. In normoxia, pVHL targets HIF-α for ubiquitination and proteosome mediated 
degradation. In response to a number of stressful stimuli including oxidative stress, 
oncogenic activation and loss of tumour suppressor function, HIF-α is stabilised, translocates 
to the nucleus and forms a complex with the constitutively expressed HIF-1β/ARNT subunit. 
The HIF-α and HIF-1β/ARNT complex binds to HRE in the promoters of target genes. 
Recruitment of the CBP/p300 co-activator forms an active HIF transcription factor, inducing 
transcription of target genes that are involved in cellular adaptation, angiogenesis, and 
tumour progression.  
 
1.3.2 The role of HIF in hypoxic gene regulation 
HIF (HIF-1 or HIF-2) is involved in regulating an array of target genes that promote 
adaptation to hypoxic stress. These include genes that are involved in metabolism, 
angiogenesis, oxygen delivery, cell growth and proliferation, metastasis and apoptosis 
(Semenza, 2001; Wenger et al., 1996). A selection of these genes have been shown in 
Figure 1.3.3. Many HIF target genes are involved in regulating angiogenesis such as 
transforming growth factor (TGF), and vascular endothelial growth factor (VEGF). HIF 
targeted genes that regulate metastasis include cadherin 1 (CDH1) which encodes the 
E-cadherin (epithelial cadherin) protein. E-cadherin is involved in maintaining tissue 
architecture and also regulates cell proliferation and cell death by its interactions with 
the catenin family of proteins (Conacci-Sorrell et al., 2002). Attenuation of CDH1 
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expression by HIF inhibits cell adhesion and promotes tumour invasion (Esteban et al., 
2006; Imai et al., 2003). Lysyl oxidase (LOX) is also a HIF target gene, and is essential 
for hypoxia induced metastasis (Erler et al., 2006). 
 
Metabolic adaptation to hypoxia is an emerging hallmark of cancer cells and numerous 
metabolic genes have been identified that are induced by HIF activity. To preserve 
energy during oxidative stress, cancer cells can efficiently switch from using 
mitochondrial respiration for ATP production, to using anaerobic glycolysis. This switch 
in metabolic signalling was originally discovered in the 1800’s by Louis Pasteur, a 
microbiologist who observed changes in yeast growth under aerobic and anaerobic 
conditions. In anaerobic conditions, yeast growth was inhibited by the conversion of 
glucose to lactate, in a process described as fermentation. These changes are now 
referred to as the Pasteur Effect and describe switches in energy consuming pathways 
when cells have limited supplies of oxygen. Warburg later studied metabolic signals in 
cancer cells and described the switch to anaerobic glycolysis from mitochondrial 
respiration as an important response for cancer cell survival. Changes in cancer cell 
metabolism have since been referred to as the Warburg Effect (Hanahan and 
Weinberg, 2011; Warburg, 1956).  
 
Many HIF target genes have been identified in hypoxic conditions that are involved in 
both inhibiting mitochondrial respiration and promoting anaerobic glycolysis. In normal 
cells, glucose is converted to pyruvate by glycolytic enzymes. Pyruvate is transported 
into mitochondria for conversion to acetyl coenzyme A (acetyl-CoA). The tricarboxylic 
acid (TCA) cycle begins when acetyl-CoA is catabolised and involves a series of 
chemical reactions leading to ATP production. In hypoxia, HIF induced expression of 
pyruvate dehydrogenase kinase 1 (PDK1) blocks conversion of pyruvate to acetyl-CoA 
by inhibiting the pyruvate dehydrogenase (PDH) enzyme complex (Kim et al., 2006; 
Papandreou et al., 2006). By enhancing PDK1 activity, HIF inhibits mitochondrial 
respiration and promotes glucose metabolism by anaerobic glycolysis. When oxygen 
supply is limited in hypoxic cells, anaerobic glycolysis is an important pathway by which 
cell growth is slowed, and energy levels are maintained. Instead of converting pyruvate 
to acetyl-CoA, anaerobic glycolysis involves a series of enzymatic reactions whereby 
pyruvate is converted to lactate (Koukourakis et al., 2005). HIF has been shown to 
activate glucose transporter-1, and -3 (GLUT-1 and GLUT-3) and increase glucose 
transport into the cell for glycolysis (Iyer et al., 1998). To further increase the efficiency 
of ATP production by anaerobic glycolysis, HIF also induces expression of numerous 
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genes that encode glycolytic enzymes involved in glucose conversion to lactate such 
as aldolase A (ALDA) and lactate dehydrogenase A (LDHA) (Semenza et al., 1996). 
 
Structural data which show differences in transactivation domain sequence suggest 
that HIF-1α and HIF-2α may have independent target genes (Tian et al., 1997). 
Consequently, previous studies have attempted to unveil the differential pathways that 
HIF-1α and HIF-2α may control during tumourigenesis (Hu et al., 2003). Conditional 
knockout studies of hif-1α and hif-2α in hypoxic epithelial cells of the intestine, for 
example have shown that HIF-2α, and not HIF-1α is involved in regulating iron 
absorption by inducing expression of the divalent metal transporter 1 (DMT1) gene 
(Mastrogiannaki et al., 2009). In VHL defective renal cell carcinoma, it is thought that 
HIF-1α and HIF-2α have contrasting functions. HIF-1α inhibits tumour growth by 
activating pro-apoptotic target genes such as BNIP3 (Bcl-2 nineteen kD interacting 
protein 3), while HIF-2α expression promotes tumour growth by inducing expression of 
the pro-tumourigenic target genes VEGF and TGFα (Kondo et al., 2002; Raval et al., 
2005). These studies not only confirm the critical role of pVHL in regulating HIF-α 
protein stability during renal cell carcinogenesis, but also highlight the unique profile 
HIF-α subunits may have in inducing tumour specific gene expression. 
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Figure 1.3.3: HIF target genes are involved in numerous cell pathways that promote 
tumourigenesis 
HIF target genes are involved in controlling an array of cellular processes that promote 
tumourigenesis including angiogenesis, cell metabolism and metastasis. Over 100 HIF target 
genes have been described and some key genes involved are highlighted and are 
abbreviated in alphabetical order as follows: ADK-3 (adenylate kinase-3), ALDA (aldolase A), 
ANG-1/-2 (angiopoetin-1/-2), APAF-1 (apoptotic peptidase activating factor-1), BNIP3 (Bcl-
2/adenovirus E1B 19kDa interacting protein 3), CCND1 (cyclin D1), COX-2 (cyclo-
oxygenase-2), CP (ceruloplasmin), CXCR4 (CXC chemokine receptor type 4), ENO1 
(Enolase 1), EPO (erythropoietin), FGF-3 (fibroblast growth factor-3), FLT-1 (VEGF receptor-
1), FLK-1 (VEGF receptor-2), FTL (ferritin light chain), GAPDH (glyceraldehyde-3-phosphate 
dehydrogenase), GLUT-1/-3 (glucose transporter-1/-3), HK1/-2 (hexokinase 1/-2), HMOX1 
(heme oxygenase 1), IGF-2 (insulin like growth factor-2), IGFBP-3 (insulin-like growth factor 
binding protein-3), IL-6/-8 (interleukin-6/-8), LDHA (lactate dehydrogenase A), LOX (lysyl 
oxidase), MIF (macrophage inhibitory factor), MMP-2/-9 (matrix metalloprotenases-2/-9), 
NOS (nitric oxide synthase), Oct4 (octamer binding transcription factor 4), PAI-1 
(plasminogen activator inhibitor-1), PDGF-β (platelet derived growth factor-β), PGF 
(placental growth factor), PGK1 (phoshoglycerate kinase 1), SDF-1 (stromal-derived factor-
1), TF (transferrin), TFR (transferrin receptor), TGF (transforming growth factor), TH 
(tyrosine hydroxylase), TIE-2 (UPAR, urokinase plasminogen activator receptor), VEGF 
(vascular endothelial growth factor). 
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As discussed, HIF is involved in promoting tumour development by inducing many 
target genes that regulate cellular adaptation to hypoxia. We are particularly interested 
in understating the role that HIF plays in regulating cell apoptosis. Hypoxic cells are 
often resistant to radiotherapy and chemotherapy induced cell death due to their 
confined location within tumours, as well as the molecular mechanisms that are 
controlled by HIF. Common HIF target genes that are involved in regulating apoptosis 
will be discussed further. 
1.3.3 The role of HIF in tumour cell apoptosis 
As well as promoting cancer cell survival through cellular adaptation, in some settings 
HIF also has an established role in promoting tumour cell apoptosis. In VHL-deficient 
tumours for example, HIF-1 (the active HIF transcription factor comprising HIF-1α and 
HIF-1β) inhibits tumour growth by inhibiting proliferation and inducing apoptosis (Acker 
et al., 2005). HIF-1 induced expression of pro-apoptotic BNip3 and the Nip3-like protein 
X (Nix) induces mitochondrial pore permbealisation, promoting mitochondrial 
dysfunction and apoptosis (Bruick, 2000). Furthermore, HIF has been shown to induce 
expression of insulin like growth factor binding protein-3 (IGFBP-3), (Tazuke et al., 
1998). Hypoxic cells are sensitised to radiation induced apoptosis by IGFBP-3 
mediated inhibition of insulin like growth factor-1 (IGF-1), resulting in higher pro-
apoptotic Bcl-2 protein levels (Butt et al., 2000). HIF-1α has also been shown to 
promote p53-dependent apoptosis by stimulating the expression of apoptotic protease 
activating factor 1 (APAF-1) and its co-factor caspase 9 (Soengas et al., 1999). 
 
Although HIF induces expression of target genes involved in apoptosis, the interplay 
between HIF and p53, the central node by which cell death is achieved, remains 
unclear. Some studies suggest that HIF and p53 have a negative relationship, in that 
high levels of HIF-1α in hypoxic tumour cells inhibit p53 transcriptional activity, and 
p53-induced apoptosis (Bertout et al., 2009). To understand the relationship between 
HIF and p53, the functional roles of p53 will be discussed in greater detail first, followed 
by how p53 activity can be modified in hypoxic cells to promote survival and tumour 
progression. 
1.4 Regulation of cellular responses to exogenous stress by p53 
The p53 protein is stabilised by stress stimuli including DNA damage, telomere erosion, 
aberrant proliferative signals, loss of key adhesion and survival signals, and non 
genotoxic forms of stress such as exposure to hypoxia and heat shock (Graeber et al., 
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1996). Stabilisation of p53 is also induced by SV40 and adenovirus transformed cells 
(Lane and Crawford, 1979; Lowe and Ruley, 1993), as well as the expression of 
cellular oncogenes such as Rb, MYC and RAS (Prives, 1998). When activated, p53 
regulates multiple signalling pathways including cell growth, differentiation, apoptosis, 
and senescence (Harris and Levine, 2005). Cellular responses mediated by p53 are 
summarised in Figure 1.4.1. 
 
 
 
 
Figure 1.4.1: p53 regulates a variety of responses to cellular stress 
Pathways regulated by p53 are activated according to the extent and duration of damage 
that cells are exposed to. Cell survival and cell death responses by p53 will vary according to 
tissue and tumour type, the specific stress signal induced, and impact of the cell’s 
microenvironment. Numerous p53 mediated pathways are transduced upon p53 activation 
which are involved in either rescuing cells through stress and promoting cell survival, or 
inducing apoptosis in defective cells. 
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1.4.1 Control of p53 stability 
Cellular levels of p53 protein are determined by rate of degradation rather than rate of 
synthesis (Vogelstein et al., 2000). In normal cells, p53 stability is regulated by ubiquitin 
mediated protein degradation via the proteosome. The HDM2 protein (originally 
identified in mice as murine double minute 2 protein, also referred to as MDM2) is an 
E3 ubiquitin ligase for p53 (Honda et al., 1997; Momand et al., 2000). In normal cells, 
basal levels of p53 are maintained by expression of HDM2 in an autoregulatory 
feedback loop (Haupt et al., 1997; Kubbutat et al., 1997).  
 
When a stress signal is elicited, the nuclear localisation signal in the C-terminus of p53 
mediates transport to the nucleus by interactions with the dynein motor protein and 
microtubule networks (Giannakakou et al., 2000). Once inside the nucleus, p53 binds 
to DNA and undergoes distinct conformational changes which promote p53 
transcriptional activity (Halazonetis et al., 1993). Active p53 induces transcription of its 
downstream target gene HDM2. Induced HDM2 protein inhibits p53 activity by forming 
a complex with the N-terminal transactivation domain (residues 19-26) of p53 and 
targeting p53 for proteosomal degradation (Chen et al., 1993; Momand et al., 1992). 
Loss of p53 activity by HDM2 mediated export and degradation allows basal levels of 
p53 to be restored once the stress signal is removed (Haupt et al., 1997; Kubbutat et 
al., 1997). Interestingly, HDM2 can also directly repress p53 transcriptional activity by 
associating with and promoting histone modification on the chromatin of p53 target 
genes (Minsky and Oren, 2004). The importance of the p53-HDM2 feedback loop is 
demonstrated by in vivo studies whereby loss of Mdm2 leads to embryonic lethality in a 
p53-dependent manner. Genetic loss of Mdmx, an HDM2 related gene also induces 
embryonic lethality suggesting that MDMX also regulates p53 (Parant et al., 2001).  
 
Because HDM2 is a critical regulator of p53 function, regulation of HDM2 is also tightly 
controlled. HDM2 is phosphorylated at multiple sites in vivo (Ashcroft et al., 2002; Hay 
and Meek, 2000) and by a number of protein kinases in response to specific forms of 
stress (Khosravi et al., 1999; Mayo et al., 1997). Under normal conditions, in response 
to growth factors, the phosphatidyl inositol-3-kinase (PI3K) signalling pathway is 
activated and its downstream substrate AKT/protein kinase B (PKB) phosphorylates 
HDM2 at serine 166 and serine 186, leading to localisation of HDM2 to the nucleus and 
inhibition of p53 activity (Ashcroft et al., 2002; Mayo and Donner, 2001). ARF (alternate 
reading frame product of the CDKN2A locus), referred to as p14ARF in humans and 
p19ARF in mice, stabilises p53 through its negative interaction with HDM2 (Sherr, 1998). 
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ARF counteracts hyperproliferation by inhibiting p53 directed ubiquitin ligase activity of 
HDM2 and also alters the subcellular localization of p53 by targeting p53 to the 
nucleosome for activation (Honda and Yasuda, 1999; Midgley et al., 2000).  
1.4.2 Regulation of p53 activity by post-translational modifications 
Once stabilised, p53 is post-translationally modified to promote its transcriptional 
activity in the nucleus (Fritsche et al., 1993). These modifications include 
phosphorylation (Meek, 1994), dephosphorylation, acetylation, ribosylation and SUMO-
1 modification (Ashcroft et al., 2000; Gostissa et al., 1999; Ljungman, 2000; Muller et 
al., 2000). Post-translational modifications at lysine residues within the caroboxyl 
terminal of p53 are important in regulating p53 activity. While acetylation at lysine 
residues activate p53, methylation retains p53 in a transcriptionally repressed state 
(Huang and Berger, 2008).   
 
Recently, Loewer et al. showed that post-translational modifications of p53 are critical 
in determining the basal dynamics of p53. In a normal cell cycle, p53 levels oscillate, 
corresponding with harmless DNA strand breaks (Loewer et al., 2010).  Although p53 is 
stabilised during a normal p53 pulse, carboxyl terminal lysine residues remain 
methylated, rendering p53 transcriptionally inactive. However, p53 that is stabilised by 
more severe forms of extrinsic stress is acetylated at the carboxyl terminus to promote 
transcriptional activity and stress induced cell cycle arrest (Loewer et al., 2010). 
Investigating the basal dynamics of p53 regulation and the numerous post-translational 
modifications that determine p53 transcriptional responses allow greater understanding 
of the mechanism by which p53 is able to filter stress inputs and always remain on 
standby as a critical and immediate response to more severe forms of stress. 
1.4.2.1 Regulation of p53 by phosphorylation 
Post-translational phosphorylation of p53 in response to many forms of genotoxic and 
microenvironmental stress is also well studied (Ashcroft et al., 2000). Phosphorylation 
of p53 in response to DNA damage is mediated by a series of highly conserved 
checkpoint kinases (Albrechtsen et al., 1999). Both the DYRK2 (Taira et al., 2007) and 
HIPK2 kinases (Calzado et al., 2007) have recently been identified as important 
initiators of apoptosis by phosphorylating p53 under severe stress. Although numerous 
kinases regulate p53 activity by phosphorylation (Meek, 1994) it has also been 
demonstrated using a series of N-terminal and C-terminal p53 mutants that 
phosphorylation of p53 is not critical for DNA damage induced stabilisation of p53 
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(Ashcroft et al., 1999). Loss of post-translational modification by phosphorylation can 
reduce the efficiency of p53 activity, without causing complete loss of function, 
suggesting that a wide range of co-dependent modifications of p53 are required for 
regulating p53 activation (Ashcroft et al., 1999; Crook et al., 1994). Common p53 post-
translational modification sites are shown in Figure 1.4.2. 
 
 
 
Figure 1.4.2: Post-translational modification of p53 
The p53 protein has three functional regions important for stabilisation, localisation and 
transcriptional activity: the N-terminal, the central core, and the C-terminal region. The N-
terminal region consists of the transactivation domain (TAD) for transcriptional activation of 
p53, and the Src homology 3-like domain (SH3), required for various protein interactions. 
The central core of the protein consists of the sequence specific DNA binding domain (DBD). 
The C-terminal region contains the nuclear localisation (NLS), tetramerisation (TET), nuclear 
export signal (NES), and regulatory (REG) regions. The domains illustrated are not to scale 
but amino acid length have been shown in brackets. An accurate representation of size is 
redrawn below. When stabilised, the p53 protein undergoes a number of post-translational 
modifications which influence p53 stabilisation and activity, including phosphorylation (P), 
acetylation (A), ubiquitination (U), neddylation (N), ribosylation (R), methylation (M), and 
sumoylation (S). Many target sites for post-translational modification of p53 by these 
mechanisms have been identified, and a few common sites are indicated along with the 
modifying proteins involved. Amino acid abbreviations: Ser (serine), Thr (threonine), Lys 
(lysine), Glu (glutamic acid), Asp (aspartic acid). Protein abbreviations (in alphabetical 
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order): AurA (Aurora A), ATM (ataxia telangiectasia mutated), ATR (ataxia telangiectasia and 
Rad3 related), CDK (cyclin dependent kinase), CHK1/-2 (checkpoint kinase 1/-2), CK1/-2 
(casein kinase 1/-2), CSN-K (casein kinase), DNA-PK (DNA dependent protein kinase), 
DYRK2 (dual specificity tyrosine phosphorylation regulated kinase 2), ERK2 (extracellular 
signal regulated kinase 2), E4F1 (E4F transcription factor 1), FBXO11 (F-box only protein 
11), GSK3β (glycogen synthase kinase 3 beta), HDM2 (human double minute 2), HIPK2/-4 
(homeodomain interacting protein kinase 2/-4), IKK2 (inhibitor of nuclear factor kappa-b 
kinase), JNK1/-2/-3 (c-Jun N-terminal kinase 1/-2/-3), MAPKAPK2 (mitogen activated protein 
kinase activated protein kinase 2), PARP-1 (poly ADP ribose polymerase), PCAF (p300/CBP 
associated factor), PKC (protein kinase C), PLK3 (polo-like kinase 3), p300/CBP (E1A 
binding protein p300/CREB binding protein), Set7/-8/-9 (SET domain containing lysine 
methyltransferase-7/-8/-9), SMYD2 (SET and MYND domain containing 4), SUMO1 (small 
ubiquitin related modifier 1).  
 
1.4.3 Important co-activators for p53 transcriptional activity 
Transcriptional co-activators are also important for activating p53 target genes. The 
apoptosis stimulating protein of p53 (ASPP) family of proteins, specifically ASPP1 and 
ASPP2 interact with p53, increasing p53 binding to DNA and promoting p53 target 
gene expression in vivo (Samuels-Lev et al., 2001). The p53BP1 and p53BP2 proteins 
identified by a yeast two-hybrid system also bind to the central DNA binding domain of 
wildtype p53 to increase p53 transcriptional activity (Iwabuchi et al., 1994). JMY 
(junction mediating and regulatory protein, p53 cofactor), (Shikama et al., 1999) and 
p300/CBP (CREB binding protein) are also important in regulating p53 transcriptional 
activity (Avantaggiati et al., 1997). Both JMY and p300 co-factors form a complex with 
activated p53 to potentiate its activity and drive the expression of p53 mediated cell 
death genes in response to stress (Shikama et al., 1999). 
1.4.4 Novel regulators of p53 target gene expression 
Chromatin immunoprecipitation studies have shown that although p53 remains 
associated to target gene promoters in the absence of stress, p53 activity is inhibited 
by specific transcriptional repressors (Jang et al., 2009; Kaeser and Iggo, 2002). 
Binding of p53 to target gene promoters allows for prompt p53 activation and target 
gene expression when cells are exposed to stress. Recently, a p53-Cabin1 (calcineurin 
binding protein) complex was described that regulated histone modification on the 
chromatin of p53 target genes such as GADD45A and CDKN1A (p21), maintaining p53 
gene expression at basal levels (Jang et al., 2009). When cells were exposed to 
genotoxic stress, Cabin1 was degraded allowing p53 to bind target sequences, 
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associate with transcriptional co-factors and induce transcription of key genes required 
for a prompt stress response. Such studies provide important insight into basal p53 
interactions and transcriptional responses that determine p53-dependent cellular 
responses to stress stimuli. 
 
Moumen et al. show that the heterogeneous nuclear ribonucleoprotein K (hnRNP K) 
cofactor complexes with p53 in the absence of stress, suggesting that like Cabin1, 
hnRNP K may also facilitate p53 promoter complex formation at basal levels and 
stabilise p53 on chromatin to activate rapid transcriptional responses to stress 
(Moumen et al., 2005). It is also possible that hnRNP K may act as an anchor to recruit 
other co-factors which modify and optimise p53 activity. A recent study analysed p53-
dependent transcription of large intergenic non-coding RNA’s (lincRNA’s), with 
particular focus on lincRNA-p21 transcription (Huarte et al., 2010). When activated, 
lincRNA-p21 was found to be recruited to p53 target gene promoters along with 
hnRNP K to form a transcriptional complex which represses a large subset of p53 
target genes involved in stress responses. Interestingly however, although association 
between lincRNA-p21 and hnRNP K led to transcriptional repression of many p53 
target genes, it also activated several pro-apoptotic genes necessary for p53-
dependent cell death by DNA damage (Huarte et al., 2010). Specific complexes at p53 
promoter sequences and specific p53 binding partners may therefore be critical in 
determining whether p53 transcription is activated or repressed under physiological 
conditions and in response to various stress stimuli.  
1.4.5 Cell cycle responses controlled by p53 
Although p53 has an established function in activating apoptosis in response to cellular 
stress, several p53 target genes also function to promote cell survival by inhibiting 
apoptosis. Cell cycle pathways that promote survival give cells an important opportunity 
to resolve DNA damage induced by genotoxic stress. Cell death responses are only 
activated if DNA damage is severe and irreparable. To ensure only healthy cells grow 
and proliferate, checkpoints are employed during each phase of the cell cycle. These 
checkpoints are complex, involving numerous factors that relay vital genomic signals 
through the cellf.     
1.4.5.1 The cell cycle and checkpoint function 
The eukaryotic cell cycle is comprised of distinct phases that ensure cells grow and 
divide with efficiency and accuracy. The G1 phase (growth phase) involves RNA 
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translation and protein synthesis of key molecules that are required for DNA 
duplication. The following DNA synthesis or replication phase is referred to as S-phase. 
The G2 phase occurs after S-phase and involves biosynthesis of key proteins required 
for mitosis, such as those that comprise the microtubules to which chromosomes 
attach prior to cell division. Finally, the M-phase (mitosis) is the process by which 
duplicated chromosomes are divided into two genetically identical daughter cells. 
Transition through the cell cycle is controlled by distinct heterodimeric complexes 
comprising cyclins and cyclin dependent kinases (CDKs). The cyclin is the regulatory 
subunit, while the CDK component forms the catalytic subunit through which the 
complex is activated. Many cyclin/CDK complexes have been identified to date which 
are involved in regulating numerous transcription factors that promote cell cycle phase 
transition (Harper and Adams, 2001). The different cell cycle phases have been 
illustrated in Figure 1.4.3. 
 
Transition through each phase of the cell cycle involves a checkpoint response. Cell 
cycle checkpoints act as gatekeeper pathways that ensure accurate cell division by 
checking each phase is completed successfully before cells can enter the next phase. 
The G1-S checkpoint is induced to resolve damaged DNA before DNA undergoes 
duplication, the S-phase checkpoint monitors DNA damage during replication, and the 
G2-M checkpoint is activated to ensure that damaged DNA which has bypassed 
previous controls is resolved before mitosis (Hartwell and Weinert, 1989). Cells 
respond to checkpoints by undergoing transient growth arrest allowing activation of 
specific repair pathways, or induction of apoptosis to eliminate cells in which DNA 
damage cannot be repaired. Checkpoints are important mechanisms by which cells 
respond to both intrinsic and extrinsic forms of DNA damage. 
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Figure 1.4.3: Cell cycle and checkpoint control 
The eukaryotic cell cycle is comprised of distinct phases that involve cell biosynthesis and 
growth (G1 phase), DNA synthesis (S-phase), chromosome alignment (G2 phase), and cell 
division or mitosis (M-phase). Progression through each phase is controlled by cell cycle 
checkpoints. Three distinct checkpoints have been described, the G1-S checkpoint, the S-
phase checkpoint, and the G2-M checkpoint. These checkpoints involve transduction of 
various signalling pathways that inhibit cyclin/CDK activity, and hence promote cell cycle 
arrest to ensure defects in cellular DNA are resolved before the cycle can continue.   
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1.4.5.2 Cell cycle checkpoints are activated by DNA damage 
Checkpoints are comprised of DNA damage sensors, signal transducers, and effectors 
which together co-ordinate responses to delay the cell cycle in response to genetic 
stress, and initiate repair (Hartwell and Kastan, 1994; Zhou and Elledge, 2000). Often, 
deregulated activity of various sensors, transducers, and effectors promote tumour 
development by allowing cells with genetic defects to continue growth and replication 
(Hartwell and Kastan, 1994). Diseases such as Bloom syndrome (BS), Fanconi 
anaemia (FA), and ataxia telangiectasia (AT) are characterized by the inability of cells 
to repair DNA damage due to mutations in specific DNA repair genes, and these 
diseases are often associated with greater predispositions to cancer (Pierce and Jasin, 
2001). 
 
The DNA damage sensors, ataxia-telangiectasia mutated protein (ATM), and ataxia 
telangiectasia and Rad3 related protein kinase (ATR) are members of the PI3K kinase 
family. ATM exists as a homodimer and undergoes DNA damage induced 
autophosphorylation at serine 1981, allowing dissociation of the homodimer complex 
and phosphorylation of p53, as well as repair proteins like NBS1 (Nijmegen breakage 
syndrome 1) and BRCA1 (breast cancer 1), (Bakkenist and Kastan, 2003). ATR does 
not exist as a homodimer like ATM, but instead forms a complex with ATRIP (ATR-
interacting protein), (Cortez et al., 2001). ATR is activated by replication stress induced 
under hypoxic conditions (Hammond et al., 2002), and in response to DNA damaging 
agents that alkylate and crosslink DNA base pairs (Zou and Elledge, 2003). Replication 
protein A (RPA) binds single stranded DNA breaks and stimulates recruitment of the 
ATR-ATRIP complex to sites of replication fork arrest. Activated ATR then induces 
phosphorylation of checkpoint kinase 1 (CHK1) to initiate checkpoint signalling (Zou 
and Elledge, 2003).  
 
The importance of ATR function is demonstrated by in vivo studies whereby atr null 
mice are non-viable (Shechter et al., 2004; Zou et al., 2002). Interestingly, although 
ATM and ATR share common substrates, loss of atm does not lead to early embryonic 
lethality suggesting that ATR has a significant role in controlling replication checkpoints 
during the normal cell cycle, while ATM is important for regulating responses to 
external stress stimuli (Shiloh, 2003). Such studies also demonstrate a level of 
redundancy between the ATM and ATR sensor kinases. 
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Activation of ATM and ATR is involved in initiating signalling through all checkpoints, 
and these have been summarised in Figure 1.4.3. The G1-S phase checkpoint is 
activated by double strand DNA breaks induced during G1-phase. ATM phosphorylates 
its downstream checkpoint kinase 2 (CHK2), and ATR leads to active CHK1 function 
(Kastan and Lim, 2000). Both CHK2 and CHK1 phosphorylate p53 at specific residues 
(some of which are shown in Figure 1.4.2). Phosphorylation of p53 by CHK2 and CHK1 
inhibits p53 binding with HDM2 (Chehab et al., 2000). As well as promoting p53 
phosphorylation through CHK1, and CHK2, ATM and ATR also phosphorylate HDM2 
directly, retaining MDM2 in the cytoplasm and preventing targeting of p53 to the 
proteasome (Maya et al., 2001). Activation of p53 increases expression of p53 target 
proteins such as p21 (also referred to as wild type p53-activated fragment 1, WAF1). 
The cyclin E/CDK2 complex is inhibited by p21 to induce G1 arrest while DNA damage 
is resolved (Kastan and Lim, 2000). The CDC25A phosphatase regulates CDK2 
activity, and both ATM and ATR kinases also target CDC25A for proteasomal 
degradation directly, rendering CDK2 inactive and hence delaying cell cycle 
progression.  
 
The S-phase checkpoint is activated by DNA damage induced during DNA replication. 
S-phase arrest inhibits replication fork progression when DNA is damaged, protecting 
against replication fork collapse and thereby inhibiting DNA strand breaks. As in the 
G1-S checkpoint, p53 is phosphorylated by CHK kinases to induce target genes 
involved in cell cycle arrest (Tibbetts et al., 1999). However, p53 is also recruited 
directly by the RecQ helicase BLM (Bloom’s syndrome helicase) to sites of stalled 
replication forks where p53 promotes homologous recombination and resolves 
damaged DNA (Sengupta et al., 2003). ATM and ATR activation during the S-phase 
checkpoint can also target the CDC25A phosphatase to inhibit cyclinA/CDK2 activity 
and the downstream substrate CDC45 which is required for recruitment of DNA 
polymerase to initiate new origin firing (Bartek and Lukas, 2003). 
 
The G2-M checkpoint prevents mitosis of cells that have unrepaired DNA damage (Xu 
et al., 2002). As with G1-S, and S-phase checkpoints, this involves activation of ATM 
and ATR to initiate effector responses involving p53 and its downstream targets 
p21WAF/CIP, GADD45-α (growth arrest and DNA damage inducible 45-α), and 14-3-3δ 
(Taylor and Stark, 2001). Activation of the cyclin B/CDK1 complex is important in 
promoting mitosis, and inhibition of CDC25A by ATM and ATR inhibits cyclin B/CDK1 
activity to induce G2 arrest while DNA breaks are repaired (Nyberg et al., 2002). In 
addition to p53 and CDC25A, ATM also activates the DNA repair protein BRCA1 in 
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response to DNA strand breaks induced by ionising radiation (Xu et al., 2001). 
Although cell cycle arrest is mediated through activation of p53 and induction of p53 
target genes, p53 null cell types can also arrest in G2 by DNA damage (Kastan et al., 
1991). CHK1 and CHK2 have additionally been shown to phosphorylate and target 
CDC25A in a p53-independent manner in response to UV light or irradiation (Falck et 
al., 2001). Selected pathways involved in the G1-S, S-phase, and G2-M checkpoints 
are shown in Figure 1.4.3. 
 
In addition to ATM and ATR, H2AX (a member of the histone H2A family) also acts as 
an important DNA damage sensor. Histones are important for organising and 
packaging DNA into nucleosomes. The H2A nucleosomal histone family is one of five 
major families of histone proteins, and includes the highly conserved variant H2AX 
(Redon et al., 2002). H2AX represents between 2-25% of total cellular H2A (Redon et 
al., 2002) and undergoes several post-translational modifications in response to DNA 
strand breaks such as acetylation, phosphorylation, and ubiquitination which promote 
chromatin remodelling, and lead to the recruitment of various repair factors that resolve 
DNA strand breaks. Phosphorylation of H2AX by activated ATM, ATR and DNA-
dependent protein kinase (DNA-PK) (Wang et al., 2005) at serine 139 is an early 
response to DNA double strand breaks (Rogakou et al., 1998). As well as 
phosphorylating H2AX, ATM also phosphorylates and activates BRCA1, 53BP1, and 
mediator of checkpoint signalling 1 (MDC1). These DNA repair factors are recruited to 
sites of phosphorylated H2AX on chromatin to form specific repair complexes (Stucki et 
al., 2005). H2AX deficient mice are hypersensitive to radiation, have DNA damage 
repair defects, and increased genomic instability (Celeste et al., 2002). The key 
sensors, transducers and effectors that are involved in the DNA damage response 
have been summarised in Figure 1.4.4. 
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Figure 1.4.4: The DNA damage response 
DNA damage is detected by the DNA damage sensors ATM and ATR that are involved in 
phosphorylating their substrates CHK2 and CHK1 respectively. CHK2 and CHK1 kinases 
phosphorylate p53 leading to transcriptional activation of p53 and induction of numerous p53 
target genes involved in mediating cell cycle arrest, DNA repair, or apoptosis. Induction of 
p21 by p53 elicits cell cycle arrest by inhibiting CDK activity. ATM/CHK2 also inhibits 
CDC25A phosphatase by targeting CDC25A for proteasomal degradation, rendering CDK 
inactive, and hence delaying cell cycle progression. In addition, the ATM sensor kinase 
phosphorylates the histone protein H2AX, leading to chromatin remodelling and the 
recruitment of a number of DNA damage repair proteins. Many p53 target genes activate the 
apoptotic cell death response if DNA damage is beyond repair. These include Bax, PUMA 
and NOXA (only Bax is shown for simplicity). 
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1.4.5.3 The role of p53 in DNA repair and genomic integrity 
As discussed, p53 is a crucial transcription factor that regulates an array of cellular 
pathways to determine cellular fate. Once stabilised in response to stress stimuli, p53 
undergoes complex post translational modifications required for its sequence specific 
binding to target gene promoters (Vogelstein et al., 2000). Cells are continuously 
subjected to intrinsic and extrinsic genomic insults and p53 has a critical role in 
maintaining genomic integrity by both transactivation dependent and transactivation 
independent mechanisms.  
 
In the transactivation dependent role of p53, p53 is an effector protein, and is 
phosphorylated at specific phosphorylation sites by the upstream kinases ATM-CHK2, 
and ATR-CHK1. Transcription of genes involved in eliciting DNA repair, apoptosis, or 
senescence are induced by binding of activated p53 to target DNA. However, p53 also 
has transactivation independent functions, and has been shown to bind DNA in a non-
sequence specific manner. The C-terminal domain of p53 can bind with high affinity to 
DNA lesions caused by insertion and deletion mismatches, and is proposed to act as 
an important recruitment factor for DNA repair proteins (Lee et al., 1995; Liu and 
Kulesz-Martin, 2001). p53 is also localised to single and double stranded DNA breaks 
induced by ionising radiation (Bakalkin et al., 1995; Reed et al., 1995). 
 
The importance of p53 in regulating DNA repair and maintaining genomic integrity is 
shown by p53’s involvement in a number of DNA repair pathways (Fukasawa et al., 
1996). Repair pathways are specific to the types of DNA damage that occur in cells 
which suffer from both intrinsic and extrinsic forms of genomic stress. The nucleotide 
excision repair pathway is an example of a DNA repair pathway that is activated in 
response to DNA damage induced by ultraviolet lesions, various carcinogens, and 
mutagens. Nucleotide excision repair involves an array of complex mechanisms that 
identify, remove, and replace damaged fragments of DNA. p53 has been shown to 
regulate the transcription of various genes that encode DNA repair proteins involved in 
nucleotide excision repair. These include p48DDB2 (p48 xeroderma pigmentosum gene) 
which binds to DNA damaged sites in a p53 dependent manner (Hwang et al., 1999). 
In irradiated cells, p48DDB2 also transports XPC (xeroderma pigmentosum 
complementation group C) to sites of DNA damage in irradiated cells leading to the 
recruitment of other repair proteins (Fitch et al., 2003). When induced by ultraviolet 
radiation, nucleotide excision repair efficiency is reduced in the absence of p53 (Smith 
et al., 1995). The base excision repair (BER) pathway is important in removing small 
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damaged lesions of DNA that arise as part of the normal cell division cycle. Co-
operation between p53 signalling and activation of the base excision repair pathway 
has also been described and is controlled by levels of genotoxic stress (Offer et al., 
1999). 
 
During non-homologous end joining (NHEJ), damaged DNA strands are repaired 
without a template strand (Hoeijmakers, 2001a). Non-homologous end joining is 
regulated by a number of sensor proteins, including DNA-PK and XRCC4 (X-ray repair 
complementing defective repair in Chinese hamster cells-4).  In response to double 
strand DNA breaks, DNA-PK phosphorylates p53 to promote p53 transactivation, while 
inhibiting the negative regulation of p53 by HDM2 (Shieh et al., 1997). This pathway 
induces significant p53-dependent apoptosis. The importance of XRCC4 in regulating 
non-homologous end joining in response to double strand DNA breaks is shown by in 
vivo studies whereby Xrcc4 knockout mice undergo significant neuronal apoptosis and 
have early embryonic lethality (Gao et al., 2000). Interestingly, this phenotype is 
rescued by loss of p53, suggesting that p53-dependent apoptosis is essential in 
determining the outcome of cells with severe genomic defects caused by loss of critical 
DNA repair proteins. Transactivation independent roles for p53 in non-homologous end 
joining have also been described (Yang et al., 1997). 
 
In homologous recombination, DNA strand breaks are resolved using the adjacent 
DNA template. Wildtype p53 can interact with several repair proteins involved in 
homologous recombination including RAD51 and RAD54 (Linke et al., 2003). As p53 
can recognise mismatched DNA bases as well as activate repair proteins, loss of p53 
function results in severe DNA defects that promote spontaneous homologous 
recombination, leading to increased repair errors and genomic instability (Dudenhoffer 
et al., 1998). Conversely, by maintaining DNA integrity, wildtype p53 represses the 
homologous recombination pathway and also inhibits tumourigenesis (Akyuz et al., 
2002). Of additional interest, Atm and Rad52 deficient mice have reduced onset of T-
cell lymphomas and increased survival rates compared to Atm deficient mice alone 
suggesting that excessive recombination events in the absence of ATM are an 
important determinant of tumour development (Treuner et al., 2004). 
  
The RecQ family of helicases unwind paired DNA in the 3’-5’ direction allowing 
localisation of repair complexes to resolve mismatched base pairs. RecQ helicases 
therefore have a critical role in maintaining genomic integrity, and deregulation of these 
helicases are involved in disorders such as Bloom syndrome (BS) and Werner 
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syndrome (WS) that are associated with an increased predisposition to cancer. Bloom 
syndrome helicase (BLM) and Werners syndrome helicase (WRN) are RecQ helicases 
that are early sensors of replication stress and have been shown to interact directly 
with p53. Complex formation between BLM and p53 is required for co-localisation of 
RAD51 to sites of stalled replication forks (Sengupta et al., 2003).  Loss of BLM and 
p53 enhances the frequency of homologous recombination indicating that BLM and 
p53 proteins have a complimentary relationship in maintaining genomic integrity during 
replication (Sengupta et al., 2003). Furthermore, mice that are null for both wrn and 
p53 have an increased incidence of tumour formation compared to mice that are p53 
null alone (Lebel et al., 2001). 
 
Overall, p53 maintains DNA integrity by regulating a number of complex DNA repair 
pathways, and defects in or loss of wildtype p53 function has detrimental effects on cell 
viability by these mechanisms (Fukasawa et al., 1996). p53 is not only an effector 
protein activated by DNA damage sensors to modulate expression of genes involved in 
cell cycle arrest, apoptosis, and senescence, but also has complex functions in 
regulating DNA repair and recombination processes via transactivation independent 
pathways. 
 
In previous sections, p53 stabilisation, post-translational modification and activation 
have been reviewed followed by p53 function in cellular maintenance. However, when 
cells are exposed to lethal forms of damage that cannot be repaired, they must 
undergo cell death to keep surrounding cells and tissues from damage. The 
involvement of p53 in cell death responses will be discussed below. 
1.4.5.4 The role of p53 in cell death responses 
Apoptosis is an evolutionarily conserved process that is essential for embryonic 
development, and for cellular homeostasis in adult tissues (Kerr et al., 1972). Cell 
death by apoptosis involves distinct molecular pathways and morphological changes in 
cells, ultimately leading to the removal of damaged cells from tissues. Apoptosis is 
divided into two distinct pathways, the intrinsic pathway which is activated by stress 
stimuli, and the extrinsic pathway which is executed by death receptors. Both intrinsic 
and extrinsic forms of apoptosis involve a relay of enzymatic events involving a family 
of cysteine aspartyl proteases called caspases (Chipuk and Green, 2006; Hill et al., 
2004). Caspases are activated when cleaved, and promote further activation of 
downstream caspases by the same process. 
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The intrinsic cell death pathway is induced by internal stress stimuli such as DNA 
damage and hypoxia. Transcriptional activation of p53 in response to such stress is 
important for inducing numerous p53 target genes that regulate Bcl-2 proteins involved 
in the intrinsic cell death process. Interestingly, Bergamaschi et al. have shown that the 
apoptosis-stimulating protein for p53 (ASPP) proteins, ASPP1 and ASPP2, can 
preferentially co-operate with p53 to induce pro-apoptotic target gene expression, as 
opposed to those involved in cell cycle arrest in response to specific stress stimuli, and 
thereby promote apoptosis (Bergamaschi et al., 2004). The first pro-apoptotic Bcl-2 
protein shown to be upregulated by p53 was Bcl-2 associated X protein (Bax), 
(Miyashita and Reed, 1995), and since then, several p53 pro-apoptotic target genes 
have been identified that are involved in regulating apoptosis such as NOXA, and 
PUMA (p53-upregulated modulator of apoptosis) (Oda et al., 2000a).  
 
Pro-apoptotic Bcl-2 proteins induced by p53 localise to the mitochondrial membrane to 
interact with anti-apoptotic Bcl-2 protein complexes on the mitochondrial surface, and 
induce mitochondrial outer membrane permbealisation (MOMP), (Spierings et al., 
2005). Activation of MOMP leads to the release of cytochrome C from the 
mitochondrial intermembrane space, and formation of the apoptotic protease activating 
factor 1 (APAF1) complex. Binding of APAF1 to caspase 9 forms an apoptosome 
complex that leads to activation of the downstream caspase cascade. The final 
caspase to be activated in this cascade is caspase 3 which completes the apoptosis 
pathway. Cells undergoing apoptosis have distinct morphological features including 
chromatin condensation, DNA fragmentation and cellular blebbing caused by the 
formation of apoptotic bodies that contain discarded cell fragments (Edinger and 
Thompson, 2004). 
 
Accumulation of p53 in the cytoplasm is regulated by HDM2 (Dumont et al., 2003). As 
well as inducing pro-apoptotic Bcl-2 proteins by transactivation dependent 
mechanisms, p53 also has extranuclear functions and has been shown to rapidly 
accumulate in the cytoplasm following radiation (Erster et al., 2004; Erster and Moll, 
2004). Cytoplasmic p53 has been shown to bind directly to Bcl-2 complexes on the 
mitochondrial membrane to induce MOMP and initiate apoptosis (Schuler and Green, 
2005). Key cell death pathways that are mediated by p53 have been summarised in 
Figure 1.4.5. 
 
The extrinsic pathway of apoptosis is activated when death receptors are ligated by the 
binding of death ligands. The tumour necrosis factor receptor (TNFR) family are death 
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receptors that bind to a number of ligands including CD95, TNF ligands, and the TNF-
related apoptosis-inducing ligand (TRAIL), (Muppidi et al., 2004). Upon binding to 
death ligands, the TNFR death receptor recruits specific adaptor molecules such as the 
FAS associated death domain protein (FADD). Recruitment of FADD acts as a platform 
for binding and activating caspase 8, followed by activation of the BH3-interacting 
domain death agonist (Bid). Translocation of Bid to the mitochondrial membrane 
induces MOMP and the consequent series of events involved in intrinsic apoptosis. 
  
Recently, autophagy has been described as an important mechanism induced by 
stress that can promote both cell survival and apoptosis. As with intrinsic apoptosis, 
p53 has been shown to regulate autophagy mediated cell death (Crighton et al., 2006). 
Autophagy is an evolutionarily conserved pathway that involves lysosomal mediated 
degradation of damaged cytoplasmic organelles (Debnath et al., 2005; Levine and 
Kroemer, 2008). Organelles such as mitochondria and the endoplasmic reticulum that 
are damaged by nutrient starvation and genotoxic stress are engulfed into double 
membrane vesicles called autophagosomes (Boya et al., 2005). Cellular contents 
within autophagosomes are transferred to lysosomes upon fusion, forming a 
degradation vesicle called the autolysosome. Lysosomal hydrolases complete 
autophagy by degrading the contents within the autolysosome (Baehrecke, 2005).  
 
AMPK (5’-AMP-activated protein kinase) is a major regulator of energy homeostasis 
(Hardie, 2007) both in normoxic and hypoxic tumour microenvironments (Laderoute et 
al., 2006), and has a well established role in mediating autophagy by acting as a 
metabolic sensor (Meley et al., 2006). AMPK is an upstream regulator of the serine 
threonine kinase mTOR (mammalian target of rapamycin), which in turn regulates 
important  signalling pathways involved in translation and cell division (Bohensky et al., 
2010). One of the earliest studies investigating the role of p53 in autophagy showed 
that p53 could activate AMPK and induce autophagy by inhibiting mTOR in response to 
glucose starvation (Feng et al., 2005). Other studies explored the expression of p53 
target genes and showed that damage regulated autophagy modulator (DRAM) was a 
p53 target gene that encoded a lysosomal protein involved in activating autophagy and 
inducing apoptosis (Crighton et al., 2006).  
 
Intrinsic, extrinsic and autophagic mechanisms that lead to the execution of apoptosis 
involve various pro-apoptotic target genes that are induced by p53 transactivation in 
response to metabolic stress and genotoxic damage that is beyond repair.  The 
importance of p53 as a tumour suppressor protein is shown by the range of pathways 
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that are regulated by p53. The role of p53 in mediating cell cycle checkpoints, DNA 
repair, and cell death responses has been reviewed in detail above. It is not surprising 
then that given the central function that p53 has in regulating cell growth, proliferation, 
and death, that p53 activity is lost in almost all cancers. Our laboratory is particularly 
interested in how p53 function is affected in hypoxic tumours that overexpress HIF 
protein levels, as these tumours are often the most difficult tumours to target with 
radiotherapy and chemotherapy. Regulation between HIF and p53 and what this 
means for specific tumour models will now be discussed further.   
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Figure 1.4.5: Regulation of apoptosis by p53 
Apoptosis is regulated by the intrinsic and extrinsic pathways. Intrinsic apoptosis is induced 
by internal stress stimuli such as DNA damage. Activation of p53 in response to DNA 
damage leads to expression of pro-apoptotic target genes such as Bax, NOXA and PUMA. 
The ASPP protein family act as co-factors for p53 to induce pro-apoptotic target gene 
expression. Pro-apoptotic Bcl-2 proteins induced by p53 translocate to the mitochondria and 
disrupt anti-apoptotic Bcl-2 complexes, such as those formed between Bcl-2 and Bcl-xL, 
thereby inducing mitochondrial pore permbealisation, and consequent cytochrome C 
release.  The APAF1 complex is activated by cytochrome C and initiates the caspase 
cascade leading to activation of caspase 3, and cell death by apoptosis. The extrinsic cell 
death pathway involves binding of the death ligands CD95, TRAIL, and TNF to the TNF 
death receptor. The receptor is activated by ligation and recruits adaptor proteins such as 
FADD which activate caspase 8, and pro-apoptotic Bid. The intrinsic response is executed 
by Bid following localisation of Bid to the mitochondrial membrane. Additionally, p53 may 
activate apoptosis through induction of autophagy, by either mTOR inhibition, or expression 
of the p53 target gene DRAM. Formation of autolysosomes during autophagy leads to 
degradation of cellular organelles, and activation of apoptosis.  
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1.5 Crosstalk between HIF-1α and p53 
HIF-1α can induce p53 activation and p53 induced apoptosis in response to gamma 
irradiation (Moeller et al., 2005) and can interact directly with p53 to promote its stability 
(An et al., 1998; Chen et al., 2003). However, activated p53 can also have significant 
inhibitory effects on the HIF pathway and on tumour angiogenesis (Ravi et al., 2000; 
Yang et al., 2009b). Supporting studies indicate that activation of p53 by the small 
molecule RITA (reactivation of p53 and induction of tumour cell apoptosis) can inhibit 
HIF-1α protein and VEGF induction, and induce cell death and antiangiogenic effects in 
hypoxia (Yang et al., 2009b). Additionally, specific knockdown of HIF-1α in hypoxic 
cells containing wildtype p53 can reverse resistance to cisplatin by upregulating pro-
apoptotic Bid, therefore activating cell death responses (Hao et al., 2008). The negative 
relationship between HIF and p53 activity suggests that in hypoxic tumours, p53 is 
transcriptionally repressed. Although some studies have addressed this relationship, 
and will be discussed in the next section, the mechanisms by which HIF and p53 
crosstalk remain unclear. 
1.5.1 p53 activity is repressed by HIF 
Koumenis et al. previously suggested that although p53 accumulates in the cell under 
hypoxic stress, the protein is transcriptionally inactive and does not induce p53-
dependent cell cycle arrest (Koumenis et al., 2001). Instead, additional signals such as 
DNA damage were required for p53 activity in hypoxia (Kaluzova et al., 2004). 
Furthermore, it has been known for some time that although p53 is stabilised by stress, 
multiple post-translational modifications are required for p53 activity, and these require 
a range of stress signals (Ashcroft et al., 2000). 
 
Using mutant C. elegans with loss of vhl, Sendoel and colleagues have overexpressed 
hif-1 specifically in sensory neurons of C. elegans, leading to transcriptional up 
regulation of the tyrosinase tyr-2. By a mechanism dependent on endocytosis, tyr-2 can 
target the C.elegans homologue of p53, cep-1, specifically in the gonads and inhibit 
cep-1 mediated apoptosis in response to stress. Sendoel et al. reveal novel 
complexities for HIF signalling pathways whereby HIF target genes can repress p53 
activity in cells at both close proximity, and at distant regions within the tumour 
microenvironment (Ahmed and Ashcroft, 2010; Sendoel et al., 2010). 
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1.5.2 p53 function is deregulated in angiogenic tumours 
VHL disease is a hereditary cancer syndrome whereby loss of VHL results in a greater 
predisposition to the development of highly vascular tumours (known as 
hemangioblastomas) of the central nervous system, and of the retina. VHL disease is 
also associated with the development of renal carcinomas and pheochromocytomas 
(Haase et al., 2001). Almost 80% of clear cell renal cell carcinomas involve the biallelic 
inactivation of VHL  (Kaelin, 2002). As expected, loss of pVHL function in renal 
carcinomas also leads to the formation of tumours that have high HIF gene expression, 
and are therefore highly vascular (Gnarra et al., 1996; Takahashi et al., 1994). Renal 
cell carcinomas are a good model to assess the interplay between deregulated HIF and 
p53 because although mutations in p53 are rarely detected in renal cell carcinomas, 
they remain highly resistant to radiotherapy and chemotherapy. The mechanisms by 
which p53 function is deregulated in renal cell carcinomas are unclear, although some 
evidence suggests a level of crosstalk between p53 activity, and overexpression of HIF 
signalling due to loss of pVHL function (Gurova et al., 2004; Lowe, 1995).  
 
Reintroduction of wildtype VHL into renal carcinoma cells can promote p53 
accumulation, suggesting both p53 and pVHL tumour suppressor functions may co-
operate in such tumour models (Galban et al., 2003). However, transactivation of 
stabilised p53 protein in renal cell carcinoma has also been shown to be suppressed 
(Gurova et al., 2004). Although the mechanism by which the transactivation function of 
p53 is inhibited in renal cell carcinoma is undefined, and even disputed by other studies 
(Warburton et al., 2005) it is an important basis for studies that use either p53 
activating agents (Roberts et al., 2009; Yang et al., 2009b) or HIF inhibition (Bertout et 
al., 2009) to effectively sensitise renal carcinoma cells to chemotherapy.  
 
Interestingly, HIF-independent functions for pVHL have also been described involving 
cell cycle and apoptotic pathways (Pause et al., 1998; Roe et al., 2006). As well as 
binding to HIF-1α (Maxwell et al., 1999) pVHL is proposed to bind directly with p53 and 
regulate p53 transcription in a HIF-independent manner (Roe et al., 2006). By binding 
to p53, pVHL inhibits p53 interactions with HDM2 leading to p53 stabilisation in 
response to genotoxic stress (Roe et al., 2006). Other studies cannot reproduce the 
association between pVHL and p53 that has been proposed by Roe et al. (Roberts et 
al., 2009), and such ambiguities make it challenging to understand the HIF-
independent mechanisms by which p53 is regulated in renal carcinomas.  
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The association between pVHL loss of function and HIF-α overexpression in renal cell 
carcinomas has led to a number of studies in which the differential effects of HIF-1α 
and HIF-2α expression have been assessed (Carroll and Ashcroft, 2006; Raval et al., 
2005). It is now considered that HIF-2α overexpression is a primary contributor to the 
progression of clear cell renal cell carcinoma (Kondo et al., 2002). Supporting studies 
have shown that HIF target gene expression in renal cell carcinoma cells is dependent 
on HIF-2α overexpression (Carroll and Ashcroft, 2006). Importantly, the mechanisms 
by which HIF-2α overexpression leads to chemoresistance remain unclear. The impact 
that loss of p53 activity has in renal cell carcinomas that overexpress HIF-2α will be 
discussed further.  
1.5.2.1 Effects of HIF-2α on p53 activity in renal cell carcinoma 
Xenograft mouse models show HIF-2α is important for progression of clear cell renal 
carcinoma (Kondo et al., 2003). The oncogenic functions of HIF-2α in renal cell 
carcinomas are strengthened by studies in which HIF-2α has been shown to co-
operate with the proto-oncogene c-myc to enhance cell proliferation, and regulate 
genomic stability (Gordan et al., 2008). Furthermore, gradual increases in the 
distribution and expression of HIF-2α protein during renal cell carcinoma progression 
have been shown, which inversely correlate with HIF-1α expression (Mandriota et al., 
2002).  
 
The inhibitory effects of HIF-2α on p53 activity contribute significantly to the 
radioresistance of clear cell renal cell carcinomas (Bertout et al., 2009). Renal 
carcinoma cells expressing HIF-2α alone have decreased p53 transcriptional activity 
and inhibition of HIF-2α protein expression sensitises cells to radiation by activating 
p53-dependent cell death responses (Bertout et al., 2009). These studies provide an 
important rationale for the development of HIF-2α inhibitors, and for the use of p53 
activating agents, either alone or in combination, to improve the therapeutic targeting of 
renal cell carcinomas. 
 
Both HIF signalling and p53-mediated pathways have been discussed in detail as 
independent regulators of the cellular response to stress, and as important pathways 
that co-operate in specific tumours to promote tumour development. Clearly, targeting 
tumours in which these pathways are deregulated has been challenging, although 
progress has been made in the development of small molecule targeted agents and 
combination strategies designed to maximise tumour cell death. The most common 
strategies that are used to treat cancer will now be reviewed along with the progress 
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that targeted agents have made in the clinic. Current challenges in targeting angiogenic 
tumours with deregulated HIF-α, and those with deregulated p53 signalling will also be 
discussed.  
1.6 Treating cancer  
The most common methods by which cancer is treated are surgery, radiotherapy, and 
chemotherapy. Treatments are often used in combination to improve therapeutic 
outcome and responses are dependent on both tumour stage (an indication of how 
widespread the tumour is in the body), and tumour grade (defined according to the 
differentiated morphology of cancer cells within a tumour). There are several grading 
systems that are commonly used, and these depend on the tumour type assessed. At 
presentation, patients are often assessed for tumour size and location, to determine 
tumour stage, and a biopsy is taken to define tumour grade. These factors are then 
used to build an individual treatment plan that best predicts patient prognosis. If a 
tumour is detected during the early developmental stages, surgery is used to remove 
the tumour.  
 
However, for tumours that are malignant, radiotherapy is often used in combination 
with chemotherapy or ‘drug therapy’ to induce lethal DNA damage in rapidly 
proliferating cancer cells, and cell death is achieved through apoptosis to inhibit tumour 
growth (Albain et al., 2009). Radiotherapy involves the use of ionizing radiation. 
Although radiation is targeted specifically to the tumour tissue, some healthy, 
surrounding tissues are also affected. Therefore, unwanted side effects are a common 
drawback of radiation therapy. Chemotherapy schedules are prescribed according to 
tumour type, age, and genetic makeup. Most chemotherapy agents are divided into 
categories according to the specific cell cycle pathway which they inhibit. Alkylating 
agents like cisplatin, for example modify cellular DNA by forming DNA cross links that 
damage DNA during replication (Alderden et al., 2006; Rosenberg et al., 1969). Normal 
cells can also be damaged by chemotherapy agents however normal cells are more 
efficient at activating cell cycle arrest and DNA repair compared to cancer cells, and 
can resume growth once treatment is over. 
 
Targeted therapies interfere with specific cell signalling pathways that are deregulated 
in cancer cells. These can be either small molecules, or antibodies directed against 
specific molecules within the pathway of interest. Common targeted therapies clinically 
used include those that inhibit the epidermal growth factor receptor (EGFR), a receptor 
often overexpressed in many cancer cells which promotes tumour growth (Zhang et al., 
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2007). Gefitinib (Iressa®) for example is a small molecule targeting EGFR and is used 
to treat non small cell lung cancer (Lynch et al., 2004; Paez et al., 2004). The 
monoclonal antibody Cetuximab (Erbitox®) also functions by inhibiting EGFR signalling 
and is used to treat patients with squamous cell carcinoma of the head and neck 
(Vermorken et al., 2008), and patients with colon cancer (Van Cutsem et al., 2009).   
 
Other common targeted agents include Bevacizumab (Avastin®), a monoclonal 
antibody that inhibits blood vessel growth in tumours by targeting VEGF (Ferrara et al., 
2004), and  Sorafenib (Nexavar®), a small molecule used in renal cell (Escudier, 2007) 
and hepatocellular carcinomas (Keating and Santoro, 2009) that also targets blood 
vessel growth by inhibiting tyrosine kinase pathways (Wilhelm et al., 2008). Because 
targeted therapies are designed to inhibit signalling pathways that are deregulated in 
cancer cells, they reduce unwanted side effects and improve treatment responses.  
 
Hormone therapy has been developed for tumours that require hormones for growth 
such as breast and prostate cancers. Selective estrogen receptor modulators (SERMS) 
such as tamoxifen inhibit binding of estrogen by blocking the estrogen receptor 
(Jordan, 2006). Aromatase inhibitors have also been developed which inhibit estrogen 
production (Mokbel, 2002). Other forms of cancer treatment include immunotherapy 
based approaches and vaccine development (Borghaei et al., 2009). Gene therapy is 
also being used to improve targeting of cancer cells (Gutierrez et al., 1992; Morgan et 
al., 2006).  
 
Overexpression of HIF-α (HIF-1α and HIF-2α) is found in numerous tumours, and is 
associated with poor patient survival. For this reason, HIF is an important therapeutic 
target, and has been pursued for the development of agents that inhibit HIF activity and 
HIF target gene expression in several tumour models. However, targeting HIF is 
challenging because HIF-1α and HIF-2α have specific functions to either promote, or 
suppress tumour progression, and these functions largely depend on the tumour type 
in which they are expressed. The various strategies that have been designed to target 
the HIF pathways and the challenges which these agents face on the road to the clinic 
will now be discussed.   
1.6.1 Strategies for targeting the HIF pathway 
Polypeptides derived from the carboxyl-terminal transactivation domain of HIF-1α can 
be used to directly inhibit interactions between HIF-1α and its transcriptional co-
activator p300 (Kung et al., 2000). HIF-1α protein may be targeted by use of HIF-1α 
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antisense plasmids (Sun et al., 2001) and inhibitory cDNA from which mRNA splicing 
produces truncated, transcriptionally inactive HIF-1α protein (Chun et al., 2001). 
Tirapazamine, a hypoxia-activated pro-drug forms highly reactive radicals in hypoxic 
cells that sensitise tumours to conventional therapy (Brown and Wilson, 2004). 
Tirapazamine was shown to synergise with cisplatin in Phase III clinical trials for non 
small cell lung cancer and improve survival rates (von Pawel et al., 2000). Hypoxia 
activated gene therapy has been explored as a means to target hypoxic cells 
specifically (Greco et al., 2006). However, as with most forms of gene therapy, the 
need for better systemic delivery is required and such challenges hinder further 
progress. 
 
Heat shock protein 90 (HSP90) is a molecular chaperone involved in the folding and 
stabilisation of HIF-1α protein (Minet et al., 1999). HSP90 inhibitors such as 17AAG 
(17-allyl-aminogel-danamycin) and galdanamycin destabilise HIF-1α and promote its 
degradation, even in renal carcinoma cells that lack functional pVHL (Isaacs et al., 
2002; Mabjeesh et al., 2002). Other agents that lead to inhibition of HIF-1α include 
activators of p53 such as RITA (Yang et al., 2009b) and nutlin-3 (LaRusch et al., 2007). 
Farnesyl transferase inhibitors that block oncogenic Ras signalling have also been 
shown to inhibit the HIF pathway (Chen et al., 2001).  
 
In breast carcinoma cells, and renal cell carcinoma models, a reciprocal relationship 
was observed between HIF-1α and HIF-2α subunits (Carroll and Ashcroft, 2006). Loss 
of HIF-2α in MCF7 cells increases HIF-1α protein expression, suggesting that in this 
breast carcinoma model, efficient targeting of both subunits will be most beneficial for 
therapy (Carroll and Ashcroft, 2006). In renal carcinoma cells lacking pVHL function, 
HIF-2α has important functions in mediating HIF target gene expression and use of 
small molecule inhibitors against both HIF-1α and HIF-2α subunits achieves the most 
significant decrease in angiogenesis and tumour growth (Carroll and Ashcroft, 2006). 
1.6.1.1 Hypoxic cells are resistant to treatment 
Hypoxic tumours are amongst the most resistant tumours. Niches in which hypoxic 
cells form are located further away from blood vessels and therefore have less 
exposure to oxygen and nutrients. Delivery of cytotoxic agents that are used to kill 
tumour cells is also less efficient (Tannock, 1998). Most chemotherapies are designed 
to target rapidly proliferating tumour cells. However, cellular proliferation also 
decreases with distance from blood vessels, further guarding hypoxic cells from 
cytotoxic agents (Tannock, 1998). Other mechanisms that hypoxic cells employ to 
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acquire resistance include deregulated p53 activity allowing aggressive cells that are 
genetically unstable to colonise tumours, and regulation of the multidrug resistant 
(MDR1) gene (Comerford et al., 2002).  
 
Many studies also demonstrate adaptive resistance strategies of tumour cells towards 
angiogenic therapy (Bergers and Hanahan, 2008). In the treatment of glioblastomas for 
example, anti-VEGF antibody treatment results in decreased tumour vessel density 
and increased apoptosis to prolong survival. However, anti-VEGF antibody treatment 
also leads to increased infiltration of surrounding vasculature, bypassing the need of 
tumours to initiate angiogenesis for survival (Rubenstein et al., 2000). Furthermore, 
anti-angiogenic agents show significant anti-tumour activity in mouse models of 
pancreatic neuroendocrine carcinoma and glioblastoma, however tumour adaptation is 
observed whereby cancer cells respond to prolonged treatment by promoting migration 
and invasion mechanisms that form more aggressive tumours (Paez-Ribes et al., 
2009).  
 
In some clinical schedules, use of combination therapy has the most significant anti-
tumour results (Kerbel, 2001). Administration of cytotoxic chemotherapies alone such 
as the taxanes and platins has been associated with severe toxicity issues in multiple 
tissues and organs. Toxicity leads to serious and often lethal side effects including 
anaemia, cardiovascular failure, renal, neurological, and gastrointestinal disorders 
(Lokich and Anderson, 1998). Schedules involving co-administration of anti-
angiogenics in combination with cytotoxics have shown increased survival benefits and 
sustained tumour regression, without toxicity and threatening signs of resistance 
(Klement et al., 2000). Combined administration of the monoclonal VEGF antibody 
bevacizumab with 5-fluorouracil, for example shows prolonged survival of colorectal 
cancer patients when compared to either agent alone (Fernando and Hurwitz, 2004). 
 
Administration of anti-angiogenics can induce vascular normalisation, improving blood 
vessel structure and function to allow more efficient delivery of cytotoxic agents to 
tumour tissue (Jain, 2005). Recently, in murine models it was shown that dosing the 
receptor tyrosine kinase inhibitor, sunitinib prior to dosing with the DNA alkylating agent 
carboplatin had more significant effects on survival than dosing both agents 
simultaneously (Zhang et al., 2011). Such studies emphasise the importance of 
designing combination strategies carefully according to the mechanism and specific 
dosing requirements of each agent.  
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The tumour suppressor functions of p53 have been discussed in detail. As well as 
targeting HIF, exploring p53 agents that induce p53 mediated cell death is also an 
important means to inhibit tumour growth. Strategies that have been used to activate 
p53 function in tumours will be discussed next, including the clinical progress of some 
targeted agents.  
1.6.2 Targeting p53 for cancer therapy 
Solid tumours that express wildtype p53 are often resistant to cell death due to 
deregulated pathways that control p53 function. The most common pathway by which 
wildtype p53 activity is inhibited involves HDM2. In vivo studies show increased 
apoptosis in radiosensitive tissues and increased fatality when wildtype p53 mice are 
crossed with Mdm2 knockout mice (Ringshausen et al., 2006). Therefore, targeting 
HDM2 by small molecules is an effective strategy with which to activate wildtype p53 
and induce p53-dependent cell death (Chene, 2003).  
 
Therapeutic strategies commonly used to target p53 activity have been summarised in 
Figure 1.6.1. Small molecules that interfere with the p53-HDM2 interaction are well 
studied (Vassilev, 2007). Antisense oligonucleotides targeted against HDM2 show 
increased radiation responses (Zhang et al., 2004), and small molecules that 
specifically target the E3 ligase activity of HDM2 have also been described (Yang et al., 
2005). 
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Figure 1.6.1: Therapeutic targeting of HDM2 and p53 
HDM2 negatively regulates p53 function in normal cells and this relationship has important 
consequences for the cellular response to intrinsic and exogenous stress stimuli. The HDM2-
p53 interaction is defective in cancer cells due to a number of genetic changes such as 
mutations and deletions affecting protein expression and function. Often these changes lead 
to cell phenotypes whereby HDM2 activity is hyper-activated, while p53 function is inhibited. 
Small molecule inhibitors have been designed to target HDM2 and its interaction with p53. 
These include the nutlins which inhibit HDM2 binding to p53, and HL198, an inhibitor that 
blocks the E3 ligase activity HDM2. Other small molecules target p53 directly to activate p53 
function and these include PRIMA and RITA. Such strategies are important for altering the 
cellular response to stress so that sufficient p53 activation and tumour cell apoptosis is 
activated.  
 
1.6.2.1 Clinical progress of HDM2 inhibitors 
Small molecule HDM2 inhibitors are designed to target the inhibitory interaction 
between HDM2 and p53, thereby enabling p53 activity. Several HDM2 inhibitors are 
progressing through clinical trials including JNJ-26854165, a p53-activating tryptamine 
derivative (Johnson and Johnson, New Brunswick, NJ, USA). JNJ-26854165 is 
currently in Phase I for advanced solid tumours, and treatment of acute leukaemias 
(Kojima et al., 2010). The nutlins are the most well studied inhibitors of HDM2, and 
RG7112 (F.Hoffman, La Roche, Basel, Switzerland) is a small molecule taken from the 
nutlin series that is currently in Phase I trials for hematologic neoplasms and advanced 
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solid tumours (Cheok et al., 2010). Another class of HDM2 inhibitors known as the 
spiro-oxiadoles have been generated based on the crystal structure of the p53-HDM2 
complex, and MI-219 is in preclinical development as an oral agent for the treatment of 
acute myeloid leukaemia (Ding et al., 2006). 
 
Several groups have investigated the relationship between HDM2 and the HIF 
pathway, and effects of HDM2 inhibitors on HIF have also been described. Nutlin-3 
stabilises p53 by targeting the p53 binding pocket on the surface of HDM2 and shows 
potent in vivo anti-tumour activity in xenografts (Supiot et al., 2008; Vassilev, 2007; 
Vassilev et al., 2004). Because HDM2 positively regulates HIF expression (Bardos et 
al., 2004), HDM2 inhibitors also target angiogenesis by p53-dependent (Secchiero et 
al., 2007), and p53-independent mechanisms (LaRusch et al., 2007).  
 
Recently, HDM2 was shown to compete with FIH (factor inhibiting hypoxia inducible 
factor) for the C-terminal transactivation domain of HIF-1α (Lee et al., 2009). By 
competing with FIH, HDM2 inhibits HIF hydroxylation, and facilitates recruitment of 
p300 to the C-terminal transactivation domain of HIF-1α to induce HIF transcription. By 
binding to HDM2, nutlin-3 interferes with the HDM2-HIF interaction so FIH can bind to 
HIF-1α, increase hydroxylation and inhibit HIF mediated responses (Lee et al., 2009). 
Interestingly, Bortezomib is a proteasome inhibitor that can also inhibit HIF activity by 
increasing FIH interactions with HIF-1α in hypoxia, and achieves significant anti-
angiogenic effects in solid tumours (Shin et al., 2008). Both studies with nutlin and 
bortezomib show the ability of targeted agents to inhibit a specific interaction between 
HDM2 and HIF-1α that is critical in the regulation of HIF activity.  
 
Previous studies have explored the idea that a number of critical cell survival pathways 
can be targeted simultaneously to elicit maximum cell death responses in tumours 
without compromising tumour cell specificity (Grinkevich et al., 2009). PRIMA-1MET for 
example, a small molecule that reactivates mutant p53 can synergise with cisplatin to 
induce tumour cell apoptosis and inhibit growth of tumour xenografts in vivo (Bykov et 
al., 2005). Many cytotoxic combinations with anti-angiogenics have also progressed 
into the clinic (Fernando and Hurwitz, 2004). More recently, ‘cyclotherapy’ has been 
described as a novel concept to minimise unwanted side effects by specifically 
targeting proliferating cells within tumours. Low dose nutlin-3 or actinomycin D (both at 
non-genotoxic concentrations) activate p53 to place normal cells into reversible cell 
cycle arrest, treatment is then followed with a mitotic inhibitor such as a taxane that 
selectively targets remaining proliferating cells within the tumour for cell death (Sur et 
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al., 2009). Cyclotherapy is promising because it utilises knowledge of tumour cell 
kinetics and mechanisms behind targeted small molecules to build specific treatment 
regimes. Combining low dose activators of p53 with specific inhibitors of the PI3K/Akt 
pathway has also been suggested (Bardos et al., 2004; Grinkevich et al., 2009).  
 
Knowing that cancer is a disease that has a makeup unique to a particular individual 
and cancer type is critical in making accurate predictions of treatment responses and 
disease outcome. Careful consideration is taken when assessing the cell and tumour 
type that could be targeted by specific agents which affect the p53-HIF pathways, 
especially in renal cell carcinoma where inhibition of HIF-2α specifically has recently 
been shown to enhance tumour cell survival by promoting the angiogenic functions of 
HIF-1α (Carroll and Ashcroft, 2008). It is also important to consider the possibility that 
restoring activity of p53 to increase apoptosis could also select for cells that are 
defective in p53 function, resulting in tumour adaptation towards a more aggressive 
and metastatic phenotype (Kastan, 2007).  
1.6.3 RITA: a small molecule activator of p53 
In a cell-based screen of HCT116 cells that differentially express p53, compounds from 
the National Cancer Institute library were assessed for their ability to inhibit cell growth 
(Issaeva et al., 2004). The small molecule RITA (2,5-bis (5-hydroxymethyl-2-thienyl) 
furan, NSC652287) was isolated from this screen on the basis that HCT116 p53+/+ 
cells treated with a dose range of RITA showed significant inhibition of cell growth 
compared to HCT116 p53-/- cells (Figure 1.6.2). As well as cell proliferation assays 
using WST-1, long term growth was also assessed using the colony formation assay. 
At a 500nM dose (the dose whereby cell proliferation is inhibited by approximately 
50%) RITA was also shown to inhibit the number of colonies formed in HCT116 p53+/+ 
cells to a greater degree compared with HCT116 p53-/- cells (Issaeva et al., 2004). 
Further studies proposed that RITA suppressed tumour growth in vitro and in vivo by 
binding with high affinity to the NH2-terminal domain of p53 resulting in a 
conformational change that inhibited the p53-HDM2 interaction and therefore stabilised 
p53 (Issaeva et al., 2004).  
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Figure 1.6.2: The structure of RITA  
Chemical structure for NSC652287 (2,5-bis (5-hydroxymethyl-2-thienyl) furan). NSC652287 
is a naturally occurring tricyclic bis-thiophene derivative. This compound was isolated from 
the National Cancer Institute library of compounds due to its role in activating p53 and 
inducing tumour cell apoptosis. NSC652287 was therefore named RITA (reactivation of p53 
and induction of tumour cell apoptosis). 
 
1.6.3.1 RITA elicits cell death responses  
Since the original identification of RITA as an activator of p53 in 2004, subsequent 
studies have explored RITA’s mechanism of action in greater detail. Activation of p53 
by nutlin-3 induces cell cycle arrest in a number of tumour cell lines while RITA is 
primarily involved in promoting apoptosis (Tovar et al., 2006). By binding to HDM2, 
nutlin-3 disrupts the p53-HDM2 interaction, p53 is stabilised, and activated to induce 
transcription of genes involved in cell cycle control and growth arrest. RITA, however, 
is proposed to bind directly to p53 and inhibit its interaction with HDM2 (Issaeva et al., 
2004). Genome wide oligonucleotide micro-array analysis was recently used to 
investigate the mechanisms which govern p53 dependent cell cycle and cell death 
responses to stress. Data from isogenic p53 positive and p53 negative HCT116 colon 
carcinoma cells was used to study differences in gene expression when p53 was 
activated by either nutlin-3 or RITA (Enge et al., 2009). RITA’s unique p53-dependent 
activity was confirmed by observation of very few changes in global gene expression 
when HCT116 p53-/- cells were treated with RITA compared to HCT116 p53+/+ cells 
or MCF7 cells expressing wildtype p53 (Enge et al., 2009). RITA was shown to 
increase the expression profiles of a number of genes involved not only in the DNA 
damage pathway, but also in PI3K/Akt signal transduction, cytoskeleton regulation, 
immune responses and oestrogen/androgen signalling (Enge et al., 2009). As 
expected, expression of apoptosis genes was higher in HCT116 p53+/+ cells treated 
with RITA compared to those treated with nutlin-3. Mitotic arrest induced by nutlin-3 
involved activation of p21 mediated cell cycle arrest (Enge et al., 2009). 
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Expression of the hnRNP K cofactor was identified as an important mechanism in 
determining the outcome of cell cycle responses in cells treated with either RITA or 
nutlin-3 (Enge et al., 2009). When cells are exposed to DNA damage, the DNA damage 
signalling kinases ATM and ATR activate hnRNP K (Moumen et al., 2005). Both p53 
and hnRNP K are recruited to promoters of cell cycle arrest genes such as GADD45 
and CDKN1A (encoding p21) to activate transcription in response to stress (Moumen et 
al., 2005). The hnRNP K cofactor is a target for HDM2 and when RITA binds to p53, 
free HDM2 degrades hnRNP K so it is unable to mediate p53-dependent transcription 
of p21 and induce cell cycle arrest (Enge et al., 2009). Instead, p53 activates 
expression of genes involved in apoptosis. In comparison, nutlin-3, by binding to 
HDM2, inhibits HDM2’s ability to target hnRNP K for degradation allowing recruitment 
of hnRNP K to p53 target gene promoters and cell cycle gene expression (Enge et al., 
2009).  
 
HDM2 mediated regulation of homeodomain interacting protein kinase 2 (HIPK2) is 
also involved in regulating cell cycle and cell death in response to p53 activation by 
nutlin-3 and RITA (Rinaldo et al., 2009). HIPK2 is a pro-apoptotic kinase activated in 
response to severe stress and induces p53 activity and DNA damage responses by 
phosphorylating p53 at serine 46 (Oda et al., 2000b). When bound to HDM2, nutlin-3 
mediates HDM2-dependent proteasomal degradation of the HIPK2 kinase to inhibit 
apoptosis while activating cell cycle arrest. Transiently inhibited HDM2 protein levels by 
higher and extended doses of RITA lead to HIPK2 stabilisation and p53-dependent 
apoptosis (Rinaldo et al., 2009).  
 
Also of interest is a recent study whereby RITA was shown to non-covalently bind 
thioredoxin reductase 1 (TrxR1) a protein involved in regulating redox dependent 
cellular pathways (Hedstrom et al., 2009). Binding of TrxR1 by RITA increases levels of 
reactive oxygen species to induce p53-dependant apoptosis suggesting a mechanism 
whereby RITA can target regions of tumours that suffer from oxidative stress 
(Hedstrom et al., 2009). Other studies from our lab have shown that RITA can elicit 
p53-dependent cell death in normoxia and hypoxia as well as induce p53-dependent 
DNA damage responses (Yang et al., 2009a; Yang et al., 2009b). Furthermore, DNA 
damage pathways that are induced by RITA also elicit cell cycle checkpoints involved 
in maintaining genomic integrity in response to stress (Ahmed et al., 2011). 
 Chapter 1: Introduction 
 
 
Page: 67 
1.6.3.2 Synergistic effects of p53 activation by RITA  
Interestingly, ‘oncogene addiction’ has been described whereby tumour cells become 
dependent on oncogene activity for survival. However, oncogene addiction also results 
in tumours gaining an Achilles heel against which many highly targeted drug 
combinations can be used (Weinstein, 2002). It was recently shown that RITA can also 
inhibit specific oncogenes at higher doses (1µM and beyond) which contributes 
significantly to p53 mediated apoptosis. Grinkevich and colleagues used microarray 
data to identify several critical oncogenes selectively inhibited by RITA in HCT116 
p53+/+ cells (Grinkevich et al., 2009). The AKT/PKB signalling pathway was inhibited, 
as was its downstream effectors mTOR and GSK3β. Further analysis of the mTOR 
pathway revealed significant inhibition of the mTOR substrate eIF4E which is involved 
in regulating the translation of several important oncoproteins, including c-myc 
(Averous et al., 2008; Averous and Proud, 2006). Inhibition of c-myc in response to 
RITA was found to occur at the level of transcription, translation, and protein stability 
(Grinkevich et al., 2009). RITA may therefore induce its p53-dependent cell death 
effects by not only activating pro-apoptotic genes and pathways (Enge et al., 2009), but 
also mediating downregulation of critical oncogenes (Grinkevich et al., 2009). Using 
RITA in combination with specific oncogene inhibitors was proposed as a strategy to 
maximise apoptotic responses. 
1.6.3.3 Using RITA to activate p53 in hypoxia 
Many agents activate p53 but are not effective in mediating tumour cell death in 
hypoxia. This is due to transcriptional repression of wildtype p53 in hypoxia, by 
unknown mechanisms (Ashcroft et al., 2000; Pan et al., 2004). RITA was used as a 
pharmacological tool in our laboratory to activate p53 and to understand the 
relationship between p53 and HIF. RITA was found to induce significant p53-
dependent tumour cell apoptosis, not only in normoxia as was previously published 
(Issaeva et al., 2004), but also in hypoxia (Yang et al., 2009b).  
 
Initial experiments by Yang et al. using flow cytometry showed a significant increase in 
the apoptotic population of hypoxic HCT116 p53+/+ cells treated with RITA and this 
was not observed in cells that were deficient or defective in p53 activity (Yang et al., 
2009b). Analysis of the mechanisms for this response revealed the induction of a 
unique p53-dependent DNA damage response signal. Additionally, RITA was found to 
inhibit key signalling pathways such as the HIF pathway by affecting the translational 
machinery (Yang et al., 2009b). Further studies revealed a critical role for the MAPK 
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pathway in mediating p53-dependent DNA damage and cell death responses (Yang, 
unpublished). The cell pathways activated by RITA are summarised in Figure 1.6.2. 
The studies conducted so far in our laboratory provide a basis for understanding the 
crosstalk between p53 and HIF in cancers with deregulated apoptotic and angiogenic 
pathways. 
 
 
              
 
Figure 1.6.3: The RITA response 
RITA elicits a DNA damage signal in wildtype p53 cells to activate p53 and induce significant 
cell apoptosis and anti-tumour effects, in both normoxia and hypoxia (Yang et al., 2009b). 
The HIF pathway is also targeted by inhibition of the translational machinery leading to anti-
angiogenic effects. These responses are dependent on the presence of wildtype p53. RITA 
mediated effects are reversed by the MEK1/2 inhibitor PD98059, therefore the MAPK 
pathway is also important for RITA induced cell death and anti-angiogenic responses. 
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1.7 Project hypothesis 
Small molecule activation of p53 can inhibit HIF mediated responses in normoxia and 
hypoxia to induce tumour cell death 
1.8 Project aims 
 Chapter 3: Understand how cell death responses are regulated in tumour cells by 
HIF and p53, in normoxia and hypoxia. 
 
 Chapter 4: Investigate DNA damage responses induced by RITA and their impact 
on the cell cycle.  
 
 Chapter 5: The MAPK pathway regulates p53-dependent cell cycle and cell death 
responses. Investigate members of the MAPK family which activate p53-dependent 
mechanisms to induce tumour cell apoptosis by RITA. 
 
 Chapter 6: Investigate effects of RITA on HIF-α status and explore the translational 
mechanisms by which the HIF pathway is suppressed by RITA mediated induction 
of p53. 
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2.1  Cell culture 
The matched colorectal cell line HCT116 p53+/+ with wildtype p53, and its isogenic 
derivative in which p53 is lost by homologous recombination, HCT116 p53-/- have 
been described previously (Bunz et al., 1998). Tetracycline inducible HCT116-pCDNA5 
(control) and HCT116-PERKΔC (PERK dominant negative) cell lines were a kind gift 
from Kasper Rouschop (University of Maastricht) and Brad Wouters (Ontorio Cancer 
Institute). The osteosarcoma Saos-2, breast adenocarcinoma MCF7, and renal 
carcinoma cell lines RCC4 VHL and RCC4 were purchased from American Type 
Culture Collection (ATCC). The 786-O EV and 786-O VHL renal cell carcinoma cell 
lines were a kind gift from Bill Kaelin (Harvard Hughes Medical Centre). All Cell lines 
were cultured in Dulbecco Modified Eagle Medium (GIBCO/Life Technologies) 
supplemented with 10% fetal calf serum (FCS, Harlan), 100IU/ml Penicillin, 100µg/ml 
streptomycin and 2mM glutamine (all from GIBCO/Life Technologies). 
2.2  siRNA oligo duplexes and transient transfection 
Custom made siRNA oligo duplexes to p53, HIF-1α and CHK1 were ordered from 
Dharmacon. Non-silencing control siRNA oligo duplex was obtained from Qiagen. 
ATM, ATR and p38α siRNAs were purchased from Dharmacon. Table 1 summarises 
the sequences and final transfection concentrations for specific custom made siRNA 
oligo duplexes. Transient transfections with siRNA oligo duplexes were performed 
using HiPerfectTM transfection reagent (Qiagen) according to manufacturer’s 
instructions. 
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Target Gene Target Sequence 
Transfection 
Concentration 
p53 5’-GCATCTTATCCGAGTGGAA-3’ 50nM 
HIF-1α 5’-TACGTTGTGAGTGGTATTATT-3’ 10nM 
HIF-2α 5’-CCCGGATAGACTTATTGCCAA-3’ 10nM 
Non-silencing control 5’-AATTCTCCGAACGTGTCACGT-3’ As specified 
CHK1 Target 5’-GGTGCCTATGGAGAAGTT-3’ 25nM 
CHK1 Reverse 5’-CTTGAAGAGGTATCCGUGG-3’ 25nM 
 
Table 1: Custom made siRNA oligo duplex sequences 
2.3 Antibodies and staining reagents 
Table 2 summarises primary and secondary antibodies used along with their 
conjugated labels, source, and specific dilutions according to application. Staining 
reagents have also been listed. 
 
Antibody 
Molecular 
Weight (kDa) 
Source Company Application Dilution 
Phospho-AKT (Ser473) 60 
Rabbit 
polyclonal 
Cell Signalling 
#9271 
Western 
blotting 
1:1000 
HIF-1 120 
Mouse 
monoclonal 
BD Biosciences 
Western 
blotting 
1:1000 
HIF-2α 100 
Rabbit 
polyclonal 
Abcam ab199 
Western 
blotting 
1:1000 
Phospho-CHK1 (Ser345) 56 
Rabbit 
polyclonal 
Cell Signalling 
#2348 
Western 
blotting 
1:1000 
CHK1 56 
Rabbit 
polyclonal 
Cell Signalling 
#2345 
Western 
blotting 
1:1000 
Phospho-CHK2 (Thr68) 62 
Rabbit 
polyclonal 
Cell Signalling 
#2662 
Western 
blotting 
1:1000 
CHK2 62 
Rabbit 
polyclonal 
Cell Signalling 
#2662 
Western 
blotting 
1:1000 
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Phospho-p44/42 MAPK 
(ERK1/2) (Thr202/Tyr204) 
 
42,44 
Rabbit 
polyclonal 
Cell Signalling 
#9101 
Western 
blotting 
1:1000 
 
p44/42 MAPK (ERK1/2) 
 
42,44 
Rabbit 
polyclonal 
Cell Signalling 
#9102 
Western 
blotting 
1:1000 
 
Phospho-SAPK/JNK 
(Thr183/Tyr185) 
 
46,54 
Rabbit 
polyclonal 
Cell Signalling 
#9251 
Western 
blotting 
1:1000 
 
Phospho-MKK3/MKK6 
(Ser189/207) (22A8) 
 
40 
Rabbit 
polyclonal 
Cell Signalling 
#9236 
Western 
blotting 
1:1000 
MKK3 40 
Rabbit 
polyclonal 
Cell Signalling 
#9232 
Western 
blotting 
1:1000 
 
Phospho-p38 MAPK 
(Thr180/Tyr182) 
 
43 
Rabbit 
polyclonal 
Cell Signalling 
#9211 
Western 
blotting 
1:1000 
 
p38 MAPK 
 
43 
Rabbit 
polyclonal 
Cell Signalling 
#9212 
Western 
blotting 
1:1000 
AMPKα 62 
Rabbit 
polyclonal 
Cell Signalling 
#2532 
Western 
blotting 
1:1000 
Phospho-AMPKα (Thr172) 62 
Rabbit 
polyclonal 
Cell Signalling 
#2531 
Western 
blotting 
1:1000 
eIF-2α 38 
Rabbit 
polyclonal 
Cell Signalling 
#9722 
Western 
blotting 
1:1000 
Phospho-eIF-2 (Ser51) 38 
Rabbit 
polyclonal 
Cell Signalling 
#9721S 
Western 
blotting 
1:1000 
PARP 
116 uncleaved, 
89 cleaved 
Rabbit 
polyclonal 
Cell Signalling 
#9542 
Western 
blotting 
1:1000 
mTOR 289 
Rabbit 
polyclonal 
Cell Signalling 
#2972 
Western 
blotting 
1:1000 
Phospho-4E-BP1 (Thr37/46) 15-20 
Rabbit 
polyclonal 
Cell Signalling 
#9459 
Western 
blotting 
1:1000 
α-tubulin 50 
Mouse 
monoclonal 
Sigma 
T6199 
Western 
blotting 
1:20,000 
-actin 42 
Mouse 
monoclonal 
AbCam 
Ab6276 
Western 
blotting 
1:10,000 
 
Phospho-Histone H2A.X 
(Ser139) 
15 
 
Mouse 
monoclonal 
Upstate #16.193 
clone JBW301 
Fluorescence 1:250 
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Rabbit 
monoclonal 
Cell Signalling 
#2577 
Western 
blotting 
1:1000 
Flow 
cytometry 
1:100 
Phospho-p53 (Ser46) 53 
Rabbit 
polyclonal 
Cell Signalling 
#2521 
Western 
blotting 
1:1000 
Phospho-p53, 16G8 (Ser15) 53 
Mouse 
monoclonal 
Cell Signalling 
#9286 
Western 
blotting 
1:1000 
p53 53 
Mouse 
monoclonal 
Calbiochem 
Ab-6 #OP43 
Western 
blotting 
1:1000 
Flow 
cytometry 
1:80 
Rabbit 
monoclonal 
Cell Signalling 7F5 
#2527 
Flourescence 1:200 
Secondary anti-rabbit HRP 
conjugate 
 Rabbit Amersham 
Western 
blotting 
1:5000 
Secondary anti-mouse HRP 
conjugate 
 Mouse Amersham 
Western 
blotting 
1:5000 
Alexa Fluor 568 goat 
anti-mouse IgG 
 Mouse 
Invitrogen 
A-11031 
Flourescence 1:500 
Alexa Fluor 488 goat 
anti-rabbit IgG 
 Rabbit 
Invitrogen 
A-11034 
Flourescence 1:500 
 
Allophycocyanin (APC) 
crosslinked goat anti-rabbit 
IgG 
 Rabbit 
Invitrogen, 
A-10931 
Flow 
cytometry 
1:200 
Polyclonal goat 
anti-mouse IgG/FITC 
(fluorescein isothiocyanate) 
goat 
 Mouse 
Dako 
F0479 
Flow 
cytometry 
1:10 
DAPI (4’,6’-diamidino-2-
phenylindole) 
  
Invitrogen 
D1306 
Flourescence 1:50,000 
Propidium Iodide   Sigma 
Flow 
cytometry 
10µg/ml 
 
Table 2: Primary, secondary antibodies and staining reagents 
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2.4  Inductions and drug treatments 
Hypoxia was achieved by incubating cells in 1% O2, 5% CO2 and 94% nitrogen in an 
LEEC dual gas incubator (GA-156) for 16 hours. RITA, 2,5-bis (5-hydroxymethyl-2-
thienyl) furan was obtained from the National Cancer Centre Drug Therapeutic 
Program (NSC-652287). The compound was dissolved in 100% DMSO, stored at -
20°C as 10mM aliquots and dosed between 0-1µM. Nutlin-3 (Calbiochem) was 
dissolved in 100% DMSO and dosed at a final concentration of 4µM. The MEK1/2 
inhibitors PD98059 (Cell Signalling Technologies) and PD184352 (Calbiochem) were 
dissolved in 100% DMSO and stored at -20°C. PD98059 was dosed at final 
concentrations of 10µM or 50µM and PD184352 was dosed at 2µM. Etoposide (dosed 
at 25µM), Doxorubicin (dosed at 1µM), and Hydroxyurea (dosed at 1mM) were 
purchased from Sigma. The caspase 3 inhibitor Z-DEVD-FMK (Tocris Bioscience) was 
dosed at a final concentration of 50µM. All reagents were prepared according to 
suppliers instructions. Length of dosing was specific to each experiment. 
2.5  Western blot analysis 
Following treatment, cells were washed in ice-cold phosphate buffered saline (PBS) 
and lysed in 2x sample buffer (125mM Tris pH 6.8, 4% sodium dodecyl sulphate 
(SDS), 0.01% bromophenol blue, 10% β-mercaptoethanol, 10% glycerol). Proteins 
were separated by 12.5% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and 
assessed by western blot using standard procedures. All antibody dilutions were 
prepared in 5% Milk with 0.1% Tween in TBS buffer (140mM sodium chloride, 250mM 
Tris). See table 2 for specific antibody dilutions. 
2.6  Fluorescence activated cell sorting (FACS) 
Flow cytometry cell cycle profiles were acquired using CyAnTM ADP technology (Dako). 
Total populations of cells, including those floating and adherent were collected and 
fixed in ice cold 100% methanol. Cells were blocked in 1% FCS/PBS and labelled with 
specific primary and fluorescent conjugated secondary antibodies (see table 2) diluted 
in blocking buffer. Prior to acquisition, cells were stained with 10µg/ml propidium iodide 
(Sigma) and ribonuclease was added at 100µg/ml (Sigma). Data was gated and 
quantified using CyAnTM Summit v4.3 software. 
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2.7 Immunoflourescence 
HCT116 p53+/+ and HCT116 p53-/- cells were seeded onto 96 well plates at 10,000 
cells/well. Following treatment, cells were fixed for 1 hour in 4% paraformaldehyde in 
1xPBS (phosphate buffered saline) at 4°C. Cells were then permeabilized with 0.5% 
Triton x-100 (Sigma) in PBS for 10 mins and washed using PBS. This was followed by 
a blocking step in IFF buffer (1% BSA (bovine serum albumin), 2% FCS in PBS) for 1 
hour.  A rabbit monoclonal antibody for p53 (Cell Signalling) was used followed by an 
Alexa Fluor 488 conjugated secondary antibody (Invitrogen). Cells were also labelled 
with a mouse monoclonal antibody against γH2AX at serine 139 followed by an Alexa 
Fluor 568 conjugated secondary antibody (Invitrogen), see Table 2 for details of all 
antibodies. Antibodies were diluted in IFF buffer and incubated on cells for 40 mins. 
Nuclei were visualised by DAPI staining (Invitrogen). Plates were analysed and 
quantified using the INCell 1000 Analyser (GE Healthcare). 
2.8  Comet assay 
The comet assay (Trevigen) was performed according to manufacturer’s instructions. 
All cells (both floating and adherent) were harvested, mixed with low melting agarose at 
2x105 cells/ml (approx 1000 cells/slide), and spread onto pre-prepared comet slides. 
Cells were incubated in alkaline lysis buffer to select for single strand DNA breaks. 
Slides were then electrophoresed using alkaline buffer at 4°C, 18v, and 300mA for 40 
mins. Following electrophoresis, slides were fixed, dried and stained using SYBR 
Green. Comets were viewed under a Zeiss fluorescent microscope at 20x 
magnification and images were captured over 20 fields of view for each slide using 
ImageProTM software. The relative length and intensity of individual SYBR Green 
stained nuclei (comets) was proportional to DNA damage and was quantified using an 
algorithm for Olive tail moment on TriTek CometScoreTM software. Over 100 comets 
were analysed for each treatment. A 20 min dose of 100µM hydrogen peroxide at 4°C 
was used as a positive control for DNA damage. 
2.9  Real-time quantitative PCR (polymerase chain reaction)  
Total RNA was extracted from cells using the RNeasy Mini kit (Qiagen) according to 
the manufacturer’s instructions and 1µg was used for first-strand cDNA synthesis. First 
strand synthesis was performed using qScript cDNA SuperMix (Quanta Biosciences) 
according to manufacturer’s instructions. Real-time quantitative PCR was performed 
using DyNAmo SYBR Green Quantitative PCR kit (Finnzymes Genetic Research 
Institute (GRI) Ltd) with a DNA Engine OPTICON 2 Continuous Fluorescence 
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Detection System (GRI). Primers for HDM2, p21 and β-actin were purchased from 
Invitrogen. Sequences are shown in Table 3. For each PCR reaction primers were 
used at a final concentration of 70nM. DNA was incubated for 16 mins at 95°C, 
denatured for 30 secs at 94°C and annealed at 60°C for 1 min followed by an 
extension step at 72°C for 1 min. Each cycle was quantified and repeated 40 times. A 
melting curve was performed from 65°C to 94°C and read every 0.4°C, holding for 1 
sec. Expression of target gene mRNA relative to reference gene mRNA (β-actin) was 
calculated using the Relative Expression Software Tool (REST), (http://www.gene-
quantification.de/download.html) 
 
Target 
Gene 
Forward primer Reverse primer 
β-actin 5’- CCCAGAGCAAGAGAGG-3’ 5’- GTCCAGACGCAGGATG-3’ 
HDM2 5’-CTTCGTGAGAATTGGCTTCC-3’ 5’-CAAAGCCCTCTTCAGCTTGT-3’ 
p21 5’-GTTCCTTGTGGAGCCGGAGC-3’ 5’-GGTACAAGACAGTGACAGGTC-3’ 
 
Table 3: Primer sequences for real-time quantitative PCR analysis 
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3.1 Introduction 
In hypoxic tumours, oxygen concentrations can fluctuate widely and reach almost 
anoxic levels of 0.5% and below (Vaupel et al., 1991). In areas of severe hypoxia 
(<0.2% oxygen), cells stop proliferating and DNA synthesis is delayed. DNA strand 
breaks are formed during replication arrest leading to activation of a DNA damage 
response that involves induction of γH2AX and activation of ATR and CHK1 signalling. 
CHK1 mediates phosphorylation of p53 to induce replication arrest and thereby 
stabilise the replication fork machinery (Hammond et al., 2002; Hammond et al., 2004). 
By activating an ATR-dependent replication arrest that is mediated by p53, cells 
conduct DNA repair pathways that protect them against DNA strand breaks during 
hypoxia (Hammond et al., 2004). The ATM kinase is also phosphorylated at 0.02% 
oxygen to activate CHK2 and elicit similar cell cycle checkpoints (Bencokova et al., 
2009).  
 
DNA damage responses involving γH2AX, ATM-CHK2, ATR-CHK1 and p53 are 
important barriers against tumour development because they initiate repair 
mechanisms that maintain genomic integrity (Bartkova et al., 2005; Di Micco et al., 
2008). However, pathways employed by cells to maintain viability have also been 
adapted by cancer cells to promote their development. Cell cycle arrest activated in 
severe hypoxia allows for resistance to many chemotherapies that target proliferating 
cells (Bencokova et al., 2009). Furthermore, hypoxia induced DNA damage responses 
involving γH2AX have been shown to enhance endothelial cell proliferation and 
neovascularisation to promote tumour growth in vivo (Economopoulou et al., 2009). In 
hypoxic environments of 1% oxygen, p53 activity is impaired (Ashcroft et al., 2000) and 
p53 requires additional signals such as genotoxic stress which is not present in 
hypoxic conditions alone for transactivation (Koumenis et al., 2001; Yang et al., 
2009b). Therefore, it is of therapeutic interest to determine whether small molecules 
such as RITA can be used to activate p53-dependent cell death responses in normoxia 
and in hypoxia.  
3.2 Hypothesis 
RITA induces p53 and elicits significant cell death in p53 positive cells, both in 
normoxia and in response to hypoxia. 
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3.3 Aims 
 Investigate p53 responses in cells that vary in p53 status using the small 
molecule RITA. 
 Assess cell death responses and the mechanisms by which p53 is induced by 
RITA in normoxia and in hypoxia. 
 Investigate whether RITA affects the HIF pathway in hypoxia. 
3.4 Cell death by RITA is distinct compared to other p53-activating agents 
RITA has been proposed to bind directly to p53, and stabilise p53 by inhibiting its 
association with HDM2. By stabilising wildtype p53, RITA can elicit p53-dependent cell 
death in vitro, and in vivo (Issaeva et al., 2004). Previous studies from our laboratory 
have shown that RITA induces p53-dependent cell death in normoxia and in hypoxia 
(Yang et al., 2009b). To investigate these findings in greater detail, RITA induced 
tumour cell death was compared to other DNA damaging agents like doxorubicin and 
hydroxyurea which also activate p53-mediated cell death responses.   
 
DNA damaging agents used in the clinic achieve anti-tumour efficacy by eliciting p53-
mediated apoptosis through distinct mechanisms. Etoposide is a topoisomerase 
inhibitor that targets cells during the S-G2 phases of the cell cycle, induces DNA strand 
breaks, and inhibits DNA synthesis (van Maanen et al., 1988). Doxorubicin, an 
anthracycline antibiotic also inhibits DNA synthesis, but does so by intercalating into 
DNA and inhibiting the activity of topoisomerase enzymes (Fornari et al., 1994). 
Hydroxyurea induces DNA damage by inhibiting ribonucleotide reductase and dNTP 
(deoxyribonucleoside triphosphate) production required for the G1-S phase transition of 
the cell cycle (Hakansson et al., 2006; Koc et al., 2004). Doxorubicin, etoposide and 
hydroxyurea have distinct cell cycle affects and elicit significant DNA damage 
responses that induce p53 and mediate tumour cell apoptosis.  
 
To compare cell death responses induced by RITA with other p53-activating agents, 
flow cytometry was used to quantify sub-G1 cell populations as an indication of cell 
death. Doses were used at which etoposide, doxorubicin and hydroxyurea induce p53 
to a similar degree as RITA, both in normoxia and in hypoxia. As shown in Figure 3.4.1, 
RITA induced significant cell death in HCT116 p53+/+ cells, both in normoxia, and in 
response to hypoxia. Cell death observed with RITA treatment was not observed to the 
same degree in cells treated with etoposide, doxorubicin, or hydroxyurea. Closer 
analysis of DNA flow cytometry profiles showed that as expected, etoposide elicited a 
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G2 arrest, doxorubicin an S-phase arrest, and hydroxyurea, a significant G1 arrest 
(Figure 3.4.1). In comparison, RITA did not elicit cell cycle arrest in HCT116 p53+/+ 
cells, instead the sub-G1 population of RITA treated cells was significantly induced 
suggesting that cell death is a primary response of HCT116 p53+/+ cells treated with 
this agent. 
 
 
  
 
Figure 3.4.1: RITA mediated cell death is distinct compared to other p53 activating 
agents 
Flow cytometry cell cycle profiles show changes in cell cycle phases when HCT116 p53+/+ 
cells are dosed with either 500nM RITA, 25µM etoposide, 1µM doxorubicin or 1mM 
hydroxyurea for 16 hours in normoxia (20% O2, shown by blue profiles) or in hypoxia (1% O2, 
shown by orange profiles). Gated regions are indicated by dashed lines to highlight different 
phases of the cell cycle, from left to right; sub-G1, G1, S, and G2 phase. The percentage of 
cells in each cell cycle phase is quantified and shown alongside each profile. Each flow 
cytometry profile shows propidium iodide fluorescent intensity on the x-axis, and cell counts 
on the y-axis. Data shown is representative of 3 independent experiments. 
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The sub-G1 population of cells from each flow cytometry profile was quantified as an 
indication of cell death. RITA treated cells had the most significant increase in sub-G1 
compared to cells treated with etoposide, doxorubicin and hydroxyurea (Figure 3.4.2).   
 
 
 
 
Figure 3.4.2: RITA activates cell death in normoxia and in hypoxia 
Graph shows the percentage of HCT116 p53+/+ cells in sub-G1 that have been treated for 
16 hours in normoxia (20% O2), or in hypoxia (1% O2), with either 500nM RITA, 25µM 
etoposide, 1µM doxorubicin or 1mM hydroxyurea. Cells were harvested for flow cytometry 
analysis and stained using propidium iodide to assess cell cycle profiles. The sub-G1 
population for each treatment was gated and quantified. Data is averaged from 3 
independent repeat experiments. An unpaired t-test was used to compare significance 
between control and treated cells and a two-tailed p-value <0.05 was considered significant 
(***p<0.0005, **p<0.005, *p<0.05). Standard error bars are shown in every graph unless 
otherwise indicated. 
 
 
To confirm that RITA was mediating cell death by activating apoptosis, HCT116 p53+/+ 
cells were treated with RITA alone or in combination with the caspase 3 inhibitor Z-
DEVD-FMK (Figure 3.4.3). Cells dosed with 500nM RITA in the presence of caspase 
inhibitor showed a significant reduction in sub-G1 content, suggesting that sub-G1 cells 
are those that are undergoing apoptotic cell death (Figure 3.4.3).  
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Figure 3.4.3: RITA mediates cell death by activating apoptosis 
Graph shows the percentage of HCT116 p53+/+ cells in sub-G1 that have been treated with 
500nM RITA alone, or in combination with the caspase inhibitor Z-DEVD-FMK for 24 hours 
in normoxia. Following treatment, cells were harvested for flow cytometry and stained using 
propidium iodide. Cell cycle DNA profiles for each treatment were gated and quantified for 
sub-G1. Data shown has been averaged from 3 independent experiments. An unpaired t-test 
was used to assess significance and a two tailed p-value of <0.05 was considered 
statistically significant.  
  
 
As cell death was induced by RITA in hypoxia, western analysis was used to assess 
whether p53 stabilisation in response to RITA affected HIF-1α protein expression. As 
indicated by cleaved PARP, another marker for apoptotic cell death, 500nM RITA 
induced cell death both in normoxia and in hypoxia. This was in agreement with flow 
cytometry data shown in Figure 3.4.2 and published previously by our laboratory (Yang 
et al., 2009b). Interestingly, RITA could also inhibit HIF-1α protein expression in 
hypoxia. Effects on HIF-1α protein expression were not observed to the same extent in 
cells that had been treated with etoposide, doxorubicin, or hydroxyurea (Figure 3.4.4).  
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Figure 3.4.4: RITA inhibits HIF-1α protein expression 
Western blot shows HIF-1α, cleaved poly ADP ribose polymerase (PARP), p53, and 
phosphorylated γH2AX  protein levels in HCT116 p53+/+ cells treated with either DMSO, 
500nM RITA, 25µM etoposide, 1µM doxorubicin or 1mM hydroxyurea for 16 hours in 
normoxia (N), or in hypoxia (H). β-actin was used as a loading control. Data shown is 
representative of 3 independent experiments. 
 
 
Unlike other DNA damaging agents that promote cell cycle effects when p53 is 
activated, RITA primarily activates apoptosis, both in normoxia, and in hypoxia. As 
shown in Figure 3.4.4, RITA also inhibits HIF-1α protein expression in hypoxia (Yang et 
al., 2009b).  
3.5 RITA elicits p53-dependent DNA damage responses 
So far, studies from our laboratory by Yang et al. have shown that RITA can induce 
p53 and inhibit HIF-1α protein expression in hypoxia (Yang et al., 2009b). Further 
analysis has shown that these effects are distinct compared to other DNA damaging 
agents which activate p53 (Figure 3.4.4). Next, I aimed to investigate the mechanism 
by which RITA activates p53 in the cell. RITA’s proposed mechanism of action was 
described to involve direct binding of RITA to the N-terminal domain of p53 leading to 
disruption of the p53-HDM2 interaction and stabilisation of p53 (Issaeva et al., 2004). In 
previous studies however, when p53 and HDM2 were both stabilised in the cell by the 
proteosomal inhibitor MG132, RITA was unable to disrupt p53-HDM2 complexes (Yang 
et al., 2009b). In contrast and as expected, the small molecule inhibitor of HDM2, 
nutlin-3 impaired p53-HDM2 binding leading to p53 activation (Yang et al., 2009b). 
Detailed studies using nuclear magnetic resonance (NMR) to assess conformational 
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shifts in p53 and HDM2 complexes upon RITA treatment also indicated that RITA does 
not interfere with the p53-HDM2 interaction in vitro and suggested that RITA may 
stabilise p53 by other mechanisms (Krajewski et al., 2005).  
 
RITA can induce protein-DNA and DNA-DNA intrastrand cross-links in vitro suggesting 
that RITA may elicit DNA damage (Nieves-Neira et al., 1999; Rivera et al., 1999). To 
explore the possibility of whether RITA could induce a DNA damage response, 
phosphorylation of p53 was assessed at sites commonly activated by genotoxic stress 
within the N-terminus (Ashcroft et al., 2000; Jimenez et al., 1999). RITA was found to 
induce phosphorylation of p53 at serine 15 and serine 46 (Figure 3.5.1, Ahmed et al., 
2011).  
 
The DNA damage protein H2AX was also phosphorylated in response to RITA 
treatment (Figure 3.4.4, 3.5.1). H2AX is a member of the H2A family which are involved 
in organising DNA into chromatin, and also form part of the replication machinery. 
When phosphorylated at serine 139, H2AX referred to as γH2AX (gamma-H2AX) 
localises to points of DNA strand breaks both during DNA synthesis, and in response to 
genotoxic stress, forming a platform on which repair and checkpoint proteins can 
mediate a response (Bonner et al., 2008). Phosphorylation of p53 and induction of 
γH2AX in response to RITA was observed only in cells with wildtype p53 (Figure 3.5.1). 
 
 
   
 
Figure 3.5.1: RITA induces phosphorylation of p53 and γH2AX 
Western blot shows phosphorylated p53 at serine 15 and serine 46, indicated as p-p53 
(Ser15) and p-p53 (Ser46), total p53, and γH2AX (phosphorylation site S139) protein levels 
in HCT116 p53+/+ and HCT116 p53-/- cells treated with 1µM RITA over a 24 hour 
timecourse in normoxia. β-actin was used as a loading control. A representative blot from 3 
independent experiments is shown. 
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Fluorescent based INCell imaging was used to confirm induction of p53 and γH2AX 
protein in cells treated with RITA. HCT116 p53+/+ cells were treated with RITA, nutlin, 
or etoposide and assessed for changes in cell number, p53 nuclear intensity and 
γH2AX nuclear intensity. As expected, p53 protein was stabilised in cell nuclei treated 
with RITA, nutlin, and etoposide. However, γH2AX nuclear intensity was only induced 
in cells treated with either RITA or etoposide (Figure 3.5.2).  
 
Basal levels of p53 protein are maintained in normal cells by the negative feedback 
loop between p53 and HDM2. HDM2 is both a transcriptional target and an E3 ligase 
for p53 (Haupt et al., 1997; Kubbutat et al., 1997). Recently, p53 protein expression 
was shown to oscillate in normal cells, and these pulses corresponded to transient, 
harmless breaks in DNA as cells progressed through the normal cell cycle (Loewer et 
al., 2010). The repeated firing of feedback loops induced by DNA damage sensors 
such as ATM are important mechanisms with which to re-evaluate DNA damage, and 
determine the length of each p53 response (Batchelor et al., 2008).  However, despite 
p53 protein being stabilised in normal cells, p53 was not transcriptionally active 
(Loewer et al., 2010). Instead, the post-translational modifications on p53 following 
specific forms of genotoxic stress were thought to play an important role in determining 
p53 transcriptional activity (Loewer et al., 2010). 
  
Changes in basal p53 protein expression were not observed when analysing p53 
protein over whole cell populations (Loewer et al., 2010). In immunoflourescent 
experiments, I also noted that 2-5% of cells in the control population had elevated 
nuclear p53 protein expression that was similar in intensity to cells treated with RITA, 
nutlin and etoposide (Figure 3.5.2). The mismatch repair (MMR) pathway involves a 
number of proteins that recognise and repair mismatched DNA base pairs, and this 
pathway is often defective in hereditary non-polyposis colorectal cancer (Toft and 
Arends, 1998). The HCT116 colon carcinoma cell line is also defective in mismatch 
repair and therefore has greater sensitivity to genomic instability compared to other 
tumour cell lines (Robinson et al., 2003). It is therefore likely, that basal p53 expression 
may also be elevated in this cell line. Nevertheless, our observations are interesting 
because they highlight significant differences in p53 dynamics in individual cells, both 
at the basal level and in response to genotoxic stress. 
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Figure 3.5.2: Immunoflourescence analysis of p53 stabilisation and γH2AX induction 
in response to RITA, nutlin and etoposide 
Immunoflourescent images show HCT116 p53+/+ cells that have been treated with DMSO 
controls and either 500nM RITA, 4µM nutlin, or 25µM etoposide for 24 hours in normoxia. 
Cells were fixed following treatment and stained using DAPI (4’6’-diamidino-2-phenylindole, 
indicated by blue staining), p53 (with an Alexa Fluor 488 conjugated secondary antibody, 
indicated by green staining), and γH2AX (with an Alexa Fluor 568 conjugated secondary 
antibody, indicated by red staining). Images were acquired using INCell1000 software at 20x 
magnification. 10 fields of view were captured for each fluorescent wavelength, and each 
treatment. Images shown are representative of 3 repeat experiments. 
 
 
Fluorescent images of HCT116 p53+/+ and HCT116 p53-/- cells treated with RITA and 
stained for cell nuclei, nuclear p53 protein, and γH2AX were quantified. HCT116 
p53+/+ cells treated with RITA, nutlin, and etoposide showed significant decreases in 
cell numbers compared to control wells indicating induction of cell death (Figure 
3.5.3A). Changes in cell number were not observed in HCT116 p53-/- cells following 
treatment. As expected, average p53 nuclear intensity was significantly increased in 
cells treated with all p53-inducing agents, compared to controls and this was only 
observed in HCT116 p53+/+ cells (Figure 3.5.3B). Interestingly, unlike nutlin, RITA 
significantly induced γH2AX nuclear intensity in a p53-dependent manner. Although 
γH2AX was also induced in cells treated with etoposide, and to a greater degree 
compared to RITA treated cells, γH2AX induction by etoposide was not p53-dependent 
(Figure 3.5.3C).  
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Figure 3.5.3: Quantification of p53 stabilisation and γH2AX in response to RITA, nutlin 
and etoposide 
Graphs show HCT116 p53+/+ (darker shades) and HCT116 p53-/- (lighter shades) cells 
treated with either DMSO controls, 500nM RITA, 4µM nutlin, or 25µM etoposide for 24 hours 
in normoxia. Cells were fixed and stained using DAPI (to indicate nuclei), p53 (followed by 
an Alexa Fluor 488 conjugated secondary antibody), and phosphorylated γH2AX (followed 
by an Alexa Fluor 568 conjugated secondary antibody). Staining was visualised using the 
INCell 1000 and images were captured for each fluorescent intensity at 20x magnification, 
over 10 fields of view. Acquired images were quantified and graphs shown indicate (A) 
average cell count/well, (B) average p53 intensity/nucleus, and (C) average γH2AX 
intensity/nucleus for each treatment. Data has been averaged from 3 independent 
experiments. An unpaired t-test was used to compare the means of control and treated cells 
for each cell line and a p-value <0.05 was considered statistically significant (*<0.05, 
**<0.005, ***<0.0005). 
 
 
Phosphorylation of CHK1 and CHK2 was analysed to assess whether the canonical 
DNA damage response pathway involving ATM and ATR was activated by RITA 
treatment. HCT116 p53+/+ cells treated with RITA showed increased phosphorylation 
of CHK1 and CHK2 and this was inhibited following siRNA mediated knockdown of 
ATR and ATM respectively (Figure 3.5.4). Interestingly, when CHK1 and CHK2 
phosphorylation was inhibited by ATR and ATM siRNA, p53 stabilisation in response to 
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RITA was not significantly affected suggesting that ATM/ATR signalling is not essential 
for driving p53 induction in response to RITA. This data show that RITA induces a DNA 
damage response involving CHK1 and CHK2 phosphorylation (Ahmed et al., 2011; 
Yang et al., 2009a). 
 
 
 
 
Figure 3.5.4: RITA induced CHK1 and CHK2 phosphorylation is inhibited by ATM and 
ATR siRNA 
Western blot shows HCT116 p53+/+ cells transfected with 100nM siRNA for ATM and ATR 
for 24 hours prior to a 24 hour dose with 500nM RITA in normoxia. DMSO was used on 
control cells. Following treatment, HCT116 p53+/+ cells were harvested for western blotting 
and analysed for phosphorylated CHK1 (p-CHK1), total CHK1, phosphorylated CHK2 (p-
CHK2), total CHK2, and p53 protein levels. β-actin was used as a loading control. A 
representative blot from 2 independent experiments is shown. 
 
 
Previous data from our laboratory has shown that induction of γH2AX and CHK1 
phosphorylation in response to RITA is p53-dependent (Ahmed et al., 2011; Yang et 
al., 2009a). To reconfirm p53-dependent induction of γH2AX (Figure 3.5.3) and CHK1, 
HCT116 p53+/+ and HCT116 p53-/- cells were treated with RITA and assessed for 
γH2AX, and CHK1 phosphorylation by western analysis (Figure 3.5.5). Phosphorylated 
CHK1 and γH2AX proteins were induced in response to RITA in HCT116 p53+/+ cells 
and this was not observed HCT116 p53-/- cells. 
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Figure 3.5.5: RITA induces phosphorylated CHK1 and γH2AX in p53 positive cells 
Western blot analysis shows HCT116 p53+/+ and HCT116 p53-/- cells treated with either 
DMSO control (indicated as -), or 500nM RITA (indicated as +) in normoxia for 24 hours. 
Cells were analysed for cleaved PARP (poly ADP ribose polymerase), phosphorylated CHK1 
(p-CHK1), total CHK1, p53 and γH2AX (phosphorylation site ser139) protein levels. α-tubulin 
was used as a loading control. Representative data from 3 independent experiments is 
shown.  
 
 
3.6 RITA induces DNA damage 
Cells that suffer from extreme oxygen deprivation (less than 0.5%) elicit cell cycle 
arrest by activating DNA damage responses involving ATM and ATR (Bencokova et al., 
2009). Such responses prevent the formation of lethal DNA strand breaks (Hammond 
et al., 2002). The mechanisms that hypoxic cells employ against DNA damage 
contribute significantly to the resistant and aggressive nature of hypoxic tumours. 
Previous data has demonstrated that RITA can elicit p53-dependent DNA damage 
responses involving γH2AX, phosphorylation of CHK1 and p53. To assess whether 
RITA treatment was sufficient to induce DNA damage responses as well as detectable 
DNA strand breaks, single cell gel electrophoresis assays, also known as the comet 
assays were performed and DNA damage was analysed in HCT116 p53+/+ and MCF7 
cells treated with 500nM RITA. Representative SYBR Green and inverted images used 
for analysis are shown in Figure 3.6.1. 
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Figure 3.6.1: RITA induces DNA strand breaks 
The comet assay was used as a method with which to assess the extent of DNA damage 
induced by RITA in individual cells. An alkaline comet assay was performed to detect single 
strand DNA breaks following 500nM RITA treatment for 24 hours. A 20 minute dose of 
100µM hydrogen peroxide (H2O2) was used as the positive control for DNA damage. 
Treated cells were mixed with agarose, lysed, and placed on slides for electrophoresis. 
Following electrophoresis, cell nuclei were fixed and stained using SYBR Green. Images of 
individual nuclei (or comets) were captured using an inverted fluorescent microscope at 10x 
magnification. Approximately 100 comets were imaged for each treatment and quantified 
using TriTek CometScore
TM
 software (see materials and methods). Images show: (A) 
HCT116 p53+/+ and (B) MCF7 cells treated with either H2O2 (hydrogen peroxide), DMSO 
control, or 500nM RITA. Top panel shows a representative SYBR Green image of a single 
comet and the inverted image used for quantification is shown below.  
  
 
Olive moment was used to quantify DNA damage in each comet as an assessment of 
the quantity of fragmented DNA and the migration distance of DNA from the comet 
head to the tail (Olive et al., 1990). As shown in Figure 3.6.2, although not statistically 
significant, HCT116 p53+/+ and MCF7 cells treated with RITA had a slight and 
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measurable increase in DNA strand breaks that was reproducible over numerous 
experiments.  
 
 
 
 
Figure 3.6.2: RITA induces DNA strand breaks 
Graph shows olive moment of HCT116 p53+/+ and MCF7 cells treated with either DMSO (as 
an untreated control), or 500nM RITA for 24 hours in normoxia. Hydrogen peroxide (H2O2) 
was used as a positive control for DNA damage and dosed at 100µM for 20 minutes at 4°C.  
Following treatment, cells were mixed with agarose and spread onto comet assay slides for 
lysing and electrophoresis (see materials and methods). Once electrophoresed, cells were 
fixed and stained for DNA using SYBR Green. Stained cells, referred to as comets were 
visualised on an inverted fluorescent microscope at 10x magnification. Approximately 100 
comets were imaged for each treatment and DNA damage was quantified using TriTek 
CometScore
TM
 software. Olive moment was used to measure extent of DNA damage in each 
nucleus (or comet) by calculating the quantity of fragmented DNA that migrates from the 
comet head to the comet tail, as well as the distance that the DNA travels through the comet 
tail. Data shown is taken from mean olive moments over 3 independent experiments. An 
unpaired t-test was used to test statistical significance and a p-value of less than 0.05 was 
considered significant.  
 
 
Cells treated with RITA for DNA damage analysis by the comet assay were harvested 
in parallel for western blotting. As shown in Figure 3.6.3, DNA strand breaks elicited by 
RITA in HCT116 p53+/+ and MCF7 cells correlate with induction of γH2AX, and with 
cell death as assessed by cleaved PARP. In summary, RITA induces detectable DNA 
strand breaks as well as p53-dependent DNA damage responses involving 
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phosphorylation of p53, γH2AX and the canonical CHK1 and CHK2 DNA damage 
signalling pathway as previously shown. 
 
 
          
 
Figure 3.6.3: DNA damage induced by RITA correlates with p53 stabilisation, γH2AX 
induction, and cleaved PARP 
Western blot shows cleaved PARP (poly ADP ribose polymerase), phosphorylated p53 at 
serine 15 (p-p53), total p53, and γH2AX protein levels of HCT116 p53+/+ and MCF7 cells 
treated with either DMSO control, or 500nM RITA for 24 hours in normoxia. β-actin was used 
as a loading control. A representative blot from 3 independent experiments is shown. 
 
 
3.7 RITA does not induce DNA damage and cell death in Saos-2 cells 
As discussed, RITA-induced cell death and DNA damage responses are only elicited in 
tumour cells with wildtype p53 (Yang et al., 2009a). In previous studies, MCF7 p53 
wildtype cells, HCT116 p53 wildtype cells, and HCT116 p53 null cells have been used 
to confirm the p53-dependent activity of RITA. To extend these studies to other cell 
lines which differ in p53 status, Saos-2 p53 null cells were also treated with RITA and 
did not show significant cell death in both normoxia and hypoxia (Figure 3.7.1).  
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Figure 3.7.1: RITA does not induce apoptosis in HCT116 p53-/- or Saos-2 cells 
HCT116 p53+/+, HCT116 p53-/-, and Saos-2 cells were treated for 24 hours with either 
DMSO as control, or 500nM RITA in normoxia (20% O2) and in hypoxia (1% O2). Following 
treatment cells were harvested for flow cytometry and stained with propidium iodide to 
analyse DNA content: (A) DNA cell cycle histograms show cell count (y-axis) against 
propidium iodide intensity (x-axis). Top panel (blue) shows profiles of cells treated in 
normoxia, and bottom panel (orange) shows cells treated in hypoxia. Cell cycle histograms 
were gated for sub-G1 populations, and representative quantifications of the percentage of 
cells in sub-G1 are indicated on each histogram, (B) Graph shows percentage sub-G1 
population for each treatment that has been averaged over 3 independent experiments.  
 
 
 
A. 
B. 
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Western analysis was used to assess Saos-2 cells for RITA induced cell death as 
indicated by cleaved PARP. Compared to HCT116 p53+/+ cells, Saos-2 cells were not 
affected by RITA treatment and showed no change in cleaved PARP (Figure, 3.7.2). 
These results show that RITA induces cell death only in transformed cells that have 
wildtype p53. 
 
 
       
 
Figure 3.7.2: RITA does not induce cleaved PARP, γH2AX or p53 in Saos-2 cells 
Western blot shows cleaved PARP (poly ADP ribose polymerase), phosphorylated γH2AX 
and p53 protein levels in HCT116 p53+/+ and Saos-2 cells treated with 1µM RITA for 24 
hours in normoxia. β-actin was used as a loading control. Data shown is representative of 3 
independent experiments. 
 
 
In addition to this, while HCT116 p53+/+ cells showed a small, but detectable increase 
in olive moment by RITA treatment, similar changes in DNA damage were not 
observed in Saos-2 cells (Figure 3.7.3). This data confirm that RITA mediated cell 
death, DNA damage responses involving γH2AX, and CHK1, and formation of DNA 
strand breaks are dependent on wildtype p53. 
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Figure 3.7.3: RITA does not induce DNA strand breaks in Saos-2 cells 
Graph shows olive moment of HCT116 p53+/+ and Saos-2 cells treated with 1µM RITA for 
24 hours in normoxia. Following treatment, cells were mixed with agarose and spread onto 
comet assay slides for lysis, and electrophoresis. Cells were then fixed and stained for 
SYBR Green to detect DNA. Cell nuclei (referred to as comets) were visualised using a 
fluorescent microscope. Images were taken over 20 fields of view at 10x magnification, and 
approximately 100 comets were quantified for each treatment using TriTeck
TM
 software (see 
materials and methods). Olive moment was used as a measure of DNA damage. An 
unpaired t-test was used to calculate statistical signifance and a p-value of less than 0.05 
was considered significant. Data shown has been averaged from 3 independent repeats. 
 
 
3.8 Discussion 
RITA was originally isolated from a cell based screen using the National Cancer 
Institute (NCI) compound library and was shown to induce p53 and mediate p53-
dependent anti-tumour effects (Issaeva et al., 2004). Previous data from our laboratory 
have shown that RITA can induce significant tumour cell death in both normoxia and 
hypoxia, by a p53-dependent pathway (Yang et al., 2009a; Yang et al., 2009b). These 
findings were extended in this chapter to assess responses of other p53-activating 
agents in normoxia and in response to hypoxia. RITA mediated cell death responses 
were of particular interest because they were found to be distinct from other DNA 
damaging agents that activate p53 and induce cell cycle arrest.  
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Because tumour cell death by RITA is p53-dependent, the mechanism by which p53 is 
induced by this agent was explored. RITA was originally proposed to activate p53 by 
disrupting the p53-HDM2 interaction (Issaeva et al., 2004) however subsequent studies 
indicated that RITA did not inhibit this interaction (Yang et al., 2009a; Yang et al., 
2009b). Instead, RITA was found to induce p53-dependent DNA damage responses 
(Yang et al., 2009a). The p53-dependent DNA damage response elicited by RITA was 
defined by phosphorylation of p53, phosphorylation of CHK1 and CHK2 to indicate 
ATM and ATR activation, and induction of γH2AX (Yang et al., 2009b). The comet 
assay was used to assess whether RITA induced DNA strand breaks. Although not 
statistically significant, RITA was found to induce detectable DNA damage that was 
p53-dependent and reproducible over numerous independent experiments. The 
proposed model for these responses is summarised in Figure 3.8.1.  
 
This is the first study in which p53-dependent DNA damage response pathways have 
been described. In the canonical DNA damage response, p53 is induced following 
activation of ATM and ATR in response to genotoxic stress. Due to the fact that DNA 
damage and DNA damage responses involving γH2AX induction and CHK1 
phosphorylation are only observed in cells that are p53 wildtype we propose that RITA 
functions directly at the level of DNA and that wildtype p53 is not only an effector 
signalling node, but also acts itself as an essential sensor of DNA damage that 
mediates downstream RITA induced DNA damage responses.  
 
This model is supported by studies where p53 has been shown to be involved in 
regulating homologous recombination directly, an important DNA repair process that 
regulates genomic integrity during DNA replication (Hoeijmakers, 2001b; Lee et al., 
1997). Homologous recombination is regulated by numerous proteins and enzymes. 
Strand exchange reactions are induced by RAD51 which is part of a large complex of 
repair enzymes, recombination proteins and helicases (Wang et al., 2000). Bloom 
syndrome protein (BLM) is a RecQ helicase that accumulates in S-phase (Bischof et 
al., 2001) and is involved in replication fork repair (Chakraverty and Hickson, 1999). By 
binding directly to BLM, p53 has been shown to co-localise with RAD51 at sites of 
stalled replication forks induced by hydroxyurea treatment and in doing so, p53 is 
proposed to have a direct function in modulating homologous recombination (Sengupta 
et al., 2003). Importantly, binding and relocalisation of p53 to sites of DNA strand 
breaks during replication is independent of its transactivation functions providing 
another level of control whereby p53 maintains cell cycle responses by directly 
inducing repair mechanisms 
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A role for p53 in sensing DNA damage has also been suggested by Rashid et al, 
whereby phosphorylated p53 is recruited to sites of DNA strand breaks in an ATM-
dependent manner (Al Rashid et al., 2005). Furthermore, p53 has been shown to 
reside at specific target gene promoters in the absence of genotoxic stress (Kaeser 
and Iggo, 2002). Localisation of p53 at the DNA not only allows p53 to function as a 
molecular sensor, but also induces rapid transcriptional responses upon binding of 
specific co-factors when stress signals are elicited (Aylon and Oren, 2007). Clearly the 
cellular localisation of p53 is an important determinant of its immediate responses to 
stress, and localisation of p53 at the DNA may provide p53 with an important 
opportunity to sense and transmit DNA damage signals to downstream effector 
pathways. Collectively, these studies and the data which has been presented in this 
chapter provide an important rationale with which to investigate the novel p53-
dependent responses described in greater detail. 
3.9 Conclusions for this chapter 
 RITA elicits cell death in normoxia and in response to hypoxia. 
 RITA inhibits HIF-1α protein expression in hypoxia. 
 RITA induces a DNA damage response involving phosphorylation of p53, induction 
of γH2AX, and phosphorylation of CHK1 and CHK2. 
 DNA damage responses involving γH2AX and phosphorylated CHK1 induced by 
RITA are p53-dependent. 
 RITA induces DNA strand breaks in cells that are p53 positive. 
3.10 Impact of these findings 
Hypoxic tumours are resistant to radio- and chemotherapy, and demonstrate poor p53 
activity (Ashcroft et al., 2000; Koumenis et al., 2001). RITA is a small molecule 
activator of p53 that induces p53-dependent cell death responses in normoxia, and in 
response to hypoxia. Our studies have demonstrated that RITA mediated DNA damage 
and DNA damage responses are dependent on wildtype p53, findings that have not 
been shown in response to other p53 activating agents. Using p53 activation in 
tumours with deregulated HIF pathways is an important strategy with which to sensitise 
radio- and chemoresistant tumours to cell death. Furthermore, use of pharmacological 
activators of p53 will strengthen our understanding of the interactions between HIF and 
p53 in hypoxia, as well as reveal novel pathways that can be used to improve the 
selective targeting of hypoxic tumours. 
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Figure 3.8.1: Induction of wildtype p53 by RITA elicits p53-dependent DNA damage 
and DNA damage responses that mediate cell death responses 
The proposed model for targeting wildtype p53 using RITA involves induction of DNA strand 
breaks and DNA damage response involving ATM-CHK2, ATR-CHK1, and γH2AX. These 
processes are dependent on p53, lead to p53 phosphorylation, and induce cell death in 
normoxia, and in hypoxia.  
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4.1 Introduction 
In studies by Isseavia et al. in which the anti-tumour effects of RITA were first 
described, RITA was proposed to activate p53 by binding to the N-terminal domain of 
p53 and disrupting its interaction with HDM2 (Issaeva et al., 2004).  In initial studies by 
Yang et al. in our laboratory, when both p53 and HDM2 were stabilised in the cell by 
the proteosome inhibitor MG132, RITA was unable to disrupt p53-HDM2 complexes 
(Yang et al., 2009b). In contrast, nutlin-3 a small molecule inhibitor of HDM2 impaired 
the ability of HDM2 to immunoprecipitate with p53 (Yang et al., 2009b). RITA therefore 
does not activate p53 by targeting the p53-HDM2 interaction suggesting that RITA has 
alternative mechanisms for stabilising and activating p53.  
 
In chapter 3 the p53-dependent activity of RITA was assessed (Yang et al., 2009a; 
Yang et al., 2009b). RITA induced a distinct DNA damage response in cells that had 
wildtype p53, and this involved phosphorylation of CHK1, CHK2, p53 and induction of 
γH2AX (Yang et al., 2009a). The DNA damage response studied in response to RITA 
is important because it requires wildtype p53 and is not observed with other agents that 
activate p53. In this chapter, the mechanisms of RITA induced p53-dependent DNA 
damage responses will continue to be addressed. 
 
Previous data in our laboratory using confocal immunoflourescent microscopy 
demonstrated that cells treated with RITA and hydroxyurea have pan-nuclear staining 
of γH2AX (Yang et al., 2009a). The γH2AX staining observed in response to RITA and 
hydroxyurea was similar to that of UV irradiated cells and distinct from other types of 
stresses such as γ-irradiation where more defined γH2AX foci form in the nucleus 
(Marti et al., 2006; Yang et al., 2009a). Marti et al. showed that pan nuclear γH2AX co-
localised with bromodeoxyuridine (BrdU) staining, a DNA precursor analogue that 
incorporates into DNA during synthesis. These studies indicated that γH2AX localises 
to sites of DNA replication during S-phase in response to stress induced by UV 
treatment. Although γH2AX was detected in cells during all phases of the cell cycle in 
response to UV treatment, γH2AX intensity was greatest during S-phase (Marti et al., 
2006). As both UV irradiation and RITA treatment lead to distinct localisation patterns 
for γH2AX it will be of interest to assess whether, like UV treatment, DNA damage 
induced by RITA also has significant effects in cells during S-phase. 
 
 
 Chapter 4: RITA activates p53-dependent cell cycle checkpoints 
 
 
Page: 102 
4.2 Hypothesis 
RITA activates p53-dependent cell cycle checkpoints.    
4.3 Aims 
 Investigate the mechanism by which RITA activates p53 to induce tumour cell 
death in more detail. 
 Characterise cell cycle checkpoints elicited by RITA in the context of the DNA 
damage response described so far. 
4.4 RITA induces p53 and γH2AX in specific cell cycle phases 
RITA not only forms DNA strand breaks, but also elicits DNA damage responses 
involving phoshorylation of CHK1, CHK2 and induction of γH2AX. Interestingly, 
phosphorylation of CHK1 and induction of γH2AX was primarily observed in cells with 
wildtype p53, and because of this, it was concluded that p53 stabilisation by RITA was 
upstream of CHK1, and γH2AX induction (Ahmed et al., 2011). The RITA induced DNA 
damage response described is therefore a p53-dependent DNA damage response.  
 
Previous immunohistochemical analyses from our laboratory have shown that both 
RITA and hydroxyurea induce pan-nuclear localisation of γH2AX rather than 
localisation of γH2AX at discrete foci (Yang et al., 2009a), a phenotype that is 
indicative of replication fork stalling, and inhibition of replication fork elongation (Marti et 
al., 2006). DNA damage induced during DNA replication often leads to the activation of 
S-phase checkpoints (Merrick et al., 2004) involving γH2AX localisation at DNA strand 
breaks, as well as activation of ATR and CHK1 signalling (Chen and Sanchez, 2004; 
Liu et al., 2000). By regulating DNA damage responses and repair in response to DNA 
strand breaks that occur during replication, S-phase checkpoints prevent cells with 
damaged DNA from progressing into the next phase of the cell cycle. Due to similarities 
in γH2AX staining between RITA, hydroxyurea, and UV treated cells, I hypothesised 
that DNA damage induced by RITA also activates cell cycle checkpoints, and that 
these checkpoints are dependent on wildtype p53.  
 
To address this hypothesis, RITA’s affects on the replication fork machinery and S-
phase progression was investigated. A DNA fibre assay was performed by our 
collaborators Apolinar Maya-Mendoza and Dean Jackson (University of Manchester, 
UK) as previously described (Jackson and Pombo, 1998). In this assay, DNA is 
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labelled with BrdU and DNA spreads are prepared to visualise the number of 
replication forks present in the DNA. RITA treatment increased the percentage of 
replication forks in HCT116 p53+/+ cells but not in HCT116 p53-/- cells, indicating 
stalling of the replication fork machinery. A delay in replication fork progression was 
also observed in cells treated with RITA, indicating prolonged S-phase. This was 
further confirmed by Apolinar Maya-Mendoza and Dean Jackson using BrdU staining to 
visualise DNA foci. Immunoflourescent analysis of BrdU foci showed that S-phase was 
delayed during mid-late stages in RITA treated cells with wildtype p53 (Ahmed et al., 
2011). 
 
Data from Apolinar Maya-Mendoza and Dean Jackson suggested that RITA affects 
cells that are in S-phase (Ahmed et al., 2011). I extended these studies using flow 
cytometry as a method to assess changes during each phase of the cell cycle. HCT116 
p53+/+ cells were analysed for both p53, and γH2AX (phosphorylated at serine 139) 
following RITA treatment in each cell cycle phase. With support from Science Support 
Services at the Wolfsson Institute (University College London) HCT116 p53+/+ cells 
were dual stained with p53, using a FITC (fluorescein isothiocyanate) conjugated 
secondary antibody, and γH2AX, using an APC (allophycocyanin) conjugated 
secondary antibody. The fluorescent tags used on the secondary antibodies did not 
have overlapping wavelengths, and could therefore be detected by the flow cyctometer 
with minimum need for compensation. Specificity of the secondary antibodies used was 
tested in untreated HCT116 p53+/+ cells. When staining HCT116 p53+/+ cells with 
secondary antibodies alone, there was no significant shift in fluorescent intensity 
compared to the unstained population suggesting that the secondary antibodies used 
do not bind to cells non-specifically. When staining with both primary and secondary 
antibodies together, a significant shift in fluorescent intensity was detected indicating 
that the secondary antibodies used are specific for their corresponding primary 
antibodies (Figure 4.4.1). 
 
 
 
 
 
 
 
 
 
 Chapter 4: RITA activates p53-dependent cell cycle checkpoints 
 
 
Page: 104 
 
 
 
Figure 4.4.1: FACS analysis of FITC and APC antibody controls 
Specificity of FITC and APC secondary antibodies was assessed using the CyAn
TM
 ADP flow 
cytometer (Dako). Graphs show untreated HCT116 p53+/+ cell counts (y-axis) against the 
fluorescent intensity of either FITC (A), or APC (B) conjugated secondary antibodies (x-axis): 
(A) HCT116 p53+/+ cells were unstained (blue), stained for FITC conjugated secondary 
antibody alone (green), or with p53 primary and FITC secondary antibodies together (red),  
(B) HCT116 p53+/+ cells were unstained (blue), stained for APC conjugated secondary 
antibody alone (green), or with γH2AX primary and APC secondary antibodies together 
(red).  Graphs were gated against the secondary antibody peak (gate is indicated by a 
dashed line), and the percentage of cells that have an increase in fluorescent intensity 
compared to the gated secondary antibody peak alone were quantified. The gated 
percentages for specific binding have been indicated below each graph. 
 
 
To assess whether p53 stabilisation and γH2AX induced by RITA could be detected 
using flow cytometry, HCT116 p53+/+ cells were treated with 500nM RITA for 24 hours 
in normoxia. As shown in Figure 4.4.2, HCT116 p53+/+ cells treated with RITA had 
significant increases in p53 fluorescent intensity (Figure 4.4.2A), and in γH2AX 
intensity (Figure 4.4.2B) compared to the untreated controls.   
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Figure 4.4.2: Cells treated with RITA stain positive for p53 and γH2AX 
HCT116 p53+/+ cells were treated with 500nM RITA for 24 hours in normoxia and harvested 
for flow cytometry. Cells were stained for both p53 and γH2AX (phosphorylated S139). 
Histograms show the control cell population (blue) and the RITA treated population (red) for 
(A) p53 staining and (B) γH2AX staining. Cell populations were gated on the control 
population at a 2% threshold, as indicated by the dashed line. The percentage of cells that 
shift in fluorescent intensity towards the gated region was calculated and averaged over 3 
independent experiments. Representative histograms are shown above, and the 
corresponding quantified data is shown in the graphs below. Statistical significance was 
assessed using the unpaired t-test and a two-tailed p-value of <0.05 was considered 
significant. 
 
 
Previous data from DNA fibre assays and pan-nuclear staining of γH2AX has indicated 
that RITA affects cells in S-phase (Ahmed et al., 2011; Yang et al., 2009a). Therefore, 
propidium iodide stained DNA profiles were gated specifically for sub-G1 and S-phase 
to assess changes in p53 stabilisation and γH2AX upon RITA treatment in these cell 
cycle phases. In treated populations there was a significant increase in p53 and γH2AX 
intensity in sub-G1, and also in S-phase populations (Figure 4.4.3). 
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Figure 4.4.3: p53 and γH2AX positive cells are detected in sub-G1 and S-phase 
populations 
Representative flow cytometry plots of cells dosed with RITA for 24 hours and assessed for 
DNA content, p53 and γH2AX (phosphorylated ser139) staining. Panels on the left show 
DNA profiles with cell counts on the y-axis, and propidium iodide staining on the x-axis.  DNA 
profiles were gated according to sub-G1 (red) and S-phase (green). Dot plots of cells taken 
from the gated region within DNA profiles are shown on the right, indicating γH2AX (y-axis) 
and p53 (x-axis) staining in sub-G1 (red-middle plot), and S-phase (green-right plot) cells.  
Changes were quantified within the top right quadrant of the dot plots indicating an increase 
in both p53 and γH2AX staining intensity. Each value on the dot plot represents a single cell 
with fluorescence for p53 and γH2AX staining. The treated population of cells is represented 
in the panel below.  
 
 
Next, because significant changes were observed in p53 and γH2AX in sub-G1 and S-
phase cells that had been treated with RITA, the remaining phases of the cell cycle 
were also analysed. Although increases in p53 and γH2AX in sub-G1, G1, S-phase, 
and G2 were observed, the changes were most significant in the sub-G1 (47% 
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increase in staining), and S-phase (34% increase) populations that had been treated 
with RITA (Figure 4.4.4). 
 
 
  
 
Figure 4.4.4: HCT116 p53+/+ cells stain positive for p53 and γH2AX in cell cycle 
phases 
HCT116 p53+/+ cells were treated with 500nM RITA for 24 hours in normoxia and harvested 
for FACS analysis. Cells were stained for propidium iodide, p53 and γH2AX (phosphorylated 
ser139). Propidium iodide DNA profiles were gated according to cell cycle phase. Graphs 
show: (A) DMSO treated control cells, and (B) cells treated with 500nM RITA. The 
percentage of cells in each phase of the cell cycle that stain positive for both p53 and γH2AX 
(black bar) are shown for each cell cycle phase (white bar). All data has been averaged from 
3 independent repeat experiments. 
 
 
As p53 and γH2AX is induced in S-phase cells, and because of supporting data that 
indicate RITA affects the replication machinery (Ahmed et al., 2011), I hypothesised 
that p53 stabilisation and γH2AX induction is important for eliciting DNA damage 
responses as a result of DNA strand breaks induced by RITA during S-phase. To 
address this hypothesis, HCT116 p53+/+ cells were treated with a dose range of RITA 
A. 
B. 
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to assess dose-dependent changes in the sub-G1 and the S-phase populations upon 
RITA treatment. A dose-dependent increase in sub-G1 cells was found following RITA 
treatment (Figure 4.4.5A) and this correlated with increases in the percentage of cells 
that stained positive for p53 and γH2AX in S-phase (Figure 4.4.5B). Interestingly, p53 
and γH2AX in S-phase cells were induced at lower doses compared to the 
accumulation of sub-G1 cells suggesting p53 induction and γH2AX have greater 
sensitivity to RITA treatment in S-phase cells and may mediate induction of the sub-G1 
population at higher doses.  
 
 
 
 
Figure 4.4.5: RITA induces p53, γH2AX and cell death in a dose-dependent manner 
HCT116 p53+/+ cells were treated with a dose range of RITA for 24 hours in normoxia and 
harvested for flow cytometry. Cells were stained for propidium iodide, p53 protein (with a 
FITC conjugated secondary) and γH2AX (with an APC conjugated secondary). DNA profiles 
of propidium stained cells were gated and quantified according to the percentage of cells in 
(A) sub-G1 and (B) the percentage of cells in S-phase that stain positive for both p53 and 
γH2AX. Graphs represent data averaged from 3 independent repeat experiments. 
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To assess whether sub-G1 and S-phase effects are time-dependent, HCT116 p53+/+ 
and HCT116 p53-/- cells were treated with RITA over a timecourse. The effects of 
RITA on the sub-G1 population, and on staining of p53 and γH2AX in S-phase cells 
was assessed to observe the timescale at which these responses to RITA treatment 
are induced. RITA was found to induce p53 and γH2AX in S-phase cells from 4 hours 
of treatment (Figure 4.4.6B), while sub-G1 cells were induced following 16 hours of 
treatment (Figure 4.4.6A). These data suggest that the S-phase population has greater 
sensitivity to the dose and the length of RITA treatment, and these responses precede 
the induction of sub-G1 cells. Interestingly, no changes in the sub-G1 population or the 
S-phase population in HCT116 p53-/- cells were observed. These are the first findings 
that show p53-dependent DNA damage responses in S-phase cells and are novel 
because they correlate p53 induction and γH2AX in S-phase cells with p53-dependent 
cell death responses elicited by RITA.  
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Figure 4.4.6: RITA induces p53, γH2AX and cell death in a time-dependent and p53-
dependent manner 
HCT116 p53+/+ and HCT116 p53-/- cells treated over a timecourse with 1µM RITA for 24 
hours in normoxia, and harvested for flow cytometry at indicated timepoints. Cells were 
stained with propidium iodide, p53 protein (with a FITC conjugated secondary), and γH2AX 
protein (with an APC conjugated secondary). DNA profiles of cells stained with propidium 
iodide were gated and quantified according to (A) the percentage of cells in sub-G1, and (B) 
the percentage of cells in S-phase that stain positive for both p53 protein and γH2AX. 
Graphs represent data averaged from 3 independent repeat experiments. 
 
4.5 RITA elicits an S-phase cell cycle checkpoint involving CHK1 
phosphorylation 
In accordance with previous data published from our laboratory (Yang et al., 2009a) I 
have shown that RITA can induce phosphorylation of both CHK1 and CHK2 kinases 
suggesting activation of the canonical ATM/ATR pathway (Figure 3.2.5). As discussed, 
RITA treatment induced p53 protein and γH2AX in S-phase cells (Figure 4.4.3), and 
also stalled the replication fork machinery in a p53-dependent manner (Ahmed et al., 
2011). Next, I assessed activation of CHK1 by RITA in greater detail. This is because 
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phosphorylation and activation of CHK1 by ATR is involved in mechanisms that 
mediate DNA replication origin firing, and the stabilisation of replication forks in 
response to UV stress and agents that stall DNA replication forks (Chen and Sanchez, 
2004; Liu et al., 2000). Therefore I hypothesised that like p53 and γH2AX, CHK1 
phosphorylation is also important in eliciting DNA damage responses during S-phase to 
mediate cell death in response to RITA. 
 
Recent studies whereby CHK1 was shown to mediate p53-dependent transcriptional 
responses during S-phase arrest elicited by genotoxic stress support this hypothesis 
(Beckerman et al., 2009). Furthermore, previous work has shown that ATR and CHK1 
dysfunction decreases the viability of cells exposed to agents that cause replication 
stress (Cliby et al., 1998). Similarly, siRNA knockdown of CHK1 sensitises cells that 
have been treated with replication inhibitors to greater apoptosis (Rodriguez et al., 
2008). Due to the established role of CHK1 in regulating checkpoints in response to 
stress (Liu et al., 2000; Takai et al., 2000), the function of CHK1 in RITA induced cell 
cycle and DNA damage responses was investigated. To begin, siRNA mediated 
knockdown of CHK1 was assessed to observe changes in sensitivity to genotoxic 
stress induced by RITA.  
 
Flow cytometry was used to assess changes in CHK1 phosphorylation when HCT116 
p53+/+ cells were treated with RITA, and also investigate changes in cell cycle 
responses when CHK1 is inhibited by siRNA. In parallel to flow cytometry, cells were 
harvested for western blotting to confirm loss of CHK1 protein by siRNA. As shown in 
Figure 4.5.1, appropriate levels of CHK1 protein knockdown was achieved upon 
siRNA, however no significant changes were observed in cleaved PARP or p53 
stabilisation following RITA treatment when CHK1 protein was inhibited by siRNA. 
Notably knocking down of CHK1 by siRNA induced p53 in the absence of RITA. 
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Figure 4.5.1: CHK1 siRNA does not affect RITA induced PARP cleavage 
HCT116 p53+/+ cells were transfected with 25nM of either CHK1 reverse control siRNA or 
CHK1 targeted siRNA. Transfections were incubated for 24 hours. Cells were then treated 
with 500nM RITA for 24 hours in normoxia and harvested for both flow cytometry and 
western blotting. Western blots were analysed for cleaved PARP as (an indicator of 
apoptosis), p53 stabilisation, and total CHK1 protein. β-actin was used as a loading control.  
Western data shown is representative of 3 independent experiments.  
 
 
To assess changes in cell cycle profiles, induction of phosphorylated CHK1 protein was 
first assessed in RITA treated cells using flow cytometry. A significant increase in 
phosphorylated CHK1 was observed in HCT116 p53+/+ cell that had been treated with 
RITA, and this was inhibited when CHK1 was targeted by siRNA (Figure 4.5.2).  
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Figure 4.5.2: CHK1 is phosphorylated in response to RITA treatment, and inhibited by 
CHK1 siRNA 
HCT116 p53+/+ cells were transfected with 25nM siRNA for either CHK1 reverse siRNA as a 
control siRNA, or CHK1 targeted siRNA. Transfections were incubated for 24 hours prior to a 
24 hour dose of 500nM RITA in normoxia. Following treatment, cells were harvested for flow 
cytometry and stained for propidium iodide and phosphorylated CHK1 (p-CHK1, serine 345). 
Representative histograms are shown, dashed lines indicate where shifts in p-CHK1 
intensity were gated and quantified. Quantified data is represented below and has been 
averaged from 2 independent experiments. Statistical significance was assessed using the 
unpaired t-test and a p-value <0.05 was considered significant, changes that are not 
significant have been indicated as n.s. 
 
 
Because CHK1 is involved in maintaining DNA integrity by mediating cell cycle 
checkpoints, I predicted that loss of CHK1 may sensitise RITA treated cells to 
apoptosis. However, as shown in Figure 4.5.1, knockdown of CHK1 by siRNA did not 
enhance cleaved PARP indicating that CHK1 siRNA does not affect cell death induced 
by RITA. Similarly, by flow cytometry, knockdown of CHK1 had no significant effect on 
the sub-G1 population of cells treated with RITA (Figure 4.5.3). In conclusion CHK1 is 
therefore not essential for mediating cell death in response to RITA.  
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Figure 4.5.3: Loss of CHK1 does not affect RITA induced sub-G1 
Graphs show DNA histograms of: (A) HCT116 p53+/+ cells treated with CHK1 reverse 
siRNA prior to a 24 hour dose of either DMSO control, or 500nM RITA in normoxia, and (B) 
HCT116 p53+/+ cells treated with CHK1 targeted siRNA prior to dosing with DMSO control 
or 500nM RITA. Cells were harvested for flow cytometry and stained using propidium iodide 
to analyse DNA content. DNA histograms show cell count on the y-axis, and propidium 
iodide intensity on the x-axis. Sub-G1 cells were quantified as an indication of cell death 
(indicated by arrows). DNA profiles are representative of 3 independent experiments.  
 
 
In addition to analysing the affects of phosphorylated CHK1 on RITA induced cell 
death, phosphorylated CHK1 was also analysed in S-phase. The S-phase population 
was assessed because CHK1 has been shown to induce cell cycle arrest and p53-
dependent DNA damage response pathways in S-phase (Beckerman et al., 2009). On 
this basis the hypothesis was made that although not important for RITA induced 
apoptosis, CHK1 phosphorylation may affect cells in S-phase. To address this, 
HCT116 p53+/+ and HCT116 p53-/- cells were dual stained for p53 protein and 
phosphorylated CHK1 following RITA treatment. The results show that CHK1 is 
phosphorylated in S-phase, and this correlates with induction of p53 in S-phase cells 
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that have been treated with RITA. Interestingly, these changes were not observed in 
HCT116 p53-/- cells (Figure 4.5.4). The data suggest p53-dependent induction of 
phosphorylated CHK1 in S-phase cells that together with p53 stabilisation may have a 
role in signalling to the DNA damage response upon genotoxic stress induced by RITA. 
 
 
 
 
Figure 4.5.4: RITA mediated phosphorylation of CHK1 is observed in the S-phase 
population of HCT116 p53+/+ cells 
HCT116 p53+/+ and HCT116 p53-/- cells were treated with 500nM RITA for 24 hours in 
normoxia. Cells were harvested for flow cytometry and stained for propidium iodide, 
phosphorylated CHK1 (p-CHK1), using an APC conjugated secondary antibody, and p53 
protein, using a FITC conjugated secondary antibody. DNA profiles were gated for S-phase 
and assessed for increases in p-CHK1 intensity and p53 intensity. Graphs show (A) 
Percentage of HCT116 p53+/+ and (B) HCT116 p53-/- cells that stain positive for p53 protein 
in S-phase, clear bars indicate the total percentage of cells in S-phase, and shaded bars 
indicate the proportion of cells in S-phase which stain positive for p53 protein, (C) 
percentage of HCT116 p53+/+ and (D) HCT116 p53-/- cells that stain positive for p-CHK1 in 
S-phase. Shaded bars indicate the proportion of cells in S-phase which stain positive for p-
CHK1. Graphs are representative of data that has been averaged from 3 independent 
experiments.  
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Phosphorylation of CHK1 has been shown in response to RITA in S-phase cells that 
have wildtype p53. Comet analysis was performed in HCT116 p53+/+ cells to assess 
whether CHK1 phosphorylation affects DNA damage induced by RITA following 24 
hour treatment. Changes in RITA-induced DNA damage were investigated in HCT116 
p53+/+ cells that had siRNA mediated knockdown of CHK1. DNA damage in response 
to 24 hour RITA treatment was not affected by CHK1 siRNA (Figure 4.5.5). 
 
 
 
 
Figure 4.5.5: CHK1 siRNA does not affect RITA induced DNA damage at 24 hours 
HCT116 p53+/+ cells were treated with CHK1 reverse siRNA, or CHK1 targeted siRNA, prior 
to dosing with either DMSO control, or 500nM RITA for 24 hours in normoxia. Following 
treatment, cells were harvested for comet analysis. Graph shows olive moment as a 
quantitative measure of DNA damage elicited by 24 hour RITA treatment. Hydrogen 
peroxide (H2O2) exposure at 100µM for 20min in 4°C was used as a positive control for DNA 
damage. Graph is representative of data averaged form 3 independent experiments. An 
unpaired t-test was used to assess statistical significance and a p-value of less than 0.05 
was considered significant. 
 
 
Loss of CHK1 by siRNA has been shown to have minimal effects on RITA induced cell 
death and DNA damage at 24 hours of treatment. Several studies suggest that CHK1 
activation is important in regulating immediate responses to DNA damage and hence 
maintaining genomic integrity (Hirao et al., 2002; Niida et al., 2010; Rodriguez et al., 
2008). Therefore, CHK1 may contribute to regulating genomic integrity when cells are 
exposed to RITA induced stress at early timepoints. To address this DNA strand 
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breaks were assessed in HCT116 p53+/+ cells with siRNA mediated knockdown of 
CHK1 following exposure to RITA treatment for 1 hour. DNA damage was found to be 
significantly induced in RITA treated cells that had loss of CHK1 compared to the 
untreated controls (Figure 4.5.6, (Ahmed et al., 2011). In conclusion CHK1 induction in 
response to RITA at early timepoints is important in maintaining genomic integrity. 
 
 
 
 
Figure 4.5.6: DNA damage is induced in CHK1 siRNA cells following RITA treatment 
for 1 hour 
Graph shows HCT116 p53+/+ cells transfected with either non-silencing control siRNA 
(NSC), or siRNA targeted against CHK1 prior to 1 hour exposure of 500nM RITA. Following 
treatment cells were harvested for comet analysis, mixed with agarose and spread onto 
comet assay slides for lysis and electrophoresis. Following electrophoresis, slides were fixed 
and stained for SYBR Green to visualise cell nuclei (referred to as comets). Comets were 
visualised using an inverted fluorescent microscope at 10x magnification, and images were 
captured over 20 fields of view for each treatment. Comets were analysed using the 
TriTeck® comet analysis software (approximately 100 comets were quantified for each 
treatment). Olive moment was used as an indication of DNA damage. Data shown is 
representative of 3 independent repeat experiments. An unpaired t-test was used to assess 
statistical significance and a p-value of less than 0.05 was considered significant. 
 
 
To assess whether CHK1 was phosphorylated following 1 hour RITA treatment, 
western analysis was used of HCT116 p53+/+ cells that had been treated with RITA for 
1 hour following siRNA knockdown of CHK1. As shown in Figure 4.5.7, CHK1 
 Chapter 4: RITA activates p53-dependent cell cycle checkpoints 
 
 
Page: 118 
phosphorylation was induced by RITA as early as 1 hour after treatment. CHK1 is 
therefore essential in regulating genomic integrity following short term exposure to 
RITA. 
 
 
 
Figure 4.5.7: CHK1 phosphorylation is induced by 1 hour exposure to RITA 
Western blot shows HCT116 p53+/+ cells treated with 500nM RITA for 1 hour following 
siRNA mediated knockdown of either non-silencing control (NSC), or CHK1 targeted siRNA. 
Western blots were analysed for phosphorylated CHK1 (p-CHK1), total CHK1, p53 and β-
actin as the loading control. Data is representative of 3 independent repeat experiments. 
 
 
In previous experiments, both p53 and γH2AX are induced in all phases of the cell 
cycle following treatment with RITA, including sub-G1 (Figure 4.4.4). The effects 
observed in p53 stabilisation, γH2AX induction, and phosphorylated CHK1 may 
therefore be a result of apoptosis, rather than effects that mediate apoptosis. To test 
this, the caspase 3 inhibitor Z-DEVD-FMK was used to inhibit apoptosis and 
phosphorylated CHK1 was investigated by flow cytometry. As expected, sub-G1 cells 
induced by RITA decreased significantly in the presence of caspase inhibitor, showing 
inhibition of apoptosis (Figure 4.5.8A). Interestingly, phosphorylated CHK1 was not 
inhibited when cells were treated with RITA in the presence of caspase inhibitor (Figure 
4.5.8B) suggesting that phosphorylation of CHK1 is induced upstream of apoptotic 
responses elicited by RITA.  
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Figure 4.5.8: CHK1 phosphorylation in response to RITA is not affected by caspase 
inhibition 
HCT116 p53+/+ cells were treated with 500nM RITA alone, or in combination with 50µM 
caspase inhibitor Z-DEVD-FMK for 24 hours in normoxia. Cells were harvested for FACS 
analysis and stained using propidium iodide and phosphorylated CHK1 (p-CHK1), with an 
APC conjugated secondary antibody: (A) DNA profiles of cells stained with propidium iodide. 
Histograms show cell count verses propidium iodide intensity. The sub-G1 population 
(indicated by arrows) was gated to assess cell death when cells were treated with RITA 
alone, or in combination with Z-DEVD-FMK, (B) Histogram displaying cell count against 
phosphorylated CHK1 (p-CHK1) intensity of control (blue), RITA treated (red), or RITA and 
Z-DEVD-FMK treated cells (green). Histograms were gated according to the control 
population (as indicated by dashed line) and the percentage of cells that shift in 
phosphorylated CHK1 intensity towards this gate was quantified. Data shown is 
representative of 2 independent repeats. 
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4.6 Discussion 
Checkpoint mechanisms are important for inhibiting cell cycle progression in response 
to stress stimuli (Hartwell and Weinert, 1989). S-phase checkpoints are activated when 
replication fork progression is inhibited due to DNA strand breaks that form during 
replication. By delaying S-phase progression in response to DNA strand breaks, 
replication forks can stabilise, and DNA repair can be initiated (Luciani et al., 2004). In 
this chapter, it was hypothesised that DNA strand breaks induced by RITA could 
activate an S-phase checkpoint and DNA fibre experiments were performed to analyse 
replication fork progression in response to RITA treatment (collaboration with Dean 
Jackson, University of Manchester). Previous immunoflourescence studies from our 
laboratory have shown that RITA also induces pan-nuclear staining of γH2AX (Yang et 
al., 2009a), a distinct pattern of staining compared to other forms of DNA damage that 
is associated with activation of an S-phase checkpoint (Marti et al., 2006). 
Consequently RITA treatment in HCT116 p53+/+ cells was shown to result in stalling of 
the replication fork machinery and a p53-dependent delay in S-phase progression 
(Ahmed et al., 2011). I have extended these studies throughout this chapter by 
analysing S-phase cells by flow cytometry and have shown induction of both p53 and 
γH2AX in response to RITA by a mechanism that is both dose and time-dependent, 
and correlates with induction of cell death.  
 
Collectively, these findings have led to a model whereby RITA is proposed to induce 
DNA strand breaks, and stall the replication fork machinery. Stalling of the replication 
machinery elicits an S-phase checkpoint that involves induction of γH2AX, stabilisation 
of p53 and phosphorylation of both CHK1 and CHK2. Of interest are the observations 
that γH2AX induction and CHK1 phosphorylation only occur in cells that have wildtype 
p53, therefore small molecule activation of p53 by RITA elicits a p53-dependent DNA 
damage response that is important for mediating both cell cycle checkpoints, and cell 
death responses. The current proposed model is summarised in Figure 4.6.1.  
 
Tumour suppressor pathways involving checkpoint proteins commonly precede 
activation of apoptosis in response to stress stimuli (Niida et al., 2010). I assessed 
CHK1 phosphorylation in response to RITA treatment in detail because CHK1 
activation in S-phase cells by replication stress has been shown to elicit cell cycle 
arrest, and regulate specific DNA repair pathways (Brown and Baltimore, 2003; Liu et 
al., 2000). Both in vitro and in vivo models demonstrate that genetic loss of Chk1 
induces proliferation defects, loss of cell cycle checkpoints in response to gamma 
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irradiation, and early embryonic lethality (Liu et al., 2000; Takai et al., 2000). Defects in 
cell cycle and cell death pathways caused by loss of Chk1 can be rescued by a single 
Chk1 allele (Niida et al., 2010). Recently, both Chk1 and Chk2 deletion were found to 
promote tumour development in vivo due to enhanced genomic instability (Niida et al., 
2010). 
 
Due to the importance of CHK1 in regulating DNA integrity in response to replication 
stress, I hypothesised that CHK1 phosphorylation is important for activating an S-
phase checkpoint in response to DNA strand breaks induced by RITA treatment. I 
addressed this hypothesis by assessing whether siRNA mediated knockdown of CHK1 
had effects on cell death responses induced by RITA. However, significant changes in 
RITA induced p53 stabilisation and cell death were not observed when CHK1 protein 
was inhibited by siRNA. Analysis of cell death in CHK1 knockdown cells was only 
performed following 24 hours of RITA treatment at which time it is likely that cell death 
responses are maximised. It will be of interest to repeat these studies at earlier 
timepoints following RITA treatment to assess whether loss of CHK1 sensitises cells to 
immediate forms of cell stress, rather than at later timepoints.   
 
DNA repair was also assessed because several studies implicate both CHK1 and 
CHK2 activation in early DNA damage repair pathways that regulate the genomic 
integrity of cells exposed to stress (Hirao et al., 2002). Proliferating cell nuclear antigen 
(PCNA) is localised at sites of DNA replication during S-phase and recruits DNA 
polymerases during replication, as well as a range of repair factors at sites of DNA 
breaks (Tsurimoto, 1999). Shimura et al. have shown that activation of p53 and PCNA 
in response to low dose radiation is important for suppressing replication fork 
progression, and initiating DNA repair pathways (Shimura et al., 2006). Formation of 
replication protein A (RPA) foci that co-localise with PCNA at replication forks and DNA 
strand breaks are important in signalling to ATR and CHK1 so that appropriate DNA 
repair pathways can be co-ordinated (Rodriguez et al., 2008).  
 
Furthermore, at timepoints as early as 1 hour after radiation, p53 is stabilised to 
regulate DNA damage repair and cell death pathways (Niida et al., 2010). Such 
processes are impaired when both CHK1 and CHK2 function is inhibited, enhancing 
genomic instability and thereby promoting cell survival and tumour development (Niida 
et al., 2010). With support from in vitro and in vivo studies that address a functional role 
for CHK1 in DNA repair, I hypothesised that checkpoint signalling in response to RITA 
treatment has an important role in regulating early DNA repair pathways to replication 
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stress. This hypothesis was addressed by analysing the contribution that CHK1 has in 
regulating genomic integrity when cells were immediately exposed to RITA induced 
stress. Data shown confirmed that CHK1 is phosphorylated following 1 hour exposure 
to RITA treatment and loss of CHK1 by siRNA sensitised RITA treated cells to DNA 
damage during this time frame (Ahmed et al., 2011). 
 
Finally, although S-phase DNA damage checkpoints are sensitive to low dose radiation 
and have been studied extensively (Brown et al., 2003), the p53-dependent DNA 
damage S-phase checkpoint that has been shown in this thesis has only been 
described in few studies. This checkpoint was originally identified in mouse zygotes 
(Agarwal et al., 1998) and then studied in mouse embryonic fibroblasts (Shimura et al., 
2006). However, the role of p53 in these responses is not well understood. In mouse 
embryonic fibroblasts that have been treated with radiation doses below 2.5Gy, an 
ATM mediated, p53-dependent decrease in replication fork progression is observed 
that is not seen in p53 null cells (Shimura et al., 2006). Therefore low dose radiation 
could be effective in mediating anti-tumour activity by similar p53-dependent 
mechanisms to those observed in response to RITA and studies to address this are in 
progress. 
4.7 Conclusions for this chapter 
 RITA induces p53 and γH2AX in S-phase. 
 RITA inhibits replication fork progression in p53 wildtype cells. 
 Stabilisation of p53, induction of γH2AX, and phosphorylation of CHK1 in response 
to RITA treatment are not observed in p53-null cells. 
 Loss of CHK1 by siRNA does not affect RITA induced cell death, or RITA induced 
DNA damage at 24 hours of treatment. However loss of CHK1 by siRNA does 
enhance DNA damage induced by immediate exposure to RITA (1 hour) indicating 
an important role for CHK1 in regulating DNA repair. 
4.8 Impact of these findings 
As CHK1 is important in initiating repair mechanisms in response to stalled replication 
forks, many studies have investigated the possibility of using CHK1 inhibitors to inhibit 
repair pathways and sensitise tumour cells to genotoxic agents. Furthermore, p53 
status seems to be essential for the apoptotic outcome of such combinations. For 
example, CHK1 depletion by siRNA sensitises p53-deficient cells to radiation (Wang et 
al., 1996) while CHK1 inhibition by the small molecule AZD7762 sensitises a range of 
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p53-mutated cell lines to radiotherapy, responses that are not observed in p53 wildtype 
tumour cells or in normal fibroblasts (Mitchell et al., 2010). Depletion of CHK1 by siRNA 
(Wang et al., 1996) and small molecule inhibition of CHK1 by PD407824 (Arora et al., 
2010) also enhances sensitivity to cytotoxics in p53-deficient cells. These combinations 
are based on the rationale that loss of p53 function inhibits cell cycle arrest in response 
to genotoxic stress and promotes cell death in cells that are rapidly proliferating. 
 
UCN-01 (7-hydroxystaurosporine) has been studied as a single agent and in 
combination in several Phase 1 clinical schedules, however poor pharmacokinetics and 
an unfavourable toxicity profile has limited the progress of UCN-01 through the clinic, 
and this seems to have been the case for most CHK1 inhibitors in clinical development 
(Ma et al., 2011). Several redundant pathways maintain cell cycle responses when 
CHK1 is inhibited. Loss of CHK1 has been shown to increase ATM and ERK1/2 cell 
survival pathways (Dai et al., 2008; Dent et al., 2011) suggesting that agents targeting 
the MAPK pathway could potentiate CHK inhibitor function. Crosstalk between CHK1 
and CHK2 is well established and studies have shown that CHK1 and CHK2 co-
operate to elicit cell cycle checkpoints in vivo. Importantly, loss of these checkpoint 
kinases promotes tumour susceptibility by enhancing genomic instability (Niida et al., 
2010). Therefore, targeting CHK1 and or CHK2 may enhance tumour susceptibility in 
certain models, and may also explain the poor toxicity profile of CHK targeted agents. 
Clearly, scheduling of combination therapies is critical, and like cyclotherapy, which has 
been recently shown to improve tumour cell death by targeting cell cycle kinetics, the 
use of CHK inhibitors will also be critical in ensuring that appropriate scheduling of 
combinations elicit maximum DNA damage that leads to maximum cell death. 
 
In this study p53-dependent cell cycle checkpoints have been investigated that are 
important in eliciting DNA damage responses induced by the small molecule RITA. 
Although loss of CHK1 sensitises tumour cells to cell death by genotoxic agents, 
enhanced tumour cell death was not achieved in response to RITA when CHK1 was 
inhibited by siRNA. Activation of wildtype p53 is therefore important in maximising 
tumour cell death and loss of CHK1 only has implications in regulating DNA repair 
following early responses to stress. Therapeutically, these studies suggest that CHK1 
inhibition may be important in sensitising cells to cell death by p53 activating agents 
only in combinations that are both time-dependent and dose-dependent. Furthermore, 
lack of anti-tumour responses in p53 deficient cells suggests that in the tumour models 
which have been studied in this thesis, p53 signalling is critical in determining cell 
death responses to genotoxic stress. Signalling through DNA repair pathways is an 
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important mechanism by which p53-dependent apoptosis is engaged in cells that have 
lethal, irreparable forms of DNA damage. These findings propose an important level of 
control for wildtype p53 in signalling to the DNA damage response and repair 
machinery, and have important implications in determining the anti-tumour activity of 
agents that regulate p53 activity. 
 
 
  
 
Figure 4.6.1: RITA activates cell cycle checkpoints 
RITA induces stalling of the replication fork machinery and the formation of DNA strand 
breaks leads to p53-dependent phosphorylation of CHK1, induction of γH2AX, and activation 
of an S-phase cell cycle checkpoint. Although CHK1 is not essential for cell death, activation 
of this cell cycle checkpoint is important for mediating DNA repair processes. 
Phosphorylation of CHK2 is also observed in response to RITA treatment however this is not 
p53-dependent. 
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5.1 Introduction 
The mitogen activated protein kinase (MAPK) family comprise serine threonine specific 
protein kinases that are activated by a range of extracellular stimuli such as mitogens, 
growth factors, osmotic stress, heat shock and pro-inflammatory cytokines (Pearson et 
al., 2001). MAPK signalling is initiated by receptor-mediated events at the cell surface 
that activate a relay of effector proteins through the cytoplasm and into the nucleus to 
induce transcriptional changes. These effector proteins comprise the MAPK kinase 
kinases (MAPKKK) that are activated by cell surface proteins, the MAPK kinases 
(MAPKK) that transduce signals through the cytoplasm, and the MAPKs that activate 
transcriptional responses in the nucleus (Raman and Cobb, 2003).  
 
Extracellular signal regulated kinase (ERK) was the first MAPK to be characterised 
(Boulton et al., 1990). The signalling pathway that leads to ERK activation has been 
studied in detail, and has been summarised in Figure 5.1.1 (Lewis et al., 1998). 
Following binding of extracellular ligands such as growth factors and various mitogens, 
receptor tyrosine kinase (RTK) receptors located on the cell surface membrane 
undergo dimerisation and autophosphorylation events that initiate complex intracellular 
signalling cascades involving a series of kinases. Firstly, receptor activation promotes 
conversion of the G-protein proto-oncogene Ras from its inactive guanosine 
diphosphate (GDP) bound form, to its active guanosine tripohosphate (GTP) bound 
form. A conformational change is induced in Ras, leading to recruitment and binding of 
the MAPKKK c-Raf to the cell membrane. Activated c-Raf phosphorylates the 
MAPKK’s MEK1/MKK1 and MEK2/MKK2 (MAPK and ERK kinases) at specific serine 
and threonine residues (Dent et al., 1992). MEK1/MKK1 and MEK2/MKK2 then 
phosphorylate the MAPK’s ERK1 (also referred to as p44MAPK) and ERK2 (also referred 
to as P42MAPK) at dual threonine and tyrosine residues (Anderson et al., 1990). 
Activated ERK1 and ERK2 are translocated to the nucleus to phosphorylate 
transcription factors such as ELK-1 which induce expression of various target genes 
involved in cell proliferation, cell survival, cell death and differentiation (Marais et al., 
1993). 
 
PD98059 [2-(2’amino-3’-methoxyphenyl)-oxanaphthalen-4-one] is an inhibitor of 
MEK1/MKK1 MAPKK (Alessi et al., 1995), and can reverse the phenotype of RAS 
transformed cell lines (Dudley et al., 1995). PD98059 was the first synthetic MAPK 
inhibitor to be identified from a compound library using an in vitro kinase screen. Both a 
constitutively active MEK1 mutant and MEK1 induced by growth factor stimulation was 
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inhibited by PD98059 with an IC50 of 2-7µM (Dudley et al., 1995). PD98059 was shown 
to be a non-competitive inhibitor of MEK1, and by binding to MEK1, could inhibit growth 
factor stimulated MEK1 activation by the upstream kinase c-RAF. At an IC50 of 50µM, 
PD98059 also inhibited phosphorylation of MEK2/MKK2 (Alessi et al., 1995; Dudley et 
al., 1995). PD98059 has been used extensively as a tool for studying the RAS-RAF-
MEK-ERK MAPK pathway, and understanding its importance. Constitutive activation of 
MEK1 and MEK2 is associated with cellular transformation and differentiation in a 
number of tumour models (Marshall, 1995), and for this reason, many MAPK inhibitors 
have also been developed for therapeutic targeting of MAPK signalling (Cowley et al., 
1994; Sebolt-Leopold et al., 1999). 
 
In certain cases, MAPK activation acts as a tumour suppressor response by regulating 
cell death induced by oncogenic, and genotoxic stimuli. Phosphorylation and activation 
of p53 by the PI3K family members ATM and ATR has been described in response to 
stress stimuli (Banin et al., 1998; Canman et al., 1998). Various stress activated MAPK 
kinases also phosphorylate and activate p53 directly (Fuchs et al., 1998b; Meek, 1998). 
For example, NFκB-dependent apoptosis is mediated by ERK1/2 regulation of p53 
stability (Ryan et al., 2000). In other studies, ERK1/2 is an upstream regulator of p53 
phosphorylation and stability in response to DNA damage induced by cisplatin, and 
inhibition of ERK1/2 activation by PD98059 represses p53-dependent cell death by this 
pathway (Persons et al., 2000).  Recently, activation of the MKK7 MAPK pathway by 
oncogenic and genotoxic induced stress was shown to suppress tumour development 
in vivo by eliciting a DNA damage response, and promoting p53 stability (Schramek et 
al., 2011). In lung cancer and breast cancer models, MKK7 knockout mice developed 
tumours early and had a poor survival outcome compared to wildtype mice. Schramek 
et al. showed that p53 activation by DNA damage responses is an important 
mechanism for tumour suppression, and that MAPK signalling is an important upstream 
mediator of this response (Schramek et al., 2011). Previous studies in our laboratory 
had found that RITA-mediated effects were sensitive to MEK-ERK inhibition (Yang, 
unpublished). Because of the importance of MAPK signalling in p53 mediated 
apoptosis, I further investigated whether RITA’s p53-dependent apoptotic effects were 
regulated by the MAPK pathway.  
 
 
 
 
 
 Chapter 5: MAPK signalling modulates RITA induced cell death 
 
 
Page: 128 
 
 
 
Figure 5.1.1: PD98059 inhibits the RAS-cRAF activated MAPK pathway 
Phosphorylation of receptor tyrosine kinase receptors upon binding of specific extracellular 
ligands on the cell surface membrane leads to activation of the GTPase RAS proto-
oncogene. This leads to a sequence of intracellular phosphorylation events involving 
MAPKKK, MAPKK and MAPK kinases. The MAPKKK c-RAF is phosphorylated by RAS, 
which in turn phosphorylates the MAPKKs MEK1/MKK1 and MEK2/MKK2 leading to 
phosphorylation and activation of ERK1 and ERK2 MAPKs, their translocation to the nucleus 
and activation of many transcription factors involved in the regulation of cell growth, 
differentiation, and development. PD98059 is an inhibitor of MEK1/MKK1 and MEK2/MKK2 
activation and has been used to elucidate the importance of RAS-RAF signalling in response 
to various extracellular stimuli in vitro and in vivo. 
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5.2 Hypothesis 
MAPK signalling modulates RITA induced cell death. 
5.3 Aims 
 Investigate MAPK activation by RITA treatment.  
 Understand the importance of MAPK signalling in the regulation of p53-
 dependent cell death responses using PD98059 and MAPK siRNAs. 
5.4 RITA induced cell death is inhibited by PD98059 
MAPK activation has been shown to be associated with cisplatin induced apoptosis 
(Persons et al., 2000). In order to investigate whether ERK1/2 is phosphorylated by 
RITA, HCT116 p53+/+ cells were treated with RITA over a 24 hour timecourse, and 
ERK1/2 phosphorylation was assessed by western blotting. PD98059 was also used to 
investigate whether inhibition of ERK1/2 phosphorylation affected RITA induced cell 
death, as assessed by cleaved PARP (Figure 5.4.1). Phosphorylation of ERK1/2 
occurred at early time points when HCT116 p53+/+ cells were treated with RITA, and 
this preceded induction of cell death as assessed by cleaved PARP. Treatment of 
HCT116 p53+/+ cells with RITA in combination with PD98059 inhibited ERK1/2 
phosphorylation, cleaved PARP and to some extent, p53 induction. These observations 
are consistent with previous studies from our laboratory that found PD98059 blocks 
RITA mediated responses (Yang, unpublished). ERK1/2 signalling is therefore 
important for mediating cell death responses by RITA. 
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Figure 5.4.1: ERK1/2 is activated in response to RITA treatment and inhibited by 
PD98059 
Western blotting of HCT116 p53+/+ cells treated with 500nM RITA in the absence or 
presence of 50µM PD98059. Cells were harvested for western blotting over a 24 hour time 
course and analysed for phosphorylated ERK1/2 at thr202/tyr204 (p-ERK1/2), PARP, 
phosphorylated p53 at ser46 (p53-46), total p53 protein, and α-tubulin as a loading control. 
Data shown is representative of 2 experiments. 
 
 
To assess cell death in greater detail, flow cytometry was used to quantify the sub-G1 
population of cells treated with RITA, either alone, or in combination with PD98059. In 
agreement with Figure 5.4.1, treating cells with PD98059 significantly inhibited cell 
death induced by RITA, as indicated by the sub-G1 population (Figure 5.4.2). 
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Figure 5.4.2: PD98059 inhibits sub-G1 cells induced by RITA 
HCT116 p53+/+ cells were treated with 500nM RITA with or without 50µM PD98059 for 24 
hours in normoxia. Cells were harvested for flow cytometry analysis and stained for 
propidium iodide to analyse DNA content: (A) Cell cycle DNA profiles shown are 
representative of 3 independent experiments. Profiles show cell count on the y-axis and 
propidium iodide intensity on the x-axis. Cells were gated for sub-G1 (as indicated by dashed 
line), (B) Percentage of cells in the population gated for sub-G1 content is quantified, and 
has been averaged from 3 independent experiments. An unpaired t-test was used to assess 
statistical significance and a p-value of <0.05 was considered significant. 
 
 
Flow cytometry was used to quantify changes in p53 and γH2AX induction following 
PD98059. In agreement with western analysis (Figure 5.4.1), flow cytometric analyses 
show that both p53 and γH2AX induction are inhibited significantly by PD98059 (Figure 
5.4.3).  
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Figure 5.4.3: PD98059 inhibits p53 and γH2AX induced by RITA 
HCT116 p53+/+ cells treated with 500nM RITA in the absence or presence of 50µM 
PD98059 for 24 hours in normoxia. Following treatment, cells were harvested and fixed for 
flow cytometry, and stained for propidium iodide, p53 (using a secondary FITC conjugated 
antibody) and γH2AX (using a secondary APC conjugated antibody). Graphs show: (A) 
analysis of cells stained for p53 induction, and (B) analysis of cells stained for γH2AX 
(phosphorylated at serine 139). Representative histograms from 3 independent experiments 
are shown, with cell counts on the y-axis, displayed against p53 fluorescent intensity (left 
panel) or γH2AX (right panel) on the x-axis. Blue indicates the control population, red 
indicates cells treated with 500nM RITA, and green represents cells treated with RITA in 
combination with 50µM PD98059. Histograms were gated against the control population 
(shown by the dashed line), and the percentage of treated cells that shift in intensity towards 
the right were quantified. Bar charts below show quantified data of the percentage of cells 
that shift in either p53 intensity (left), or phosphorylated γH2AX intensity (right), and have 
been averaged from 3 independent experiments. An unpaired t-test was used to assess 
statistical significance and a p-value of <0.05 was considered significant. 
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To evaluate p53 and γH2AX localisation, the INCell 1000 imaging platform was used 
(GE Healthcare Life Sciences). As for flow cytometry optimisation experiments (Figure 
4.4.1), antibody controls were used to assess the specificity of primary p53 antibody 
binding to its Alexa Fluor 488 conjugated secondary antibody, and primary γH2AX 
antibody binding to its secondary Alexa Fluor 568 conjugated antibody. These 
antibodies were optimised so that dual staining of p53 and γH2AX could be performed 
in a 96 well format. As shown in Figure 5.4.4, Alexa Fluor 488, and Alexa Fluor 568 
secondary antibodies that bind p53 and γH2AX respectively did not cause non-specific 
background staining. At the concentrations used, they gave specific and reproducible 
staining only in the presence of p53 and γH2AX primary antibodies. 
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Figure 5.4.4: Immunoflourescent staining of p53 and γH2AX 
Images show untreated HCT116 p53+/+ cells stained with DAPI to view nuclei (blue), total 
p53 primary with Alexa Fluor 488 conjugated secondary antibodies to view p53 intensity in 
the nucleus (green), and γH2AX primary with Alexa Fluor 568 conjugated secondary 
antibodies to view γH2AX intensity in the nucleus (red). Staining was performed with either 
secondary antibodies alone (indicated as 488 alone, or 568 alone), or with primary and 
secondary antibodies together. Bottom panel of images shows dual staining of cells with total 
p53 and Alexa Fluor 488, together with γH2AX and Alexa Fluor 568 antibodies, See 
materials and methods for specific antibody concentrations used. Cells were analysed using 
the high throughput INCell 1000 screening platform. 10 fields of view were captured for each 
duplicate well at 20x magnification. Representative images from one field of view are shown. 
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Using PD98059, MEK-ERK signalling has been shown to be important in regulating 
p53 stabilisation in response to RITA treatment (Figure 5.4.1 and Figure 5.4.3). I 
hypothesised that induction of nuclear p53 by RITA would also be affected by 
PD98059. To address this, HCT116 p53+/+ cells were treated with RITA alone, or in 
combination with PD98059, and nuclear p53 and γH2AX was analysed using the INCell 
platform. Increases in p53 and γH2AX nuclear intensity were observed following RITA 
treatment that was inhibited by PD98059 (Figure 5.4.5). This data supports the 
requirement of MEK-ERK signalling for stabilising p53 in the nucleus following RITA 
treatment, and inducing DNA damage responses involving γH2AX.  
 
 
 
 
Figure 5.4.5: RITA induced nuclear p53 and γH2AX is inhibited by PD98059  
HCT116 p53+/+ cells were treated with 500nM RITA for 24 hours in normoxia in the 
absence/presence of 50µM PD98059. Cells were fixed and stained for DAPI to indicate 
nuclei (blue), total p53 staining in the nucleus, as shown by Alexa Fluor 488 staining (green), 
and γH2AX intensity in the nucleus, shown by Alexa Fluor 568 staining (red). Staining was 
analysed using the INCell 1000 high content screening platform at 20x magnification. 10 
fields of view were captured from each triplicate well. Representative images from 3 
independent experiments are shown.  
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To investigate the affects of PD98059 on HCT116 p53+/+ and HCT116 p53-/- cells 
treated with RITA, INCell images were quantified and assessed for changes in nuclear 
p53 and γH2AX. In agreement with Figure 5.4.5, RITA treatment led to significant 
increases in nuclear p53 which was inhibited in the presence of PD98059. Importantly, 
PD98059 alone had no effects on p53 stabilisation in the nucleus and as expected, no 
changes in p53 intensity were observed in HCT116 p53-/- cells (Figure 5.4.6). Cell 
counts were also greater in cells treated with RITA and PD98059, compared to RITA 
treatment alone indicating inhibition of RITA induced cell death in the presence of 
PD98059. 
 
The number of nuclear γH2AX foci was increased in RITA treated cells, and inhibited in 
the presence of PD98059. However, induction of γH2AX foci in response to RITA was 
not p53-dependent. The p53 dependency of γH2AX induction in response to RITA has 
been described in chapter 3 and published previously from our laboratory (Ahmed et 
al., 2011; Yang et al., 2009a). The sensitivity of quantifying individual cell responses 
using the INCell analyser allows for more robust analysis of p53-dependent responses 
to stress. In conclusion, the results presented so far show that PD98059 has significant 
effects on p53 and γH2AX in cell nuclei following RITA treatment. 
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Figure 5.4.6: PD98059 inhibits RITA induced nuclear p53 and γH2AX 
HCT116 p53+/+ and HCT116 p53-/- cells were treated with 500nM RITA for 24 hours in 
normoxia, either alone or in combination with 50µM PD98059. Plates were fixed and stained 
with immunoflourescent antibodies. DAPI staining was used to assess cell counts by 
visualising nuclei, p53 nuclear intensity was assessed using a total p53 antibody with an 
Alexa Fluor 488 conjugated secondary antibody, and γH2AX foci were assessed using a 
γH2AX antibody (serine 139) with an Alexa Fluor 568 conjugated secondary antibody. 
Images were captured over 10 fields of view for each duplicate well at 20x magnification and 
quantified using INCell 1000 Software. Data has been averaged from 3 independent 
experiments. An unpaired t-test was used to compare statistical significance and a p-value of 
<0.05 was considered significant. 
 
 
PD98059 not only inhibits cell death induced by RITA, but also affects the DNA 
damage response, as shown by inhibition of γH2AX. On this basis, it was therefore 
hypothesised that PD98059 may also inhibit RITA induced DNA damage. To 
investigate effects of PD98059 on DNA damage, HCT116 p53+/+ that had been 
treated with RITA in the absence or presence of PD98059 were assessed by comet 
analysis. Importantly, PD98059 alone had no significant effect on DNA damage, 
however, RITA induced DNA damage was inhibited by PD98059 (Figure 5.4.7). The 
MEK-ERK pathway is therefore an important upstream mediator of RITA-induced DNA 
damage.   
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Figure 5.4.7: PD98059 inhibits RITA induced DNA damage 
Graph shows comet assay data from HCT116 p53+/+ cells treated with RITA alone, or in 
combination with PD98059. Following treatment, cells were harvested, counted and mixed 
with agarose for electrophoresis. Comets (cell nuclei) were visualised using SYBR Green at 
10x magnification. Images were captured over 20 fields of view and approximately 100 
comets were quantified for each treatment using the TriTek
TM
 comet score analysis software. 
Olive moment was used as a measure of DNA damage. Data has been averaged from 2 
independent repeat experiments. 
 
5.5 PD98059 inhibits cell cycle responses in RITA treated cells 
Flow cytometric analysis has previously been used to show that RITA induces p53-
dependent cell death. Interestingly, although cell death was not observed in HCT116 
p53-/- cells treated with RITA, preliminary experiments showed increases in the G2 
population of cells treated with RITA. I hypothesised that because PD98059 inhibits 
RITA induced cell death in HCT116 p53+/+ cells, PD98059 could also affect cell cycle 
effects elicited by RITA in HCT116 p53-/- cells. To address this, HCT116 p53+/+ and 
HCT116 p53-/- cells were treated with RITA alone or in combination with PD98059, 
and flow cytometric analysis was used to assess changes in cell cycle phases. Both 
RITA induced cell death in HCT116 p53+/+ cells and RITA induced effects on the G2 
population in HCT116 p53-/- cells were inhibited by PD98059 (Figure 5.5.1).  
 
 
 
 
 
 Chapter 5: MAPK signalling modulates RITA induced cell death 
 
 
Page: 139 
 
 
 
Figure 5.5.1: RITA induced cell cycle effects are inhibited by PD98059 in HCT116 
p53+/+ and HCT116 p53-/- cells 
HCT116 p53+/+ and HCT116 p53-/- cells were treated with RITA with or without 50µM 
PD98059 for 24 hours in normoxia and harvested for flow cytometry. Profiles shown are of 
DNA content stained using propidium iodide. Cell counts are represented on the y-axis, and 
propidium iodide fluorescent intensity on the x-axis. DNA profiles for HCT116 p53+/+ cells 
are shown in the panel above, and DNA profiles for HCT116 p53-/- treated cells are shown 
below. Each DNA profile was gated for cell cycle phase (indicated by dashed lines) and the 
percentage of cells in each phase was calculated. Profiles and quantifications shown are 
representative of 3 independent experiments.  
 
 
To quantify HCT116 p53+/+ and HCT116 p53-/- cells treated with RITA and PD98059, 
propidium iodide flow cytometry profiles were gated and the percentage of cells in each 
cell cycle phase was calculated. As shown in Figure 5.5.2, cell death was induced by 
RITA in HCT116 p53+/+ cells (indicated by an increase in the sub-G1 population), and 
was inhibited in cells treated with RITA and PD98059 (Figure 5.5.2A). Effects on sub-
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G1 were not observed in HCT116 p53-/- cells. Both HCT116 p53+/+ and HCT116 p53-
/- cells showed decreases in the G1 population upon RITA treatment, which was 
inhibited by PD98059 (Figure 5.5.2B). Changes in S-phase cells were not observed for 
both HCT116 p53+/+ and HCT116 p53-/- populations (Figure 5.5.2C). In agreement 
with Figure 5.5.1, a G2 arrest was only induced in HCT116 p53-/- cells treated with 
RITA and inhibited in the presence of PD98059 (Figure 5.5.2D). The data shown 
indicate that MEK-ERK signalling is required for p53-dependent cell death in HCT116 
p53+/+ cells, and also has an important role to play in eliciting cell cycle arrest 
responses in HCT116 p53-/- cells treated with RITA. 
 
 
 
 
Figure 5.5.2: PD98059 blocks cell cycle effects induced by RITA in HCT116 p53+/+ and 
HCT116 p53-/- cells 
Graphs show HCT116 p53+/+ (black bars) and HCT116 p53-/- (grey bars) cells treated with 
500nM RITA with or without 50µM PD98059 for 24 hours in normoxia. Cells were harvested 
for flow cytometry and stained using propidium iodide to analyse DNA content. DNA profiles 
for each treatment were gated according to each cell cycle phase and the percentage of 
cells in each phase was quantified. Bar charts show the percentage of cells in each cell cycle 
phase: (A) sub-G1, (B) G1, (C) S-phase, (D) G2 analysis. Data shown has been averaged 
from 3 independent experiments.  
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In Chapter 4 cell cycle checkpoints elicited by RITA were investigated and affects of 
RITA on the replication fork machinery, and on S-phase progression were described. 
Significant changes in the percentage of HCT116 p53+/+ cells in S-phase that express 
p53, γH2AX, and phosphorylated CHK1 were also observed (Figures 4.4.3 and 4.5.4). 
It was concluded that p53-dependent cell cycle checkpoints induced by RITA are 
involved in signalling DNA damage and maintaining genomic integrity during early 
responses to stress. So far, MEK-ERK inhibition by PD98059 has been shown to inhibit 
cell cycle responses in HCT116 p53+/+, and HCT116 p53-/- cells. Therefore PD98059 
may also affect DNA damage responses that are observed during S-phase in RITA 
treated cells.  
 
To address this, HCT116 p53+/+ and HCT116 p53-/- cells were treated with RITA and 
PD98059, and assessed for changes in p53 and γH2AX by flow cytometric analysis. 
Both p53 and γH2AX induction in S-phase cells treated with RITA were inhibited by 
PD98059 (Figure 5.5.3). In agreement with previous conclusions from chapter 4 
whereby RITA induced DNA damage responses are p53-dependent, changes in p53 
and γH2AX induction following RITA and PD98059 treatment were not observed in 
HCT116 p53-/- cells. Overall the data presented suggest that RITA can affect the cell 
cycle in both HCT116 p53+/+ and HCT116 p53-/- cells and these outcomes are 
modulated by MEK-ERK signalling. 
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Figure 5.5.3: PD98059 inhibits RITA induced p53 and γH2AX in the S-phase population 
of HCT116 p53+/+ 
Graph shows HCT116 p53+/+ (black bars) and HCT116 p53-/- cells (white bars) treated with 
500nM RITA with or without 50µM PD98059 for 24 hours in normoxia. Cells were harvested 
for flow cytometry and stained for propidium iodide to visualise DNA content, total p53 and 
γH2AX. DNA cell cycle profiles for each treatment were gated for S-phase and the 
percentage of cells in each S-phase population that were positive for both p53 and γH2AX 
was quantified. Data shown has been averaged from 3 repeat experiments. An unpaired t-
test was used to assess statistical significance and a p-value <0.05 was considered 
significant. 
 
 
Finally, because PD98059 inhibited RITA mediated responses in both HCT116 p53+/+ 
and HCT116 p53-/- cells, I hypothesised that phosphorylation of ERK1/2 by RITA is not 
dependent on p53 status. To assess ERK1/2 phosphorylation in HCT116 p53+/+, and 
HCT116 p53-/- cells following RITA treatment, western analysis was used and the 
induction of ERK1/2 phosphorylation by RITA was found in both HCT116 p53+/+ and 
HCT116 p53-/- cells (Figure 5.5.4). 
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Figure 5.5.4: ERK1/2 phosphorylation induced by RITA is not p53-dependent 
HCT116 p53+/+ and HCT116 p53-/- cells were treated with 500nM RITA over a timecourse 
in normoxia and harvested for western blot analysis. Western blots were analysed for 
phosphorylated ERK1/2 (p-ERK1/2), total ERK1/2, p53, and β-actin as a load control. Data 
shown is representative of 3 independent repeat experiments. 
 
5.6 PD184352 does not inhibit RITA induced cell death  
Studies using PD98059 have shown that MEK-ERK signalling is important for 
regulating cell cycle responses and cell death in response to RITA. Next, I aimed to 
assess whether other MAPK inhibitors have similar effects to PD98059 in cells that 
have been treated with RITA. PD184352 [2-(-chloro-4-iodo-phenylamino)-N-
cyclopropylmethoxy-3,4-difluoro-benzamide], a potent inhibitor of MEK1 with an IC50 of 
300nM in vitro was investigated (Sebolt-Leopold et al., 1999). Compared to PD98059, 
PD184352 was shown to be more potent, and more selective for MEK1 inhibition 
(Sebolt-Leopold et al., 1999). Therefore I assessed whether PD184352, like PD98059, 
could also inhibit RITA induced cell death.  
 
To confirm that the concentrations of PD98059 and PD184352 used inhibited ERK1/2 
phosphorylation, HCT116 p53+/+ cells and HCT116 p53-/- cells were treated with 
50µM PD98059, and 2µM PD184352, doses at which both inhibitors have been shown 
to inhibit MEK1/2 phosphorylation. Western analysis confirmed that both 50µM 
PD98059 and 2µM PD184352 are sufficient to block ERK1/2 phosphorylation (Figure 
5.6.1) 
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Figure 5.6.1: PD98059 and PD184352 inhibit ERK1/2 phosphorylation 
HCT116 p53+/+ and HCT116 p53-/- cells were treated with either 50µM PD98059 or 2µM 
PD184352 for 24 hours and harvested for western blot analysis. Western blot analysis 
shows phosphorylated ERK1/2 (p-ERK1/2), total ERK1/2, and β-actin as a loading control. 
Western blots are representative of 3 independent repeat experiments. 
 
 
Flow cytometric analysis was used to assess the effects of PD184352 on RITA induced 
cell death. Treatment of HCT116 p53+/+ cells with either PD98059 or PD184352 did 
not affect the cell cycle (Figure 5.6.2A). Interestingly, unlike PD98059, PD184352 did 
not inhibit RITA induced cell death in HCT116 p53+/+ cells, as indicated by analysing 
sub-G1 cells (Figure 5.6.2B). These observations are consistent with previous studies 
from our laboratory that have found PD184352 to have no significant affects on RITA 
mediated responses (Yang, unpublished). 
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Figure 5.6.2: PD184352 does not affect RITA induced cell death 
Flow cytometry analysis of: (A) HCT116 p53+/+ cells treated with DMSO control, 50µM 
PD98059, and 2µM PD184352, (B) HCT116 p53+/+ treated with 500nM RITA alone or in 
combination with either 50µM PD98059 or 2µM PD184352. Following 24 hour treatment, 
cells were stained for propidium iodide and analysed for DNA content by flow cytometry. 
Graphs show cell count against propidium iodide fluorescent intensity and have been gated 
for sub-G1 as an indicator of cell death. The percentage of cells in each treated population 
that are in sub-G1 is shown. Graphs are representative of 3 independent experiments. 
 
 
To continue assessing whether cell death induced by RITA is affected by MEK1/2 
inhibition in response to PD98059 and PD184352 treatment, HCT116 p53+/+ and 
HCT116 p53-/- cells were treated with RITA alone or in combination with either 
PD98059 or PD184352. DNA profiles from flow cytometry were quantified for sub-G1 
as an indication of cell death (Figure 5.6.3). As anticipated, RITA treatment increased 
the percentage of HCT116 p53+/+ cells in sub-G1 to greater than 30% and this 
increase was not observed in HCT116 p53+/+ cells that had been treated with RITA in 
combination with PD98509. When HCT116 p53+/+ cells were treated with RITA and 
PD184352, the sub-G1 population increased to greater than 40%. There was little 
effect on sub-G1 when HCT116 p53+/+ cells were treated with PD98059 or PD184352 
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alone. As expected, the sub-G1 population of HCT116 p53-/- cells was not affected to 
the same extent as in HCT116 p53+/+ cells. In summary, PD98059 but not PD184352 
blocks RITA induced cell death in HCT116 p53+/+ cells. 
 
 
   
 
Figure 5.6.3: PD184352 does not inhibit RITA induced sub-G1 in HCT116 p53+/+ cells 
Graph shows HCT116 p53+/+ (black bars) and HCT116 p53-/- (grey bars) treated with 
500nM RITA for 24 hours alone or in combination with either 50µM PD98059 or 2µM 
PD184352. Following treatment, cells were stained for propidium iodide and cell cycle DNA 
profiles were analysed by flow cytometry. DNA profiles were gated and quantified for sub-
G1. The percentage of cells in sub-G1 is plotted against each population of treated cells. 
Data shown has been averaged from 3 independent experiments. An unpaired t-test was 
used to assess statistical significance between control and treated populations and a p-value 
of <0.05 was considered significant (indicated by *) 
 
 
Previous data have shown that PD98059 does not only inhibit p53 stabilisation, and 
cell death by RITA, but PD98059 also affects γH2AX induction in S-phase cells, and 
DNA damage (Figure 5.6.3). To investigate whether PD184352 had similar effects to 
PD98059 in mediating RITA induced DNA damage responses, flow cytometry was 
used to assess p53 and γH2AX induction in HCT116 p53+/+ and HCT116 p53-/- cells 
treated with RITA and either PD98059 or PD184352. PD184352 did not inhibit RITA-
induced p53 and γH2AX in S-phase cells (Figure 5.6.4) suggesting that because 
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PD184352 has greater selectivity for MEK1/2 inhibition compared to PD98059, a non-
specific MAPK may be inhibited by PD98059 that mediates induction of p53-dependent 
responses by RITA.  
 
 
 
 
Figure 5.6.4: PD184352 does not inhibit RITA induced p53 and γH2AX in S-phase cells 
HCT116 p53+/+ cells were treated with 500nM RITA for 24 hours alone or in combination 
with either PD98059 or PD184352. Following treatment, cells were fixed for flow cytometric 
analysis and stained using propidium iodide to assess DNA cell cycle profiles, total p53 
protein (using a secondary FITC conjugated antibody), and γH2AX (using a secondary APC 
conjugated antibody). Cell cycle profiles were gated for the S-phase population, and the 
percentage of cells in S-phase that stained positive for p53 and γH2AX was quantified. 
Graph shows percentage of cells in S-phase from each treated population that have a 
positive shift in both p53 (viewed by a shift in FITC fluorescent intensity), and in γH2AX 
(viewed by a shift in APC fluorescent intensity) compared to the control S-phase population. 
Data shown has been averaged from 3 independent experiments. 
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PD98059 was used at a final concentration of 50µM for all studies so far because this 
is the screening concentration that has been used to achieve greater than 50% 
inhibition of MEK1/2 and also assess the specificity profile of PD98059 compared to 
other MAPK inhibitors (Davies et al., 2000). Previously, 50µM PD98059 was shown to 
inhibit ERK1/2 protein phosphorylation (Figure 5.6.1). However, 50µM PD98059 may 
also have several off target effects compared to lower concentrations. Therefore, 
studies were repeated with the PD98059 IC50 dose for MEK1 inhibition of 10µM 
(Dudley et al., 1995) and effects were compared with 50µM PD98059 used previously. 
As shown in Figure 5.6.5, 10µM PD98059 also suppressed RITA induced ERK1/2 
phosphorylation, p53 induction, and cell death, as indicated by cleaved PARP. 
 
 
           
 
Figure 5.6.5: 10µM PD98059 inhibits RITA induced ERK1/2 activation, cleaved PARP 
and p53 induction 
HCT116 p53+/+ cells were treated with 500nM RITA alone or in combination with 10µM 
PD98059 for 16 hours in normoxia. Cells were harvested for western blot analysis and 
analysed for phosphorylated ERK1/2 (p-ERK1/2), total ERK1/2, cleaved PARP, 
phosphorylated p53 at serine 46 (p53-46), and total p53 protein. β-actin was used as a 
loading control. Western data shown is representative of 3 independent repeat experiments.  
 
 
In Figure 5.4.3 50µM PD98059 was shown to inhibit RITA induced DNA damage 
responses involving γH2AX. As with 50µM PD98059, 10µM PD98059 was found to 
have inhibitory effects on RITA induced cell death. Therefore, I hypothesised that 10µM 
PD98059 would also inhibit RITA induced DNA damage responses. To address this 
HCT116 p53+/+ cells were treated with RITA alone or in combination with 10µM 
PD98059, and changes in γH2AX and phosphorylated CHK1 and CHK2 proteins was 
assessed by western analysis. DNA damage responses involving induction of γH2AX 
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and phosphorylation of both CHK1 and CHK2 were found to be inhibited by 10µM 
PD98059 (Figure 5.6.6).  
 
 
 
Figure 5.6.6: 10µM PD98059 inhibits RITA induced DNA damage responses 
HCT116 p53+/+ cells were treated with 500nM RITA alone or in combination with 10µM 
PD98059 for 24 hours in normoxia. Cells were harvested for western blotting and analysed 
for γH2AX, phosphorylated CHK1 (p-CHK1), total CHK1 (T-CHK1), phosphorylated CHK2 
(p-CHK2), and total CHK2 (T-CHK2), β-actin was used as a loading control. Western data is 
representative of 3 independent repeat experiments.  
 
 
To assess effects of 10µM PD98059 on the cell cycle, HCT116 p53+/+ cells were 
treated with RITA in combination with 10µM PD98059, and analysed for DNA content 
by flow cytometry. In agreement with Figure 5.6.2, RITA induced sub-G1 cells were 
inhibited by 10µM PD98059 in HCT116 p53+/+ (Figure 5.6.7). 
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Figure 5.6.7: 10µM PD98059 inhibits RITA induced cell death 
HCT116 p53+/+ cells were treated with 500nM RITA alone, or in combination with 10µM 
PD98059 for 24 hours in normoxia. Following treatment, cells were harvested and fixed for 
flow cytometry analysis. Propidium iodide was used to stain for DNA content: (A) DNA cell 
cycle profiles are shown with cell counts displayed on the y-axis against propidium iodide 
intensity on the x-axis. Profiles were gated for sub-G1 content to indicate cell death (shown 
by dashed line) and quantified. DNA profiles are representative of 3 independent 
experiments, (B) Graph shows percentage of cells in each treated population that are in sub-
G1. Quantified data has been averaged from 3 repeat experiments. A t-test was used to 
assess statistical significance and a p-value of <0.05 was considered significant. 
 
 
INCell analyses was previously used to quantify and assess p53 protein and γH2AX 
localisation in single cells (Figure 5.3.6). I continued to use the INCell screening 
platform to assess changes in nuclear p53 and γH2AX protein levels following 
treatment of HCT116 p53+/+ cells with RITA and either PD98059 or PD184352. As 
shown in Figure 5.6.8, both 10µM and 50µM PD98059 inhibited loss of cell number 
induced by RITA and this was not observed in the presence of PD184352 indicating 
that PD184352 does not affect RITA induced cell death (Figure 5.6.8A). Similarly, 
unlike PD98059, PD184352 did not inhibit RITA induced nuclear p53 (Figure 5.6.8B) 
and γH2AX (Figure 5.6.8C). 
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Figure 5.6.8: Unlike PD184352, PD98059 inhibits cell death, p53 and γH2AX nuclear 
intensity in RITA treated cells 
HCT116 p53+/+ cells were treated with 500nM RITA alone, or in combination with 10µM, 
50µM PD98059 or 2µM PD184352, either alone or in combination. Cells were dosed for 24 
hours in normoxia, fixed and stained using DAPI (to indicate nuclei), total p53 antibody (with 
an Alexa Fluor 488 conjugated secondary antibody), and γH2AX (with an Alexa Fluor 568 
conjugated secondary antibody). Cells were visualised using the INCell 1000 analyser at 20x 
magnification and images over 10 fields of view were captured for each well. INCell software 
was used to quantify images for cell number, p53 nuclear intensity, and γH2AX nuclear 
intensity. Graphs show: (A) % cell number/well, (B) average p53 intensity/nucleus, and (C) 
average γH2AX intensity/nucleus. All data shown has been averaged from 3 independent 
experiments. A t-test was used to compare the means of control and treated cells and a p-
value of <0.05 was considered statistically significant, as indicated by *.  
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Nutlin-3 is a small molecule activator of wildtype p53 and stabilises p53 by binding to 
HDM2, but unlike RITA does not activate a DNA damage response. I hypothesised that 
unlike RITA, p53 stabilisation by nutlin-3 would not be affected by PD98059. To 
address this, HCT116 p53+/+ cells were treated with nutlin-3 alone, or in combination 
with either PD98059 or PD184352, and assessed for changes in p53 and γH2AX 
nuclear intensity using the INCell analyser. As shown in Figure 5.6.9, neither PD98059 
nor PD184352 inhibited loss of cell number (Figure 5.6.9A) and induction of p53 
nuclear intensity (Figure 5.6.9B) in response to nutlin-3. As anticipated for the 
mechanism of action for nutlin-3, no significant changes were observed in γH2AX 
nuclear intensity following treatment with nutlin-3 and PD98059, or PD184352 (Figure 
5.6.9C). Therefore, in conclusion MEK-ERK signalling does not affect nutlin-3 
responses. 
 
In chapter 3, p53 induction and cell death in response to RITA was compared to other 
DNA damaging agents that activate p53. RITA was found to be the only agent used 
that induced significant cell death in HCT116 p53+/+ cells, both in normoxia and in 
hypoxia. Studies have shown that cisplatin induced apoptosis can be inhibited with 
PD98059 (Persons et al., 2000). Like cisplatin, etoposide is a common DNA damaging 
agent that mediates its cellular effects through p53 activation. I hypothesised that like 
RITA, etoposide-induced p53 activation and cell death responses may also be affected 
by MEK-ERK inhibition.  
 
To address this, INCell analysis was used to assess the effects of PD98059 and 
PD184352 in HCT116 p53+/+ cells that had been treated with etoposide. As shown in 
Figure 5.6.10, cell number (Figure 5.6.10A), p53 nuclear intensity (Figure 5.6.10B) and 
γH2AX nuclear intensity (Figure 5.6.10C) induced by etoposide was not affected by 
either PD98059 or PD184352. The mechanism by which RITA induces p53 and cell 
death responses is therefore distinct compared to nutlin-3, etoposide and other p53 
activating agents. 
 
 
 
 
 
 
 
 
 
 Chapter 5: MAPK signalling modulates RITA induced cell death 
 
 
Page: 153 
 
 
 
Figure 5.6.9: PD98059 and PD184352 do not affect p53 induced by nutlin-3 
HCT116 p53+/+ cells were treated with 4µM nutlin-3 alone, or in combination with 10µM, 
50µM PD98059 or 2µM PD184352. Cells were dosed for 24 hours in normoxia, fixed and 
stained for DAPI, total p53 protein with an Alexa Fluor 488 conjugated secondary antibody, 
and γH2AX with an Alexa Fluor 568 conjugated secondary antibody. Cells were visualised 
on the INCell 1000 analyser at 20x magnification and images were captured over 10 fields of 
view for each treated well. INCell software was used for quantification. Graphs show (A) Cell 
number/well, (B) Ave p53 intensity/nucleus, (C) Ave γH2AX intensity/nucleus. All data has 
been averaged from 3 independent experiments. A t-test was used to assess statistical 
significance between control and treated samples and a p-value of <0.05 was considered 
significant, as indicated by *.  
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Figure 5.6.10: PD98059 and PD184352 do not affect nuclear p53 and γH2AX induced in 
response to etoposide 
HCT116 p53+/+ cells were treated with 25µM etoposide alone, or in combination with either 
10µM, 50µM PD98059 or 2µM PD184352. Cells were dosed for 24 hours in normoxia, fixed 
and stained using DAPI, p53 with an Alexa Fluor 488 conjugated secondary antibody, and 
phosphorylated γH2AX with an Alexa Fluor 568 conjugated antibody. Following staining, 
cells were visualised on the INCell 1000 analyser and images were captured over 10 fields 
of view for each well at 20x magnification. INCell software was used for quantification. 
Graphs show: (A) cell number, (B) average p53 intensity/nucleus and (C) average 
phosphorylated γH2AX intensity/nucleus. Data has been averaged from 3 independent 
experiments. A t-test was used to assess statistical significance between control and treated 
samples and a p-value of <0.05 was considered significant, as indicated by *.  
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In earlier experiments (Figures 5.4.2-7) the effects of PD98059 on RITA treated cells 
were investigated at 24 hour timepoints. However, DNA damage responses and cell 
death induced by RITA are both dose, and time-dependent. To assess the effects of 
PD98059 on RITA responses over a timecourse, HCT116 p53+/+ cells were treated 
with RITA alone or in combination with 10µM PD98059. Changes in sub-G1 and S-
phase cells were assessed over 24 hours using flow cytometry. RITA induced sub-G1 
was inhibited when HCT116 p53+/+ cells were treated with RITA in the presence of 
10µM PD980059, over a timecourse (Figure 5.6.11A), as was p53 and γH2AX 
induction in S-phase cells (Figure 5.6.11B). 
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Figure 5.6.11: RITA induced sub-G1, and induction of p53 and γH2AX during S-phase 
is inhibited by 10µM PD98059 
HCT116 p53+/+ cells were treated with 500nM RITA alone or in combination with 10µM 
PD98059 in normoxia. Cells were harvested for flow cytometric analysis over a 24 hour 
timecourse, fixed, and stained for propidium iodide, total p53 (using a FITC conjugated 
secondary antibody), and γH2AX (using an APC conjugated secondary antibody). DNA cell 
cycle profiles were gated and quantified for sub-G1 and S-phase. Graphs show: (A) sub-G1 
analysis of RITA treated cells (black bars) and RITA treated cells in combination with 
PD98059 (grey bars), and (B) analysis of the percentage of cells in S-phase that stain 
positive for p53 and γH2AX, as before RITA treated cells (black bars), and RITA treated 
cells in combination with PD98059 (grey bars) are shown over a 24 hour timecourse. All 
data has been averaged from 3 independent experiments. An unpaired t-test was used to 
compare the mean of DMSO controls against RITA treated samples, and a p-value of less 
than 0.05 was considered statistically significant (as indicated **<0.005, *<0.05). 
 
 
Several studies have addressed differences in specificity between PD98059 and 
PD184352. In 2000, Davies et al. screened a range of commonly used protein kinase 
inhibitors against a large panel of protein kinases to assess their target profiles. 
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Although both PD98059 and PD184352 inhibited ERK1/2 phosphorylation, PD98059 
also inhibited numerous other MAPKs. This was not observed with PD184352 which 
was concluded to be the most specific MEK1/2 inhibitor in the screen (Davies et al., 
2000). Later studies showed that the ERK5/BMK1 pathway was inhibited by PD98059 
while remaining unaffected by PD184352, and suggested that the anti-proliferative and 
anti-tumour effects mediated by PD184352 were dependent on ERK1/2 signalling 
alone (Squires et al., 2002).  
 
Also of interest were studies showing that PD184352 could only inhibit HIF-1 activity in 
response to growth factor stimulation, while PD98059 did so in response to hypoxia 
and growth factors (Sutton et al., 2007).  Therefore, ERK1/2 signalling was concluded 
to be important in regulating HIF activation in response to growth factors, while HIF-1 
activity in response to hypoxic stress was suggested to be regulated by additional 
MAPK signalling pathways (Sutton et al., 2007). Interestingly, PD98059 has also been 
shown to inhibit pathways that are not involved in MAPK signalling. For example, 
PD98059 targets cyclo-oxygenase activity directly leading to inhibition of arachidonic 
acid metabolism, decreased platelet aggregation and significant anti-inflammatory 
effects (Borsch-Haubold et al., 1998). 
 
Many MAPK signalling pathways are induced by genotoxic stress to regulate cell death 
responses. To investigate likely MAPKs that are targeted by PD98059, and could be 
involved in activating p53-dependent cell death by RITA, a candidate kinase approach 
was used. I investigated MAPKs that are known to be involved in p53-dependent 
apoptosis in response to genotoxic stress to assess whether they are important in 
eliciting cell death by RITA. 
5.7 The p38 MAPK is phosphorylated by RITA and targeted by PD98059 
The Jun N-terminal kinase (JNK) and the p38 stress activated protein kinase are 
members of the MAPK family. Pathways regulated by JNK and p38 are activated by a 
number of environmental and genotoxic stimuli, and are involved in critical cell survival, 
and inflammatory responses, as well as those involved in proliferation and 
differentiation (Wagner and Nebreda, 2009). JNK and p38 signalling pathways are 
often deregulated in many cancers and have been shown to correlate with poor patient 
survival (Demuth et al., 2007). The p38 kinase is important in mediating tumour 
suppression by inhibiting proliferation, and activating apoptosis in response to cellular 
stress (Brancho et al., 2003; Bulavin and Fornace, 2004).  Mechanisms by which p38 
inhibits cell growth involve regulation of cell cycle checkpoints (Thornton and Rincon, 
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2009), inhibitory effects on cyclin D (Lavoie et al., 1996) and CDC25 phosphatase 
(Manke et al., 2005), and activation of the Rb and p53 tumour suppressor pathways 
(Bulavin et al., 2002). The p38 MAPKs are encoded by four genes, MAPK14 encodes 
p38α (also known as SAPK2), MAPK11 encodes p38β (SAPK2b), MAPK12 encodes 
p38γ (SAPK3) and MAPK13 encodes p38δ (SAPK4), (Wagner and Nebreda, 2009). 
The most extensively studied p38 MAPK is p38α. Although several studies describe 
p38α’s role as a tumour suppressor, in certain cell types, p38α has also been 
associated with oncogenic functions such as migration, invasion (Dolado and Nebreda, 
2008), and angiogenesis (Emerling et al., 2005). 
 
RAS induced tumourigenesis is often accompanied by activation of a number of 
biochemical pathways including the MAPK and PI3K pathways (Downward, 2003a). 
The importance of p38 signalling in tumour suppression is demonstrated in studies 
which show p38 to negatively regulate malignant transformation induced by oncogenic 
H-RAS. In response to reactive oxygen species (ros) induced by oncogenic H-RAS, 
p38 activation has been shown to induce apoptosis and inhibit formation of 
subcutaneous tumours, suggesting a role for p38 as an important sensor of oxidative 
stress (Dolado et al., 2007). The p38 pathway may also inhibit oncogenic mediated 
tumour progression by suppressing the ERK1/2 pathway (Li et al., 2003), activating 
premature senescence (Wang et al., 2002), cell cycle inhibitors such as p16INK4a 
(Bulavin and Fornace, 2004) and p21 (Nicke et al., 2005), and activating p53-
dependent cell cycle arrest (Bulavin et al., 2002).  
 
Of interest to this thesis, loss of p38 can inhibit apoptosis and promote cell survival 
following exposure to chemotherapeutic agents (Sanchez-Prieto et al., 2000). 
Phosphorylation of p53 at the N-terminus is important for p53 stability (Shieh et al., 
1997), and p38 has been shown to localise to the nucleus, complex with p53 and 
phosphorylate p53 directly on serine 33 and serine 46 in response to genotoxic stress 
(Bulavin et al., 1999; Sanchez-Prieto et al., 2000). In addition, Cuadrado et al. have 
identified p18HAMLET as a novel p38 MAPK regulated protein that acts as a 
transcriptional co-activator for p53. By interacting with p53 in response to genotoxic 
stress induced by UV irradiation or cisplatin, p18HAMLET stimulates transcription of many 
p53 regulated pro-apoptotic genes to activate apoptosis (Cuadrado et al., 2007). 
Clearly, p38 signalling has an integral role to play in p53 mediated cell death responses 
and is important in maintaining cellular homeostasis in response to genotoxic stress 
and oncogenic stimuli.  
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I have shown that p53-dependent DNA damage and cell death responses elicited by 
RITA are inhibited by PD98059. Due to the role of p38 MAPK in activating p53-induced 
apoptosis (Bulavin and Fornace, 2004), I hypothesised that p38 could be targeted by 
PD98059 to inhibit RITA-induced cell death. To address this, western analysis was 
used to assess p38 phosphorylation in HCT116 p53+/+ and HCT116 p53-/- cells 
treated with RITA. RITA treatment in HCT116 p53+/+ induced p38 phosphorylation 
over a timecourse, and this was not observed to the same extent in HCT116 p53-/- 
cells (Figure 5.7.1). Induction of p38 phosphorylation also correlated with p53 
phosphorylation at serine 46, a site that has been shown to be phosphorylated directly 
by p38 in previous studies (Bulavin et al., 1999; Sanchez-Prieto et al., 2000). 
 
 
       
 
Figure 5.7.1: RITA induces p38 MAPK phosphorylation  
HCT116 p53+/+ and HCT116 p53-/- cells were treated with 1µM RITA in normoxia over a 24 
hour timecourse. Cells were harvested for western blotting and analysed for phosphorylated 
p38 (p-p38), total p38, phosphorylated p53 at serine 46 (p-p53), total p53, and β-actin as a 
loading control. Data shown is representative of 3 independent repeats. 
 
 
To assess whether phosphorylation of p38 by RITA was inhibited by PD98059, 
HCT116 p53+/+ cells were treated with RITA, either alone or in combination with 
PD98059. PD98059 significantly inhibited ERK1/2 phosphorylation and also inhibited 
p38 phosphorylation in response to RITA. These data are consistent with previous 
studies from our laboratory showing that RITA induces p38 phosphorylation (at doses 
as low as 200nM) and this is blocked by PD98059 at 10µM and 50µM concentrations 
(Yang, unpublished). These studies suggest that p38 is a non-specific target of 
PD98059. 
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Figure 5.7.2: RITA induced phosphorylation of p38 is inhibited by PD98059 
HCT116 p53+/+ cells were treated with 500nM RITA with or without 50µM PD98059 and 
harvested for western analysis over a 24 hour timecourse. Western blot analysis shows 
phosphorylated ERK1/2 (p-ERK1/2), phosphorylated p38 (p-38), total p38, phosphorylated 
p53 at serine 46 (p53-46), and total p53.  β-actin was used as a loading control. Data shown 
is representative of 3 independent repeats.   
 
 
Compared to PD98059, PD184352 does not affect RITA mediated DNA damage 
responses and cell death. To assess the effects of PD184352 on RITA induced p38 
phosphorylation, HCT116 p53+/+ and HCT116 p53-/- cells were treated with RITA, 
either alone, or in combination with PD98059 and PD184352. Phosphorylation of p38 
in response to RITA was inhibited by PD98059, and not with PD184352 (Figure 5.7.3). 
These findings confirm that p38 is a non-specific target of PD98059.  
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Figure 5.7.3: Phosphorylation of p38 MAPK by RITA is not affected by PD184352 
Western blot analysis shows HCT116 p53+/+ and HCT116 p53-/- cells treated with 500nM 
RITA alone, or in combination with either 50µM PD98059, or 2µM PD184352. Cells were 
harvested after 24 hours and analysed by western blotting for phosphorylated p38 (p-p38), 
total p38, and β-actin as a loading control. Data shown is representative of 3 independent 
repeats. 
 
 
So far, p38 phosphorylation has been demonstrated in HCT116 p53+/+ cells treated 
with RITA, and these responses are inhibited in the presence of PD98059. Based on 
data previously showing that PD98059 inhibits RITA induced cell death, I hypothesised 
that p38 phosphorylation is essential for eliciting cell death by RITA. To address this, 
p38α protein expression was blocked by siRNA in HCT116 p53+/+ cells, and RITA-
induced cell death was assessed by flow cytometry. Western analysis was used to 
confirm that p38 was efficiently knocked down by siRNA. As shown in Figure 5.7.4, p38 
was inhibited by siRNA and no significant changes were observed in RITA induced p53 
or γH2AX (Figure 5.7.4) 
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Figure 5.7.4: p38α siRNA does not inhibit RITA induced p53 stabilisation, γH2AX, or 
cleaved PARP 
Western blot shows HCT116 p53+/+ cells transfected for 24 hours with either 50nM non-
silencing control (NSC) siRNA, or 50nM p38 siRNA using HiPerfect (as in materials and 
methods). Following transfection, cells were treated with either DMSO control (indicated by -) 
or 500nM RITA (indicated by +) and incubated in normoxia for 24 hours. Western blots were 
analysed for total p38, γH2AX, and total p53 protein expression. β-actin was used as a 
loading control. Data shown is representative of 3 repeats. 
 
 
In order to quantify cell death responses in parallel with the above experiments, flow 
cytometry cell cycle profiles were analysed of HCT116 p53+/+ cells treated with RITA 
following p38 siRNA knockdown. The sub-G1 population of cells was quantified as an 
indication of cell death (Figure 5.7.5). Changes in RITA induced cell death were not 
observed in cells with p38α knockdown. 
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Figure 5.7.5: p38 siRNA does not affect RITA induced cell death 
HCT116 p53+/+ cells transfected for 24 hours with either 50nM non-silencing control (NSC) 
siRNA, or 50nM p38 siRNA prior to 24 hour dosing with 500nM RITA in normoxia. Following 
treatment, cells were harvested for flow cytometry, fixed and stained using propidium iodide. 
Cell cycle DNA profiles were gated and quantified for sub-G1 as an indication of cell death. 
Graph shows the percentage of each treated population in sub-G1. Data shown has been 
averaged from 2 independent repeat experiments.  
 
 
PD98059 inhibits RITA induced DNA damage (Figure 5.6.7). Phosphorylation of p38 by 
RITA is also inhibited by PD98059, I therefore hypothesised that p38 signalling is 
important for inducing DNA damage by RITA. To address this, HCT116 p53+/+ cells 
were treated with RITA following siRNA mediated knockdown of p38, and DNA strand 
breaks were assessed using the comet assay. Loss of p38 was found to have no affect 
on DNA damage elicited by RITA. In conclusion, although p38 phosphorylation is 
induced by RITA and targeted by PD98509, p38 is not essential for eliciting RITA 
induced DNA damage or cell death responses. 
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Figure 5.7.6: p38 siRNA does not affect RITA induced DNA damage 
HCT116 p53+/+ cells harvested for western blotting to confirm siRNA induced p38 
knockdown (Figure 5.7.4), and for flow cytometry to assess sub-G1 (Figure 5.7.5), were also 
harvested for comet analysis. Following 50nM non-silencing control (NSC) or 50nM p38 
siRNA transfection, HCT116 p53+/+ cells were dosed with 500nM RITA for 24 hours in 
normoxia. Hydrogen peroxide (H2O2) was used as a positive control for DNA damage at 
100µM for 20 mins, prior to comet preparation. For comet analysis, cells were counted, 
mixed with agarose, and spread onto comet slides for electrophoresis (see materials and 
methods). Following electrophoresis, slides were fixed and cells were stained for SYBR 
Green. Cell nuclei (described as comets) were visualised on an inverted fluorescent 
microscope at 10x magnification, and images over 20 fields of view for each treatment were 
captured using ImagePro® software. The TriTek® comet score software programme was 
used to calculate olive moment as an indication of DNA damage in each cell nucleus 
(approx 100 comets/treatment). Graph shows olive moment for each treatment and has 
been averaged from 2 independent repeat experiments.  An unpaired t-test was used to 
calculate statistical significance and a p-value of less than 0.05 was considered significant. 
 
 
The JNK kinase is activated in response to genotoxic stress elicited by UV irradiation, 
γ-irradiation and chemotherapeutic drugs (Ip and Davis, 1998). Like p38, JNK kinase 
also suppresses RAS transformation in vivo (Kennedy and Davis, 2003; Kennedy et al., 
2003), and promotes p53 stability by either interfering with p53-HDM2 interactions with 
HDM2, or by direct binding (Adler et al., 1997; Fuchs et al., 1998a). Both JNK and p38 
MAPK pathways share several upstream regulators (Cuevas et al., 2007) and a 
complex level of crosstalk exists between these two pathways (Cheung et al., 2003; 
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Hui et al., 2007). At the level of p53, it is likely that JNK and p38 co-operate closely to 
elicit p53-mediated cell death responses.  
  
Previously, p38 kinase was shown to be phosphorylated by RITA, however p38 was 
not essential for eliciting cell death responses by RITA. I extended these studies to 
include JNK signalling. As JNK kinase is known to activate p53 in response to 
genotoxic stress, I hypothesised that RITA also induces phosphorylation of JNK, and 
this contributes to p53-induced cell death. To address this hypothesis, western analysis 
was used to assess HCT116 p53+/+ cells treated with 500nM RITA over a timecourse, 
either alone or in combination with PD98059. Like p38, JNK was also phosphorylated 
in response to RITA, and these responses were inhibited when cells were treated with 
RITA in the presence of PD98059 (Figure 5.7.7).  
 
In summary, induction of DNA damage responses and cell death by RITA involves 
phosphorylation of p38 and JNK stress activated kinases. Because p38 and JNK 
MAPK’s are non-specific targets of the MEK1/2 inhibitor PD98059, I hypothesised that 
p38/JNK signalling may mediate DNA damage and cell death pathways in response to 
RITA. However, closer analysis using siRNA mediated knockdown of p38α has shown 
that although p38 signalling may have an important role in p53-dependent responses 
activated by RITA, p38 is not essential for p53-dependent cell death.  It is possible that 
p53-dependent cell death responses involve co-ordinated phosphorylation of p53 by 
several upstream kinases. The possibility that both p38 and JNK may have a co-
dependent function in RITA activated cell death requires further investigation.  
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Figure 5.7.7: JNK kinase is phosphorylated in response to RITA and inhibited by 
PD98059 
Western blot shows HCT116 p53+/+ cells treated with 500nM RITA either alone or in 
combination with 50µM PD98059. Cells were harvested over a 24 hour timecourse and 
analysed by western blotting for phosphorylated JNK (p-JNK), phosphorylated ERK1/2 (p-
ERK1/2), and α-tubulin  as a loading control. Data shown is representative of 3 independent 
repeats. 
 
5.8 Performing a high-throughput siRNA screen 
In section 5.7, a candidate kinase approach was used to assess MAPKs that are 
involved in eliciting p53-dependent cell death responses. Although p38 was induced by 
RITA, and inhibited by PD98059, closer analysis showed that p38 is not essential in 
eliciting cell death responses by RITA. Therefore PD98059 may target other MAPKs 
that are essential in activating p53-dependent responses. To address this, I performed 
a MAPK siRNA screen. 
 
The INCell 1000 high content screening platform was used in previous experiments to 
assess changes in nuclear p53 and γH2AX intensity. Using INCell technology enables 
robust and quantitative analyses of multiple phenotypes within individual cells that are 
exposed to stress stimuli. I optimised a 96 well high throughput immunoflourescence 
based assay that could be used to screen multiple targets using the INCell platform 
(see chapter 2 section 2.7, materials and methods). This assay was previously used to 
simultaneously analyse both nuclear p53 and γH2AX localisation when cells were 
treated with RITA alone, or in combination with PD98059 (Figure 5.4.5). The data 
obtained from these experiments provided a reliable basis with which to screen a 
MAPK siRNA library. 
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To begin optimising the immunoflourescent INCell assay for the MAPK siRNA screen, 
the standard siRNA protocol was optimised to a high throughput 96 well format. RITA 
induced cell death and DNA damage responses are p53-dependent. Therefore, p53 
siRNA was used to assess whether efficient knockdown of p53 could be quantified 
using INCell technology, and if this correlated with loss of RITA induced cell death, p53 
stabilisation, and γH2AX induction. As a comparison, HCT116 p53-/- cells were also 
treated in parallel to assess the efficiency of p53 knockdown in HCT116 p53+/+ cells 
(Figure 5.8.1). 
 
As shown in Figure 5.8.1, inhibition of RITA induced p53 stabilisation was achieved in 
HCT116 p53+/+ cells that had been transfected with p53 siRNA compared to the non-
silencing control (NSC). Knockdown of p53 by siRNA in HCT116 p53+/+ cells treated 
with RITA also inhibited nuclear γH2AX intensity. Induction of nuclear p53 and γH2AX 
following RITA treatment was not observed in HCT116 p53-/- cells. In conclusion, the 
INCell screening platform was successfully used to assess nuclear p53 and γH2AX 
following RITA treatment in cells that had been transfected with siRNA in a 96 well 
format. 
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Figure 5.8.1: Induction of nuclear p53 and γH2AX in RITA treated cells is inhibited by 
p53 siRNA 
Images show HCT116 p53+/+ (top panel) and HCT116 p53-/- (bottom panel) cells 
transfected with either non-silencing control (NSC) siRNA or p53 siRNA for 24 hours using 
HiPerfect (see materials and methods). Following 24 hour transfection, cells were treated 
with 500nM RITA and incubated for a further 24 hours in normoxia. Plates were then fixed 
and stained using specific antibodies against p53 (with an Alexa Fluor 488 conjugated 
secondary antibody), and γH2AX (with an Alexa Fluor 568 conjugated secondary antibody), 
DAPI was used to stain nuclei. The INCell 1000 was used to capture 10 images for every 
well, at each fluorescent intensity using 20x magnification. Representative images from one 
field and 3 independent experiments are shown.  
 
 
The INCell 1000 software was used to quantify immunoflourescent images taken by the 
INCell. RITA induced cell death (indicated by loss of cell counts) was inhibited following 
knockdown of p53 by siRNA (Figure 5.8.2A). Consistently, changes in cell number 
were not observed in HCT116 p53-/- cells treated with RITA. Induction of nuclear p53 
following RITA treatment was only detected in HCT116 p53+/+ cells, and not in 
HCT116 p53-/- cells, or HCT116 p53+/+ cells that had loss of p53 by siRNA (Figure 
5.8.2B). Notably, nuclear γH2AX induced by RITA was detected in HCT116 p53+/+ 
cells with siRNA mediated knockdown of p53, and not in HCT116 p53-/- cells, 
suggesting that p53 siRNA was not sufficient to inhibit nuclear γH2AX localisation 
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induced in response to RITA (Figure 5.8.2C). Overall, siRNA knockdown can be 
optimised for a 96 well format and quantified in a reproducible and reliable way 
according to defined phenotypes established in cells treated with RITA. Following 
preliminary siRNA experiments, a reverse transfection siRNA library comprising 58 
MAPK siRNA oligo’s was purchased from Dharmacon. To complete the siRNA screen, 
the following protocol was recommended by Dharmacon (Figure 5.8.3). 
 
 
 
 
Figure 5.8.2: RITA induced p53 and γH2AX is inhibited by p53 siRNA 
Graphs show INCell quantification of HCT116 p53+/+ and HCT116 p53-/- cells transfected 
with either non-silencing control siRNA (NSC) or p53 siRNA prior to 500nM RITA treatment 
for 24 hours in normoxia. Cells were stained for: (A) DAPI to visualise nuclei and quantify cell 
number, (B) total p53 (with an Alexa Fluor 488 conjugated secondary antibody) to quantify 
p53 nuclear intensity, and (C) phosphorylated γH2AX (with an Alexa Fluor 568 secondary 
antibody) to assess γH2AX phosphorylation in the nucleus. Images were captured for each 
fluorescent intensity over 10 fields of view using the INCell analyser at 20x magnification. All 
images were quantified using INCell software analysis. Data shown has been averaged from 
3 independent experiments. An unpaired t-test was used to assess statistical significance 
between control and treated samples, and a p-value of less than 0.05 was considered 
significant.  
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Figure 5.8.3: Performing a high throughput siRNA screen 
A Dharmacon siRNA library of 58 MAPK’s was purchased. Optimisation plates were supplied 
with the library to optimise seeding densities and Dharmacon specific transfection reagents. 
The screening protocol involves combining optimised volumes of transfection reagent with 
cell culture reagent to form a rehydration solution that is added to every well containing pre-
seeded siRNA. The siRNA oligo’s are rehydrated and complexes form during an incubation 
period. Cells are then seeded directly onto the siRNA mix. Following an overnight 
transfection incubation, the plate is dosed with 500nM RITA and incubated for a further 24 
hours before fixing and staining for nuclei, p53 induction and γH2AX. The plate is read on an 
INCell 1000 analyser for image acquisition and data analysis. 
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Before performing the MAPK siRNA screen, optimisation plates were used to test the 
knockdown efficiency of a standard siRNA, in this case p53, against transfection 
reagents provided specifically by Dharmacon for the screening format. HCT116 p53+/+ 
cells were treated with RITA in the absence of transfection reagent, and with either a 
non-silencing control (NSC) siRNA, or p53 targeted siRNA using Dharmacon 
transfection reagents. As shown in Figure 5.8.4A, the transfection reagent used caused 
a significant decrease in cell viability compared to untreated cells. However, nuclear 
p53 induced in response to RITA was inhibited in HCT116 p53+/+ cells following p53 
siRNA transfection (Figure 5.8.4B). Inhibition of nuclear γH2AX foci induced by RITA 
was also observed when cells were treated with p53 siRNA (Figure 5.8.4C). The 
optimisation data presented is consistent with that in Figure 5.8.2. Therefore siRNA 
knockdown can be achieved using both standard and screen specific transfection 
protocols to quantify and evaluate RITA responses. 
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Figure 5.8.4: Optimising p53 siRNA transfection using Dharmacon reagents 
HCT116 p53+/+ cells were seeded into 96 well plates containing either non-silencing control 
(NSC) siRNA, or p53 targeted siRNA. Following 24 hour transfection, cells were treated with 
500nM RITA for 24 hours in normoxia, fixed and stained with DAPI, total p53 (with an Alexa 
Fluor 488 secondary antibody), and phosphorylated γH2AX (with an Alexa Fluor 568 
antibody). Images at each fluorescent intensity were captured using the INCell analyser at 
20x magnification, and quantified using INCell software. Graphs show: (A) average cell 
count/well (quantified using DAPI staining), (B) average p53 intensity/nucleus, (C) average 
phosphorylated γH2AX foci/nucleus. Data has been averaged from 2 independent repeat 
experiments. An unpaired t-test was used to assess statistical significance between control 
and treated samples, and a p-value of <0.05 was considered significant. 
 
 
To identify MAPK siRNAs that inhibit RITA mediated responses, p53 and γH2AX 
induction in cells treated with RITA was compared in cells with either non-silencing 
control siRNA, or p53 siRNA (Figure 5.8.5). RITA induced cell death (indicated by cell 
number/well) was inhibited in p53 siRNA wells compared to NSC siRNA controls 
(Figure 5.8.5A). Unfortunately, significant loss in cell viability was observed following 
MAPK siRNA transfection. An unpaired t-test was used to compare the mean statistical 
difference between RITA induced nuclear p53 in NSC control wells, compared with 
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MAPK siRNA’s. RITA treated cells transfected with MAPK siRNA’s that showed a 
statistically significant decrease in nuclear p53 (with a two tailed p-value of <0.05) are 
highlighted in black (Figure 5.8.5B). Out of 58 siRNA oligos screened, 9 oligos were 
shown to significantly reduce nuclear p53 induction upon RITA treatment compared to 
the non-silencing control. Similar criteria were used to assess nuclear γH2AX foci 
(Figure 5.8.5C). Out of 58 oligos, 37 oligos showed significant inhibition in RITA-
induced nuclear γH2AX compared to the non-silencing controls. 
 
To highlight statistically significant data from the siRNA screen (indicated previously as 
black bars in Figure 5.8.5) graphs were redrawn to indicate the specific MAPKs that 
show significant decreases in RITA induced nuclear p53 (Figure 5.8.6A) and γH2AX 
(Figure 5.8.6B). In agreement with previous data using the MEK1/2 inhibitors PD98059, 
and PD184352, loss of MAP2K1 (MEK1/MKK1) and MAP2K2 (MEK2/MKK2) by siRNA 
significantly inhibited nuclear p53 and γH2AX in RITA treated cells. Although several 
MAPK siRNAs were identified in our screen as inhibiting p53 and γH2AX induction, I 
investigated MAPK2K3 (MKK3) in further detail as MKK3 is an upstream regulator of 
the p38 kinase which has been studied previously in mediating p53-dependent cell 
death responses by RITA. 
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Figure 5.8.5: siRNA screening data 
HCT116 p53+/+ cells were transfected with non-silencing control siRNA (NSC), p53 siRNA, 
or MAPK siRNAs prior to 500nM RITA treatment for 24 hours in normoxia. Following 
treatment cells were fixed and stained using DAPI, total p53 protein (with an Alexa Fluor 488 
secondary antibody), and γH2AX (with an Alexa Fluor 568 secondary antibody). Cells were 
imaged using the INCell analyser at 20x magnification for each fluorescent intensity. Up to 
10 fields of view were captured for each treated well. Images were quantified using INCell 
software. Graphs show: (A) average cell count/well, (B) average p53 intensity/nucleus and 
(C) average γH2AX foci/nucleus. An unpaired t-test was used to assess statistical 
significance and a two-tailed p-value <0.05 was considered significant. Treated wells in 
which a statistically significant decrease in protein expression is seen compared to the non-
silencing control are highlighted in black. Corresponding well numbers for each MAPK siRNA 
are labelled on the x-axis. All data shown has been calculated from 2 independent repeat 
screens. 
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Figure 5.8.6: Statistically significant MAPK screening data 
Graphs show HCT116 p53+/+ cells transfected with either non-silencing control siRNA 
(NSC), p53 siRNA or MAPK siRNA’s prior to 24 hour, 500nM RITA treatment in normoxia. 
Following treatment, HCT116 p53+/+ cells were fixed and stained using DAPI, total p53 
protein (with an Alexa Fluor 488 conjugated secondary antibody), and γH2AX (with an Alexa 
Fluor 568 conjugated secondary antibody). Images were captured using the INCell analyser 
at 20x magnification over 10 fields of view, and quantified using INCell software. Graphs 
show: (A) average p53 intensity/nucleus, and (B) average γH2AX foci/nucleus for HCT116 
p53+/+ cells treated with RITA following MAPK siRNA tranfection. Data has been taken from 
the screen shown in Figure 5.8.6, and has been redrawn to indicate RITA treated siRNA 
wells in which there is a statistically significant decrease in nuclear p53, and γH2AX 
compared to non-silencing control (NSC) cells. An unpaired t-test was used to assess 
significance (where two-tailed p-value <0.05). All data has been calculated from 2 
independent repeat screens. 
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5.9 Investigating MKK3 as a target kinase for PD98059  
The MAPK siRNA screen identified several siRNAs which showed a decrease in RITA 
mediated induction of nuclear p53 and γH2AX. The MAP2K3 MAPK kinase (MKK3) 
was of particular interest because MKK3 has been shown to phosphorylate and 
activate p38 MAPK specifically, without having any affects on the JNK and ERK 
signalling pathways (Derijard et al., 1995). Phosphorylation of p38 has already been 
demonstrated in cells treated with RITA. Consistently, RITA mediated responses are 
not reversed when p38α is targeted by siRNA, suggesting that p38 is not essential for 
inducing cell death in response to RITA (Figure 5.9.4).  
 
As MKK3 kinase is an upstream activator of p38 signalling, I hypothesised that MKK3 
may be involved in regulating RITA-induced cell death through the p38 signalling 
pathway. To address this, MKK3 data was isolated from the MAPK siRNA screen data 
set (Figure 5.8.5). As shown in Figure 5.9.1, RITA induced stabilisation of nuclear p53 
(Figure 5.9.1A) and γH2AX (Figure 5.9.1B) was significantly inhibited in the presence 
of MKK3 siRNA. These responses were also observed in the presence of MAP2K1 
(MKK1/MEK1) and MAP2K2 (MKK2/MEK2), the target kinases for PD98059. 
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Figure 5.9.1: RITA induced p53 and γH2AX is inhibited by MKK3 siRNA 
Graphs show HCT116 p53+/+ cells treated with 50nM of either non-silencing control (NSC) 
siRNA, p53 siRNA, MAPK2K1 (MKK1/MEK1) siRNA, MAP2K2 (MKK2/MEK2) siRNA, or 
MAP2K3 (MKK3/MEK3) siRNA using the Dharmacon screening protocol. Following 24 hour 
transfection, cells were treated with 500nM RITA for another 24 hours in normoxia. Cells 
were fixed following treatment and stained for DAPI, total p53 protein (with an Alexa Fluor 
488 secondary antibody), and γH2AX (with an Alexa Fluor 568 secondary antibody). The 
INCell analyser was used to capture images for each treatment over 10 fields of view, at 20x 
magnification and INCell software was used for quantification. Graphs show: (A) average 
p53 intensity/nucleus and (B) average γH2AX foci/nucleus for specific siRNA oligos indicated 
on the x-axis. Statistical significance was assessed between RITA treated non-silencing 
control (NSC) siRNA, and RITA treated MAPK siRNA cells. An unpaired t-test (where two-
tailed p-value <0.05) was used to calculate significance, (*p<0.05, **p<0.005, ***p<0.0005). 
All data has been averaged from 2 independent repeat screens. 
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PD98059 can inhibit p53-dependent DNA damage and cell death responses elicited by 
RITA and this is not observed in cells that are treated with RITA in combination with 
PD184352. Because PD98059 has a broader target profile compared to PD184352, a 
MAPK siRNA screen was performed and MKK3 was isolated as a potential non-
specific target of PD98059 which, when targeted by siRNA mediated knockdown, could 
inhibit RITA induced p53 and γH2AX (Figure 5.9.1).  
 
To confirm whether MKK3 is targeted by PD98059, HCT116 p53+/+ cells were treated 
with 500nM RITA over a timecourse, either alone, or in combination with 50µM 
PD98059. Phosphorylation of MKK3 was induced in cells that had been treated with 
RITA over a timecourse, and inhibited in cells that had been treated with RITA in 
combination with PD98059 (Figure 5.9.2). The data presented suggest that like p38 
kinase, MKK3 is also a non-specific target of PD98059. 
 
 
 
 
Figure 5.9.2: Phosphorylation of MKK3 is inhibited by PD98059 
Western blot shows HCT116 p53+/+ cells treated with 500nM RITA for 24 hours in 
normoxia, either alone or in combination with 50µM PD98059. Cells were harvested for 
western analysis over a 24 hour timecourse and assessed for phosphorylated MKK3 (p-
MKK3), phosphorylated ERK1/2 (p-ERK1/2), total p53 protein, and α-tubulin as a loading 
control. Data shown is representative of 3 independent repeats. 
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5.10 Discussion 
Previous studies with PD98059 have shown that MAPK signalling is important in 
regulating p53-dependent cell death in response to genotoxic stress (Persons et al., 
2000; Ryan et al., 2000). The studies presented in this chapter are consistent with 
these findings and show that PD98059 inhibits many of RITA’s distinct p53-dependent 
effects on cells including induction of DNA damage, activation of DNA damage 
responses involving γH2AX, CHK1, and CHK2 phosphorylation, stabilisation of p53, 
and induction of p53-dependent cell death.  
 
A candidate kinase approach was taken, and a MAPK siRNA screen (Dharmacon) was 
performed to identify MAPKs that are targeted by PD98059 and are not affected by 
other MAPK inhibitors. The p38 and JNK MAPK signalling pathways were assessed as 
candidates for their contribution to RITA induced cell death. The upstream activator of 
p38 signalling, MKK3 was also identified in the MAPK siRNA screen. MKK3 was both 
phosphorylated in response to RITA, and inhibited in the presence of PD98059. 
Although p38 was also phosphorylated by RITA and inhibited by PD98059, siRNA 
mediated knockdown of p38α did not inhibit RITA induced cell death. Therefore, 
although p38 phosphorylation is induced, it is not essential for eliciting cell death and 
DNA damage responses by RITA. 
 
Studying the MKK3-p38 pathway has led us to question why MKK3 siRNA inhibits RITA 
induced p53 and γH2AX responses while p38α siRNA, a downstream target of MKK3 
has no significant effects on RITA responses. If not through p38, how then is MKK3 
mediating its effects on RITA induced cell death? Independent functions of MKK3 and 
p38 are shown by in vivo models whereby Mkk3 null mice are viable and fertile (Lu et 
al., 1999; Tanaka et al., 2002), while inactivation of p38α results in early embryonic 
lethality (Adams et al., 2000) suggesting a more significant role for p38 in cell growth 
and survival during development. The disconnect between MKK3 and p38 in vivo 
phenotypes has not been addressed directly but suggests a level of redundancy for 
some upstream MAPKKs. Thus the case may be that MKK3 interacts with other 
pathways not yet identified which are independent of p38 signalling. Furthermore 
although we knocked down p38α by siRNA, four other isoforms of p38 have been 
described which may have independent roles in regulating p53-dependent cell death 
responses (Freshney et al., 1994). It will be of interest to assess other p38 isoforms in 
greater detail.  
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The physiological functions of both JNK and p38 stress pathways may be overlapping 
and several studies support this hypothesis (Ip and Davis, 1998). The apoptosis signal 
regulating kinase 1 (ASK1) MAPKKK activates two subgroups of MAPKKs, the MKK4/7 
kinases that lead to JNK activation, and the MKK3/6 kinases that activate p38 signalling 
in response to TNF-α induced apoptosis (Ichijo et al., 1997), and in response to 
chemotherapeutic agents (Chen et al., 1999). Such studies which show that upstream 
MAPKKKs link multiple stress pathways suggest again that MAPKs have overlapping 
and redundant functions depending on cell type and stress stimuli. 
 
PD98059 targets several MAPKs that are not inhibited by PD184352, therefore 
combined inhibition of numerous MAPKs may be essential for blocking p53-dependent 
cell death in response to RITA. Further clues arise from the siRNA screen presented in 
this thesis whereby several MAPK siRNAs were shown to significantly inhibit RITA 
induced p53 and γH2AX. It is difficult to speculate at this stage exactly which MAPKs 
have a critical role to play in RITA induced cell death responses, and further studies will 
be required, taking clues from both siRNA screening data, and from the literature 
whereby multiple MAPK pathways have been studied in response to stress stimuli both 
with individual and co-operative effects.       
 
In this study, PD184352 was used as a potent and selective inhibitor of MKK1 
compared to PD98059 based on previous screens conducted by Davies et al. (Davies 
et al., 2000). As PD184352 had no significant effects on RITA mediated responses, it 
was concluded that PD98059 may target non-specific kinases that are essential for 
eliciting RITA induced cell death responses. On this basis, a MAPK siRNA screen was 
conducted. However, data from the screen showed that knockdown of MKK1 and MKK2 
significantly inhibited induction of p53, and γH2AX in response to RITA, suggesting that 
in fact, MKK1 and MKK2 are important in eliciting RITA mediated responses. Why then 
did the selective MKK1/MKK2 inhibitor PD184352 not affect RITA mediated responses? 
The answer lies within understanding the importance of comparing the selectivity 
profiles of related small molecules before making definitive conclusions of the pathways 
that they target. Firstly, although PD184352 is a selective inhibitor of MKK1, PD184352 
does target other structurally related kinases that are not affected by more potent 
inhibitors such as PD0325901 (Bain et al., 2007). Furthermore, the selective inhibition 
of MKK1/MKK2 by PD184352 may upregulate other pathways that compensate for 
promoting tumour cell death in response to p53 activating agents such as RITA. 
PD98059 may not induce such responses due to broader targeting of kinases. 
Collectively, these data highlight the importance of using siRNA mediated knockdown of 
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specific kinases in parallel to small molecule inhibitors when assessing specific cellular 
pathways. The contribution that MKK1 and MKK2 have in regulating p53-dependent cell 
death in response to RITA cannot be ignored and I therefore propose that targeted 
inhibition of MKK1/MKK2 as well as other kinases by PD98059 promotes the cell 
survival phenotype that has been observed in the experiments presented throughout 
this chapter. 
 
Using PD98059, I have also shown that ERK1/2 signalling is important in regulating cell 
cycle responses in both HCT116 p53+/+ and HCT116 p53-/- cells. In HCT116 p53+/+ 
cells, ERK1/2 phosphorylation mediates RITA induced cell death responses, while in 
HCT116 p53-/- cells, ERK1/2 phosphorylation promotes RITA induced G2 arrest, which 
is inhibited in the presence of PD98059. Interestingly, p38 MAPK has an important 
function in eliciting G2 arrest in p53 null cells during early timepoints after UV irradiation 
(Bulavin et al., 2001). By regulating cell cycle checkpoints in p53 null cells, p38 
signalling promotes cell survival (Reinhardt et al., 2007). Furthermore, Reinhardt et al. 
demonstrate a requirement for ATM and ATR in activating p38 MAPK and MAPK 
kinase 2 (MK2), a downstream target kinase of p38 required for UV induced cell cycle 
checkpoints (Manke et al., 2005). MK2 in turn regulates Cdc25 protein phosphatases 
that control G2/M transitions following DNA damage (van Vugt et al., 2004). Loss of 
MK2 function promotes premature mitotic entry and apoptosis in response to DNA 
damaging agents, and has significant anti-tumour activity in vivo (Reinhardt et al., 
2007). For this current study, it will be of interest to assess cell cycle effects of p38 or 
MK2 knockdown in HCT116 p53-/- cells that have been treated with RITA.  Collectively, 
these studies describe an important function for MAPK signalling in regulating cell 
death, and cell cycle responses induced by stress stimuli and demonstrate how DNA 
damage responses can rewire complex signalling networks to induce specific cell cycle 
and cell death effects that are dependent on p53 status. 
5.11 Conclusions for this chapter 
 PD98059 inhibits RITA induced cell death, DNA damage, and DNA damage 
responses involving γH2AX, and phosphorylation of both CHK1 and CHK2. 
 RITA elicits G2 arrest in HCT116 p53-/- cells that is inhibited when cells are treated 
with RITA in the presence of PD98059. 
 PD184352 does not affect RITA treated cells. 
 The MAPK pathway involving MKK3 and p38 phosphorylation is induced by RITA, 
and inhibited by PD98059. 
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5.12 Impact of these findings 
Sorafenib was developed as a specific inhibitor of RAF-MEK-ERK signalling, however 
during clinical progression, sorafenib was shown to have activity against various RAF 
isoforms and against VEGFR-2, VEGFR-3, PDGFR-β, c-Kit and Flt-3 tyrosine kinases 
(Wilhelm et al., 2004). For this reason, sorafenib is now classed as a multiple kinase 
inhibitor. Deregulation of VEGF, PDGF-β, and TGF-β is implicated in the malignant 
phenotype of renal cell carcinoma due to loss of pVHL function, and sorafenib has 
therefore been used widely in the clinic to treat patients with renal cell carcinoma. The 
favoured toxicity profile of sorafenib, together with marked tumour regression and 
improved survival of subjects also suggests that sorafenib could be used in combination 
with other targeted agents. Bevacizumab for example inhibits multiple VEGF isoforms 
(Presta et al., 1997) however activity is limited in the clinic due to acquired resistance 
strategies such as compensatory increases in serum VEGF levels (Yang et al., 2003). 
Use of sorafenib in combination with bevacizumab may enhance anti-tumour effects by 
maximising VEGF inhibition. Furthermore, therapeutic potential of the mTOR inhibitor 
RAD001 has been shown to be limited by the consequent increases in MAPK activity 
(Carracedo et al., 2008). Use of RAD001 in combination with the MEK-ERK inhibitor 
PD0325901 has been shown to improve anti-tumour responses by targeting both 
signalling pathways (Carracedo et al., 2008). 
 
Studies presented in this chapter show that MAPK signalling is important for stabilising 
wildtype p53 in response to RITA, and activating DNA damage responses involved in 
cell cycle and cell death responses that determine anti-tumour outcomes. These key 
findings are summarised in Figure 5.10.1. Therefore, in the tumour models that have 
been studied so far in this thesis, MAPK inhibition would not be a desirable therapeutic 
strategy in combination with p53-activating agents. Due to the importance of MAPK 
signalling in regulating p53-dependent apoptosis, it would be essential to base MAPK 
combination therapies according to p53 status, and such therapeutic combinations have 
not been investigated to date. In renal cell carcinoma, which has elevated levels of HIF 
signalling, as well as deregulated p53 activity, it will be of interest to assess the effects 
of sorafenib which already has efficacy in this tumour model, in combination with p53 
targeted agents like RITA. We would predict that combined inhibition of HIF signalling, 
as well as induction of p53-dependent cell death in this model would have significant 
anti-tumour affects. 
 
 
 Chapter 5: MAPK signalling modulates RITA induced cell death 
 
 
Page: 183 
 
                        
 
Figure 5.10.1: PD98059 inhibits the anti-tumour activity of RITA 
MAPK signalling is important for stabilising wildtype p53 in response to RITA and eliciting 
DNA damage responses that mediate cell cycle and cell death effects. Overall, MAPK 
signalling is important for determining the apoptotic outcome of p53 wildtype cells that have 
been exposed to RITA. 
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6.1 Introduction 
Previous data from our laboratory has shown that RITA not only stabilises p53, but also 
inhibits HIF-1α protein induction in hypoxia (Yang et al., 2009a; Yang et al., 2009b), 
and I have demonstrated that this response is distinct compared to other DNA 
damaging agents that activate p53 (Figure 3.1.4). Downregulation of HIF-1α protein 
expression in response to p53 induction by RITA is supported by studies whereby p53 
activity has been shown to negatively regulate HIF-1α protein and angiogenesis (Ravi 
et al., 2000). Although the relationship between HIF and p53 has been described in 
several studies, the mechanism for these interactions remain poorly understood.  
 
RITA induces p53 in hypoxic tumours and elicits p53-dependent cell death. These 
studies are important because they not only utilise small molecule activation of p53 to 
elicit cell death and anti-angiogenic responses, but they also provide us with a tool that 
can be used to study mechanisms that are deregulated in hypoxic cells. Indeed, the 
use of RITA as a molecular tool in this thesis has unveiled novel p53-dependent 
mechanisms that regulate cell cycle, and DNA damage responses which have not been 
described in previous studies (Ahmed et al., 2011). 
 
It is of interest to study RITA induced cell death in tumours that have deregulated pVHL 
function and overexpress HIF-1α and HIF-2α protein levels. Tumour models such as 
renal cell carcinoma and neuroblastoma are important because they rarely express 
mutant p53, and often have deregulated wildtype p53 activity making them angiogenic 
due to loss of pVHL function, and resistant to conventional forms of chemo- and 
radiotherapy. By inducing p53, and inhibiting the HIF pathway, RITA provides an 
opportunity with which to sensitise such tumours to p53-dependent cell death. 
However, these studies need greater understanding of the mechanisms by which HIF 
and p53 pathways are deregulated. In this chapter, I will investigate how HIF-1α and 
HIF-2α protein expression affects p53-induced cell death in various tumour models.   
 
So far, by showing that p53 induction can inhibit HIF-1α protein expression and induce 
significant tumour cell apoptosis, I have confirmed the negative relationship that exists 
between p53 activity and HIF-1α status, while also revealing the presence of novel 
mechanisms by which small molecule activation of p53 targets HIF signalling in 
hypoxia. To investigate the effects of p53 activation by RITA in greater detail, p53 
target proteins will be analysed, as changes in p53 target gene expression in response 
to genotoxic stress have significant effects on the apoptotic phenotype of cells. 
Therefore, RITA induced DNA damage and cell cycle responses may also be 
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influenced by p53 induced target gene expression. In this chapter, I will explore the 
mechanism by which RITA regulates p53 activity, and p53 target proteins, as well as 
the mechanisms by which p53 induction by RITA affects HIF-1α protein expression. 
6.2 Hypothesis 
RITA affects p53 targets and HIF-1α protein expression. 
6.3 Aims 
 Investigate the p53 targets p21 and HDM2 at both the protein and mRNA levels 
when cells are treated with RITA. 
 Study translational pathways that inhibit HIF-1α in response to RITA. 
 Investigate the importance of HIF status in p53-dependent cell death using 
various tumour models that have deregulated HIF signalling. 
6.4 RITA downregulates the expression of p53 targets p21 and HDM2 
The tumour suppressor response controlled by p53 involves induction of numerous p53 
target genes that regulate cell cycle arrest, DNA repair, and cell death pathways when 
cells are exposed to stress. Regulation of HDM2 gene expression by p53 is important 
because HDM2 is an E3 ligase for p53, and forms a negative feedback loop by 
targeting p53 for proteosomal degradation.   Expression of p21 by p53 is also important 
because p21 is involved in regulating cell cycle arrest pathways that mediate DNA 
repair. Activation of p21 favours cell cycle arrest in response to specific forms of stress 
rather than activation of apoptosis (Gartel and Tyner, 2002). I investigated HDM2 and 
p21 protein expression in response to RITA, as both HDM2 and p21 are important in 
determining the apoptotic outcome of cells induced to stress. To begin these studies, I 
hypothesised that p53 stabilisation would correlate with induction of both HDM2, and 
p21 protein expression in response to RITA. Changes in p21 and HDM2 protein 
expression following increasing doses of RITA were assessed. 
 
The results show that RITA induces expression of both p21 and HDM2 in a dose-
dependent manner (Figure 6.4.1). Interestingly, as p53 levels remained stabilised at 
500nM RITA treatment, decreased expression of HDM2 and p21 protein levels was 
observed. Contrary to reports which suggest that RITA treatment upregulates HDM2 
expression by binding directly to p53 and interfering with the p53-HDM2 interaction 
(Enge et al., 2009; Issaeva et al., 2004), the data presented here indicate that at higher 
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doses where RITA stabilises p53 protein (at doses of 500nM and above), HDM2 
protein expression is inhibited. 
 
 
 
 
Figure 6.4.1: 500nM RITA inhibits p21 and HDM2 protein expression 
Western blot showing HCT116 p53 +/+ cells treated with 0-500nM RITA over 24 hours in 
normoxia. Cells were harvested for western analysis and blotted for total p53, HDM2, p21 
and β-actin as the loading control. Data shown is representative of 3 independent repeat 
experiments. 
 
 
To assess whether inhibition of p21 and HDM2 protein levels was due to changes in 
HDM2 and p21 mRNA, RT-PCR was used. As shown in Figure 6.4.2, changes in 
HDM2 and p21 mRNA were not detected following RITA treatment suggesting that 
RITA does not affect HDM2 and p21 protein expression at the level of mRNA. 
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Figure 6.4.2: RITA does not affect p21 and HDM2 mRNA levels 
Graph shows RT-PCR analysis of p21 and HDM2 mRNA levels in HCT116 p53+/+ cells 
treated with 0-500nM RITA (as indicated) for 24 hours in normoxia. Following RT-PCR, 
mRNA abundance was adjusted relative to the β-actin control. Data shown has been 
averaged from the means of 3 independent experiments. 
 
6.5 RITA inhibits protein synthesis 
HIF-1α is regulated either at the level of protein synthesis, in response to HER2 
receptor tyrosine kinase activity (Laughner et al., 2001), and in response to growth 
factor stimulation (Bardos et al., 2004), or at the level of protein stability by pVHL 
mediated degradation (Cockman et al., 2000; Jaakkola et al., 2001). To investigate 
whether RITA affects HIF-1α at the level of protein stability, HIF-1α protein expression 
in RCC4 cells that have constitutively high HIF-1α protein expression due to genetic 
loss of pVHL function was assessed. As shown in Figure 6.5.1, RITA inhibited HIF-1α 
protein in RCC4 cells that have deregulated pVHL, suggesting that RITA does not 
affect HIF-1α in these cells by regulating pVHL mediated protein stability. Previous data 
from our laboratory has shown that the proteosome inhibitor MG132 could not recover 
HIF-1α levels inhibited by RITA (Yang et al., 2009b). I therefore proposed that RITA 
could inhibit HIF-1α at the level of protein synthesis. 
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Figure 6.5.1: RITA inhibits constitutively expressed HIF-1α 
Western blot showing HIF-1α protein expression in RCC4/VHL cells and RCC4 cells treated 
with 0-1µM RITA for 24 hours in normoxia. β-actin was used as a loading control. Data 
shown is representative of 3 repeats. 
 
 
To explore loss of HIF-1α protein by RITA at the level of protein synthesis, components 
of the translational machinery were evaluated. The mTOR and the unfolded protein 
response (UPR) pathways are important pathways that determine transcriptional and 
translational responses to hypoxic stress, nutrient deprivation, and DNA damage 
(Wouters and Koritzinsky, 2008). Activation of p53 by stress stimuli has been 
associated with inhibition of mTOR mediated protein translation (Budanov and Karin, 
2008; Levine et al., 2006), and changes to cell growth and survival by both mTOR and 
UPR translational pathways are important in determining tumour development 
(Zetterberg et al., 1995).  
  
The mammalian target of rapamycin (mTOR) pathway was assessed first. Growth 
factors positively regulate mTOR through the PI3K-AKT/PKB pathway (Wullschleger et 
al., 2006). The AMP-activated protein kinase (AMPK) regulates mTOR and when 
activated, the mTOR complex phosphorylates various proteins including the ribosomal 
protein S6 kinase (p70S6K) and eukaryotic initiation factor 4E binding protein 1 (4E-
BP1), that are involved in the initiation step of mRNA translation (Browne and Proud, 
2004; Wouters and Koritzinsky, 2008). Due to the role of mTOR signalling in regulating 
protein synthesis and cell survival in response to stress, I hypothesised that RITA 
treatment could affect mTOR signalling. To address this, changes in key components 
of the mTOR pathway were evaluated following RITA treatment. Levels of mTOR 
protein expression and phosphorylation of AMPK, and 4E-BP1 were not significantly 
affected in HCT116 p53+/+ cells that had been treated with RITA. The data suggest 
that mTOR signalling is not involved in regulating protein synthesis in response to RITA 
(Figure 6.5.2). 
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Figure 6.5.2: RITA treatment does not significantly affect the mTOR stress response 
pathway 
HCT116 p53+/+ cells were treated with 0-500nM RITA for 16 hours in hypoxia (1% O2). Cells 
were harvested for western analysis following treatment. Western blot shows p53, 
phosphorylated AMPK (p-AMPK), total AMPK, mTOR, phosphorylated 4EBP1 (p-4EBP1) 
and α-tubulin protein levels as loading controls. All data shown is representative of 3 repeat 
experiments. 
  
 
The unfolded protein response (UPR) occurs when endoplasmic reticulum (ER) stress 
is induced during changes in glycosylation, redox status, glucose availability and 
protein load (Zhang and Kaufman, 2006). Inhibition in protein synthesis that results as 
a consequence of ER stress promotes cell survival by allowing sufficient time for the 
endoplasmic reticulum to resolve its protein load and improve function (Cullinan and 
Diehl, 2004). Sensors of the UPR pathway include the PKR-like ER kinase (PERK), the 
inositol-requiring protein-1 (IRE1) and the activating transcription factor 6 (ATF6) which 
signal to members of the translation initiation machinery known as the eukaryotic 
initiation factors (eIF) (Koumenis et al., 2002). The eIF-2 initiation complex consists of 
the eukaryotic initiation factor-2α (eIF-2α) subunit that binds GTP and the initiator tRNA 
(Met) to form a complex on the 80S ribosome and initiate mRNA translation (Asano et 
al., 2000). In response to hypoxia and other forms of ER stress, the eIF-2α subunit is 
phosphorylated at ser51 by PERK leading to inhibition of global mRNA translation 
(Koumenis et al., 2002).  
 
Since RITA treatment has been shown to have no significant effect on the mTOR 
pathway, regulation of protein translation by the UPR pathway was investigated in 
response to RITA. The phosphorylation status of eIF-2α in HCT116 p53+/+ cells that 
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had been treated with RITA over increasing timepoints was assessed (Figure 6.5.3). 
Phosphorylation of eIF-2α was induced in response to RITA treatment, and this 
correlated with loss of HIF-1α protein expression, and stabilisation of p53. Therefore, it 
is proposed that RITA induces an ER stress response which inhibits protein translation 
by activating the UPR pathway. 
 
 
    
 
Figure 6.5.3: RITA induces eIF-2α phosphorylation 
Western blot shows HCT116 p53+/+ cells treated with 500nM RITA over a 24 hour 
timecourse in hypoxia (1% O2). Following treatment cells were harvested for western blotting 
and analysed for HIF-1α, p53, phosphorylated eIF-2α (p-eIF-2α), total eIF-2α, and α-tubulin 
as a loading control. All data shown is representative of 3 repeat experiments. 
 
 
As discussed, PERK is an important sensor of the UPR pathway. RITA responses were 
assessed in HCT116 p53+/+ cells that had been stably transfected with a dominant 
negative form of PERK (PERKΔC), (a gift from Brad Wouters, Ontario Cancer Institute, 
Canada). Compared to the parental pCDNA5 cell line, HCT116 p53+/+ PERKΔC cells 
had a decrease in basal eIF-2α levels, as expected, as well as loss of eIf-2α 
phosphorylation induced by RITA, Figure 6.5.4, (Yang et al., 2009b). PERK activity 
may therefore be important in phosphorylation of eIF-2α by RITA. 
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Figure 6.5.4: PERK is important for phosphorylating eIF-2α in response to RITA 
Western blot analysis of HCT116 cells that have been stably transfected with either pcDNA5 
as a vector control, or a dominant negative form of PERK (PERKΔC). Cells were treated with 
0-500nM RITA for 16 hours in hypoxia (1% O2). Cells were harvested for western blotting 
and analysed for phosphorylated eIF-2α (p-eIF-2α), total eIF-2α protein levels, and α-tubulin 
as a loading control. All data shown is representative of 3 independent experiments. 
 
6.7 Loss of HIF-1α sensitises cells to RITA mediated cell death 
HIF-1α can promote p53 activation and p53 induced apoptosis in response to gamma 
irradiation (Moeller et al., 2005), and has been shown to complex directly with p53 to 
promote p53 stability (An et al., 1998). However, activated p53 can also have 
significant inhibitory effects on the HIF pathway and on tumour angiogenesis (Ravi et 
al., 2000). Similarly, studies from our laboratory have indicated that activation of p53 by 
RITA can inhibit the HIF pathway and achieve cell death and anti-angiogenic effects in 
hypoxia (Yang et al., 2009b). However, the mechanism by which p53 and HIF co-
operate in hypoxia-related radio- and chemoresistance is unclear.  
 
In renal cell carcinoma, the HIF pathway is deregulated due to loss of pVHL function, 
while wildtype p53 is deregulated by unknown mechanisms (Gurova et al., 2004). I 
hypothesised that RITA could be used to induce wildtype p53 and activate p53-
dependent apoptosis in renal cell carcinoma cells. RITA activity was investigated in 
RCC4 cells that have constitutively high HIF-1α expression due to loss of pVHL 
(RCC4), and in RCC4 cells which have functional pVHL, and therefore do not express 
HIF-1α (RCC4/VHL). As indicated by cleaved PARP, RCC4/VHL cells with loss of HIF-
1α expression were sensitised to cell death at lower concentrations of RITA compared 
to RCC4 cells (Figure 6.7.1). The data shown suggest that HIF-1α status in RCC4 cells 
is important for determining the apoptotic outcome of cells treated with RITA.   
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Figure 6.7.1: RITA induces cleaved PARP in RCC4/VHL cells 
Western blot showing HIF-1α, and cleaved PARP protein levels in RCC4/VHL and RCC4 
cells treated with 0-0.8µM RITA for 24 hours in normoxia. β-actin was used as a loading 
control. Data is representative of 3 repeats. 
 
 
As well as renal carcinoma cells, HCT116 p53+/+ cells were also used to assess 
whether HIF-α status is important in determining apoptosis in colon carcinoma cells 
treated with RITA. The affects of RITA treatment was investigated following siRNA 
mediated knockdown of HIF-1α in hypoxia (Figure 6.7.2). HCT116 p53+/+ cells were 
found to have greater sensitivity to RITA induced apoptosis following knockdown of 
HIF-1α protein in hypoxia. Interestingly, basal p53 levels were also greater in cells that 
had lost HIF-1α protein expression, suggesting that wildtype p53 is stabilised in the 
absence of HIF-1α expression. In conclusion, the data presented show that HIF-α 
status is important in regulating basal levels of p53 protein, as well as the extent of 
p53-dependent cell death induced in response to RITA treatment. 
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Figure 6.7.2: Loss of HIF-1α by siRNA sensitises HCT116 p53+/+ cells to cell death in 
response to RITA   
Western blot of HCT116 p53+/+ cells transfected with 20nM of either non-silencing control 
siRNA (NSC), or HIF-1α targeted siRNA for 24 hours. Following transfection, cells were 
treated with 0-500nM RITA for 16 hours in hypoxia (1% O2) and analysed for HIF-1α protein, 
p53, cleaved PARP and β-actin as a loading control. 
 
 
We have shown that HIF-α status in renal and colon carcinoma cells affects p53-
dependent cell death in response to RITA (as indicated by cleaved PARP).  Studies 
using mouse xenograft models have shown that the HIF-2α subunit is important for 
promoting the development of clear cell renal carcinoma (Kondo et al., 2003), and 
neuroblastoma (Holmquist-Mengelbier et al., 2006). Recently, Bertout et al. assessed 
the relationship between HIF-2α and p53 mediated apoptosis in renal carcinoma cells 
that only express HIF-2α (Bertout et al., 2009). Studies showed that siRNA mediated 
knockdown of HIF-2α in renal cell carcinoma cells enhances radiation induced cell 
death by activating p53 transcriptional responses (Bertout et al., 2009). Since I have 
shown that loss of HIF-1α sensitises renal carcinoma cells to cell death by RITA, I 
hypothesised that HIF-2α expression alone could also affect p53-dependent cell death 
in response to RITA.  
 
The 786-O renal carcinoma cell line only expresses HIF-2α protein when pVHL function 
is deregulated.  Cell death induced in response to RITA was assessed in 786-O cells 
that express HIF-2α (786-O EV), and in 786-O cells that do not express HIF-2α (786-O 
VHL). Although p53 protein was induced in 786-O EV cells, cleaved PARP was not 
observed suggesting that 786-O EV cells are resistant to RITA induced apoptosis 
(Figure 6.7.3). Interestingly, basal p53 protein levels were significantly increased in 
786-O VHL cells, compared to 786-O EV cells, and following RITA treatment, stabilised 
p53 was phosphorylated, and cell death was induced as indicated by cleaved PARP. 
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Phosphorylation of γH2AX was also observed following treatment with RITA in 786-O 
VHL cells, indicating induction of DNA damage (Figure 6.7.3). The data shown indicate 
that HIF-2α stabilisation contributes to the chemo-resistant phenotype of renal cell 
carcinoma, and loss of HIF-2α protein expression sensitises cells to RITA induced cell 
death. 
 
 
      
 
Figure 6.7.3: RITA induces p53 phosphorylation and cleaved PARP in 786-O cells with 
functional pVHL 
Western blotting of 786-O EV and 786-O VHL cells treated with 500nM RITA for 24 hours in 
normoxia (- indicates DMSO treatment, and + indicates 500nM RITA treatment). Western 
blots show analysis of HIF-2α protein levels, phosphorylated p53 at serine 15 and serine 46 
(p53-Ser15, p53-Ser46), total p53 protein, cleaved PARP, and phosphorylated γH2AX. β-
actin was used as a loading control. Data shown is representative of 3 repeat experiments. 
 
6.8 Discussion 
6.8.1 RITA affects p53 targets 
The studies I have presented in this chapter have shown that 500nM RITA can inhibit 
HIF-1α protein expression, and block the expression of p53 target proteins p21 and 
HDM2 (Yang et al., 2009b). Recently, low dose treatment with RITA was shown to 
induce HDM2 mediated degradation of hnRNP K, a specific co-factor for p53 involved 
in activation of p21 expression (Enge et al., 2009). By inhibiting hnRNP K activity, cell 
cycle responses involving p21 were repressed, and RITA could preferentially induce 
activation of apoptotic pathways. RITA’s mechanism of action was distinct compared to 
nutlin-3 which activated p21 expression and cell cycle effects by inhibiting HDM2 and 
thereby promoting hnRNP K activity (Tovar et al., 2006; Vassilev et al., 2004). 
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Consistent with this study, I also found that 500nM RITA inhibits p21 protein 
expression, however this was not dependent on increased HDM2. Although HDM2 was 
induced by RITA at lower doses, and shorter timepoints, treatment with 500nM RITA 
where significant tumour cell death was observed correlated with reduced HDM2 
protein levels. Clearly, HDM2-dependent effects induced by RITA regulate hnRNP K 
mediated cell cycle and cell death responses by dose-, and time-dependent 
mechanisms (Enge et al., 2009).  
 
The effects of RITA on p53 targets are further supported by studies which describe 
important mechanisms involving transient repression of HDM2 in response to RITA 
(Rinaldo et al., 2009). Pro-apoptotic HIPK2 phosphorylates p53 at serine 46 to activate 
apoptosis in response to severe genotoxic stress (Rinaldo et al., 2007). Rinaldo et al. 
propose that inhibition of HDM2 by RITA treatment prevents HDM2 mediated 
degradation of HIPK2, and therefore promotes apoptosis by activating p53 (Rinaldo et 
al., 2009). Collectively the studies which assess RITA mediated activation of p53 
targets show that HDM2 status following p53 activation is important in determining cell 
cycle and cell death responses. 
6.8.2 RITA inhibits protein translation 
Inhibition of p53 target proteins p21 and HDM2 in response to RITA is not regulated at 
the level of mRNA, and inhibition of HIF-1α protein expression by RITA is not affected 
by MG132, or in cells that have deregulated pVHL function (Yang et al., 2009b). 
Therefore, I hypothesised that RITA regulates protein levels by affecting protein 
synthesis. I investigated the mechanism by which HIF-1α protein expression and p53 
target proteins are inhibited by RITA and explored both the mTOR pathway, and the 
unfolded protein response (UPR) pathway. Activation of p53 in response to genotoxic 
stress induces p53 target genes that are important for signalling to mTOR and 
inhibiting protein synthesis (Budanov and Karin, 2008). Many proteins targeted by 
mTOR signalling are involved in controlling the translational machinery and include the 
ribosomal protein S6 kinases that regulate initiation and elongation phases of 
translation, as well as eIF4E that is often deregulated in many tumours (Averous and 
Proud, 2006). The data presented in this chapter show that activation of p53 by RITA 
induced stress does not affect the mTOR pathway suggesting this pathway is not 
involved in inhibiting HIF and p53 targets in response to RITA. 
 
The unfolded protein response is activated when hypoxia induces endoplasmic 
reticulum stress (Koumenis et al., 2002). This response involves key sensors such as 
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PERK which is involved in the initiation events of mRNA translation. By inhibiting 
protein synthesis in response to stress, the unfolded protein response allows energy 
consuming processes to be conserved so protein load is decreased on the 
endoplasmic reticulum, and cellular function is improved. RITA induces 
phosphorylation of eIf-2α, a downstream target of PERK, and this pathway is important 
for inhibiting protein translation. These findings have been summarised in Figure 6.8.1.  
6.8.3 Loss of HIF-α sensitises cells to RITA induced apoptosis  
Overexpression of both HIF-1α and HIF-2α is associated with an increase in tumour 
vascularisation and poor prognosis of many cancers such as breast, ovarian and non-
small cell lung cancer (Bertout et al., 2008).  Clear cell renal cell carcinomas account 
for 75% of kidney cancers, and are very aggressive cancers that show poor responses 
to both radiotherapy and chemotherapy due to deregulated HIF-α, and loss of 
functional p53 (Gurova et al., 2004). Both HIF-1α and HIF-2α have differential effects 
on the progression of renal cell carcinoma. While HIF-1α contributes towards tumour 
cell death in these tumours, HIF-2α has important tumour promoting functions (Raval et 
al., 2005). Restoring pVHL function in renal cell carcinoma inhibits HIF-2α protein 
expression and significantly decreases tumour growth in vivo (Kondo and Kaelin, 
2001). HIF-1α and HIF-2α therefore have distinct tumourigenic effects according to the 
tumour type in which they are expressed (Raval et al., 2005).  
 
Renal cell carcinoma cells were used to understand how deregulated HIF-α expression 
affects p53 function in response to stress. Deregulation of wildtype p53 by unknown 
mechanisms contributes to the resistant phenotype of renal cell carcinoma cells. 
Roberts et al. have suggested that HIF-2α suppresses wildtype p53 in renal cell 
carcinoma cells by promoting HDM2 mediated degradation of p53 (Roberts et al., 
2009). Renal carcinoma cells were sensitised to chemotherapy by using nutlin-3 to 
stabilise p53, and also inhibiting HIF-2α protein expression, by either siRNA, or 
reconstitution of wildtype pVHL (Roberts et al., 2009). Recently, siRNA mediated 
knockdown of HIF-2α protein was also shown to activate p53-dependent apoptosis in 
radioresistant clear cell renal cell carcinomas (Bertout et al., 2009).  
 
I have shown that RCC4/VHL renal carcinoma cells have higher levels of basal p53, 
and have greater sensitivity to RITA induced apoptosis compared to RCC4 cells that 
have high basal HIF-1α protein expression due to loss of pVHL function. RITA induced 
cell death was also evaluated in 786-O renal carcinoma cells that only express HIF-2α. 
Loss of HIF-2α protein expression by siRNA was recently found to sensitise 786-O 
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cells to doxorubicin (Roberts et al., 2009), as well as radiation (Bertout et al., 2009). I 
investigated the effects of RITA in 786-O cells and showed that p53 is stabilised 
following RITA treatment in 786-O cells that express HIF-2α. However, stabilised p53 
does not correlate with cleaved PARP or induction of γH2AX. In 786-O cells with pVHL, 
basal levels of wildtype p53 were significantly increased, and following RITA treatment, 
significant cell death was induced in these cells. The use of small molecule activators 
of p53 in renal cell carcinoma provides a novel therapeutic strategy with which to 
restore wildtype p53 activity and sensitise resistant tumour cells to apoptotic signals. 
While nutlin-3 sensitises 786-O EV cells to doxorubicin and etoposide induced cell 
death (Roberts et al., 2009), I have shown that RITA can both stabilise p53, and induce 
DNA damage responses in renal carcinoma cells with deregulated HIF-α. 
6.9 Conclusions for this chapter 
 Treatment of HCT116 p53+/+ cells with 500nM RITA inhibits HIF-1α protein 
expression in hypoxia, and inhibits the p53 target proteins, p21 and HDM2. 
 RITA does not affect protein stability or mRNA levels of HIF-1α and p53 targets 
p21 and HDM2. 
 Phosphorylation of eIF-2α by RITA is dependent on PERK activity. 
 Loss of HIF-1α and HIF-2α in renal cell carcinoma sensitises cells to RITA induced 
cell death.  
6.10 Impact of these findings 
Activation of p53 by RITA induced stress drives cell death and DNA damage responses 
in cells with low HIF-1α and HIF-2α expression. HIF-α status is important in 
determining the apoptotic response elicited by RITA and the data presented in this 
chapter suggest that inhibition of specific HIF-α subunits in specific tumours could be 
used in combination with p53 activating molecules to improve therapeutic targeting of 
tumours with deregulated HIF and p53 pathways.  
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Figure 6.8.1: RITA inhibits HIF-α protein in hypoxia and p53 targets by engaging the 
PERK translational pathway 
RITA targets p53 wildtype cells to induce DNA damage and activate cell cycle and DNA 
damage responses that mediate anti-tumour activity. Studies with PD98059 demonstrate 
that the MAPK pathway is important in activating p53 through this pathway. In addition to 
these findings, RITA also elicits an ER stress response involving activation of PERK and 
phosphorylation of eIF2-α which lead to inhibition of protein synthesis. Specifically, loss of 
HIF-1α protein expression and the p53 targets p21 and HDM2 has been observed (Yang et 
al., 2009b). These responses also contribute significantly to the anti-tumour activity of RITA.  
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7.1 General Summary 
Activation of p53 is important for the antitumor effects of most chemotherapies and loss 
of p53 function in cancer has been associated with increased resistance to many forms 
of therapy (El-Deiry, 2003). As with p53, HIF-1α status is also an important determinant 
for responses to chemo- and radiotherapy, and the severity of hypoxia in tumours 
correlates with poor patient prognosis (Moeller et al., 2005). Thus, both p53 and HIF-1α 
have emerged as important therapeutic targets.  
 
Nutlin-3 and RITA have been investigated as small molecule activators of p53-
dependent cell death in hypoxic tumours. Nutlin-3, can sensitise hypoxic tumour cells 
with wildtype p53 when used in combination with radiotherapy (Supiot et al., 2008). The 
small molecule RITA not only activates p53 by eliciting p53-dependent cell cycle and 
DNA damage responses, but also targets the HIF pathway, thus achieving both 
apoptotic and anti-angiogenic effects in hypoxia. The data presented in this thesis 
strengthens the negative relationship that exists between p53 activity and HIF status in 
a number of tumour models, while also revealing the presence of novel mechanisms by 
which small molecule activation of p53 targets HIF signalling in hypoxia.  
 
Several small molecule activators of p53 have been described with distinct 
mechanisms of action. In order to understand the importance of the studies presented 
so far, the clinical progress of p53 targeted agents will be discussed briefly, as well as 
the benefits and drawbacks of investigating agents like RITA.   
7.1.1  Clinical importance of p53 activating agents 
To date over 150 clinical trials have been designed using p53 status as a clinical 
biomarker (Cheok et al., 2011). Initial strategies to target wildtype p53 in tumours were 
developed with caution due to the possibility that normal cells with wildtype p53 would 
also be targeted by such agents. Studies by Ringhausen et al. showed that loss of 
mdm2 expression in vivo resulted in spontaneous cell death and tissue damage in 
adult mice, raising concerns that HDM2 inhibitors would be excessively cytotoxic 
(Ringshausen et al., 2006). However subsequent studies showed that moderate 
decreases in mdm2 activity were well tolerated and had significant anti-tumour activity 
in vivo (Mendrysa et al., 2006). Small molecules that disrupt the p53-HDM2 interaction 
such as the nutlins and the spiro-oxindoles have since shown anti-tumour activity that 
is p53-dependent and tumour selective (Shangary et al., 2008; Vassilev et al., 2004). 
As a result, the most advanced p53 activating molecules in the clinic are inhibitors of 
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HDM2 (Shangary and Wang, 2008) and analyses of clinical samples correlate 
responses to HDM2 inhibition with wildtype p53 status (Saddler et al., 2008).  
 
Despite the progress that p53 activating agents have made in the clinic, there is 
continuous need to improve the safety profile of targeted agents, both as 
monotherapies and in strategic combinations. The advantages and disadvantages of 
p53 activating agents will be discussed further with particular focus on RITA as a small 
molecule activator of p53-dependent cell death that I have studied. 
7.1.2 The advantages and drawbacks of small molecule activators of p53 
Conventional cytotoxic therapy is aimed at targeting rapidly proliferating cancer cells. 
Some cancers such as high grade lymphomas are highly proliferative and undergo 
maximum tumour cell death following cytotoxic therapy. However the main drawback of 
many cytotoxic agents is that rapidly proliferating normal cells of the bone marrow, 
gastrointestinal mucosa, hair follicles and gonads are also targeted resulting in severe 
unwanted side effects such as mylosuppression, nausea, vomiting, hair loss and 
reduced fertility (Corrie, 2008). Non-genotoxic small molecule agents were developed 
with the intention of specifically targeting deregulated signalling pathways to enhance 
tumour cell specificity while reducing the onset of resistance, and the serious side 
effects that are associated with conventional cytotoxics. To this end, several p53 
activating molecules have been identified and are lead compounds for the development 
of anticancer drugs (Lane et al., 2010). However, small molecule activators of p53 are 
also important tools for studying p53 functional activity. For this study, RITA has been 
used as a pharmacological tool to investigate p53-dependent cell death responses in 
normoxia and in hypoxia.  
 
The most significant advantage of RITA as a small molecule is that RITA selectively 
induces apoptosis in cells that are p53 positive, and mediates anti-tumour effects both 
in vitro and in vivo by this mechanism. However the studies presented in this thesis 
have shown that RITA also affects numerous other pathways. RITA not only elicits 
DNA damage, but also induces DNA damage responses, and affects components of 
the translational machinery. Multiple target pathways affected by RITA have also been 
investigated in other reports (Enge et al., 2009; Rivera et al., 1999). As discussed in 
this thesis, these pathways collectively contribute to the anti-tumour activity of RITA. 
Although DNA damage induced by RITA is not observed to the same extent as 
conventional DNA damaging agents like cisplatin, RITA would not be an ideal 
candidate for clinical development, as it would be regarded as a cytotoxic agent and 
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would be predicted to elicit numerous side effects in normal cells. Both in vitro and in 
vivo data suggest that RITA has tumour cell specificity at low doses, and without 
significant side effects (Issaeva et al., 2004; Yang et al., 2009b) however these studies 
would need to be conducted in greater detail if RITA was to be pursued as a clinical 
agent, both as a monotherapy, and in combination against other targeted agents. 
 
Combination therapy is used to maximise tumour cell apoptosis, and also avoid 
acquired resistance (Brummelkamp et al., 2006). Recently, cyclotherapy was described 
whereby low doses of a non-genotoxic p53 inducing agent was used to induce 
reversible cell cycle arrest in normal cells (Carvajal et al., 2005) prior to dosing with a 
specific agent that targeted the remaining proliferating cancer cells (Sur et al., 2009). 
Cyclotherapy proved to be an effective strategy for inducing tumour cell death while 
inhibiting effects on normal cells that are otherwise associated with the development of 
unwanted side effects (Sur et al., 2009). In other schedules, nutlin-3 was used in 
combination with the X-linked inhibitor of apoptosis (XIAP) to improve tumour cell death 
in patients with acute myeloid leukaemia (Carter et al., 2010). My studies have shown 
that loss of HIF-α by either siRNA mediated knockdown, or due to restoration of pVHL 
function, can sensitise resistant renal cell carcinoma cells to cell death in response to 
RITA. These studies are supported by previous findings whereby loss of HIF-2α can 
sensitise renal cell carcinoma cells to irradiation (Bertout et al., 2009) and provide an 
important rationale for combination therapies involving both p53 activating agents and 
HIF inhibitors in specific tumour models whereby both pathways are deregulated.  
 
Tumourigenesis is now considered a multistep process involving sequential 
deregulation of multiple signalling pathways. Therefore the rationale for developing a 
‘magic bullet’ which could target a single deregulated molecule in cancer cells has now 
been replaced with strategies whereby ‘multi-targeted’ agents affect several 
deregulated pathways in the same disease. Such multi-targeted kinase inhibitors have 
better safety profiles compared to conventional cytotoxics (Arora and Scholar, 2005; 
Crean et al., 2009). Sorafenib for example inhibits different isoforms of the RAF serine 
kinase as well as targeting other receptor tyrosine kinases such as VEGFR, EGFR and 
PDGFR and this broad spectrum target profile improves the inhibitory affects of 
sorafenib on tumour cell proliferation and angiogeneisis (Strumberg, 2005). Indeed I 
have shown that RITA targets both deregulated p53 and HIF pathways in specific 
tumour models, and although I have suggested that RITA’s effects on the DNA may be 
a disadvantage in terms of RITA’s safety profile, this multi-target profile may also give 
RITA an advantage over other DNA damaging agents in certain tumour models. 
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Overall, these studies support the fact that multiple pathways lead to p53 activation and 
suggest that simultaneous targeting of specific co-operative oncogenic pathways could 
have significant effects on treatment responses. 
 
In summary, the most significant disadvantage that we have discussed of targeted p53 
activating agents such as RITA is the possibility that they may have an undesirable 
therapeutic window, and for this reason may cause unwanted side effects, as is the 
case with conventional cytotoxics. Most small molecule activators of p53 have 
overcome these barriers and have made significant progress in clinical schedules. In 
conclusion, whether or not RITA is a desirable agent for clinical development due to its 
DNA damaging effects, the most important advantage of this small molecule is its 
ability to induce p53-dependent cell death by numerous pathways. For this reason, 
RITA has been used extensively as a pharmacological tool to understand the 
mechanisms by which RITA induces p53-dependent cell death responses in normoxia 
and in hypoxia. The novel mechanisms such as the p53-dependent cell cycle 
checkpoints that have been described involving CHK1 phosphorylation are important in 
understanding how tumour cells respond to immediate forms of genotoxic stress, and 
how abrogation of these pathways at specific timepoints can be used to suppress 
tumour growth. The key findings from this thesis will now be summarised for the 
different signalling pathways that have been studied in response to RITA. 
7.1.3 Summary of key findings and ongoing studies 
7.1.3.1 RITA induces p53-dependent cell death in normoxia and hypoxia 
RITA was identified as a small molecule that could induce p53-dependent cell death in 
tumour models by binding to wildtype p53, inhibiting its interaction with HDM2, and 
therefore promoting p53 activation (Issaeva et al., 2004). My studies have shown for 
the first time that RITA mediated cell death is distinct compared to other agents that 
activate p53, in that RITA can elicit p53-dependent DNA damage responses involving 
γH2AX and CHK1, and also induce significant cell death both in normoxia and hypoxia.   
7.1.3.2 RITA activates p53-dependent cell cycle checkpoints 
Further elucidation of the mechanism of action by which RITA elicits p53-dependent 
cell death responses in normoxia and hypoxia showed that following DNA damage, 
RITA can induce the canonical DNA damage response involving CHK1 and CHK2. 
Induction of γH2AX was also shown in response to RITA, another marker of DNA 
damage due to its localisation at DNA strand breaks. The p53-dependent CHK1 
Chapter 7: General Summary 
 
 
Page: 205 
phosphorylation in response to RITA was investigated. Although CHK1 phosphorylation 
was not essential for p53-dependent cell death by RITA, a novel p53-dependent cell 
cycle checkpoint was described that has importance in modulating DNA repair and 
hence maintaining DNA integrity in response to genotoxic stress.  
7.1.3.3 RITA induced apoptosis is mediated by MAPK signalling 
MAPK signalling regulates cell death responses when cells are exposed to a variety of 
microenvironmental and external stress stimuli. I investigated whether RITA engages 
MAPK signalling to promote p53 stability and activity. PD98059, a MEK1/MEK2 
inhibitor was used to show that ERK1/2 phoshorylation by RITA is important for eliciting 
p53-dependent DNA damage and cell death responses described previously. Several 
MAPKs were identified that are induced in response to RITA including JNK kinase, p38 
kinase, and the p38 upstream MAPKK, MKK3. A MAPK siRNA screen was also 
conducted in which knockdown of numerous kinases was shown to inhibit p53 
stabilisation, and γH2AX induction in response to RITA treatment. It will be of interest 
to reconfirm the MAPKs identified in the screen and evaluate their contribution to RITA 
mediated responses. 
7.1.3.4 HIF status influences RITA induced cell death 
Stabilisation of p53 by RITA induces the p53 targets HDM2 and p21, however this 
response is transient and at doses of 500nM and above where p53 stabilisation is 
maintained, p21 and HDM2 protein expression is inhibited. Initial studies from our 
laboratory showed that RITA can also inhibit HIF-1α protein expression in hypoxic cells. 
I explored the mechanism by which p53 target proteins and HIF-1α protein expression 
is inhibited in cells treated with RITA. RITA was found to induce an ER stress 
response, and by activating the PERK and eIF-2α pathway was able to inhibit global 
protein synthesis and therefore the expression of p21, HDM2 and HIF-1α. 
 
Following the findings that RITA can induce both p53 and inhibit HIF-1α, RITA 
responses were studied in tumour cells in which HIF signalling and p53 activity is 
deregulated. Renal cell carcinoma cells were used that express both HIF-1α and HIF-
2α, or HIF-2α alone due to loss of pVHL function. I showed that renal cell carcinoma 
cells are sensitised to RITA induced cell death following inhibition of HIF expression by 
either reconstitution of pVHL, or by siRNA mediated knockdown. The studies presented 
show that HIF status is important in influencing p53-dependent apoptosis, and provide 
novel opportunities for the therapeutic targeting of tumours in which HIF signalling is 
deregulated. 
Chapter 7: General Summary 
 
 
Page: 206 
Inactivation of pVHL is associated with development of hereditary and sporadic clear 
cell renal carcinoma (Kondo et al., 2003), however cell cycle and apoptosis pathways 
mediated by pVHL are not always dependent on deregulation of the HIF pathway 
(Kondo et al., 2002; Roe et al., 2006). In response to DNA damage, pVHL is proposed 
to bind directly to p53 and stabilises p53 by inhibiting p53 binding to HDM2 and 
suppressing its nuclear export. It will be of interest to understand whether tumour cell 
apoptosis induced by RITA in renal carcinoma cells is dependent on pVHL and/or HIF-
α activity.  
7.2 Future studies 
7.2.1 Exploring transcriptional co-factors for p53 in hypoxia 
Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is a transcriptional regulator 
that interacts with many factors involved in chromatin remodelling and has an important 
role to play in both transcriptional and translational pathways (Bomsztyk et al., 2004). 
Previously, hnRNP K has been shown to be induced by the DNA damage response 
pathway, and is important for maintaining cell cycle checkpoints in response to stress 
(Moumen et al., 2005). Interestingly, hnRNP K acts as an important cofactor for p53 
target gene expression (Moumen et al., 2005). Although little is known about the 
regulation of hnRNP K itself, its involvement in regulating p53 transcription is 
established and the dependency of this partnership is clear in studies whereby loss of 
hnRNP K abrogates p53 mediated checkpoints when cells are exposed to DNA 
damaging agents (Moumen et al., 2005).  
 
Recently, Enge et al. described mechanisms by which differential responses occur to 
the small molecules nutlin and RITA, both involved in activating p53. While nutlin 
primarily induced cell cycle arrest by activating p53, RITA induced significant cell death 
responses. By inhibiting HDM2, nutlin was shown to promote p53 stabilisation, and its 
association with the transcriptional cofactor hnRNP K to induce p21 gene expression, 
and subsequent cell cycle arrest (Enge et al., 2009). Moumen and colleagues have 
previously shown that hnRNP K is regulated at the level of protein stability by HDM2 
mediated degradation (Moumen et al., 2005). By binding directly to p53, RITA induced 
HDM2 targeting of hnRNP K for proteosomal degradation. Cell death responses were 
activated by RITA due to loss of hnRNP K and inhibition of cell cycle arrest by p21 
(Enge et al., 2009). 
 
Chapter 7: General Summary 
 
 
Page: 207 
Because of the involvement of hnRNP K as a critical component of the p53 DNA 
damage response (Moumen et al., 2005), and data which suggests that hnRNP K 
activity is modulated in the presence of RITA (Enge et al., 2009), it would be of interest 
to assess hnRNP K and whether this could act as a critical co-factor for the p53-
dependent responses that we have described in our study.  
7.2.2 Investigating low dose radiation 
The role of p53 in eliciting G1/S and G2/M checkpoints has been described in many 
studies (Levine, 1997). DNA damage checkpoints induced during S-phase have been 
studied frequently as mechanisms by which DNA synthesis is inhibited in response to 
DNA damage. However the role of p53 in mediating S-phase checkpoints is less 
established. DNA damage can inhibit DNA synthesis by blocking replication origin firing 
and delaying replication fork progression. Delaying DNA synthesis by activating the S-
phase checkpoint is an important mechanism by which DNA repair pathways are given 
enough time to resolve DNA strand breaks (Boddy and Russell, 2001).  
 
Low dose radiation (below 2.5 Gray) has previously been used to study a p53-
dependent S-phase checkpoint in mouse embryonic fibroblasts (MEFs) (Shimura et al., 
2006). Shimura et al. show that p53 null MEFs are resistant to inhibition of replication 
fork progression that is observed in p53 wildtype cells following exposure to low dose 
irradiation. Furthermore, ATM activation is essential for eliciting the S-phase checkpoint 
described in p53 wildtype MEFs (Shimura et al., 2006). To my knowledge, our study is 
the first to describe a p53-dependent S-phase checkpoint that is mediated by CHK1 
phosphorylation.  
 
It will be of interest to elucidate whether CHK1 is essential for the replication fork block 
that has been observed in p53 wildtype cells that have been treated with RITA. Such 
insights will provide important information on the levels at which p53 and CHK1 
regulate genomic integrity. Furthermore, RITA has been used as a tool for 
understanding how p53 activation can mediate cell death responses in normoxia and in 
hypoxia. Like low dose irradiation, RITA elicits DNA damage that is moderate, but 
appears sufficient to transmit significant cell cycle and cell death responses. Studying 
low dose irradiation as an alternative means with which to activate p53 in normoxia, 
and in hypoxia will be worthwhile. By targeting p53-dependent cell cycle checkpoints 
and DNA repair pathways, low dose radiation may therefore be an alternative 
therapeutic strategy with which to sensitise hypoxic tumours to cell death. 
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7.2.3 Investigating effects of RITA on ROS production 
Alternative targets for RITA have been investigated in several studies. Recently, as 
well as targeting p53 to elicit p53-dependent apoptosis (Issaeva et al., 2004), RITA was 
shown to target Thioredoxin reductase 1 (TrxR1), (Hedstrom et al., 2009). TrxR1 is a 
critical thioredoxin that regulates redox dependent pathways involved in many cell 
signalling pathways (Arner and Holmgren, 2006; Nordberg and Arner, 2001). 
Treatment of HCT116 p53+/+ and HCT116 p53-/- cells with RITA was shown to 
increase reactive oxygen species (ROS) production due to direct inhibition of TrxR1 
activity (Hedstrom et al., 2009). Detection of the fluorescence based conversion of 
2’,7’-dichlorodihydrofluorescein diacetate (DCF-DA) using flow cytometry showed that 
RITA induced ROS production was only observed in HCT116 p53+/+ cells. 
Furthermore, TrxR1 is often overexpressed in human cancers, and the absence RITA 
mediated ROS production in normal fibroblast cells supported the tumour selective role 
for cell death in response to RITA (Hedstrom et al., 2009). Overall, Hedstrom and 
colleagues suggested that RITA sensitises tumour cells to cell death by promoting both 
p53 stability, and oxidative stress.   
 
It will be of interest to investigate RITA induced ROS production in HCT116 p53+/+ 
cells and HCT116 p53-/- cells over the dose range at which p53-dependent DNA 
damage responses and cell death responses have been described in this thesis. This 
is because TrxR1 has also been shown to be targeted by common alkylating agents 
and platinum compounds (Witte et al., 2005). Furthermore, because ROS generation 
has been shown to be enhanced under hypoxic stress (Chandel et al., 1998), studying 
the effects of ROS in hypoxia, both in the absence and presence of RITA treatment will 
provide greater insight into the distinct role that oxidative stress has in eliciting p53-
dependent cell death in hypoxia. To strengthen these observations, responses will also 
be compared to those induced by hydrogen peroxide, and in response to N-acetyl-
cysteine (NAC), a commonly used ROS inhibitor. 
 
Finally, the role that RITA induced ROS production has on induction of the unfolded 
protein response and on global protein translation should also be assessed. The 
oxidative environment of the endoplasmic reticulum is tightly regulated to ensure 
correct protein folding. Deregulated protein oxidation and elevated ROS levels can 
activate the unfolded protein response, hence affecting protein synthesis, and cell 
survival (Malhotra and Kaufman, 2007). Therefore, activation of ROS in response to 
RITA may also link the unfolded protein response to the p53-dependent pathways that 
have been described throughout this thesis.  
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7.3 Final Conclusions 
Hypoxia, defined as low oxygen tension, is a common characteristic of growing 
tumours. Tumour cells adapt to their hypoxic microenvironment by inducing 
angiogenesis and escaping cell death. In doing so, tumour cells become resistant to 
radiotherapy and many forms of chemotherapy. Hypoxia signalling and angiogenesis is 
mediated by the hypoxia-inducible factor (HIF) transcriptional complex. HIF can cross-
talk to the p53 tumour suppressor protein, a critical regulator of cellular responses to 
stress. This study has aimed to understand how cell death responses are regulated in 
tumour cells by HIF and p53, in normoxia and in hypoxia. These findings are 
summarised below, and in Figure 7.3.1. 
 
1. Chapter 3: I have investigated activation of p53 by the small molecule RITA. Flow 
cytometry, comet assays and western blot analysis was used to reveal a novel 
p53-dependent DNA damage response that occurs as a result of DNA strand 
breaks, and induces significant cell death of tumour cells with wildtype p53.  
 
2. Chapter 4: In addition, I have assessed S-phase cells and describe a novel p53-
dependent cell cycle checkpoint that involves phosphorylation of CHK1 in 
response to replication stress induced by RITA. Although not essential for RITA 
induced cell death, I show that activation of this cell cycle checkpoint is important 
for DNA repair and genomic integrity. 
 
3. Chapter 5: I have also investigated the MAPK pathway as a critical mediator of 
RITA induced p53-dependent cell death. Inhibition of MEK-ERK phosphorylation 
by the MAPK signalling inhibitor PD98059 inhibits p53-mediated apoptotic 
responses by RITA.  
 
4. Chapter 6: RITA inhibits global protein synthesis, resulting in significant inhibitory 
effects on HIF-1α in hypoxia, and the p53 targets p21 and HDM2.  
 
Novel mechanisms have been revealed for p53 activation involving MAPK signalling 
and p53-dependent pathways that elicit DNA damage, cell cycle and cell death 
responses. Understanding the mechanisms by which the small molecule RITA 
achieves anti-tumour effects provides novel insights into the numerous signalling 
pathways that integrate at the level of stress induced p53 activation, both in normoxia 
and in hypoxia. These pathways have significance in tumour models like renal cell 
carcinoma whereby both HIF and p53 pathways are deregulated rendering such 
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tumours resistant to radiotherapy and many forms of chemotherapy. By harnessing p53 
stress induced pathways strategically and in combination with other targeted agents, 
the therapeutic profile of highly resistant tumours with deregulated HIF and p53 can be 
significantly improved. 
 
 
 
 
Figure 7.3.1: RITA induced p53 targets multiple signalling pathways that promote 
tumour cell death in normoxia and hypoxia 
RITA activates the MAPK pathway and targets wildtype p53 to elicit p53-dependent cell 
death responses. Several signalling pathways are involved in these responses. I have 
investigated DNA damage responses induced by RITA, cell cycle checkpoints, and ER 
stress responses that inhibit protein synthesis. p53 is an integral mediator of all these 
signalling pathways that together contribute significantly to the anti-tumour activity of RITA.  
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The p53 tumor suppressor protein negatively regulates hypoxia-inducible factor 1 (HIF-1). Here, we show
that induction of p53 by the small-molecule RITA (reactivation of p53 and induction of tumor cell apoptosis)
[2,5-bis(5-hydroxymethyl-2-thienyl) furan] (NSC-652287) inhibits HIF-1 and vascular endothelial growth
factor expression in vivo and induces significant tumor cell apoptosis in normoxia and hypoxia in p53-positive
cells. RITA has been proposed to stabilize p53 by inhibiting the p53-HDM2 interaction. However, induction of
p53 alone was insufficient to block HIF-1 induced in hypoxia and has previously been shown to require
additional stimuli, such as DNA damage. Here, we identify a new mechanism of action for RITA: RITA
activates a DNA damage response, resulting in phosphorylation of p53 and H2AX in vivo. Unlike other DNA
damage response-inducing agents, RITA treatment of cells induced a p53-dependent increase in phosphory-
lation of the  subunit of eukaryotic initiation factor 2, requiring PKR-like endoplasmic reticulum kinase
activity, and led to the subsequent downregulation of HIF-1 and p53 target proteins, including HDM2 and
p21. Through the identification of a new mechanism of action for RITA, our study uncovers a novel link
between the DNA damage response-p53 pathway and the protein translational machinery.
Solid tumors require blood vessels to supply them with ox-
ygen and nutrients in order to grow beyond the macroscopic
level or metastasize to other organs. Characteristically, solid
tumors contain areas of low oxygen tension (hypoxia). The
cellular response to hypoxia is primarily mediated by hypoxia-
inducible factors (HIFs) hypoxia-inducible factor 1 (HIF-1)
and HIF-2 (12, 42). HIFs are transcription factors that are
often deregulated in cancer and play a key role in promoting
angiogenesis and tumor progression. Hypoxia usually confers
tumor resistance to chemotherapy and radiotherapy (8), and
HIF-1 is an important determinant for this resistance (7, 35,
38, 49). Thus, targeting HIF has the potential not only to block
tumor angiogenesis but also to improve the efficacy of chemo-
therapy and radiotherapy within a given cancer setting.
HIF-1 and HIF-2 are heterodimeric complexes consisting of
HIF-1 and HIF-2 (HIF-), respectively, that dimerize to a
constitutively expressed  subunit (HIF-1). HIF transcrip-
tional activity is regulated by the availability of the  subunit
which is hydroxylated at conserved prolyl and asparaginyl res-
idues in normoxia. Hydroxylation allows for the binding of von
Hippel-Lindau protein (pVHL) E3 ligase that targets HIF-
for ubiquitin-mediated degradation by the proteasome (24,
25). In hypoxia, inhibition of hydroxylation results in stabiliza-
tion of HIF- and leads to transcriptional activation of target
genes involved in angiogenesis, cell survival, and metabolic
adaptation (42).
The p53 tumor suppressor protein is induced and activated
in response to a variety of cellular stressors, including DNA
damage, oxidative stress, and cellular senescence (3, 48), and is
a potent negative regulator of HIF-1, mediating both apop-
totic (20, 43) and antiangiogenic effects when overexpressed
(27, 39). p53 plays an important role in apoptosis in hypoxic
tumor cells in that only wild-type p53-expressing cells undergo
strong apoptosis (20), while apoptosis is significantly reduced
when tumors express mutant p53 (20, 43). HIF-1 accumula-
tion is blocked by overexpression (39) or activation (27) of p53.
In addition, HIF-1-dependent transcription negatively corre-
lates with p53 status (41). p53 is mutated in about 50% of
human cancers, and several agents that can reactivate mutant
p53 (11, 19) or activate wild-type p53 (23, 45, 47) in tumor cells
have been reported. However, many of these emerging p53-
targeted agents have not yet been evaluated for their ability to
affect the HIF-1 pathway or assessed for their effectiveness at
mediating tumor cell death in hypoxia. Recently, a small-mol-
ecule activator of p53, RITA (reactivation of p53 and in-
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duction of tumor cell apoptosis) [2,5-bis(5-hydroxymethyl-2-
thienyl) furan] was described (23). RITA was shown to induce
tumor cell apoptosis in a p53-dependent manner and to inhibit
tumor growth in vivo (23). RITA was proposed to stabilize and
activate p53 by disruption of the p53-HDM2 interaction (23).
However, subsequent nuclear magnetic resonance (NMR)
studies did not support this proposed mechanism (31).
In this study, we assess the effects of RITA on HIF-1
accumulation and apoptotic responses in normoxia and hyp-
oxia. We demonstrate that RITA induces and activates p53,
mediating significant tumor cell apoptosis in both normoxia
and hypoxia. Furthermore, we demonstrate that RITA blocks
HIF-1 and vascular endothelial growth factor (VEGF) ex-
pression in vitro and in vivo. We propose that RITA functions
by inducing a DNA damage response indicated by increased
p53 and H2AX phosphorylation in vitro and in vivo. Unlike
other DNA-damaging agents, RITA treatment of cells induces
phosphorylation of the  subunit of eukaryotic initiation factor
2 (eIF-2) and subsequently leads to the downregulation of
HIF-1 and p53 target proteins, including HDM2 and p21, in
a dose-, time-, and p53-dependent manner. Our study provides
new mechanistic insight into p53-dependent antiangiogenic
and apoptotic responses mediated by activation of the DNA
damage response-p53 pathway.
MATERIALS AND METHODS
Cell culture. All tumor cell lines were maintained in Dulbecco modified Eagle
medium. Medium was supplemented with 10% fetal calf serum purchased from
Harlan (Oxford, United Kingdom), 100 IU/ml penicillin, 100 g/ml streptomy-
cin, and 2 mM glutamine (all purchased from Gibco/Life Technologies, Paisley,
United Kingdom). The matched colorectal cell lines p53/ HCT116 and p53/
HCT116 have been described previously (10). The tetracycline-responsive
(TetON) p53-inducible Saos-2 cell line was a gift from Karen Vousden (Beatson
Institute for Cancer Research, Glasgow, United Kingdom) and has been de-
scribed previously (36). The tetracycline-inducible HCT116-pCDNA5 (control)
and HCT116-PERKC (PKR-like endoplasmic reticulum kinase [PERK] dom-
inant-negative) cell lines were a kind gift from Kasper Rouschop (University of
Maastricht, Maastricht, The Netherlands) and Brad Wouters (Ontario Cancer
Institute, Toronto, Ontario, Canada). The breast carcinoma cell lines MCF-7 and
MDA-MB-231 were purchased from the American Type Culture Collection
(ATCC).
siRNA duplexes and transient transfection. The small interfering RNA
(siRNA) to p53 (human p53, 5-GCATCTTATCCGAGTGGAA-3) was ob-
tained as a gel-purified annealed duplex from Dharmacon (Lafayette, CO) and
used at a final concentration of 5 nM. The siRNA to p21 was described previ-
ously (4) and purchased from Dharmacon (Lafayette, CO). The nonsilencing
control siRNA duplex (5-AATTCTCCGAACGTGTCACGT-3) was obtained
from Qiagen (Crawley, United Kingdom). Transient transfections with siRNA
duplexes were carried out using HiPerfect transfection reagent (Qiagen) accord-
ing to the manufacturer’s instructions.
Antibodies. The HIF-1 monoclonal antibody was purchased from BD Trans-
duction Laboratories (Oxford, United Kingdom). The p53 monoclonal antibody
(DO-1) was purchased from Calbiochem (Merck Biosciences, Nottingham,
United Kingdom). The p53 polyclonal antibody, the monoclonal anti-phospho-
S15-p53, polyclonal anti-phospho-S51-eIF-2, anti-phospho-T172-AMPK (an-
tibody to AMP-activated protein kinase [AMPK] with T172 phosphorylated),
anti-AMPK, anti-phospho-T37/46-4E-BP1, and anti-phospho-T389-p70S6K
were all purchased from Cell Signaling Technologies (Danvers, MA). The anti-
phospho-S139-H2AX monoclonal antibody was purchased from Upstate (Mil-
lipore, United Kingdom).
Inductions and drug treatments. Physiological hypoxia was achieved by incu-
bating cells in 1% O2, 5% CO2 and 94% nitrogen in a LEEC dual gas incubator
(GA-156). The hypoxic mimetic agent deferoxamine mesylate was used at a final
concentration of 500 M. RITA [2,5-bis(5-hydroxymethyl-2-thienyl) furan] was ob-
tained from the National Cancer Centre, Drug Therapeutic Program, Frederick,
MD (NSC-652287) and dissolved in dimethyl sulfoxide (DMSO). Nutlin-3 (Sigma,
Gillingham, United Kingdom) was used at a final concentration of 4 M. The
proteasome inhibitor MG132 (Calbiochem-Merck Biosciences, Nottingham, United
Kingdom) was used at 10 M unless otherwise stated, and the caspase-3 inhibitor
Z-DEVD-FMK [Z-Asp(OCH3)-Glu(OCH3)-Val-Asp(OCH3)-FMK] tone) (Cal-
biochem) was used at the indicated concentrations.
Western blot analysis and immunoprecipitation. After treatment, cells were
washed in ice-cold phosphate-buffered saline (PBS) and lysed in 2	 sample
buffer (125 mM Tris [pH 6.8], 4% sodium dodecyl sulfate, 0.01% bromophenol
blue, 10% -mercaptoethanol, 10% glycerol). Alternatively, cells were harvested
in NP-40 lysis buffer (100 mM Tris [pH 8.0], 100 mM NaCl2, 1% NP-40) con-
taining an EDTA-free protease inhibitor cocktail (Boehringer Mannheim-Roche
Diagnostics Ltd., Burgess Hill, United Kingdom) to determine total protein
concentration using a standard protein assay (Bio-Rad, Hemel Hempstead,
United Kingdom). For immunoprecipitation of p53 complexes, cells were lysed
in 40 mM HEPES (pH 7.5), 120 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol,
50 mM NaF, 1.5 mM Na3VO4, and 1% Triton X-100 containing EDTA-free
protease inhibitor cocktail (Boehringer Mannheim). After centrifugation, 5 g of
the p53 monoclonal antibody DO-1 (Calbiochem) was added to the supernatant
and rotated for 3 h at 4°C. Then, 50 l of 50% slurry of protein G-Sepharose
(Pierce Biotechnology Inc., Rockford, IL) was added and rotated for another 2 h
at 4°C. Immunoprecipitated complexes were washed three times with lysis buffer.
Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis and assessed by Western blotting using standard procedures. Western
blots were quantified by densitometric analysis as described recently (12).
VEGF quantification. Following treatment, conditioned medium was removed
from cells and analyzed by an enzyme-linked immunosorbent assay for secreted
vascular endothelial growth factor (VEGF) (QuantiGlo; R&D Systems, Minne-
apolis, MN). Samples were assessed in duplicate, and a calibration curve was
performed for each experiment.
FACS. Cell death was analyzed by fluorescence-activated cell sorting (FACS)
using a Beckman Coulter Diagnostics machine (High Wycombe, United King-
dom). Briefly, total populations of cells, including floating and adherent cells,
were fixed in 70% ethanol and stained with propidium iodide (50 g/ml). RNase
was added at 100 g/ml. The percentage of cells with a sub-G1 DNA content was
taken as a measurement of apoptosis.
Immunofluorescence. HCT116 (p53/ and p53/), MCF-7, and MDA-MB-
231 cells were cultured on sterile glass coverslips in six-well dishes. Following
treatment, cells were fixed for 1 h with 4% paraformaldehyde in 1	 PBS and
then blocked with IFF buffer (PBS containing 1% bovine serum albumin and 2%
fetal calf serum) for 1 h. Cells were permeabilized with PBS containing 0.5%
Triton X-100 for 10 min and washed with PBS. The p53 (DO-1; Calbiochem) and
phospho-Ser139-H2AX (Upstate-Millipore, United Kingdom) monoclonal an-
tibodies were used at 2 g/ml in IFF blocking buffer. The secondary antibody
Alexa Fluor 488-conjugated goat anti-mouse immunoglobulin G1 (Molecular
Probes, Leiden, Netherlands) was used at 1/200 in IFF buffer. Nuclei were
visualized by TO-PRO-3 staining (Molecular Probes).
Real-time quantitative PCR. Total RNA was extracted from cells using the
RNeasy minikit (Qiagen, Crawley, United Kingdom). Five micrograms of total
RNA was used for first-strand cDNA synthesis using the SuperScript II first-
strand synthesis system (Invitrogen, Paisley, United Kingdom) and random hex-
amers according to the manufacturer’s instructions. Real-time PCR was per-
formed using DyNAmo Sybr green quantitative PCR kit (Finnzymes, GRI Ltd.,
Braintree, United Kingdom) and the DNA Engine Opticon2 system (GRI Ltd.,
Braintree, United Kingdom) as we have previously described (12). Primer se-
quences used are as follows: 5-GCAAGCCCTGAAAGCG-3 (forward) and
5-GGCTGTCCGACTTTGA-3(reverse) for HIF-1, 5-GTTCCTTGTGGAG
CCGGAGC-3 (forward) and 5-GGTACAAGACAGTGACAGGTC-3 (re-
verse) for p21, and 5-ATGGGGAAGGTGAAGGTCG (forward) and 5-TA
AAAGCAGCCCTGGTGACC-3 (reverse) for glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH). Where indicated, PCR samples were separated by 3%
agarose gel electrophoresis in the presence of ethidium bromide.
In vivo analysis. All procedures involving animals were performed within
guidelines set out by The Institute of Cancer Research’s Animal Ethics Com-
mittee and the United Kingdom Co-ordinating Committee for Cancer Research
Committee on the Welfare of Animals in Experimental Neoplasia (46). To
determine the distribution of RITA in mice, RITA was prepared at 2.5 mg/ml in
PBS containing 10% DMSO and 5% Tween 20 and administered intraperitone-
ally (25 mg/kg of body weight) to female BALB/c mice. Mice were terminated by
exsanguination under anesthesia at 0.08, 0.25, 0.5, 1, 2, 6, and 24 h after admin-
istration of RITA, and plasma, liver, spleen, kidney, and lung samples were
removed for pharmacokinetic analysis. Tissue samples were homogenized with
3	 (vol/wt) PBS, and 50 l was extracted by the addition of 150 l of methanol.
Plasma samples (50 l) were extracted by protein precipitation with 150 l of
methanol. Extracts were analyzed by liquid chromatography-mass spectrometry
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using a reverse-phase Synergi Polar-RP (Phenomenix) analytical column (50 by
2.1 mm) and positive-ion mode electrospray ionization and single-ion monitor-
ing. To assess the effects of RITA on p53, HIF-1, HDM2, p21, VEGF, and
phosphorylated H2AX proteins, 2 million p53/ HCT116 cells were injected
subcutaneously into bilateral flanks of female NCr athymic mice at 6 to 8 weeks
of age and treated intraperitoneally with either solvent control or 10 mg of RITA
per kg. Each group contained eight mice. One tumor per mouse was used for
pharmacokinetic analysis (as described above), and samples from the second
tumor were bisected. Half the samples were snap-frozen using liquid nitrogen for
examination of protein expression by Western blotting, and the remaining sam-
ples were fixed in 10% formalin for immunohistochemical analysis. For protein
extraction, frozen tumors were ground using a bead grinder homogenizer (Pre-
cellys; Stretton Scientific, Stretton, United Kingdom) in freshly prepared lysis
buffer. Samples were assessed for total protein concentration using a standard
protein assay (Bio-Rad) and subjected to Western blot analysis.
RESULTS
RITA induces p53-dependent downregulation of HIF-1
and VEGF expression. RITA has been shown to induce p53,
mediate apoptosis, and inhibit tumor growth in vivo (23).
Given that active p53 downregulates HIF-1 expression (27,
39), we hypothesized that RITA could potentially mediate
antiangiogenic effects by inhibiting HIF activity. To address
this, we assessed the effects of RITA on a series of tumor cells
that express either wild-type p53 (p53/ HCT116, MCF-7,
U2OS, and RCC4), mutant p53 (MDA-MB-231 and HT29) or
are p53 null (p53/ HCT116 and Saos-2). We found that
RITA induced p53 to comparable levels in normoxia and hyp-
oxia and blocked HIF-1 induction in hypoxia in MCF-7 cells
(Fig. 1A). In addition, HIF-1 induction in response to the
hypoxia mimetic agent deferoxamine mesylate was also
blocked by RITA in p53/ HCT116 cells (data not shown).
However, RITA did not induce p53 or affect HIF-1 levels in
MDA-MB-231 cells, which express mutant p53 (Fig. 1B). Sim-
ilar results were obtained for the wild-type p53-expressing
U2OS and RCC4 cells, while HIF-1 levels were not affected
by RITA in HT29 cells, which express mutant p53, or in p53-
null Saos-2 cells (data not shown). These data suggest that the
ability of RITA to block HIF-1 was p53 dependent. To assess
this further, matched p53/ HCT116 and p53/ HCT116
cells (10) were used. We found that RITA blocked HIF-1
induction only in response to hypoxia in p53/ HCT116 cells
(Fig. 1C) and resulted in a significant inhibition of VEGF
expression (Fig. 1D). Our data indicate that RITA blocks
HIF-1 and VEGF induction in response to hypoxia and that
this is p53 dependent.
RITA induces p53-dependent cell death in normoxia and
hypoxia. Induction of apoptosis by p53 contributes to the an-
titumor effect of most conventional chemotherapeutic drugs
(14, 33). However, hypoxia confers tumor cell resistance to
killing by chemotherapy and radiotherapy (1, 8). Since RITA
selectively kills tumor cells bearing wild-type p53 (23) and
inhibits HIF-1 expression (Fig. 1A to C), we next determined
whether RITA could induce cell death in tumor cells in re-
sponse to hypoxia. We found that RITA could induce a clear
increase in rounding and displacement of cells from monolay-
ers in tissue culture, indicative of apoptosis, to a similar extent
in normoxia and hypoxia (Fig. 2A). Using FACS, we also found
that there was a marked increase in the sub-G1 content of cells
(28 to 30%) induced by RITA (Fig. 2B) and an increase in
poly(ADP-ribose) polymerase (PARP) cleavage (Fig. 2C), in-
dicating that RITA induced apoptosis in cells exposed to nor-
moxia and hypoxia. Consistent with the effects we observed for
HIF-1 (Fig. 1A to C), RITA did not mediate cell death in
MDA-MB-231 cells in either normoxia or hypoxia (Fig. 2A) or
in p53/ HCT116 cells (Fig. 2B). To further confirm the role
of p53 in RITA-induced cell death, we used siRNA to knock
down p53. We found that p53 knockdown reduced PARP
cleavage induced by RITA in both normoxia and hypoxia,
indicating that p53 is important for RITA-induced apoptosis
(Fig. 2C). In addition, we found that inhibition of caspase-3
activation by the inhibitor Z-DEVD-FMK could block PARP
FIG. 1. RITA induces p53-dependent inhibition of HIF-1 and VEGF in normoxia and hypoxia. (A to C) Western blot analysis shows HIF-1
and p53 protein levels in MCF-7 cells (A), MDA-MB-231 (B), and p53/ HCT116 or p53/ HCT116 cells (C) treated with RITA over a
concentration range for 16 h in normoxia or hypoxia (1% O2). Actin was used as a load control. (D) The graph shows VEGF (pg/ml) secreted into
cell culture medium from p53/ and p53/ HCT116 cells treated with RITA (0 to 1 M) for 16 h in hypoxia (1% O2).
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cleavage induced by RITA in normoxia and hypoxia in a dose-
dependent manner without affecting the ability of RITA to
block HIF-1 accumulation in hypoxia (Fig. 2D). These data
suggest that the cell death induced by RITA per se is not
responsible for the inhibition of HIF-1, indicating that these
are potentially mechanistically separable responses. Taken to-
gether, our data show that RITA blocks HIF-1 and VEGF
induced in hypoxia and mediates p53-dependent tumor cell
apoptosis in normoxia and hypoxia.
RITA induces p53-dependent eIF-2 phosphorylation and
blocks HIF-1 protein. HIF- expression is usually regulated
at the level of protein stability (24, 25) and synthesis (32, 44).
To examine the mechanism by which RITA inhibits the ex-
pression of HIF-1, we next assessed the effects of RITA on
HIF-1 expression in the presence of the MG132 proteasome
inhibitor. We found that MG132 did not affect the ability of
RITA to block HIF-1 expression in either normoxia or hyp-
oxia (Fig. 3A). Again, these effects were dependent on p53
(Fig. 3A). In addition, RITA could significantly block HIF-1
protein constitutively stabilized in RCC4 cells in normoxia due
to loss of pVHL function (Fig. 3B). Furthermore, quantitative
PCR analysis showed that RITA had no significant effect on
HIF-1 mRNA expression either in the presence or absence of
p53 (Fig. 3C). Collectively, these data indicate that RITA po-
tentially affects HIF-1 at the level of protein synthesis. Recent
studies have shown that activation of p53 by genotoxic stress
blocks protein translation via inhibition of mammalian target
of rapamycin (mTOR) signaling (9, 15, 17). To address this
here, components of the translational machinery were evalu-
ated. We found that phosphorylation of the downstream effec-
tor of mTOR, p70S6K was moderately increased in response to
RITA in a p53-dependent manner (Fig. 3D), while phosphor-
ylated 4E-BP1 was not significantly altered in RITA-treated
cells (data not shown and Fig. 4B), suggesting that the mTOR
pathway may not be involved here. In contrast, we found that
RITA induced a marked phosphorylation of eIF-2 on Ser51
in a p53-dependent manner (Fig. 3D).
Activation of p53 by genotoxic stress has been shown to
induce the phosphorylation of AMP-activated protein kinase
(15, 17) and blocks translation via the mTOR pathway (9). To
FIG. 2. RITA induces p53-dependent cell death in normoxia and hypoxia. (A) Photographic images of MCF-7 and MDA-MB-231 cells treated
with RITA (1 M) for 24 h in normoxia and hypoxia (1% O2). Cells treated with RITA have displaced into the culture medium. (B) FACS analysis
of p53/ and p53/ HCT116 cells treated with RITA (1 M) for 24 h in normoxia or hypoxia (1% O2). Graphs show DNA content of cells
(events) measured by propidium iodide (PI) stain and FACS analysis. The percentage of sub-G1 content (the percentage shown under the M1 bar)
indicates the apoptotic population of cells. (C) Western blot analysis shows p53 protein and cleaved PARP cleavage as an indicator of apoptosis
in p53/ HCT116 cells transiently transfected with siRNA to p53 or a nonsilencing control (NSC) siRNA duplex. Twenty-four hours after
transfection, cells were treated with RITA () (1 M) for 16 h in normoxia or hypoxia (1% O2). Actin was used as a load control. (D) Western
blot analysis shows HIF-1, cleaved PARP, and p53 proteins in p53/ and p53/ HCT116 cells treated with RITA () (1 M) for 16 h in
normoxia and hypoxia (1% O2) in the presence or absence () of the caspase-3 inhibitor Z-DEVD-FMK at 25 M or 50 M.
2246 YANG ET AL. MOL. CELL. BIOL.
FIG. 3. RITA induces phosphorylation of eIF-2 and blocks HIF-1 protein. (A) Western blot analysis shows HIF-1 and p53 protein levels
in p53/ HCT116 cells or p53/ HCT116 cells treated with the indicated concentrations of RITA for 16 h in normoxia or hypoxia (1% O2) in
the presence or absence of the proteasome inhibitor MG132 (50 M). Actin was used as a load control. (B) Western blot analysis shows HIF-1
protein levels in RCC4 cells treated with RITA (1 M) for 16 h. Actin was used as a load control. (C) Evaluation of HIF-1 transcripts by
quantitative real-time PCR. p53/ HCT116 cells were treated with the indicated concentrations of RITA for 16 h in hypoxia (1% O2). Total RNA
was prepared, and quantitative real-time PCR was performed. The graph shows the HIF-1 transcript levels relative to the level of the GAPDH
control. PCR products were separated by 3% agarose gel electrophoresis and visualized by ethidium bromide. GAPDH was used as a load control.
(D) Western blot analysis shows phosphorylated eIF-2 (P-eIF-2), phosphorylated p70S6K (P-70S6K), and eIF-2 proteins in p53/ HCT116
and p53/ HCT116 cells treated with the indicated concentrations of RITA for 16 h in normoxia or hypoxia (1% O2). Actin was used as a load
control. (E) Western blot analysis shows phosphorylated AMPK (P-AMPK) and total AMPK protein in p53/ HCT116 cells treated with the
indicated concentrations of RITA for 16 h in normoxia or hypoxia (1% O2). Actin was used as a load control.
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address whether phosphorylation of AMPK was induced in
response to RITA, we treated cells with RITA at increasing
concentrations curve and assessed phosphorylated AMPK pro-
tein. We found that AMPK phosphorylation was not signifi-
cantly altered in response to RITA treatment of cells, while
eIF-2 phosphorylation increased in a dose-dependent man-
ner (Fig. 3E). Taken together, our data indicate that RITA
affects protein translation via eIF-2.
RITA induces p53-dependent eIF-2 phosphorylation and
downregulates p53 targets. The alpha subunit of eukaryotic
initiation factor 2 is responsible for binding of Met-tRNAiMet
to the 40S ribosome for protein translation initiation (2). Phos-
phorylation of eIF-2 on Ser51 usually results in general pro-
tein synthesis inhibition (13). To evaluate this further, p53/
HCT116 cells were treated with RITA over a concentration
range in normoxia and hypoxia. We found that RITA induced
p53 and the p53 targeted p21 and HDM2 in a dose-dependent
manner in normoxia and hypoxia (Fig. 4A and B). Surprisingly,
as p53 levels continued to increase in response to increasing
concentrations of RITA, the expression levels of not only
HIF-1 but also of HDM2 and p21 proteins were also down-
regulated (Fig. 4A and B). Concurrently, eIF-2 phosphoryla-
tion increased and cell death was induced by PARP cleavage
(Fig. 4B and C). Further analysis indicated that the downregu-
lation of p21 protein induced by RITA treatment of cells was
not due to a decrease in p21 mRNA (Fig. 4D). These findings
are consistent with our findings for HIF-1 (Fig. 3C). Inter-
estingly, knockdown of p21 using siRNA could increase basal
PARP cleavage in HCT116 cells and enhance the overall
cleaved PARP induced in response to RITA (data not shown),
suggesting that knocking down p21 can drive the p53-mediated
apoptotic response induced by RITA.
PERK activity is important for RITA-mediated induction of
eIF-2 phosphorylation. Recent studies have shown that hyp-
oxia mediates a time-dependent transient induction of eIF-2
phosphorylation, which results in inhibition of protein synthe-
FIG. 4. RITA induces phosphorylation of eIF-2 and downregulates p53 targets. (A and B) Western blot analysis shows HIF-1, p53, HDM2,
p21, phosphorylated eIF-2 (P-eIF-2), total eIF-2, cleaved PARP, and phosphorylated 4E-BP1 (P-4E-BP1) in p53/ HCT116 cells treated with
RITA over a concentration range (0 to 500 nM) for 16 h in normoxia (A) and hypoxia (1% O2). (B) Actin was used as a load control. (C) The
graph shows the results of densitometric analysis of the Western blot for hypoxia conditions as in panel B. HIF-1, HDM2, and p21 protein levels
are represented relative to the actin load control, and phosphorylated eIF-2 levels are represented relative to total eIF-2 protein. (D) Total RNA
was prepared from p53/ HCT116 cells treated with RITA and exposed to hypoxia as described above for panel A, and quantitative real-time
PCR was performed. The graph shows the p21 transcript levels relative to the level of the GAPDH control and averaged for two independent
experiments. Western blot analysis shows p53 and p21 proteins. Actin was used as a load control.
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sis (29, 30). We found that eIF-2 phosphorylation was in-
duced and maintained in hypoxia by treatment of cells with
RITA (Fig. 5A), suggesting that protein synthesis was blocked
by RITA. In hypoxia, PKR-like endoplasmic reticulum kinase
is activated to control translation via direct phosphorylation of
eIF-2 (5, 50). To assess whether PERK activity is important
for the induction of eIF-2 phosphorylation in response to
RITA treatment of cells, we used a dominant-negative form of
PERK (PERKC). We found that the expression of PERKC
blocked basal eIF-2 phosphorylation and significantly inhib-
ited the ability of RITA to induce eIF-2 phosphorylation in
cells (Fig. 5B), indicating that PERK activity is important for
the p53-mediated eIF-2 phosphorylation induced in response
to RITA.
RITA does not disrupt the p53-HDM2 interaction. Since
RITA could induce significant cell death in both normoxia and
hypoxia, we next addressed its mechanism of action. RITA was
originally proposed to stabilize and activate p53 by disruption
of p53-HDM2 interaction by binding to the N-terminal domain
of p53 (23). Recent studies using NMR techniques have indi-
cated that RITA does not block the p53-HDM2 interaction in
vitro (31). In addition, we found that RITA induced a p53-
dependent induction of HDM2 at very low concentrations
(
100 nM), but at doses which induced apoptosis, RITA ac-
tually downregulated HDM2 expression (Fig. 4A and B). To
evaluate this further, p53 complexes were immunoprecipitated
from p53/ HCT116 cell lysates, and associated HDM2 was
assessed in the presence of RITA. We found that RITA was
not able to disrupt immunoprecipitated p53-HDM2 complexes
even at submillimolar concentrations in vitro (data not shown).
In contrast, we found that the small-molecule nutlin-3 that has
been shown to disrupt the p53-HDM2 interaction by binding to
HDM2 (47) could significantly impair the ability of HDM2 to
coimmunoprecipitate with p53 (Fig. 6A), indicating that RITA
may activate p53 via mechanisms that do not target the p53-
HDM2 interaction. Interestingly, we found that induction and
activation of p53 in the absence of eliciting a stress response
either by using a tetracycline-inducible system (Fig. 6B) or by
treatment of cells with nutlin-3 (Fig. 6C) was not sufficient to
inhibit HIF-1 in response to hypoxia, further supporting the
possibility that RITA may induce and activate p53 via mecha-
nisms other than disruption of the p53-HDM2 interaction.
RITA induces a DNA damage response. RITA has previ-
ously been reported to cause protein-DNA and DNA-DNA
intrastrand cross-links (37, 40), suggesting that it may activate
p53 by inducing a DNA damage response. To investigate this,
we first assessed the phosphorylation status of p53 in response
to RITA, since phosphorylation of p53 within the N terminus
is usually induced by genotoxic stress (3, 26). p53/ HCT116,
MCF-7, and U2OS cells were treated with RITA in normoxia
or hypoxia and assessed for phosphorylation of p53 at Ser15
(Fig. 7A and D). We found that RITA induced N-terminal
phosphorylation of p53, while nutlin-3 was unable to mediate
p53 phosphorylation (Fig. 7A). In addition, assessment of
H2AX, a histone protein usually phosphorylated by DNA
damage-induced stress (6, 28), showed that RITA induced the
phosphorylation of H2AX at Ser139 and that p53 and phos-
phorylated H2AX proteins were induced by RITA and local-
ized to the nucleus in both normoxia and hypoxia (1% O2) to
a similar extent (Fig. 7B and C). Similar data were obtained for
other p53-positive cells, such as MCF-7 and U2OS cells, indi-
cating that these responses were not specific to HCT116 cells
(data not shown). Previous studies have shown that H2AX
phosphorylation is induced in extreme hypoxia (
0.02% O2)
FIG. 5. PERK activity is important for RITA-mediated induction of eIF-2 phosphorylation. (A) Western blot analysis shows HIF-1,
phosphorylated eIF-2 (P-eIF-2), and total eIF-2 proteins in p53/ HCT116 cells treated with RITA (1 M) and exposed to hypoxia (1% O2)
for the times indicated (in hours). Actin was used as a load control. (B) Western blot analysis shows phosphorylated eIF-2 and total eIF-2
proteins in HCT116 cells stably expressing a pCDNA5 control plasmid (control) or a dominant-negative form of PERK (PERKC) under the
control of the tetracycline promoter. Cells were treated with RITA (1 M) and exposed to hypoxia (1% O2) for 16 h. Actin was used as a load
control.
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and is localized to discrete nuclear foci (21). However, we
found that exposure of cells to hypoxia at 1% O2 did not induce
H2AX phosphorylation in cells (Fig. 7C), consistent with a
another study (21). Intriguingly, we found that unlike other
agents that activate a DNA damage response, RITA induced
eIF-2 phosphorylation, which correlated with a significant
inhibition of HIF-1 in p53-positive cells (Fig. 7D). Taken
together, our study identifies a new mechanism of action for
RITA: RITA functions by activating a DNA damage response.
RITA induces p53 and H2AX phosphorylation and blocks
HIF-1 and VEGF expression in vivo. RITA has previously
been shown to mediate antitumor activity in a subcutaneous
HCT116 colon carcinoma xenograft model (23). We next de-
termined whether RITA induced a DNA damage response and
downregulation of HIF-1 and VEGF expression in p53/
HCT116 cell-derived tumor xenografts. Consistent with a pre-
vious study (23), we found that RITA was well-tolerated in
mice at 10 to 25 mg/kg daily dosing. In addition, we detected
RITA in the plasma and tissues of mice (kidney, liver, lung,
and spleen) by liquid chromatography-mass spectroscopy (data
not shown), indicating that the compound was distributed in
vivo. We found that p53, Ser15 phosphorylation of p53, and
Ser139 phosphorylation of H2AX were induced at 24 h with
a reduction in HIF-1 and HDM2 in tumors from the RITA-
treated group compared with the solvent (DMSO) control
group (Fig. 8A). We also observed a marked decrease in
VEGF levels in tumor lysates from the RITA-treated group
compared to those of the DMSO-treated control group (Fig.
8B). Immunohistochemical analysis indicated that p53 and
phosphorylated H2AX staining correlated with increased tu-
mor cell apoptosis (data not shown). Our analyses confirm that
RITA induces a DNA damage response and mediates a reduc-
tion in HIF-1 and VEGF expression in vivo.
DISCUSSION
The p53 tumor suppressor protein is a potent negative reg-
ulator of HIF-1 and VEGF in hypoxia (39). In addition, the
induction of apoptosis by p53 contributes to the antitumor
effects of most conventional chemotherapeutic drugs (14, 33).
However, hypoxia and HIF-1 status in tumor cells are impor-
tant determinants for resistance to chemotherapeutic agents
and radiotherapy (7, 35, 38, 49). Therefore, the possibility that
small-molecule activation of wild-type p53 could potentially
mediate both antiangiogenic effects via blockade of the HIF
pathway and apoptosis in hypoxic tumor cells is of particular
interest.
In this study, we have explored the mechanistic properties of
the small-molecule activator of p53, RITA. RITA was origi-
nally identified in a cell-based screen using the National Can-
cer Institute (NCI) compound library and has been shown
recently to mediate p53-dependent antitumor activity in vivo
(23). Here, we show that RITA blocks HIF-1 and VEGF
expression in vivo and mediates significant cell death responses
in hypoxic tumor cells in a p53-dependent manner. Inhibition
of HIF-1 was not due to an effect on protein degradation or
changes in mRNA levels, indicating an effect on HIF-1 pro-
tein synthesis. We discovered that RITA induced p53-depen-
FIG. 6. RITA does not disrupt the p53-HDM2 interaction. (A) Western blot analysis of p53-HDM2 immunoprecipitated (IP) complexes.
p53/ HCT116 cells were treated with RITA (1 M) or nutlin-3 (4 M) in the presence of MG132 (10 M) for 16 h. Cell lysates were
immunoprecipitated with a monoclonal antibody to p53 (DO-1), and immunoprecipitated p53 complexes were assessed for associated HDM2
protein by Western blotting. Total immunoprecipitated p53 protein was evaluated using a polyclonal antibody. WCE, whole-cell extracts.
(B) Western blot analysis shows HIF-1 and p53 proteins in TetON p53-inducible Saos-2 cells treated with doxycycline (Dox) (800 ng/ml) () for
24 h, then washed with PBS, and treated with RITA (1 M) () for a further 16 h in normoxia or hypoxia (1% O2). (C) Western blot analysis
shows HIF-1, HDM2, and p53 proteins in p53/ HCT116 cells treated with nutlin-3 (4 M) () in normoxia (N), hypoxia (H), or deferoxamine
mesylate (D) for 16 h. Actin was used as a load control.
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dent phosphorylation of eIF-2, which correlated with its abil-
ity to block HIF-1 induction in hypoxia. Concurrently, we
found that RITA also blocked expression of the p53 target
proteins HDM2 and p21, indicating that RITA may affect
protein synthesis via phosphorylation of eIF-2. Of particular
interest is how the p53-dependent response induced by RITA
signals to the translational machinery at the level of eIF-2,
since other known activators of p53 used in this study did not
induce phosphorylation of eIF-2. Activation of p53 by RITA
did not appear to significantly block components of mTOR
signaling, ruling out the possibility that downregulation of
HIF-, p21, and HDM2 were due to p53 cross talk to AMPK-
mTOR signaling as reported recently (9, 15–17). Interestingly,
we discovered that the activity of PERK, an upstream kinase
that phosphorylates eIF-2 in response to hypoxia, was impor-
tant for the induction of eIF-2 phosphorylation in response to
RITA (5), suggesting that p53 signals to the translational ma-
chinery by regulating PERK–eIF-2 activation. Indeed, a re-
cent report has linked the unfolded protein response pathway
with p53 accumulation via a PERK-dependent mechanism
(51).
Further investigation into the mechanism of action of RITA
indicated that RITA did not appear to block the p53-HDM2
interaction as originally proposed to be its mechanism of ac-
tion for inducing p53 (23). In fact, we found that RITA acti-
vated a DNA damage response in vitro and in vivo. Previous
studies have shown that RITA causes protein-DNA and DNA-
DNA intrastrand cross-links (37, 40), supporting the notion
that RITA could induce and activate p53 by eliciting a DNA
damage response in cells. Indeed, the ability of RITA to me-
diate both apoptotic and antiangiogenic effects in hypoxia may
be due to its ability not only to induce p53 but also to elicit a
concurrent DNA damage response. Intriguingly however, un-
like other agents that mediate a DNA damage response,
RITA-mediated effects are entirely dependent on p53.
Activation of the DNA damage response by RITA was ap-
parent in both normoxia and hypoxia to a similar extent. While
transient overexpression of p53 has been reported to block
FIG. 7. RITA induces a DNA damage response. (A) Western blot analysis shows HDM2, p53, and phosphorylated-S15-p53 (P-S15-p53)
proteins in p53/ HCT116 cells treated with RITA (1 M) or nutlin-3 (4 M) for 16 h. (B and C) Immunofluorescence analysis shows p53 (B) and
phosphorylated-S139-H2AX proteins (fluorescein isothiocyanate [FITC]) (C) in p53/ HCT116 cells treated with RITA (1 M) in normoxia or
hypoxia (1% O2) for 16 h. Nuclei (blue) were visualized with TO-PRO-3 staining. Images (	40) were captured using a confocal microscope (Leica).
(D) Western blot analysis shows HIF-1, p53, phosphorylated S15-p53, HDM2, p21, eIF-2, phosphorylated eIF-2, and PARP proteins in p53/
and p53/ HCT116 cells treated with DMSO, 1 M RITA, 1 mM hydroxyurea (HU), doxorubicin (Dox), cisplatin (Cisp), or 25 M etoposide
(Etop) for 16 h in hypoxia (1% O2). The status of p53 is shown above the lanes: , present; , absent.
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HIF-1 and VEGF induced in hypoxia (39), a previous report
has shown that DNA damage is a prerequisite for p53-medi-
ated downregulation of HIF-1 (27). Interestingly, we found
that RITA’s ability to inhibit HIF-1 was not affected by block-
ade of apoptosis, indicating that the p53-dependent apoptotic
and antiangiogenic responses mediated by RITA are mecha-
nistically separable processes. While the p53-dependent apop-
totic function induced by RITA did not appear to influence the
observed HIF-1 blockade, conversely we found that in renal
carcinoma cells expressing constitutively high basal levels of
HIF- protein due to loss of pVHL function, RITA was at
least fivefold less potent in blocking tumor cell growth than in
renal carcinoma cells expressing pVHL. In addition, we found
that p21 knockdown by siRNA could enhance basal PARP
cleavage and increase overall PARP cleaved in response to
RITA (data not shown). These observations are consistent
with the mTOR inhibitor RAD001 (4). Collectively, these find-
ings indicate that the HIF- status in cells contributes to
RITA’s apoptotic outcome and that downregulation of p21 by
RITA may help drive the apoptotic response induced by p53.
The ability to both induce apoptosis and suppress tumor
angiogenesis by targeting p53 is of significant interest thera-
peutically. Clinical studies have shown that the combined ad-
ministration of chemotherapeutic agent 5-fluorouracil and be-
vacizumab, a monoclonal antibody targeted against VEGF,
produced a dramatic increase in survival in colorectal cancer
patients (18, 22). However, bevacizumab did not yield long-
term survival benefits as a single agent (34). This suggests that
combination of drugs that lead to both tumor cell death and
suppression of angiogenesis would be more clinically desirable,
even when one agent is a classical cytotoxin. Indeed, RITA
appears to be able to mediate both processes as a single agent:
RITA induces a DNA damage response, resulting in p53-
mediated apoptosis, and also blocks HIF-1 expression, result-
ing in a significant reduction in VEGF expression.
In conclusion, our study utilizes the small-molecule activator
of p53 RITA to evaluate mechanisms by which p53 can both
induce apoptosis and suppress tumor angiogenesis. By identi-
fying a new mechanism of action for RITA, we have uncovered
the existence of a DNA damage response that when activated
leads to the death of hypoxic tumor cells and blockade of the
HIF-1/VEGF pathway in vivo. Further evaluation of this re-
sponse and the identification of other agents or activators of
this response will be of particular interest and may lead to
improved targeting of HIF/hypoxia signaling in tumor cells.
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Hypoxia is a common feature of solid tumors that renders them 
resistant to conventional chemotherapeutic agents and radiotherapy.2 
Hypoxia inducible factors (HIFs) are essential components of the 
hypoxic response in cells, linking tumor hypoxia to angiogenesis 
and tumor progression through the upregulation of key angiogenic 
factors such as vascular endothelial growth factor (VEGF). The HIF 
pathway is deregulated in most human cancers and targeting HIF has 
become an attractive strategy for the development of new therapeutic 
agents.6 Indeed, the ability to induce both tumor cell apoptosis and 
mediate anti-angiogenic effects is of particular interest therapeutically. 
The p53 tumor suppressor protein is a potent negative regulator 
of the HIF pathway, mediating both apoptotic and anti-angiogenic 
effects when induced.5,9 Several agents have been described that 
can activate wild-type p53,4,7,8 or reactivate mutant p53,1,3 in 
tumor cells. However, many of these new p53-targeted agents have 
not yet been evaluated for their ability to inhibit the HIF pathway 
or assessed for their effectiveness at mediating tumor cell death in 
hypoxia. Recently, we have explored the mechanistic properties of 
the small molecule activator of p53, RITA (reactivation of p53 and 
induction of tumor cell apoptosis).9 RITA (NSC-652287) was originally 
identified in a cell-based screen using the National Cancer Institute 
(NCI) compound library and has been shown previously to mediate 
p53-dependent anti-tumor activity in vivo.4 We have found that RITA 
can mediate significant tumor cell apoptosis in normoxia and hypoxia 
in a p53-dependent manner (Fig. 1A and reviewed in ref. 9) and 
promote both apoptotic and anti-angiogenic effects in vivo.9 In addi-
tion, we have found that RITA activates a DNA damage response in 
vitro and in vivo.9 Further exploration of the DNA damage response 
induced by RITA as indicated by phosphorylated p53,9 γH2AX and 
CHK1 proteins suggested that this response only occurred in cells 
expressing wild-type p53 (Fig. 1B) but did not occur in the absence 
of p53 (Fig. 1B) nor was the DNA damage response induced by 
RITA observed in cells expressing mutant p53 (Fig. 1C). Moreover, 
immunohistochemical analysis showed that RITA induced a pan-
nuclear localization of phosphorylated γH2AX only in cells expressing 
wild-type p53 (Fig. 1D). In contrast however, several well known 
DNA-damage response inducing agents including hydroxyurea, doxo-
rubicin, cisplatin and etoposide could readily induce phosphorylated 
γH2AX in both p53-/- and p53+/+ HCT116 cells (Fig. 1E), and in p53 
mutant MDA-MB-231 cells (Fig. 1F). Collectively, our data indicate that 
unlike the DNA-damaging agents used here, RITA uniquely activates 
a p53-dependent DNA damage response. Activation of p53 by RITA 
leads to both apoptotic4 and anti-angiogenic effects in vivo.9 Since 
RITA can induce significant tumor cell apoptosis in normoxia and 
hypoxia, the identification of components of this p53-dependent DNA 
damage response may lead to a potential strategy for improving the 
therapeutic targeting of hypoxic tumor cells.
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Figure 1. (See previous page) (A) Flow cytometric analysis of p53-/- and p53+/+ HCT116 cells treated with RITA (1 μM) for 24 hr in normoxia or 
hypoxia (1% O2). DNA content of cells (events) was measured by propidium iodide (PI) stain. Graph shows the percentage (%) subG1 population of 
cells (events) as a measure of the apoptotic population. (B) Western blot analysis (upper) shows p53, phosphorylated-S139-H2AX, and PARP proteins 
in p53-/- and p53+/+ HCT116 cells treated with RITA at the indicated concentrations for 16 hr in normoxia or hypoxia (1% O2). Actin was used as 
a load control. Western blot analysis (lower) shows phosphorylated-S345-CHK1 protein in p53-/- and p53+/+ HCT116 cells treated with RITA at the 
indicated concentrations for 16 hr in normoxia or hypoxia (1% O2). Actin was used as a load control. (C) Western blot analysis shows phosphorylated-
S139-H2AX and PARP proteins in p53-/- and p53+/+ HCT116 cells, or MDA-MB-231 cells (p53 mutant) treated with RITA (1 μM) for 16 hr. Actin was 
used as a load control. (D) Immunofluorescence analysis shows phosphorylated-S139-H2AX protein (FITC) in p53-/- and p53+/+ HCT116 cells treated 
with RITA (1 μM) or 1 mM of hydroxyurea (HU) for 16 hr in hypoxia (1% O2). Nuclei (blue) were visualized with TO-PRO-3 staining. Images (x40) 
were captured using a confocal microscope (Leica). (E) Western blot analysis shows phosphorylated S139-H2AX protein in p53-/- and p53+/+ HCT116 
cells treated with DMSO (control) RITA (1 μM), hydroxyurea (HU, 1 mM), doxorubicin (Dox, 1 μM), cisplatin (Cisp, 10 μg/ml), etoposide (Etop, 25 
μM) for 16 hr in hypoxia (1% O2). Actin was used as a load control. (F) Immunofluorescence analysis of phosphorylated-S139-H2AX protein (FITC) in 
MDA-MB-231 cells. Cells were treated with DMSO (control) RITA (1 μM), hydroxyurea (HU, 1 mM), doxorubicin (Dox, 1 μM), cisplatin (Cisp, 10 μg/
ml), etoposide (Etop, 25 μM) for 16 hr in hypoxia (1% O2). Nuclei were visualized with TO-PRO-3 staining (blue). Images (x40) were captured using 
a confocal microscope (Leica).
Pharmacological activation of a novel p53-dependent
S-phase checkpoint involving CHK-1
A Ahmed1, J Yang1,3, A Maya-Mendoza2, DA Jackson2 and M Ashcroft*,1
We have recently shown that induction of the p53 tumour suppressor protein by the small-molecule RITA (reactivation of p53
and induction of tumour cell apoptosis; 2,5-bis(5-hydroxymethyl-2-thienyl)furan) inhibits hypoxia-inducible factor-1a and
vascular endothelial growth factor expression in vivo and induces p53-dependent tumour cell apoptosis in normoxia and
hypoxia. Here, we demonstrate that RITA activates the canonical ataxia telangiectasia mutated/ataxia telangiectasia and Rad3-
related DNA damage response pathway. Interestingly, phosphorylation of checkpoint kinase (CHK)-1 induced in response to
RITA was influenced by p53 status. We found that induction of p53, phosphorylated CHK-1 and cH2AX proteins was significantly
increased in S-phase. Furthermore, we found that RITA stalled replication fork elongation, prolonged S-phase progression and
induced DNA damage in p53 positive cells. Although CHK-1 knockdown did not significantly affect p53-dependent DNA damage
or apoptosis induced by RITA, it did block the ability for DNA integrity to be maintained during the immediate response to RITA.
These data reveal the existence of a novel p53-dependent S-phase DNA maintenance checkpoint involving CHK-1.
Cell Death and Disease (2011) 2, e160; doi:10.1038/cddis.2011.42; published online 19 May 2011
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Solid tumours characteristically contain areas of low oxygen
tension (hypoxia). Hypoxia stabilises the expression of
the hypoxia-inducible factor (HIF)-a transcription factor.
Deregulated overexpression of HIF-a in tumour cells initiates
a transcriptional programme that renders tumour cells
resistant to chemotherapy and radiotherapy, resulting in a
more aggressive and metastatic cancer phenotype.1 Targeting
HIF/hypoxia signalling, therefore, has become an attractive
strategy for the development of new cancer treatments.2
The p53 tumour suppressor protein is a potent negative
regulator of HIF-1a, mediating both apoptotic3,4 and anti-
angiogenic effects when overexpressed.5,6 HIF-1a accumula-
tion in hypoxia is blocked by overexpression5 or activation6 of
p53, and HIF-1-dependent transcription negatively correlates
with p53 status.7 p53 is mutated in about 50% of human
cancers, and several agents have been described that can
reactivate mutant8,9 or activate wild-type p5310–12 in tumour
cells. However, many of these emerging p53-targeted agents
have not yet been evaluated for their effectiveness at
mediating tumour cell death in normoxia and hypoxia. We
have been exploring the mechanistic properties of the small-
molecule activator of p53, RITA (reactivation of p53 and
induction of tumour cell apoptosis; 2,5-bis (5-hydroxymethyl-
2-thienyl) furan, NSC-652287).12–14 RITA was originally
identified in a cell-based screen using the National Cancer
Institute compound library and was shown to mediate p53-
dependent antitumour activity in vivo.12 Subsequently, we
have found that RITA significantly inhibits HIF-1a induction
and elicits p53-dependent apoptotic responses in normoxia
and hypoxia, and promotes both apoptotic and antiangiogenic
effects in vivo.15 RITA was originally proposed to stabilise and
activate p53 by disruption of the p53–human double minute 2
(HDM2) interaction,12 and mediate p53-dependent apoptosis
and other cellular responses via the regulation of p53
transcriptional responses.16 Recently, we have shown that
RITA mediates an effect on the protein translation machinery
and downregulates both HDM2 and p21 protein levels in a
dose- and time-dependent manner while concurrently indu-
cing apoptosis.15 Moreover, and consistent with previous
reports indicating that RITA causes protein–DNA and DNA–
DNA intrastrand crosslinks,13,14 we have found that RITA
activates a DNA damage response.17 Collectively, these
studies indicate that RITA exhibits a complex mechanism of
action that leads to p53 activation and apoptotic responses.
Here, we further explore the mechanism of action of RITA,
with particular focus on the DNA damage response. We
demonstrate that RITA activates the canonical ataxia telan-
giectasia mutated/ataxia telangiectasia and Rad3-related
(ATM/ATR) DNA damage cascade and induces DNA
damage in p53 positive cells. Interestingly, RITA also
mediates checkpoint kinase (CHK)-1 phosphorylation and
slows replication fork elongation and S-phase progression in a
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p53-dependent manner. Loss of CHK-1 does not significantly
affect p53-mediated apoptotic responses induced by RITA,
but does significantly enhance DNA damage upon short term
exposure to RITA. Our study identifies a novel p53-dependent
S-phase checkpoint involving CHK-1.
Results
RITA induces a DNA damage response. Recently, we
have found that RITA can mediate significant tumour cell
apoptosis in normoxia and hypoxia in a p53-dependent
manner and activate a DNA damage response in vitro and
in vivo.15 Consistent with our previous studies,17 here, we
found that RITA induced phosphorylation of the histone
protein H2AX at Ser139 ((gH2AX); Figure 1a), which is
usually associated with DNA damage-induced stress.18
Concurrently, we found that RITA increased cleaved poly
ADP ribose polymerase (PARP; Figure 1a) and the
percentage of cells in sub-G1 (Figure 1b), indicative of
increased apoptosis. Both DNA damage and apoptotic
responses induced by RITA were observed in normoxia
and hypoxia, only in p53-positive cells (Figure 1).
To further explore the DNA damage response induced by
RITA, we first assessed the phosphorylation status of p53
in response to RITA, as phosphorylation of p53 within the
N-terminus is usually induced by genotoxic stress.19 p53þ /þ
HCT116 cells were treated with RITA over a concentration
curve and assessed for Ser15, Ser20 and Ser46 phosphor-
ylation of p53 (Figure 2a). We found that RITA induced
N-terminal phosphorylation of p53 (Figure 2a). DNA damage
is usually sensed by the PI-3K-related protein kinases ATM
and ATR, which activate the transducer checkpoint kinases
CHK-2 and CHK-1, respectively.20 ATM/ATR directly phos-
phorylates p53 at Ser15, whereas CHK-2/CHK-1 phospho-
rylates Ser20 on p53.21 Consistent with activation of the
canonical ATM/ATR DNA damage response pathway, we
found that RITA also induced phosphorylation of Ser345 on
CHK-1 and Thr68 on CHK-2 (Figure 2a), and increased
gH2AX in a dose-dependent manner (Figure 2a). These
responses correlated with a dose-dependent increase of cells
in sub-G1, indicative of apoptosis (Figure 2a, graph). In
addition, we found that induction of phosphorylated CHK-1,
CHK-2, p53 and gH2AX proteins was time-dependent
(Figures 2b and c) and correlated with a time-dependent
increase in cells in sub-G1 (Figure 2d). Thus, the DNA
damage response induced by RITA is both dose- and
time-dependent.
We found that the induction of phosphorylated p53
(Ser15 and Ser20), CHK-1 and CHK-2 proteins in response
to RITA was blocked by wortmannin, a kinase inhibitor
of ATM/ATR and other phosphatidylinositol 3-kinase
family members (Figure 2e), whereas the induction of
cleaved PARP was only marginally affected (Figures 2e
and f). Interestingly, we found that wortmannin had no
significant effect on the induction of eukaryotic initiation
factor-2a phosphorylation or the downregulation of
HDM2 and p21 proteins induced by RITA (Figure 2f),
which we have previously described.15 These data indicate
that the DNA damage and translational responses induced
by RITA are potentially separable processes. As we
would anticipate from the wortmannin effects observed
(Figures 2e and f), in response to RITA, we found that ATM
or ATR siRNA blocked the induction of phosphorylated
CHK-1 and CHK-2 (Figure 2g), which are downstream
targets of ATR and ATM, respectively. Finally, further
analysis of the DNA damage response induced by RITA
indicated a slight but measurable increase in DNA damage
in p53-positive HCT116 and MCF-7 cells (Figures 3a and b),
which was not observed in p53-null HCT116 or Saos-2
cells (Figure 3c). Taken together, these data suggest
that RITA activates the canonical ATM/ATR DNA damage
response pathway and induces DNA damage in p53
positive cells.
RITA stalls replication fork elongation and prolongs
S-phase progression in p53-positive cells. We have
previously observed that most cells treated with RITA
showed an intense pan-nuclear staining of gH2AX.17 A
similar pan-nuclear staining pattern was observed in
response to hydroxyurea treatment.17,22 This type of DNA
damage response is indicative of potential stalling of the
replication fork or inhibition of replication fork elongation, and
can be mediated during processing of bulky DNA lesions.22
During replication, cells usually respond to DNA damage by
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activating an intra-S-phase checkpoint.23 Therefore, we next
assessed whether RITA mediated a p53-dependent DNA
damage response by affecting the replication fork and
S-phase progression. To do this, we treated p53/ or
p53þ /þ HCT116 cells with RITA and performed a DNA fibre
assay, as previously described.24,25 We found that RITA
induced a marked increase in the percentage of replication
forks in p53þ /þ cells but not in p53/ cells (Figure 4a,
compare p53/ with p53þ /þ , lanes 2 and 3). Intriguingly,
this effect was only observed in a sub-population of
replicons, such that the second and third classes were very
substantially affected by RITA treatment, whereas the
seventh/eight/ninth classes were less affected (Figure 4a,
compare untreated versus RITA-treated in p53þ /þ cells,
lanes 2 and 3 with lanes 7, 8 and 9). Statistical analysis
(t-test) showed significance (P-value¼ 4.85E25) in p53þ /þ
HCT116 cells for untreated versus RITA-treated (Figure 4b).
Visualisation of DNA foci using bromodeoxyuridine (BrdU)
pulse labelling and immunohistochemical analyses was
performed to assess S-phase progression in unsynchro-
nised p53/ and p53þ /þ HCT116 cells. We found that
although the S-phase programme was maintained upon
treatment with RITA, our data indicated that S-phase was
prolonged at mid-late stages (Figure 4c).
Previous studies have shown that CHK-1 predominantly
regulates DNA replication, fork elongation and effects
S-phase progression.25 As we found that RITA induced
a p53-dependent increase in replication fork number
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P-S15-p53
P-S20-p53
P-S46-p53
CHK2
CHK1
P-S345-CHK1
P-T68-CHK2
P-S139-H2AX
-actin
60
20
40
%
 o
f c
el
l p
op
ul
at
io
n 
in
Su
b-
G
1
0
RITA (nM)
PARP
p53
RITA (1M):
116 kDa
89 kDa
RITA 
(1M):
p53
HCT116 +/+ HCT116 -/-
CHK1
CHK2
P-S345-CHK1
P-T68-CHK2
P-S15-p53
P-S46-p53
-actin
P-S139-H2AX
-actin
P-S139-H2AX
HCT116 p53+/+
HCT116 p53-/-
40
50
60
10
20
30
hour (RITA 1M)
0%
 o
f c
el
l p
op
ul
at
io
n 
Su
b-
G
1
116 kDa
- +Wortmannin:
- +RITA:
116 kDa
- - +Wortmannin:
- + - +RITA:
p53
PARP89 kDa
PARP
89 kDa
HDM2
P-S15-p53
p53
P-S20-p53
P-S345-CHK1
P-S1981-ATM
P-eIF-2
eIF-2
p21
P-T68-CHK2
-actin
-actin -actin
NSC
siRNA
ATM
siRNA
- +RITA (500nM): +
ATR
siRNA
P-S345-CHK1
CHK1
p53
P-T68-CHK2
CHK2
RITA: 0 5 10 20 50 100 200 500 (nM)
0 50 100 200 500
0 2 4 8 16 hour
0 2 4 8 16 0 2 4 8 16 hour 
0 2 4 8 16 24
-
+
+
+
Figure 2 RITA induces a DNA damage response. (a) Western blot analysis of DNA damage response markers in p53þ /þHCT116 cells treated with the indicated
concentrations of RITA for 16 h. Western blot analysis shows p53, phosphorylated p53 (S15, S20, S46), phosphorylated-S345-CHK-1, phosphorylated-T68-CHK-2,
phosphorylated-S139-gH2AX, CHK-1 and CHK-2 proteins. Actin was used as a loading control. In parallel, cells were harvested for flow cytometric analysis. Cells were fixed
and stained using propidium iodide to visualise DNA profiles. The graph shows the percentage (%) of cells in sub-G1 in response to RITA treatment as indicated. Data is
averaged from three independent experiments. (b) Western blot analysis of DNA damage response markers in p53þ /þHCT116 cells treated with RITA (1mM) for the
indicated time. Western blot analysis shows p53, phosphorylated-S345-CHK-1, phosphorylated-T68-CHK-2, phosphorylated-S139-gH2AX, CHK-1 and CHK-2 proteins Actin
was used as a loading control. (c) Western blot analysis shows p53, phosphorylated p53 (S15 and S46) and phosphorylated-S139-gH2AX in p53þ /þHCT116 cells and p53/
HCT116 cells treated with RITA (1 mM) for the indicated time. Actin was used as a loading control. (d) In parallel with the western analysis described in c, cells were harvested
for flow cytometric analysis. Cells were fixed and stained using propidium iodide to visualise DNA profiles. The graph shows the percentage (%) of cells in sub-G1 in response
to RITA treatment as indicated. Data are averaged from three independent experiments. (e and f) p53þ /þHCT116 cells were treated with RITA (1 mM) in the presence or
absence of wortmannin (10 mM) for 16 h and assessed by western blot for p53, phosphorylated p53 (S15 and S20), phosphorylated-S1981-ATM, phosphorylated-S345-CHK-
1, phosphorylated-T68-CHK-2 proteins, HDM2, p21, phosphorylated eukaryotic initiation factor-2a (eIF-2a), total eIF-2a, and cleaved PARP proteins. Actin was used as a
loading control. (g) p53þ /þHCT116 cells were transfected with a non-silencing control siRNA (NSC), ATM siRNA or ATR siRNA. Cells were treated with RITA (500 nM) for
24 h then harvested for western analysis. Western blot analysis shows p53, phosphorylated-S345-CHK-1, phosphorylated-T68-CHK-2, CHK-1 and CHK-2 proteins. Actin was
used as a loading control
Activation of a p53-dependent S-phase checkpoint
A Ahmed et al
3
Cell Death and Disease
(Figures 4a and b) and affected S-phase progression
(Figure 4c), we next assessed whether CHK-1 phosphoryla-
tion was also affected by p53 status. To do this, p53/ and
p53þ /þ HCT116 cells were treated with RITA. We found that
both CHK-1 and CHK-2 were phosphorylated in response to
RITA treatment (Figure 4d). However, we found that
phosphorylation of CHK-1 at Ser345 induced by RITA was
affected by p53 status, whereas RITA-induced phosphory-
lated CHK-2 was observed in both p53/ and p53þ /þ cells to
a similar extent (Figure 4d). Taken together, our studies
indicate that RITA activates a p53-dependent DNA damage
response involving CHK-1 that functions to stall DNA
replication fork elongation and prolong S-phase progression.
RITA induces p53 and phosphorylated CHK-1 and cH2AX
proteins in S-phase. Given that RITA induces significant
p53-dependent apoptotic (Figure 1) and S-phase responses
(Figure 4), we next explored the induction of p53 and gH2AX
proteins in sub-G1 and S-phase cell populations
using fluorescence-activated cell sorting (FACS) analysis
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(Figure 5a). We found that p53 protein was induced in
response to RITA in all cell cycle phases (G1¼ 38%,
S¼ 43% and G2¼ 40%). Interestingly, after treatment with
RITA, a higher proportion of cells in S-phase were positive for
gH2AX protein (G1¼ 22%, S¼ 26% and G2¼ 10%). More-
over, we found a dose- and time-dependent increase in
both p53 and gH2AX protein levels in cells in S-phase
in response to RITA (Figures 5b and c). In addition, we found
a significant increase in the proportion of cells in
S-phase expressing phosphorylated CHK-1 protein (Figures
5d and e), whereas an increase in cells expressing
phosphorylated CHK-1 protein was not observed in cells
in sub-G1 (data not shown). Together, these data suggest
that RITA activates a p53-dependent S-phase checkpoint
involving CHK-1.
CHK-1 knockdown does not affect RITA-induced
apoptosis but affects DNA damage in cells treated with
RITA. To further assess whether CHK-1 was required for
p53-dependent apoptotic and DNA damage responses
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induced by RITA, we knocked down CHK-1 using siRNA
(Figure 5e). Interestingly, we found that CHK-1 knockdown
had no significant effect on p53-dependent apoptotic
responses induced by RITA (Figures 6a and b), whereas
the inhibition of caspase-3 activation by the inhibitor
Z-DEVD-FMK blocked the increase in cells in sub-G1
(Figure 6a) and the increase in cleaved PARP (Figure 6b),
but had no significant effect on phosphorylated CHK-1
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induced by RITA (Figure 6c). CHK-1 has an important role in
DNA repair26 and is essential for the maintenance of
genomic stability,27 particularly during DNA replication
and replication fork progression.25,28–30 Thus, we next
investigated whether CHK-1 knockdown affected the DNA
damage response induced by RITA. We found that CHK-1
knockdown had no significant effect on the small amount of
accumulated DNA damage at 24 h of exposure to RITA
(Figure 6d), nor was there any significant effect on the gH2AX
induced by RITA in CHK-1 knockdown cells at this time point
(Figure 6e). Notably, a previous report has shown that
phosphorylation at Ser345 on CHK-1 increases its turnover,
and thereby reduces total CHK-1 protein levels.31
Consistently, we found that total CHK-1 protein levels
decreased in the presence of RITA (Figure 6e). This effect
was more dramatic in the presence of CHK-1 siRNA (Figure 6e).
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Finally, consistent with a role for CHK-1 in DNA repair
and maintenance,26,27 we found that CHK-1 but not CHK-2
knockdown significantly enhanced DNA damage induced
at only 1 h of RITA treatment (Figure 6f), indicating that CHK-1
is essential for maintaining DNA integrity upon short term
exposure of cells to RITA. Consistently, we found that CHK-1
phosphorylation was induced by RITA during this time frame
(data not shown).
Discussion
HIF is upregulated in most human cancers due to changes in
tumour microenvironmental stimuli and genetic abnormal-
ities.1 Of particular interest, is the small-molecule approaches
that have been taken recently to target the HIF pathway as a
basis for the development of new therapeutics in the treatment
of cancer.2,32 The p53 tumour suppressor protein is a potent
negative regulator of HIF signalling in tumours.5 We have
recently shown that small-molecule activator of p53, RITA,
can mediate both antiangiogenic effects via blockade of the
HIF pathway and elicit apoptosis in hypoxic tumour cells
in vitro and in vivo.15 Intriguingly, unlike other p53-activating
agents, RITA causes significant tumour cell apoptosis in
normoxia and hypoxia (1% O2), without eliciting either a
measurable G1 and/or G2 arrest.15 Given that hypoxic
tumour cells expressing high basal levels of HIF-a are usually
resistant to killing by conventional radio and chemotherapeutic
agents, in this study, we further investigated the mechanistic
properties of RITA, with particular focus on exploring the DNA
damage response.
Here, we found that RITA activated the canonical ATM/ATR
DNA damage response pathway that leads to activation
of CHK-1 and CHK-2 phosphorylation. Intriguingly, however,
and confirming our recent findings,17 we found that the
induction of phosphorylated CHK-1 and gH2AX proteins
observed in response to RITA was dependent on p53 status.
Previous studies have reported a p53-dependent DNA
damage checkpoint.33,34 Activation of a p53-dependent
S-phase DNA damage checkpoint occurs to delay DNA
synthesis and to allow time to resolve a potential replication
block.33,35 Our earlier immunohistochemical analyses
showed that RITA induced a pan-nuclear localisation of
gH2AX opposed to localisation to discrete nuclear foci.17 This
type of DNA damage response indicates potential stalling of
the replication fork or is mediated during processing of bulky
DNA lesions.22 Indeed, we found that RITA induced a p53-
dependent increase in replication fork number in a sub-
population of replicons. Notably, a decline in replication fork
rate is known to be consistent with increased rates of local
origin activation and higher replication fork densities,25
indicating that RITA stalled DNA replication elongation and
affected replication fork rate.
Consistent with these observations, we found that treat-
ment of cells with RITA also prolonged mid-late S-phase
progression in p53-positive cells. Our findings indicate
that RITA activates a p53-dependent checkpoint that may
involve CHK-1.
CHK-1 has been shown to have an important role in
regulating DNA replication fork elongation and S-phase
progression.25 In response to RITA, we found that the relative
percentage of cells in S-phase expressing either p53 or
gH2AX protein was increased compared with other cell cycle
phases. Concurrently, we observed a significantly high
percentage of cells in S-phase expressing phosphorylated
CHK-1 upon RITA treatment. Activation of CHK-1 is crucial for
eliciting replication checkpoints in response to DNA-dama-
ging agents, providing protection to cells by allowing a slowing
of S-phase progression,28,29 and appears to be critically
involved in stabilising stalled replication forks.30 In addition,
CHK-1 is important in DNA repair upon exposure to hydro-
xyurea.26,36 Interestingly, we found that knockdown of CHK-1
by siRNA had only a minimal effect on the induction of
p53-dependent apoptosis and gH2AX in response to RITA.
However, knockdown of CHK-1 but not CHK-2 significantly
increased DNA damage induced within only 1 h of RITA
treatment, indicating that the activation of CHK-1 mediated by
RITA is important for maintaining DNA integrity.
RITA was originally identified using a cell-based screen12
and proposed to bind to the N terminus of p53 and induce p53
stabilisation by disruption of the p53–HDM2 interaction.12
Other studies have shown that RITA can also cause protein–
DNA and DNA–DNA intrastrand crosslinks,13,14 thereby
suggesting that RITA may also act to stabilise p53 by
interchelating with DNA. This latter possibility is supported
by the observations that RITA activates the canonical DNA
damage response. Of significance here is our observation that
induction of CHK-1 phosphorylation by RITA is affected by
p53 status. These findings suggest that RITA functions
mechanistically both at the level of DNA and at the level of
p53. Along with its role in G1/S- and G1/M-dependent cell
cycle checkpoints, p53 has also been implicated in S-phase
processes and DNA repair. Specifically, p53 is transported to
sites of stalled DNA replication forks and binds to RAD51,37
thus p53 provides an S-phase-specific role that is indepen-
dent of its known transcriptional activities.37 In addition,
CHK-1 binds to and phosphorylates RAD51, providing a vital
role in DNA repair upon exposure to hydroxyurea.36 Collec-
tively, these events ensure that DNA integrity is maintained,
and it may be that p53 itself provides an important role in a
molecular sensor mechanism at the level of DNA.
In conclusion, our study highlights a novel role for p53 in the
activation of a p53-dependent S-phase replication checkpoint
that involves CHK-1 and functions to protect the integrity of
DNA. As we have previously shown that exposure of tumour
cells to RITA leads to significant p53-dependent apoptosis in
normoxia and hypoxia,15 it will be of particular interest to
further examine the precise molecular mechanisms under-
lying this p53-dependent S-phase checkpoint in hypoxia.
Materials and Methods
Cell culture. All tumour cell lines were maintained in Dulbecco modified Eagle’s
medium. Medium was supplemented with 10% fetal calf serum purchased from
Harlan (Oxford, UK), 100 IU/ml penicillin, 100mg/ml streptomycin and
2 mM glutamine (all purchased from Gibco/Life Technologies, Paisley, UK).
The matched colorectal cell lines p53/HCT116 and p53þ /þHCT116 have been
described previously.38 Human MCF-7 (breast carcinoma) and Saos-2
(osteosarcoma) cells were purchased from American Type Culture Collection
(Manassass, VA, USA).
siRNA duplexes and transient transfection. The siRNA to CHK-1
(50-GGTGCCTATGGAGAAGTT-30) or CHK-2 (50-CTTGAAGAGGTATCCGUGG-30)
was obtained as a gel-purified annealed duplex from Dharmacon (Lafayette, CO,
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USA) and used at a final concentration of 25 nM, respectively. The non-silencing
control siRNA duplex (50-AATTCTCCGAACGTGTCACGT-30) was obtained from
QIAGEN (Crawley, UK) and has been used by us previously.39 Transient
transfections with siRNA duplexes were carried out using HiPerfect transfection
reagent (QIAGEN) according to the manufacturer’s instructions.
Antibodies. The HIF-a monoclonal antibody was purchased from BD
Transduction Laboratories (Oxford, UK). The p53 monoclonal antibody (DO-1)
was purchased from Calbiochem (Merck Biosciences, Nottingham, UK). The CHK1
monoclonal and CHK2 polyclonal antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). The p53 polyclonal antibody, polyclonal
anti-phospho-S345-CHK1, polyclonal anti-phospho-T68-CHK2, monoclonal anti-
phospho-S15-p53, polyclonal anti-phospho-S20-p53 and polyclonal anti-phospho-
S46P-p53 were all purchased from Cell Signaling Technologies (Danvers, MA,
USA). The anti-phospho-S139-gH2AX monoclonal antibody was purchased from
Upstate (Millipore, Newtownabbey, Northern Ireland).
Inductions and drug treatments. Physiological hypoxia was achieved by
incubating cells in 1% oxygen, 5% carbon dioxide and 94% nitrogen in a LEEC
(Nottingham, UK) dual gas incubator (GA-156). The hypoxic mimetic agent,
deferoxamine mesylate (DFX), was used at a final concentration of 500mM. RITA
was obtained from the National Cancer Centre, Drug Therapeutic Program,
Frederick, MD, USA (NSC-652287) and dissolved in dimethyl sulfoxide.
Wortmannin (Sigma, Gillingham, UK) was used at a final concentration of 10 mM.
The caspase-3 inhibitor Z-DEVD-FMK (Calbiochem) was used at 50mM.
Western blot analysis. After treatment, cells were washed in ice-cold
phosphate-buffered saline and lysed in 2 sample buffer (125 mM Tris (pH 6.8),
4% SDS, 0.01% bromophenol blue, 10% b-mercaptoethanol, 10% glycerol).
Alternatively, cells were harvested in NP-40 lysis buffer (100 mM Tris (pH 8.0),
100 mM NaCl2, 1% NP-40) containing an EDTA-free protease inhibitor cocktail
(Boehringer Mannheim-Roche Diagnostics Ltd, Burgess Hill, UK) to determine
total protein concentration using a standard protein assay (Biorad, Hemel
Hempstead, UK).
Flow cytometric analysis. Cell death was analysed by FACS using a
Beckman Coulter Diagnostics machine (High Wycombe, UK). Briefly, total
populations of cells, including floating and adherent cells, were fixed in 70%
ethanol and stained with propidium iodide (50 mg/ml). Ribonuclease was added at
100mg/ml. The percentage of cells with sub-G1 DNA content was taken as a
measurement of apoptosis.
Comet assay. The comet assay was performed using reagents from Trevigen
(Gaithersburg, MD, USA) and according to the manufacturer’s instructions. Cells
were dosed for 24 h with RITA (at the concentrations indicated) in complete media.
Following dosing, cells were harvested, mixed with low-melting agarose at 2 105
cells/ml (B1000 cells/slide) and spread onto preprepared comet slides. Cells were
lysed and incubated in alkaline buffer to select for single-strand DNA breaks. Slides
were then electrophoresed using alkaline electrophoresis buffer at 4 1C, 18 v and
300 mA for 40 min. Following electrophoresis, slides were fixed, dried and stained
using Sybr green (Trevigen). Comets were viewed using a Zeiss (Zeiss Ltd, Welwyn
Garden City, Hertfordshire, UK) fluorescent microscope at  20 magnification, and
images were captured over 20 fields of view for each slide using ImagePro software
(Media Cybernetics Inc., Bethesda, MD, USA). The relative length and intensity of
Sybr green-stained nuclei (comets) were proportional to DNA damage in individual
nuclei. This was quantified using an algorithm for Olive tail moment on the
CometScore software (TriTek Corporation, Sumerduck, VA, USA). At least 100
comets were analysed for each treatment. A 20-min dose of 100mM hydrogen
peroxide at 4 1C was used as a positive control for DNA damage.
DNAfibre assay. Replication tracks were labelled in culture medium containing
25mM BrdU. RITA (500 nM) was added 16 h before each experiment. DNA fibre
spreads were prepared, as previously described.24 BrdU-labelled tracks were
detected with BrdU anti-sheep antibody (Biodesign, Lewisville, TX, USA; M20105S;
1:1000 dilution; 1 h at 20 1C) using either Cy3- or AlexaFluor-488-conjugated
donkey anti-sheep secondary antibody (Invitrogen Ltd, Paisley, UK). Fibres were
examined using a Zeiss LSM 510 confocal microscope using a  100 (1.4NA) lens,
labelled tracks measured using the LSM software (Zeiss Ltd) (white bars on
individual images show examples of measurements recorded) and converted to kbp
using a conversion factor of 1 mm¼ 2.59 kbp. Measurements were recorded in
randomly selected fields (selected at low power) from dispersed, untangled areas of
the DNA spread. As the analysis of single, unbroken fibres is a key, routine quality
control for spreading of different cell types under different experimental conditions
was performed using direct DNA labelling with YOYO.23 For the S-phase analysis,
cells were grown on microscope coverslips and pulsed labelled for 20 min with
25mM BrdU. RITA (500 nM) was added 16 h before each experiment. The cells
were fixed using 4% PF, and BrdU detected as described above and previously.25
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are already in clinical testing to interfere
with TGF-b signaling, PD-1, Tregs, and
IDO, and it is not difficult to envision
combination studies to block two or
more pathways in concert, in the near
future. Finally, signal transduction inhibi-
tors that block the activity of specific
mutated kinases in melanoma, including
B-Raf and c-kit, have shown high rates
of clinical activity in patients bearing
melanomas with the relevant mutations.
Agents that target other pathways are
also in clinical development. As many of
the clinical responses to these agents
appear to be of short duration, integrat-
ing an immunotherapeutic strategy in
combination is logical to consider, per-
haps to capitalize on the rapid tumor cell
death that occurs that could deliver
tumor-derived antigens to the host
immune system.
It is indeed exciting to have a spec-
trum of active agents in clinical develop-
ment for melanoma. A thoughtful path
forward is likely to improve the out-
come of patients with this disease,
while catering therapeutic choices to
specific biologic properties of the
tumors in individual patients.
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Sustained angiogenesis is a common
hallmark of many tumours and contrib-
utes significantly to the invasion and
metastatic potential of tumour cells.
The hypoxia inducible factor (HIF) is a
key transcription factor responsible for
maintaining oxygen homeostasis and
regulating angiogenesis (Bertout et al.,
2008; Kaelin and Ratcliffe, 2008). HIF is
deregulated across a broad range of
cancers and is associated with increa-
sed mortality and treatment failure
(Semenza, 2010). Previous studies have
demonstrated that HIF-a, the regulatory
subunit of HIF, is not only involved in
cellular adaptation to oxidative stress,
but also has an important function in
regulating p53-dependent cell death res-
ponses (Carmeliet et al., 1998). Tumour
cells that adapt to evade cell death and
induce angiogenesis in response to
changes in the tumour microenviron-
ment are generally more aggressive and
metastatic. However, precisely how HIF
and p53 co-operate to maintain cellular
integrity is unclear and many avenues
of HIF-p53 regulation and interaction are
yet to be explored.
A recent study by Sendoel and
colleagues has utilized the nematode
Caenorhabditis elegans to provide novel
insights into mechanisms linking HIF
and apoptosis (Sendoel et al., 2010).
Both HIF and the apoptotic machinery
are evolutionarily conserved and well
characterised in C. elegans. Irradiation
induced DNA damage and cell death in
the germ line of C. elegans is regulated
by Cep-1 (the C. elegans homologue of
p53). Intriguingly, Sendoel and col-
leagues identify a mechanism by which
Cep-1 is transcriptionally repressed by
HIF-1 (Sendoel et al., 2010). Sendoel
and colleagues begin their investigation
by demonstrating that in wildtype
C. elegans, DNA damage induced by
ionizing radiation (IR) increases germ
cell apoptosis. However, in C. elegans
that overexpress HIF-1 due to vhl-1
(von-Hippel Lindau) mutation [vhl-
1(ok161)], apoptosis is significantly
impaired. HIF-1 is subsequently shown
to protect C. elegans against apoptosis
by targeting Cep-1 specifically (Sendoel
et al., 2010). In contrast to these find-
ings, a previous report has shown that
HIF-1a binds and stabilizes p53, thus
promoting p53-mediated activation (An
et al., 1998). Other studies have
shown that p53 activation inhibits HIF-
1a-mediated responses in tumour cells
(Yang et al., 2009).
Sendoel and colleagues now present
a novel mechanism for Cep-1 inhibition
by HIF-1 that involves transcriptional
upregulation of the tyrosinase family
member tyrosinase-related protein 2
(TYR-2). Tyrosinases are specific enzy-
mes involved in catalysing production
of the pigment melanin in melano-
cytes. TYR-2 expression is induced by
stabilised HIF-1a in vhl mutant C. ele-
gans and this occurs specifically in ASJ
neurons present in the head of C. ele-
gans. TYR-2 is secreted by the ASJ
neurons and is taken up by endocyto-
sis to inhibit apoptosis specifically in
germ cells, in a non-autonomous fash-
ion. The dependency of this effect on
TYR-2 was confirmed by Sendoel and
colleagues using RNAi to knock down
TYR-2 which restored sensitivity to
IR-induced apoptosis in the germ cells
of vhl-1 mutant C. elegans (Sendoel
et al., 2010). The fascinating model
proposed by Sendoel and colleagues in
which neurons are able to regulate HIF
transcription and transmit a long range
signal to protect distant tissues from
DNA damage and stress is summar-
ised in Figure 1A.
The anti-apoptotic functions of TYR-2
in C. elegans appear to translate to
human cells: Sendoel and colleagues
found that shRNA inhibition of human
Coverage on: Sendoel, A., Kohler, I.,
Fellmann, C., Lowe, S.W., and Hengart-
ner, M.O. (2010). HIF-1 antagonizes
p53-mediated apoptosis through a
secreted neuronal tyrosinase. Nature
465, 577–583.
doi: 10.1111/j.1755-148X.2010.00746.x
News and Views
ª 2010 John Wiley & Sons A/S 581
tyrosinase-related protein 2 (TRP-2), the
homologue of TYR-2 in the WM266-4
metastatic melanoma cell line sensitis-
es these cells to cisplatin-induced apop-
tosis (Sendoel et al., 2010) (Figure 1B).
As an enzyme that functions in synthes-
ising melanin, TRP-2-mediated inhibition
of p53 allows for an effective cell sur-
vival mechanism in melanocytes that
are often exposed to damage induced
by UV radiation. Increased expression
of TRP-2 has been shown to correlate
with decreased apoptosis in several
human melanoma cell lines, and hence
confers resistance to radiation therapy
and chemotherapy (Pak et al., 2004).
Interestingly, despite this, the fre-
quency of p53 mutations in metastatic
melanoma is only present at 25%,
much lower compared to other cancers.
Instead, deregulated p53 signalling
often co-operates with other pathways,
such as the Rb pathway and BRAF sig-
nalling to contribute to melanocyte
transformation.
Indeed, Sendoel and colleagues pro-
pose that TRP-2 may act downstream of
BRAF through its transcriptional regula-
tion by microphthalmia-associated tran-
scription factor (MITF) to affect tumour
progression. Activating mutations in
BRAF occur with a frequency of 50–70%
in melanoma. Therefore targeting TRP-2
may offer an attractive strategy to the
treatment of aggressive melanomas that
have transcriptionally repressed wildtype
p53. Increased expression of TRP-2 has
also been observed in other cancer lines.
Thus it would be of particular interest to
extend the study by Sendoel et al. to
other aggressive cancers such as renal
cell carcinoma where HIF signalling
is deregulated by loss of VHL tumour
suppressor function.
One obvious drawback of the study
by Sendoel and colleagues is that it
concentrates on phenotypes where
HIF-1 is overexpressed in the context
of vhl-1 mutation. Therefore, the contri-
bution that HIF-1 specifically makes to
the anti-apoptotic effect of TRP-2 in
response to hypoxia remains to be clari-
fied. Despite this, the novelty of Send-
oel et al.’s study lies in the
characterisation of TYR-2 in C. elegans
as an important pro-survival signalling
molecule that has not been previously
implicated in regulating apoptosis in
response to deregulated HIF-1. Further-
more, the non-autonomous regulation
of apoptosis by this mechanism may
potentially provide another level of com-
plexity within the tumour microenviron-
ment whereby HIF is able to
transcriptionally regulate p53-mediated
apoptosis in other, distant regions of
the tumour. Finally, the study by Send-
oel and colleagues highlights a mecha-
nism by which HIF co-operates with
p53 to mediate resistance in highly
metastatic and aggressive cancers such
as melanoma and provides important
information for designing novel targeted
therapies.
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Figure 1. (A) HIF induces TYR-2-dependent inhibition
of Cep-1-mediated apoptosis in Caenorhabditis
elegans. HIF-a is degraded by von Hippel-Lindau (vhl-
1)-mediated ubiquitination. In vhl mutant C. elegans
HIF-a is constitutively stabilised and leads to formation
of the HIF transcriptional complex. HIF upregulates the
expression of the tyrosinase TYR-2 specifically in the
ASJ sensory neurons found in the head of C. elegans.
Cep-1 mediates apoptosis in the germ line in response
to a DNA damage signal. The uptake of TYR-2 is
dependent on endocytosis and inhibits Cep-1-mediated
apoptosis in distant germline cells in the gonad. (B)
Targeting TRP-2 sensitises melanoma cells to cisplatin-
induced apoptosis. In human BRAF mutant WM266-4
metastatic melanoma cells, TRP-2 has inhibitory
effects on wildtype p53 and confers resistance to
cisplatin-induced cell death. When TRP-2 is inhibited
by shRNA in WM266-4 cells, p53 is stabilised and
apoptosis is induced by cisplatin.
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